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Abstract 
Huntington’s disease (HD) is caused by a CAG repeat expansion in HTT on chromosome 4. Onset and progression are 
inversely correlated with repeat length, but a significant proportion of the variability in each is due to modifiers elsewhere 
in the genome. Recent genome-wide association studies have identified the DNA repair genes FAN1 and MSH3 as 
modifiers of onset and progression respectively. This thesis finds that variants associated with HD disease course also 
influence onset in other polyglutamine diseases, suggesting a shared pathogenic mechanism involving DNA repair. In 
blood from HD patients there is significant transcriptional dysregulation, particularly involving immune, metabolic and 
DNA repair pathways, which correlates with disease severity, parallels dysregulation seen in the most affected HD brain 
regions and overlaps with Alzheimer’s disease. To study the role of DNA repair, several cell models of somatic instability 
were developed, including patient-derived lymphoblasts and induced pluripotent stem cells, which show exponential 
repeat expansion that continues in differentiated medium spiny neurons (MSNs). In a FAN1 knockout U20S cell model of 
HD, FAN1 is shown to protect against repeat instability, and this function is dependent on protein concentration and CAG 
repeat length, but does not require its nuclease activity. shRNA-mediated FAN1 knockdown accelerates repeat expansion 
in both patient-derived iPSCs and MSNs. Through chromatin immunoprecipitation, FAN1 is shown to bind, but not 
specifically target, CAG repeat DNA. AAV9-mediated miRNA Fan1 knockdown in the striatum and liver of R6/2 mice did 
not accelerate repeat expansion, likely because only 23% knockdown was achieved. Illumina sequencing of the MSH3 
region that influences HD progression identified a repeat variant that is associated with decreased MSH3 expression, 
reduced somatic expansion, delayed onset and slower progression in HD and myotonic dystrophy type 1 (DM1). These 
results suggest MSH3 promotes and FAN1 protects against repeat instability, which in turn influences the course of repeat 
expansion diseases. 
Impact statement 
This thesis suggests that in repeat expansion diseases, a network of DNA repair proteins causes somatic instability, which 
in turn influences disease course. Modulation of DNA repair components, such as FAN1 and MSH3, has significant 
therapeutic potential in some of the commonest genetic neurodegenerative disorders through the reduction of somatic 
expansion. The blood transcriptomic signature of HD, with dysregulation of the immune system, DNA repair, RNA 
processing and energy metabolism also overlaps with that of Alzheimer’s disease. Several synthetic and patient-derived 
Huntington’s disease cell models of repeat length-dependent somatic instability were generated, including medium spiny 
neurons, the cells most vulnerable to the disease. These will permit the elucidation of the wider DNA repair network 
responsible and the investigation of compounds that reduce instability. FAN1 has been shown for the first time to bind 
CAG repeat DNA and increasing its expression may protect against expansion through a novel mechanism that is 
independent of its nuclease activity. Conversely, decreasing expression of MSH3 may reduce somatic expansion, delay 
onset and slow progression in several repeat expansion diseases. 
  
6 
Table of Contents 
Declaration .................................................................................................................................................................. 3 
Acknowledgements ..................................................................................................................................................... 4 
Abstract ....................................................................................................................................................................... 5 
Impact statement ........................................................................................................................................................ 5 
Figures ...................................................................................................................................................................... 10 
Tables ........................................................................................................................................................................ 15 
Abbreviations ............................................................................................................................................................ 18 
Chapter 1 Introduction ........................................................................................................................................ 26 
1.1 DNA repeat expansion ..................................................................................................................................... 26 
1.2 Huntington’s disease ....................................................................................................................................... 28 
1.3 DNA repair ....................................................................................................................................................... 37 
1.4 FAN1 ................................................................................................................................................................ 42 
1.5 MSH3 ............................................................................................................................................................... 46 
1.6 The immune system in neurodegenerative disease ........................................................................................ 51 
Chapter 2 Materials and methods ....................................................................................................................... 53 
2.1 Cell lines .......................................................................................................................................................... 53 
2.2 Cell culture ...................................................................................................................................................... 62 
2.3 Cell imaging ..................................................................................................................................................... 68 
2.4 Genetics ........................................................................................................................................................... 68 
2.5 Protein ............................................................................................................................................................. 82 
Chapter 3 DNA repair variants modify phenotype in polyglutamine diseases ...................................................... 83 
3.1 Background ...................................................................................................................................................... 83 
3.2 Aims ................................................................................................................................................................. 87 
3.3 Methods .......................................................................................................................................................... 88 
3.4 Contributions ................................................................................................................................................... 91 
3.5 Results ............................................................................................................................................................. 92 
3.6 Discussion ........................................................................................................................................................ 95 
7 
3.7 Summary ......................................................................................................................................................... 96 
3.8 Publications relating to this chapter ................................................................................................................ 96 
Chapter 4 Transcriptional dysregulation in Huntington’s disease patient blood ................................................... 97 
4.1 Background ...................................................................................................................................................... 97 
4.2 Aim ................................................................................................................................................................ 100 
4.3 Methods ........................................................................................................................................................ 100 
4.4 Contributions ................................................................................................................................................. 103 
4.5 Results ........................................................................................................................................................... 105 
4.6 Discussion ...................................................................................................................................................... 121 
4.7 Summary ....................................................................................................................................................... 124 
4.8 Publications relating to this chapter .............................................................................................................. 124 
Chapter 5 Cell models of HTT CAG repeat instability .......................................................................................... 125 
5.1 Background .................................................................................................................................................... 125 
5.2 Aims ............................................................................................................................................................... 128 
5.3 Methods ........................................................................................................................................................ 130 
5.4 Contributions ................................................................................................................................................. 132 
5.5 Results ........................................................................................................................................................... 133 
5.6 Discussion ...................................................................................................................................................... 158 
5.7 Summary ....................................................................................................................................................... 160 
5.8 Publications relating to this chapter .............................................................................................................. 160 
Chapter 6 FAN1 activity at HTT CAG repeat DNA ............................................................................................... 161 
6.1 Background .................................................................................................................................................... 161 
6.2 Aims ............................................................................................................................................................... 162 
6.3 Methods ........................................................................................................................................................ 163 
6.4 Contributions ................................................................................................................................................. 168 
6.5 Results ........................................................................................................................................................... 169 
6.6 Discussion ...................................................................................................................................................... 190 
6.7 Summary ....................................................................................................................................................... 192 
6.8 Publications relating to this chapter .............................................................................................................. 193 
8 
Chapter 7 Fan1 knockdown in R6/2 mice ........................................................................................................... 194 
7.1 Background .................................................................................................................................................... 194 
7.2 Aims ............................................................................................................................................................... 196 
7.3 Methods ........................................................................................................................................................ 196 
7.4 Contributions ................................................................................................................................................. 203 
7.5 Results ........................................................................................................................................................... 204 
7.6 Discussion ...................................................................................................................................................... 235 
7.7 Summary ....................................................................................................................................................... 236 
Chapter 8 MSH3 modifies somatic instability and disease severity in Huntington’s disease and myotonic 
dystrophy type 1 ...................................................................................................................................................... 238 
8.1 Background .................................................................................................................................................... 238 
8.2 Aims ............................................................................................................................................................... 239 
8.3 Methods ........................................................................................................................................................ 240 
8.4 Contributions ................................................................................................................................................. 244 
8.5 Results ........................................................................................................................................................... 245 
8.6 Discussion ...................................................................................................................................................... 264 
8.7 Summary ....................................................................................................................................................... 265 
8.8 Publications related to this chapter .............................................................................................................. 266 
Chapter 9 Conclusions and future work ............................................................................................................. 267 
9.1 Conclusions .................................................................................................................................................... 267 
9.2 Future work ................................................................................................................................................... 273 
Chapter 10 Appendix ........................................................................................................................................... 276 
10.1 p’HRsincpptUCOE+htt exon1 IRES eGFP 129CAG vector sequence .............................................................. 276 
10.2 U20S curve modelling in R ............................................................................................................................. 278 
10.3 pSUPER.retro.puro vector sequence ............................................................................................................. 279 
10.4 pcDNA5-GFP-FAN1/FRT/TO vector sequence ............................................................................................... 280 
10.5 Sequencing of A2UCOE HTT exon 1 construct CAG repeat regions ............................................................... 282 
10.6 MSH3 MiSeq primer sequences .................................................................................................................... 283 
10.7 PhIX reference sequence ............................................................................................................................... 284 
9 
10.8 MSH3 reference sequences ........................................................................................................................... 285 
10.9 MiSeq library quality control Galaxy workflow ............................................................................................. 295 
10.10 MSH3 repeat genotyping Galaxy workflow ................................................................................................... 302 
10.11 MSH3 variant calling Galaxy workflow .......................................................................................................... 305 
10.12 Base-wise conservation scores across the MSH3 9bp tandem repeat region ............................................... 307 
10.13 MSH3 and DHFR expression quantitative trait loci (eQTL) ............................................................................ 309 
10.14 HD transcriptome-wide association study (TWAS) ........................................................................................ 313 
Publications relating to this thesis ........................................................................................................................... 322 
Funding ................................................................................................................................................................... 323 
References ............................................................................................................................................................... 324 
 
  
10 
Figures 
Figure 1.1. Potential future therapeutic targets in Huntington's disease. ......................................................................... 33 
Figure 1.2. Relationship between expanded CAG repeat length (x axis) and onset of diagnostic motor signs (y axis). .... 34 
Figure 1.3. Manhattan plot of meta-analysis from GeM GWAS of HD motor onset. ......................................................... 36 
Figure 1.4. Schematic representation of FAN1. .................................................................................................................. 43 
Figure 1.5. FAN1 interactome. ............................................................................................................................................ 45 
Figure 1.6. Schematic representation of MSH3. ................................................................................................................. 47 
Figure 1.7. MSH3 protein interactions. .............................................................................................................................. 48 
Figure 1.8. Alignment of mouse and human MSH3 protein sequences. ............................................................................ 50 
Figure 1.9. Conservation of the MSH3 N-terminal domain between mouse and human. ................................................. 51 
Figure 2.1. p’HRsincpptUCOE+htt exon1 IRES eGFP 129CAG vector. ................................................................................. 54 
Figure 2.2. Micrographs of ReN VM cells transduced to express HTT exon 1 with 129 CAG repeats and GFP. ................. 54 
Figure 2.3. Schematic representation of FAN1. .................................................................................................................. 57 
Figure 2.4. CAG repeat sizing in 250Q lymphoblasts from Nance et al. (1999). ................................................................. 58 
Figure 2.5. BD vacutainer centrifugation. ........................................................................................................................... 59 
Figure 2.6. Micrographs of 125Q pluripotent ESCs. ........................................................................................................... 60 
Figure 2.7. Representative light micrograph of 109Q iPSCs (5x). ....................................................................................... 61 
Figure 2.8. pcDNA5/FRT/TO vector containing Cas9-Flag under a tetracycline-inducible promoter and a hygromycin 
resistance gene. ........................................................................................................................................................ 61 
Figure 2.9. Light micrograph of U20S FAN-/- cells in culture. .............................................................................................. 62 
Figure 2.10. Neuronal differentiation of ReN VM cells expressing HTT exon 1 with 129 CAG repeats. ............................. 63 
Figure 2.11. Neuronal differentiation of ReN CX cells expressing HTT exon 1 with 129 CAG repeats. .............................. 64 
Figure 2.12. Scratch pattern 1 for MSN differentiation passage 1. .................................................................................... 66 
Figure 2.13. Scratch pattern 2 for MSN differentiation passage 2. .................................................................................... 66 
Figure 2.14. Light micrographs of differentiated medium spiny neurons (MSN). .............................................................. 67 
Figure 2.15. Light micrograph of 109Q neural stem cells. .................................................................................................. 68 
Figure 2.16. Primers for CAG repeat sizing. ........................................................................................................................ 70 
Figure 2.17. Boxplot of variability in CAG sizing from cell lines with a range of repeat lengths. ....................................... 72 
Figure 2.18. Change in modal CAG repeat length. ............................................................................................................. 73 
Figure 2.19. Instability index calculation from Lee et al. (2010). ........................................................................................ 74 
Figure 2.20. Proportional expansion analysis. .................................................................................................................... 75 
Figure 2.21. Representative example of fragment analysis traces from mouse #79 for the tissues and ages indicated 
(left). ......................................................................................................................................................................... 75 
Figure 2.22. Schematic representation of HTT primers on the genomic sequence. .......................................................... 79 
Figure 2.23. HTT CAG repeat primers marked on the genomic sequence. ........................................................................ 80 
Figure 2.24. Schematic representation of ATXN3 primers on the genomic sequence. ...................................................... 80 
Figure 2.25. Schematic representation of DMPK primers on the genomic sequence. ....................................................... 81 
11 
Figure 2.26. Schematic representation of FXN primers on the genomic sequence. .......................................................... 81 
Figure 2.27. Schematic representation of TBP primers on the genomic sequence. ........................................................... 81 
Figure 4.1. Upregulated pathways in HD versus control blood. ....................................................................................... 107 
Figure 4.2. Downregulated pathways in HD versus control blood. .................................................................................. 107 
Figure 5.1. Cloning FAN1 shRNA into the pSUPER.retro.puro vector. .............................................................................. 131 
Figure 5.2. Oxidative stress in ReNeuron VM 129Q cells. ................................................................................................ 133 
Figure 5.3. Representative CAG repeat sizing from ReN VM neural stem cells (NSC) differentiated for 56 days. ........... 134 
Figure 5.4. Repeat expansion analysis in ReN VM cells cultured as neural stem cells (NSC) or differentiated (MSN) for 56 
days. ........................................................................................................................................................................ 134 
Figure 5.5. Representative CAG repeat sizing from ReN VM 129Q neural stem cells (NSC) chronically stressed with H2O2 
during differentiation for 48 days. .......................................................................................................................... 135 
Figure 5.6. Representative CAG repeat sizing from ReN VM 129Q NSCs 44d after initiation of differentiation, chronically 
stressed with H2O2 from day 15. ............................................................................................................................. 135 
Figure 5.7. Representative CAG repeat sizing in ReN CX 129Q cells differentiated in the presence of chronic oxidative 
stress. ...................................................................................................................................................................... 136 
Figure 5.8. Representative CAG repeat sizing in ReN CX 129Q cells differentiated for 14 days. ..................................... 137 
Figure 5.9. CAG repeat sizing in ReN VM 129Q single cell clones (SCC). .......................................................................... 138 
Figure 5.10. CAG expansion analysis of ReN VM 129Q single cell clones. ........................................................................ 139 
Figure 5.11. Oxidative stress in HD lymphoblastoid (LB) cells. ......................................................................................... 140 
Figure 5.12. Representative CAG repeat sizing in lymphoblastoid (LB) cells chronically stressed with the indicated H2O2 
concentration. ......................................................................................................................................................... 141 
Figure 5.13. Repeat expansion analysis in a 43Q, 44Q, 52Q and p.R507H LB lines chronically exposed to oxidative stress.
 ................................................................................................................................................................................ 142 
Figure 5.14. CAG repeat sizing in 250Q lymphoblasts (LB) by TP-PCR capillary electrophoresis. .................................... 143 
Figure 5.15. Oxidative stress in QS3.2 and 109Q iPSCs. ................................................................................................... 143 
Figure 5.16. shRNA mediated FAN1 knockdown in QS3.2 and 109Q iPSCs. ..................................................................... 144 
Figure 5.17. Baseline CAG repeat sizing in QS3 iPSCs. ...................................................................................................... 145 
Figure 5.18. CAG expansion analysis in QS3 iPSCs in culture, chronic oxidative stress and differentiation as NSCs or 
MSNs. ...................................................................................................................................................................... 146 
Figure 5.19. CAG repeat sizing of whole blood from a 125Q HD subject sampled 3 years apart. .................................... 147 
Figure 5.20. CAG repeat sizing of lymphoblasts (LB) from a subject with 125 CAG repeats at baseline and following the 
emergence of a clone. ............................................................................................................................................. 148 
Figure 5.21. CAG repeat expansion analysis in 125 CAG LB cells. .................................................................................... 149 
Figure 5.22. CAG repeat sizing in 125Q iPSCs. .................................................................................................................. 150 
Figure 5.23. Exponential model of modal CAG repeat expansion in 109Q iPSCs. ............................................................ 151 
Figure 5.24. CAG repeat expansion in 109Q iPSCs exposed to chronic oxidative stress. ................................................. 152 
Figure 5.25. Immunofluorescence confocal microscopy of differentiated 109Q medium spiny neurons (MSNs) treated 
with either FAN1 knockdown, empty vector or in control conditions. ................................................................... 153 
12 
Figure 5.26. Stable shRNA-mediated FAN1 knockdown in 109Q iPSCs and MSNs. .......................................................... 154 
Figure 5.27. Comparison of exponential expansion models in 109Q iPSC, NSC and MSNs. ............................................. 155 
Figure 5.28. CAG repeat expansion in 109Q iPSCs and MSNs following shRNA-mediated FAN1 knockdown. ................ 156 
Figure 5.29. Comparison of CAG repeat expansion rate in HD cell lines. ......................................................................... 157 
Figure 6.1. Colony screening by restriction digest. ........................................................................................................... 166 
Figure 6.2. Transient transfection of HEK293 cells with full length Myc-tagged FAN1 variants. ..................................... 169 
Figure 6.3. Stable transfection of HEK293 cells. ............................................................................................................... 170 
Figure 6.4. Confocal immunofluorescence shows Myc-tagged FAN1 is expressed in the nucleus and forms repair foci 
that colocalise with FANCD2 following MMC. ........................................................................................................ 171 
Figure 6.5. siRNA mediated knockdown of endogenous FAN1 in HEK293 cells stably transfected with Myc-tagged 
p.R507H FAN1. ........................................................................................................................................................ 172 
Figure 6.6. Patient-derived LB cell MMC sensitivity. ........................................................................................................ 173 
Figure 6.7. Immunoblot for FAN1 expression in HD lymphoblasts from subjects with the given rs3512 genotype. ....... 174 
Figure 6.8. Sanger sequencing confirming SDM of the pcDNA5/FRT/TO FAN1 vector. ................................................... 175 
Figure 6.9. Tetracycline induction reverses the protective effect of GFP-FAN1. ............................................................. 176 
Figure 6.10. Tetracycline dose titration in p.R507H FAN1 U20S cells exposed to MMC. ................................................. 177 
Figure 6.11. γ-H2AX assay following cisplatin exposure in U20S cells. ............................................................................. 178 
Figure 6.12. FAN1 knockout sensitises U20S cells to MMC-induced interstrand crosslinks (ICL) and expression of wild 
type or variant GFP-FAN1 restores resistance. ....................................................................................................... 179 
Figure 6.13. Genotoxin assays in U20S cells. .................................................................................................................... 180 
Figure 6.14. Model of U20S FAN1-/- 118Q exponential expansion. .................................................................................. 181 
Figure 6.15. FAN1 protects against U20S 118Q CAG repeat expansion in a dose-dependent manner. .......................... 182 
Figure 6.16. Model of U20S FAN1-/- 97Q exponential expansion. .................................................................................... 183 
Figure 6.17. CAG repeat expansion in U20S FAN1-/- cells is length dependent. ............................................................... 184 
Figure 6.18. Change in modal CAG repeat length of U20S FAN1-/- cells expressing HTT exon 1 with 29-118Q. ............. 184 
Figure 6.19. Overlay of U20S FAN1-/- exponential expansion. .......................................................................................... 185 
Figure 6.20. FAN1 nuclease and p.R507H variants do not modify CAG repeat expansion rate. ...................................... 186 
Figure 6.21. FAN1 binds HTT CAG repeat DNA. ................................................................................................................ 187 
Figure 6.22. FAN1 interacts with endogenous HTT DNA of 109Q iPSCs. .......................................................................... 188 
Figure 6.23. FAN1 interacts with endogenous HTT DNA of 125Q iPSCs. .......................................................................... 188 
Figure 6.24. FAN1 interacts with endogenous HTT DNA of HD lymphoblasts (LB). .......................................................... 189 
Figure 6.25. Potential mechanisms by which FAN1 may protect against CAG repeat expansion. ................................... 192 
Figure 7.1. miRNA design. ................................................................................................................................................ 197 
Figure 7.2. Fan1 silencing in 3T3 mouse embryonic fibroblasts (MEF) using AAV9 cB7 eGFP miRNA constructs. ........... 198 
Figure 7.3. Experimental protocol. ................................................................................................................................... 201 
Figure 7.4. qPCR cycle threshold in pilot study of Fan1 expression in R6/2 tissues at 4 and 14 weeks. .......................... 205 
Figure 7.5. Relative Fan1 expression level in pilot study of R6/2 tissues at 4 and 14 wk age. ......................................... 206 
Figure 7.6. Comparing DNA and RNA yield and purity from 3-in-1 and traditional extractions. ...................................... 207 
13 
Figure 7.7. Comparing Fan1 expression level in 3-in-1 or traditional RNA-extracted cortex samples. ............................ 208 
Figure 7.8. Western blot comparing Fan1 protein levels from 3-in-1 or traditional protein extractions from cortex. .... 209 
Figure 7.9. A striatal sample (left) divided into thirds (right). .......................................................................................... 209 
Figure 7.10. Fragment analysis from 1/3 of a striatum. Representative trace. ................................................................ 210 
Figure 7.11. Protein extraction from 1/3 striatum of R6/2 mice. ..................................................................................... 210 
Figure 7.12. RNA extraction from 1/3 striatum and Fan1 expression. ............................................................................. 211 
Figure 7.13. Fan1 knockdown in R6/2 following AAV9 cB7 eGFP.oligo 09 transduction. ................................................. 212 
Figure 7.14. Fan1 knockdown in R6/2 liver. ..................................................................................................................... 213 
Figure 7.15. GFP expression following intrastriatal delivery of AAV9.mFan1 or AAV9.Scrambled control miRNA. ......... 214 
Figure 7.16. Representative sagittal sections showing GFP expression in the striatum. ................................................. 214 
Figure 7.17. GFP distribution pattern in R6/2 mice receiving intrastriatal injection of AAV9.mFan1.miRNA. ................. 215 
Figure 7.18. GFP expression in the liver. .......................................................................................................................... 215 
Figure 7.19. GFP expression pattern across all study groups receiving IP injections ....................................................... 216 
Figure 7.20. GFP intensity profile in transduced striatum and liver of R6/2 mice. ........................................................... 216 
Figure 7.21. Mutant huntingtin aggregates in transduced R6/2 striatum. ....................................................................... 217 
Figure 7.22. Weight and temperature in 11-week mice. .................................................................................................. 218 
Figure 7.23. Liver Fan1 expression. .................................................................................................................................. 219 
Figure 7.24. Striatum Fan1 relative expression. ............................................................................................................... 221 
Figure 7.25. Striatum Fan1 expression. ............................................................................................................................ 223 
Figure 7.26. Fan1 knockdown in R6/2 tissues. ................................................................................................................. 224 
Figure 7.27. Modal CAG repeat size at baseline (12 day tail). .......................................................................................... 225 
Figure 7.28. Change in modal CAG repeat length relative to 12 day tail. ......................................................................... 226 
Figure 7.29. Somatic instability index relative to 12 day tail. ........................................................................................... 228 
Figure 7.30. Proportional expansion analysis. .................................................................................................................. 230 
Figure 7.31. Change in modal CAG repeat length against Fan1 expression. .................................................................... 232 
Figure 7.32. Somatic instability index against Fan1 expression. ...................................................................................... 233 
Figure 7.33. Proportional expansion analysis against Fan1 expression. ........................................................................... 234 
Figure 8.1. Schematic of sequencing design for the MSH3 exon 1 region. ...................................................................... 242 
Figure 8.2. MSH3/DHFR 9bp tandem repeat allele structure and frequency observed in HD and DM1 cohorts. ........... 246 
Figure 8.3. Representative Sanger sequencing of a 3a heterozygote. ............................................................................. 247 
Figure 8.4. The MSH3 N-terminal region is poorly conserved between species. ............................................................. 248 
Figure 8.5. The number of MSH3 3a repeat alleles is associated with HD and DM1 phenotypes. .................................. 249 
Figure 8.6. Variants at the MSH3/DHFR locus are associated with phenotypes in HD and DM1. .................................... 253 
Figure 8.7. MSH3 expression in 6a and 3a repeat homozygotes. ..................................................................................... 259 
Figure 8.8. Association of the MSH3 3a allele with MSH3 and DHFR expression in HD whole blood. ............................. 260 
Figure 8.9. MSH3 repeat length correlation with somatic expansion, age at onset, progression score and blood 
expression of MSH3 and DHFR in HD. ..................................................................................................................... 261 
14 
Figure 8.10. Association of the MSH3 3a allele with MSH3 and DHFR expression in the TRACK-HD prefrontal cortex 
TWAS. ...................................................................................................................................................................... 262 
Figure 8.11. MSH3 repeat length correlation with prefrontal cortex expression of MSH3 and DHFR in TRACK-HD. ...... 263 
Figure 8.12. CAG repeat expansion correlation with MSH3 or DHFR expression in TRACK-HD prefrontal cortex. .......... 263 
Figure 9.1. Potential mechanisms by which FAN1 may protect against CAG repeat expansion. ..................................... 272 
Figure 10.1. Schematic representation of pcDNA5-GFP-FAN1/FRT/TO vector ................................................................ 281 
Figure 10.2. Sanger sequencing of A2UCOE HTT exon 1 construct CAG repeat regions. ................................................. 282 
 
  
15 
Tables 
Table 1.1 Genetic HD phenocopies. ................................................................................................................................... 31 
Table 1.2. Acquired HD phenocopies. ................................................................................................................................ 31 
Table 1.3. Notable studies proposing genetic modifiers of Huntington’s disease. ............................................................ 35 
Table 2.1. FAN1 variants identified by whole exome sequencing (WES) in fast and slow progressing subjects from 
TRACK-HD. ................................................................................................................................................................. 56 
Table 2.2. Track-HD patient-derived lymphoblastoid (LB) cell lines used in this study. ..................................................... 56 
Table 2.3. Calculation of CAG repeat size. .......................................................................................................................... 72 
Table 2.4. Variability in CAG sizing from cell lines with a range of repeat lengths. ............................................................ 73 
Table 2.5. HTT PCR primers. ............................................................................................................................................... 79 
Table 2.6. ATXN3 PCR primers. ........................................................................................................................................... 80 
Table 2.7. DMPK PCR primers. ............................................................................................................................................ 80 
Table 2.8. FXN PCR primers. ............................................................................................................................................... 81 
Table 2.9. TBP PCR primers. ............................................................................................................................................... 81 
Table 3.1. Characteristics of the polyglutamine diseases. .................................................................................................. 84 
Table 3.2. Phenotypes of polyglutamine diseases. ............................................................................................................. 85 
Table 3.3. Cohort characteristics. ....................................................................................................................................... 88 
Table 3.4. Characteristics of single nucleotide polymorphisms (SNPs) used in this study. ................................................ 89 
Table 3.5. Seed sense sequences for SNP KASP assay design. ........................................................................................... 90 
Table 3.6. Effects of repeat length of the expanded allele on age at onset. ...................................................................... 90 
Table 4.1. 12 genes significantly upregulated in HD blood from Borovecki et al. (2005). .................................................. 99 
Table 4.2.Top 10 up and downregulated genes in HD blood from Mastrokolias et al. (2015). .......................................... 99 
Table 4.3. Track-HD and Leiden cohorts for RNA-Seq analysis. ........................................................................................ 101 
Table 4.4. Top 10 genes from the differential expression analysis in the combined Track-HD and Leiden cohort. ........ 105 
Table 4.5. Overlap analysis of Track-HD and Leiden cohorts shows that a significant excess of pathways are associated 
with HD (p < 0.05) in both datasets. ....................................................................................................................... 106 
Table 4.6. The 10 most significantly up and downregulated ‘generic’ pathways in HD versus control blood GSEA. ....... 106 
Table 4.7. Top genes in top pathways. ............................................................................................................................. 108 
Table 4.8. Groups of pathways upregulated in HD blood vs controls. ............................................................................. 109 
Table 4.9. Groups of pathways downregulated in HD blood vs controls. ........................................................................ 110 
Table 4.10. Overlap between HD blood and myeloid cells. .............................................................................................. 110 
Table 4.11. Top 10 upregulated pathways that overlap between HD blood and myeloid cells. ...................................... 111 
Table 4.12. WGCNA brain expression modules in HD versus control blood. ................................................................... 112 
Table 4.13. Top 10 genes in WGCNA modules. ................................................................................................................ 113 
Table 4.14. Brain expression modules significantly dysregulated both in HD brain and HD blood. ................................. 114 
Table 4.15. Top 10 genes in module 48 (CNpos2) that are dysregulated (p < 0.05) in both blood and caudate, ranked by 
their kME value. ...................................................................................................................................................... 114 
16 
Table 4.16. Top 10 pathways dysregulated (p < 0.05) in both HD prefrontal cortex (Labadorf et al., 2015) and blood. . 115 
Table 4.17. Top 10 modules dysregulated (p < 0.05) in both HD prefrontal cortex (Labadorf et al., 2015) and blood. .. 116 
Table 4.18. Top 10 genes with expression in correlation with disease severity (total motor score). .............................. 116 
Table 4.19. Top 10 pathways enriched for up and downregulation in HD blood that also enriched for genes correlated 
with disease severity (TMS) in the same direction. ................................................................................................ 117 
Table 4.20. Modules dysregulated in HD blood that also correlated with disease severity (TMS) in the same direction.
 ................................................................................................................................................................................ 118 
Table 4.21. Top 10 differentially expressed genes from Mastrokolias et al (Mastrokolias et al., 2015) that correlated 
with disease severity (TMS) in Track-HD blood. ..................................................................................................... 119 
Table 4.22. Modules from Gibbs et al. (2010) that are dysregulated in both Alzheimer’s disease brain (International 
Genomics of Alzheimer's Disease, 2015) and HD blood. ........................................................................................ 119 
Table 4.23. Top 10 co-expression modules from Alzheimer’s disease brain(Zhang et al., 2013) that are dysregulated in 
HD blood. ................................................................................................................................................................ 120 
Table 5.1. Antibodies for immunofluorescence. .............................................................................................................. 131 
Table 5.2. Taqman qPCR probes. ...................................................................................................................................... 132 
Table 5.3. Repeat expansion analysis in ReN VM 129Q NSCs chronically stressed with H2O2 during differentiation for 48 
days. ........................................................................................................................................................................ 135 
Table 5.4. Repeat expansion analysis in ReN VM 129Q NSCs 44d after initiation of differentiation, chronically stressed 
with H2O2 from day 15. ........................................................................................................................................... 136 
Table 5.5. CAG repeat sizing analysis for two single cell clones in culture and during differentiation. ........................... 139 
Table 5.6. Exponential modelling of modal CAG expansion in 109Q iPSCs. ..................................................................... 151 
Table 6.1. Full length Myc-tagged FAN1 construct. .......................................................................................................... 164 
Table 6.2. Sequencing primers to confirm SDM. .............................................................................................................. 166 
Table 7.1. Animals used in the toxicity study. .................................................................................................................. 199 
Table 7.2. Animals used in experimental study. ............................................................................................................... 200 
Table 7.3. TaqMan qPCR probes. ...................................................................................................................................... 202 
Table 7.4. Change in modal CAG relative to 12 day tail. ................................................................................................... 227 
Table 7.5. Somatic instability index relative to 12d tail. ................................................................................................... 229 
Table 7.6. Proportional expansion analysis. ..................................................................................................................... 231 
Table 8.1. Regression models of the relationships between allele structures, relative rate of somatic expansion and 
disease phenotypes in Huntington’s disease and myotonic dystrophy type 1. ...................................................... 244 
Table 8.2. MSH3 9 bp tandem repeat alleles observed in HD and DM1 cohorts. ............................................................ 246 
Table 8.3. MSH3 9 bp tandem repeat alleles and their association with phenotypes in DM1 and HD. ........................... 250 
Table 8.4. Detailed investigation of the role of repeat alleles in phenotypic modification. ............................................ 251 
Table 8.5. MSH3 exon 1 region variants. .......................................................................................................................... 254 
Table 8.6. MSH3 exon 1 region variants and the association of their alternative alleles with phenotypes in DM1 and HD.
 ................................................................................................................................................................................ 255 
Table 8.7. Associations of SNP alternative alleles with phenotypes conditional on the repeat structure (Table 4). ....... 256 
17 
Table 8.8. MSH3 exon 1 region haplotypes. ..................................................................................................................... 257 
Table 8.9. MSH3 exon 1 region haplotypes and their association with phenotypes in DM1 and HD. ............................. 258 
Table 10.1. Nextera XT Index Kit v2 primers for the MSH3 repeat region. ...................................................................... 283 
Table 10.2. Base-wise conservation scores across the MSH3 exon 1 9bp tandem repeat region. .................................. 307 
Table 10.3. MSH3 and DHFR expression quantitative trait loci associated with phenotypes in HD and DM1. ................ 309 
Table 10.4. Transcriptome-wide association study (TWAS) of HD prefrontal cortex. ...................................................... 313 
  
18 
Abbreviations 
6-MTG 6-methylthioguanine  
AAO Age at onset 
AAV Adeno-associated virus 
ABI Applied Biosystems 
ACMG American College of Medical Genetics 
ACTB Actin, cytoplasmic 1 
AD Alzheimer's disease 
ADORA2A Adenosine A2a Receptor 
ADP Adenosine diphosphate 
ADPRH ADP-Ribosylarginine Hydrolase 
ADR Adrenal gland 
ALS Amyotrophic lateral sclerosis 
APTX Aprataxin 
ARPP21 CAMP Regulated Phosphoprotein 21 
AT Ataxia telangiectasia 
ATLD Ataxia-telangiectasia-like disorder 
ATM Serine-protein kinase ATM 
ATP Adenosine triphosphate 
BDNF Brain-derived neurotrophic factor 
BER Base excision repair 
BMI Body mass index 
BS Brainstem 
BSA Bovine serum albumin 
BWA Burrows-Wheeler Aligner 
BWT Burrows-Wheeler transform 
CAG Cytosine-Adenine-Guanine 
CALB1 Calbindin 1 
CB Cerebellum 
CBM Carbamazepine 
CBP Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 
CHDI Cure Huntington's Disease Initiative 
CJD Creutzfeldt-Jakob disease 
CMC CommonMind Consortium 
CN Caudate nucleus 
CNS Central nervous system 
CNV Copy-number variation 
19 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CSF Cerebrospinal fluid 
CTD C-terminal domain 
CTG Cytosine-Thymine-Guanine 
CTIP DNA endonuclease RBBP8 
CX Cortex 
DAPI 4ʹ,6-diamidino-2-phenylindole 
DARPP-32 Protein phosphatase 1 regulatory subunit 1B (PPP1R1B) 
DDR DNA damage response 
DHFR Dihydrofolate reductase 
DLX1 Distal-Less Homeobox 1 
DLX2 Distal-Less Homeobox 2 
DLX5 Distal-Less Homeobox 5 
DLX6 Distal-Less Homeobox 6 
DMEM Dulbecco's Modified Eagle's medium 
DMPK Myotonin-protein kinase 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DRD1 Dopamine Receptor D1 
DRD2 Dopamine Receptor D2 
DRIP DNA-RNA immunoprecipitation 
DRPLA Dentatorubral-pallidoluysian atrophy 
DSB Double strand break 
DSBR Double strand break repair 
DTT Dithiothreitol 
EBF1 Early B Cell Factor 1 
EBV Epstein-Barr virus 
ECACC European Collection of Authenticated Cell Cultures 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol-bis(β-aminoethyl ether)-N,N,Nʹ,Nʹ-tetraacetic acid) 
EHDN European Huntington's Disease Network 
EMBL European Molecular Biology Laboratory 
EMQN European Molecular Genetic Quality Network 
EMS Ethylmethanesulphonate  
EPC Erythroid progenitor cells 
FA Fanconi anaemia 
FACS Fluorescence activated cell sorting 
FAN1 FANCD2 And FANCI Associated Nuclease 1 
20 
FANCA Fanconi anemia group A protein 
FANCI Fanconi anemia group I protein 
FANCM Fanconi anemia group M protein 
FB Fibroblast 
FBS Fetal bovine serum 
FC Frontal cortex 
FCTX Frontal cortex 
FDR False discovery rate 
FGF Fibroblast growth factor 
FOXP2 Forkhead Box P2 
FRDA Friedreich ataxia 
FRT Flippase recognition target 
FTD Frontotemporal dementia 
FTL Ferritin light chain 
FXN Frataxin 
FXS Fragile X syndrome 
GAD1 Glutamate Decarboxylase 1 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GB Gillian Bates 
GDNF Glial cell line-derived neurotrophic factor 
GFP Green fluorescent protein 
GSEA Gene Set Enrichment Analysis 
GSX2 GS Homeobox 2 
GWAS Genome-wide association study 
HBV Hepatitis B virus 
HCL Hydrochloric acid 
HCV Hepatitis C virus 
HD Huntington's disease 
HDAC Histone deacetylase 
HDL-1 Huntington’s disease like syndrome 1 
HDL-2 Huntington’s disease like syndrome 2 
HGVS Human Genome Variation Society 
HIPP Hippocampus 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
HNPCC Hereditary nonpolyposis colorectal cancer 
HTT Sodium-dependent serotonin transporter 
HWE Hardy-Weinberg equilibrium 
21 
ICL Interstrand crosslink 
IDCL Interdomain connector loop  
IDL Insertion-deletion loops  
IGAP International Genomics of Alzheimer’s Disease Consortium 
IGFALS Insulin Like Growth Factor Binding Protein Acid Labile Subunit 
IHC Immunohistochemistry  
IP Immunoprecipitation 
IRB Institutional review board 
IRES Internal ribosome entry site 
IS Intrastriatal 
IT Intrathecal 
IV Intravenous 
KD Knockdown 
KEGG Kyoto Encyclopedia of Genes and Genomes 
KIN Karyomegalic interstitial nephritis 
LB Lymphoblastoid cell 
LDH Lactate dehydrogenase 
LGE Lateral ganglionic eminence  
LHX6 LIM Homeobox 6 
LIV Liver 
LOAD Late-onset Alzheimer’s disease 
MAPK Mitogen-activated protein kinase 
MEF Mouse embryonic fibroblast 
MEM Minimum Essential Medium Eagle 
MGI Mouse Genome Informatics 
MHC Major histocompatibility complex 
MHF Centromere Protein S 
MJD Machado–Joseph disease 
MMC Mitomycin C 
MMLV Moloney Murine Leukemia Virus Reverse Transcriptase 
MMR Mismatch repair 
MMS Methyl methanesulfonate 
MRC Medical Research Council 
MRC PPU Medical Research Council Protein Phosphorylation and Ubiquitylation Unit 
MRI Magnetic resonance imaging 
MS Multiple sclerosis 
MSI Microsatellite instability 
MSN Medium spiny neuron 
22 
MTM-HD Multiple Tissue Molecular Signatures in Huntington's Disease 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAD Nicotinamide adenine dinucleotide 
NADPH Nicotinamide adenine dinucleotide phosphate 
NANOG Nanog Homeobox 
NCBI National Center for Biotechnology Information 
NCI National Cancer Institute 
NEB New England Biolabs 
NEFL Neurofilament light polypeptide 
NER Nucleotide excision repair 
NES Normalised effect size 
NGS Next-generation sequencing 
NHEJ Nonhomologous end joining 
NKX2-1 NK2 Homeobox 1 
NOLZ1 Zinc Finger Protein 503 
NSC Neural stem cell 
NTD N-terminal domain 
NVC Naive Variant Caller 
OB Olfactory bulb 
OCP Oral contraceptive pill 
OMIM Online Mendelian Inheritance in Man 
OPL Outer plexiform layer 
ORF Open reading frame 
PACRGL Parkin Coregulated Like 
PANDAS Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection 
PBL Peripheral blood lymphocytes  
PBMC Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
PCA Principal component analysis 
PCNA Proliferating cell nuclear antigen 
PCNP PEST proteolytic signal-containing nuclear protein 
PCR Polymerase chain reaction 
PCTP Phosphatidylcholine Transfer Protein 
PD Parkinson's disease 
PDGFD Platelet Derived Growth Factor D 
PDPN Podoplanin 
PENK Proenkephalin 
PEST PEST Proteolytic Signal Containing Nuclear Protein 
23 
PFA Paraformaldehyde 
PFC Prefrontal cortex 
PGC1α PPARG Coactivator 1 Alpha 
PHAROS Prospective Huntington At Risk Observational Study 
PHE Public Health England 
PIGH Phosphatidylinositol Glycan Anchor Biosynthesis Class H 
PIGN Phosphatidylinositol Glycan Anchor Biosynthesis Class N 
PIGX Phosphatidylinositol Glycan Anchor Biosynthesis Class X 
PIP box PCNA-interacting peptide (PIP) box 
PMS2 PMS1 Homolog 2, Mismatch Repair System Component 
PNPK Polynucleotide kinase 3ʹphosphatase 
PRNP Major prion protein 
PTN Phenytoin 
QC Quality control 
RAN translation Repeat-associated non-ATG (RAN) translation 
REST RE1-silencing transcription factor 
RIPA Radioimmunoprecipitation assay buffer 
RMA Robust Multi-array Average 
RNA Ribonucleic acid 
ROB Rest of brain 
RPA Replication protein A 
RPMI Roswell Park Memorial Institute medium 
RT-qPCR Reverse transcription quantitative polymerase chain reaction 
SAGE Serial analysis of gene expression  
SAM Sequence Alignment Map 
SAP SAF-A/B, Acinus and PIAS 
SBMA Spinal and bulbar muscular atrophy 
SBS Sequencing by Synthesis 
SCA Spinocerebellar ataxia 
SCC Single cell clone 
SD Standard deviation 
SDHA Succinate Dehydrogenase Complex Flavoprotein Subunit A 
SDM Site-directed mutagenesis 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SE Standard error 
SEM Standard error of the mean 
SIFT Sorting Intolerant From Tolerant 
SII Somatic instability index 
24 
SIN Somatic instability network 
SIX3 SIX Homeobox 3 
SL Left striatum 
SLE Systemic lupus erythematosus 
SMAD Caenorhabditis elegans SMA ("small" worm phenotype) and Drosophila MAD ("Mothers Against 
Decapentaplegic") family of genes 
SNP Single nucleotide polymorphism 
SPATAX Spastic paraplegias (SP) and cerebellar ataxias (CA) network 
SPSS Statistical Package for the Social Sciences 
SSBR Single-strand break repair 
SSRI Selective serotonin reuptake inhibitor 
STR Striatum 
STRING Database of known and predicted protein-protein interactions 
SVP Sodium valproate 
TAC1 Tachykinin Precursor 1 
TATA Promoter region containing repeating T and A base pairs 
TBP TATA-box-binding protein 
TBS Tris-buffered saline 
TCTX Temporal cortex 
TDP1 Tyrosyl-DNA phosphodiesterase 1 
TEMED Tetramethylethylenediamine 
TFC Total functional capacity 
TLS Translesion synthesis 
TMS Total motor score 
TNF Tumor necrosis factor 
TRIS Tris(hydroxymethyl)aminomethane 
TWA Transcriptome-wide association 
TWAS Transcriptome-wide association study 
TX-100 Triton X-100 
UBZ Ubiquitin-binding zinc finger 
UCL University College London 
UCLH University College London Hospitals 
UCSC University of California Santa Cruz 
UHDRS Unified Huntington's Disease Rating Scale 
UK United Kingdom 
UTR Untranslated region 
UV Ultraviolet 
VC Visual cortex 
25 
VCF Variant Call Format 
VCP Valosin Containing Protein 
VM Ventral mesencephalon 
VRR Nuc Viral replication and repair nuclease domain 
WES Whole exome sequencing 
WGCNA Weighted gene correlation network analysis  
WGE Whole ganglionic eminence 
WPRE Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element 
WT Wild type 
XL X-linked inheritance 
XLD X-linked dominant inheritance 
XPF DNA repair endonuclease XPF 
  
26 
Chapter 1 Introduction 
1.1 DNA repeat expansion 
1.1.1 Repetitive DNA 
Over 65% of the human genome consists repetitive elements from microsatellites of a few base pairs up to arrays of 
whole genes, which have a range of functions, including the regulation of chromatin structure and transcription (Hall et 
al., 2017, Budworth and McMurray, 2013, Biscotti et al., 2015). Microsatellites are common, constituting around 2% of 
the genome, so it is not their presence itself that is pathogenic. 
1.1.2 Repeat expansion diseases 
For reasons which remain unclear, repeat expansion diseases often have a neurological phenotype (Madabhushi et al., 
2014, Neil et al., 2017). Huntington’s disease (HD), myotonic dystrophy type 1 (DM1), spinal and bulbar muscular atrophy 
(SBMA), dentatorubral-pallidoluysian atrophy (DRPLA) and several spinocerebellar ataxias (SCA 1,2,3,6,7,12 and 17) are 
caused by (CAG)n/(CTG)n repeats, Friedreich’s ataxia (FA) by (GAA)n, fragile X syndrome (FXS) by (CGG)m, myotonic 
dystrophy type 2 (DM2) by (CCTG)n, SCA10 by (ATTCT)n and C9orf72 by (GGGGCC)n (Neil et al., 2017). For the 
polyglutamine diseases, the pathogenic threshold is around 35-45 CAG repeats (Massey and Jones, 2018). Pathogenic 
repeat expansions can occur either outside or within the coding sequence, with non-coding expansions tending to be 
longer. Though mechanisms driving repeat expansion may be similar, the repeats occur in different genomic contexts 
and proteins which are functionally unrelated. It is likely that differences in protein function and expression profile 
produce the distinctive phenotype of each condition (Orr and Zoghbi, 2007). 
Trinucleotide repeat diseases are individually rare, but together represent a relatively common group of 
neurodegenerative diseases and a significant source of morbidity. Fragile X syndrome is caused by a CGG expansion in 
the FMR1 gene, and is the most common, affecting 1/4000 males and 1/8000 females. Myotonic dystrophy (DM1), caused 
by a CTG expansion in DMPK, affects around 1/8,000 and Huntington’s disease, caused by a CAG expansion in HTT, affects 
around 1/10,000. The spinocerebellar ataxias each have a prevalence of around 1/100,000 (McKusick, 2007). 
1.1.3 Repeat instability 
1.1.3.1 Somatic instability 
Pathogenic DNA repeats are inherently unstable and tend to expand throughout life in particular tissues, depending on 
the disease. The extent to which somatic expansion influences human disease course is not known, but it is seen in 
postmortem human HD brain neurons and correlates with earlier onset (Kennedy et al., 2003, Shelbourne et al., 2007b, 
Swami et al., 2009). Though somatic expansions in HD brain tissue may be large (Kennedy et al., 2003), the level of somatic 
mosaicism in peripheral tissues, such as blood, is low (Telenius et al., 1995, Leeflang et al., 1995). Despite this, using a 
single molecule PCR approach, length-dependent, expansion biased somatic mosaicism has previously been 
demonstrated in HD patient buccal cells (Veitch et al., 2007). In transgenic and knock-in mouse models there is expansion 
in postmitotic neurons of the brain, particularly the striatum which correlates with symptom onset (Mangiarini et al., 
1997) and may explain its selective vulnerability (Gonitel et al., 2008, Lee et al., 2011a). There is also expansion in the 
liver, but stability in the cerebellum, blood and tail. In DM1, large expansions occur in muscle, the tissue most prominently 
affected, which may cease after terminal differentiation (Thornton et al., 1994, Zatz et al., 1995), as well as in lymphocytes 
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throughout life (Martorell et al., 1995). In HD (Benitez et al., 1995) and SBMA (Jedele et al., 1998), instability is detectable 
only in adults, and not foetuses, whereas in fragile X syndrome it is seen only in foetal tissue and not postnatally (Reyniers 
et al., 1999, Devys et al., 1992, Taylor et al., 1999). Unlike other polyglutamine diseases, the SBMA CAG tract is stable in 
CNS and, like DM1, expands in muscle (Tanaka et al., 1999). The observation of repeat instability in postmitotic CNS 
neurons (Gonitel et al., 2008) and continued expansion when the cell cycle is arrested in transgenic mouse cells (Gomes-
Pereira et al., 2014b) suggests expansion, at least of this type of repeat, occurs during DNA repair or transcription, rather 
than replication.  
The tissue specificity of somatic instability and neuropathology often overlap, for example in HD, DM1 and FRDA (Goula 
et al., 2012). As discussed above, in HD the striatum shows the most prominent CAG expansion and degeneration, but 
both also occur in the cortex and are limited in the cerebellum (Wheeler et al., 1999, Goula et al., 2012, Shelbourne et 
al., 2007a). In DM1, the striatum has not been studied, but CTG expansion is greatest in muscle and also occurs in cortex, 
though is limited in cerebellum (Anvret et al., 1993, Wong et al., 1995, Ashizawa et al., 1993, Lopez Castel et al., 2011). 
In Friedreich’s ataxia (FRDA), the GAA repeat expands significantly in the cerebellum and dorsal root ganglia, two tissues 
conspicuously affected by the disease (De Biase et al., 2007, Clark et al., 2007b). However, the CAG expansion profile in 
SCA1 (Watase et al., 2003, Kraus-Perrotta and Lagalwar, 2016, Zuhlke et al., 1997, Lopes-Cendes et al., 1996), SCA3 (La 
Spada, 1997, Hashida et al., 1997) and DRPLA (Hashida et al., 2001, Watanabe et al., 2000, Aoki et al., 1996, Zuhlke et al., 
1997, Lopes-Cendes et al., 1996, Takano et al., 1996, Ueno et al., 1995) is similar to that of HD, with instability in basal 
ganglia and cortex, and stability in cerebellum, a prominently affected tissue (La Spada, 1997). Therefore, there is not 
always a clear correlation between somatic instability and tissue vulnerability. Brain region and cell type-specific 
instability may reflect the different developmental history of these regions, or tissue and cell specific factors such as DNA 
repair protein expression. 
Interruptions in the repeat sequence, which reduce the stability of hairpin structures, have been shown to restrict 
expansion in many trinucleotide repeat disorders, including the HD, SCAs 1-3 and 17, fragile X syndrome, Friedreich’s 
ataxia and DM1 (Massey and Jones, 2018), and delay onset in HD (Lee et al., 2019, Wright et al., 2019). CAG interruptions 
usually alter the third base of the codon and can reduce hairpin loop formation (Menon et al., 2013, Pearson et al., 1998, 
Sobczak and Krzyzosiak, 2004, Kraus-Perrotta and Lagalwar, 2016). 
1.1.3.2 Germline instability 
In all trinucleotide repeat disorders the repeat is also unstable in germ cells, causing the length to increase in successive 
generations (Jones et al., 2017). Most polyglutamine disorders have a paternal expansion bias (Pearson et al., 2005b), 
and there is significant CAG length mosaicism in HD patient sperm that correlates with expansion on transmission 
(Telenius et al., 1995). In transgenic mice, expansion occurs after meiosis, again implicating DNA repair or transcription 
rather than replication (Kovtun and McMurray, 2001). Expansions increase with increasing paternal age in several 
transgenic CAG/CTG mouse models (Pearson et al., 2005b). Contrastingly, there is a maternal expansion bias in fragile X 
syndrome and DM1, and there is a paternal contraction bias in SCA8, Friedreich’s ataxia and fragile X syndrome, which 
may be related to reduced methylation of repeats in testes (Pearson et al., 2005b). Unlike male germ cells, oogenic 
meiosis occurs in utero and then arrests for years until puberty, resuming minutes before ovulation and continuing until 
fertilisation (Pearson et al., 2005b). Therefore, the relationship between instability and cell division, transcription and 
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DNA repair is not straightforward, and it is likely that tissue-specific and cis or transacting factors act to modify expansion 
(Pearson et al., 2005b). 
1.1.3.3 Pathogenicity 
Though many unstable repeat regions have been linked to disease, the mechanisms by which their expansion above a 
threshold lead to disease remains unclear. In fragile X syndrome and Friedreich’s ataxia, repeat expansion results in 
silencing of expression (Colak et al., 2014). In myotonic dystrophy (DM1), the expansion causes the formation of RNA foci 
(Thornton, 2014). Repeat-associated non-ATG translation (RAN) was first identified in DM1 and SCA8 (Zu et al., 2011) and 
has also been found in other trinucleotide disorders including Huntington’s disease and fragile X syndrome (Banez-
Coronel et al., 2015, Cleary and Ranum, 2014). Toxicity of the resulting dipeptides has been demonstrated in C9ORF72 
associated frontotemporal dementia and amyotrophic lateral sclerosis, though their role in other repeat expansion 
diseases is unclear. In the CAG expansion diseases the repeat-containing protein aggregates as insoluble protein 
inclusions within cells, a feature that is also seen in other neurodegenerative diseases such as Alzheimer’s (Knowles et 
al., 2014). 
1.2 Huntington’s disease 
Huntington’s disease (HD), the most common monogenic neurodegenerative disorder in the developed world (Evans et 
al., 2013), is caused by a CAG repeat expansion in the HTT gene and is characterised by motor, cognitive and psychiatric 
features. It was named after George Huntington, who described the condition in 1872 (Huntington, 1872), but it was not 
until 1983 that the genetic locus was mapped (Gusella et al., 1983) and 1993 when the gene was discovered (Group, 
1993). Onset occurs around 45 years on average and inversely correlates with CAG repeat length (Langbehn et al., 2010). 
The disease progresses inexorably and, with the exception of late-onset cases, is uniformly fatal a median of 18 years 
from motor onset (Ross et al., 2014). HD is currently incurable and no treatments slow progression. 
1.2.1 Epidemiology 
In the UK, HD affects around 1 in every 7300 people (Bates et al., 2015c). Prevalence has progressively increased owing 
to increasing survival and the introduction of a genetic test that has allowed the diagnosis of de novo and late onset cases 
(Evans et al., 2013, Morrison, 2012). HD is found around the world, but at higher frequencies in populations of European 
descent (Bates et al., 2015c). In East Asian populations the prevalence is around 1-7 per million, potentially because mean 
CAG repeat length in the population is shorter. 
1.2.2 Aetiology 
HD is caused by a (CAG)n repeat expansion in exon 1 of the HTT gene on chromosome 4 (Group, 1993). Repeat lengths 
from 36 to 39 units have reduced penetrance, and those ≥40 are fully penetrant (Bates et al., 2015c). The mechanism 
underlying this length-dependent trigger remains unclear, as does the nature of the toxic species underlying its 
pathogenicity (Bates et al., 2015c). 
1.2.3 Pathogenesis 
HTT is expressed throughout the body, though at varying levels in different cell types. The protein is mostly cytoplasmic, 
but forms can be found in the nucleus and cytoplasm, and are able to shuttle between the two compartments (Bates et 
al., 2015c). It has many interacting partners, particularly at the N-terminus, suggesting it acts as a scaffold for complexes 
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of proteins (Ross and Tabrizi, 2011). Its normal function is still unclear, but it has roles in nervous system development 
and protein homeostasis.  
Expansion of the HTT CAG repeat results in neuronal dysfunction and death through numerous mechanisms. It undergoes 
extensive post-translational modification, with proteolytic fragmentation producing a toxic N-terminal fragment of 
around 100 amino acids that readily aggregates (Bates et al., 2015c). Aggregated inclusions rich in mutant HTT (mHTT) 
form in neuronal nuclei, but also elsewhere in the cell, including the cytoplasm, dendrites and axon terminals (Vonsattel, 
2008). However, several reports have suggested their density does not correlate with cell toxicity, leading to the idea 
they may be a protective cellular response to misfolded protein (Kim et al., 1999, Arrasate et al., 2004, DiFiglia et al., 
2007). Cells may be able to take up small fibrils of polyglutamine protein, which seed aggregates by recruiting endogenous 
protein in a prion-like mechanism of cell-to-cell transmission (Cicchetti et al., 2014, Pecho-Vrieseling et al., 2014). 
Expression of mHTT causes proteostasis to deteriorate, with chaperone levels decreasing, endoplasmic stress increasing 
and the proteasomal and autophagy systems becoming compromised (Bates et al., 2015c), limiting cells’ ability to 
respond to stress. Toxic forms of mutant huntingtin disrupt many fundamental cellular processes, including transcription 
(Seredenina and Luthi-Carter, 2012), mitochondrial function (Reddy and Shirendeb, 2012, Johri et al., 2013), synapses 
(Nithianantharajah and Hannan, 2013) and intracellular signalling (Labbadia and Morimoto, 2013), cellular transport 
(Reddy and Shirendeb, 2012) and secretion (Vidal et al., 2011), endocytic recycling (Kim et al., 1999), and the immune 
system (Ellrichmann et al., 2013). HTT RNA itself may have toxic properties, potentially involving antisense mechanisms 
or toxic repeat associated non-ATG (RAN) translation proteins (Banez-Coronel et al., 2015, Ross and Tabrizi, 2011, 
Cattaneo et al., 2005). The interaction of these disrupted pathways produces an extremely complex set of pathogenic 
mechanisms (Ross and Tabrizi, 2011, Bates et al., 2015c). 
Medium spiny neurons (MSN) of the striatum are selectively vulnerable. The cause is unclear, but D2 receptors may be a 
factor as they are expressed by indirect, but not direct pathway MSNs and they have been implicated in pathogenesis 
(Deyts et al., 2009). Other potential mechanisms include loss of brain derived neurotrophic factor (BDNF) support or 
glutamate excitotoxicity from cortico-striatal projections (Ross and Tabrizi, 2011). 
1.2.4 Pathology 
In early disease, the brain can look macroscopically normal, but as disease progresses there is prominent atrophy of the 
basal ganglia, particularly the caudate nucleus, as well as cortical atrophy with ventricular dilatation (Wood, 2012). 
Microscopically there is selective loss of MSNs in the striatum (Ferrante et al., 1985) and microglial activation (Sapp et 
al., 2001). The Vonsattel grade provides a histopathological classification in symptomatic patients ranging from 0, with 
no gross or microscopic abnormalities, to 4, in which there is extreme atrophy (Vonsattel et al., 1985). 
HD research has traditionally focused on the brain due to the presence of characteristic mutant huntingtin protein 
aggregates (Bates et al., 2015c) and because the prominent symptoms and signs can be linked to neurodegeneration in 
the basal ganglia and cerebral cortex (van der Burg et al., 2009). However, mutant HTT is ubiquitously expressed (Trottier 
et al., 1995) and mounting evidence suggests it has direct effects in peripheral tissues (van der Burg et al., 2009, Carroll 
et al., 2015). HD patients demonstrate peripheral immune dysfunction presymptomatically (Tai et al., 2007a, Bjorkqvist 
et al., 2008, Kwan et al., 2012c, Träger et al., 2015), as well as weight loss that leads to cachexia with advancing disease 
(Carroll et al., 2015). There is progressive muscle wasting (Busse et al., 2008), endocrine dysfunction (Saleh et al., 2009), 
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liver impairment (Carroll et al., 2015) and cardiac dysfunction (Lanska et al., 1988, Mihm et al., 2007, Pattison et al., 
2008). Mutant HTT protein aggregates can be found in the peripheral tissues of HD mice (Orth et al., 2003), as well as 
advanced patients (Turner et al., 2007). These peripheral features may contribute to central nervous system (CNS) 
pathology, disease progression and mortality (Carroll et al., 2015, van der Burg et al., 2009), and strongly suggest that HD 
is a systemic disorder. It is unclear whether peripheral effects are distinct, or parallel those in the brain. Mechanisms of 
dysfunction include transcriptional dysregulation, disordered protein folding, deficient protein degradation and 
inflammatory activation (Bates et al., 2014, Bates et al., 2015c). 
1.2.5 Clinical features 
After an asymptomatic premanifest period, a prodromal phase with subtle motor, cognitive and psychiatric features often 
precedes formal diagnosis of motor onset by up to 15 years (Bates et al., 2015c). Motor onset occurs at around 45 years 
on average (Langbehn et al., 2010) and is followed by inexorable progression (Ross et al., 2014). Onset is often difficult 
to clearly discern, and many have early psychiatric and cognitive symptoms. Definitive diagnosis is made when there are 
unequivocal motor signs. 
1.2.5.1 Motor 
Motor manifestations often begin with subtle restlessness, fidgeting and fine involuntary movements, and progress to 
chorea. Eye movements are an early sign, with delayed and slow saccades and impaired pursuit with saccadic intrusions 
(Wood, 2012). There are also varying degrees of dystonia, parkinsonism and bradykinesia, but impairment of voluntary 
motor function is often more functionally disabling. Impaired walking and postural reflexes lead to falls. Dysarthria causes 
communication problems, with much frustration for patients and carers, and as the disease progresses patients often 
become mute. Dysphagia is common, and choking is often reported early. Initially it can be the result of impulsive and 
disordered eating, but later there is mechanical discoordination. 
1.2.5.2 Cognition 
Cognitive and psychiatric features are usually the most disabling. Cognitive impairment is universal, though it affects 
specific functions so the term ‘dementia’ tends not to be used. There is limited impact on language and spatial skills, but 
prominent involvement of executive function, with impaired planning, judgement and multi-tasking. There tends to be 
psychomotor slowing, and apathy and a lack of initiative can make caring challenging. Patients themselves often complain 
of poor concentration and attention. With progression, patients are less able to care for themselves, though often lack 
insight (Wood, 2012). 
1.2.5.3 Psychiatric 
Depression and anxiety are common (Craufurd and Snowden, 2002) and suicide rates are higher than in the general 
population (Farrer, 1986). Irritability is a common feature, and some can be aggressive. Obsessions and compulsions can 
develop. Psychosis is rare. 
1.2.5.4 Systemic features 
Patients often lose weight. The cause is thought to be multifactorial, including poor intake, dysphagia and increased 
energy expenditure due to involuntary movements. However, HTT is expressed ubiquitously (Trottier et al., 1995) and 
the peripheral phenotype is well established (van der Burg et al., 2009, Carroll et al., 2015, Tai et al., 2007a, Bjorkqvist et 
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al., 2008, Kwan et al., 2012c, Träger et al., 2015, Busse et al., 2008, Saleh et al., 2009, Lanska et al., 1988, Mihm et al., 
2007, Pattison et al., 2008, Orth et al., 2003, Turner et al., 2007). Higher premorbid BMI is associated with slower 
progression, so patients are encouraged to maintain their weight (Myers et al., 1991). Patients often have a disturbed 
sleep-wake cycle due to disruption of circadian rhythm (Morton, 2013). 
1.2.5.5 Juvenile-onset HD 
This is defined as onset before 20 years and is usually associated with over 60 CAG repeats (Fusilli et al., 2018). The 
disease is more severe and carries a shorter life expectancy. Patients tend to have a more akinetic-rigid form with minimal 
chorea but increased dystonia, as well as seizures. 
1.2.6 Diagnosis 
Genetic testing is definitive, whereas imaging, blood and cerebrospinal fluid analysis are not particularly useful in 
diagnosis. MRI may show caudate and cortical atrophy early in disease (Wood, 2012, McColgan et al., 2015, Gregory et 
al., 2018, Tabrizi et al., 2011b). 
Around 1% of those presenting with HD signs test negative for the HTT expansion (Andrew et al., 1994a). The differential 
diagnosis of autosomal dominant HD phenocopies is broad and is summarised in the tables below. Ultimately, a genetic 
diagnosis is found in only 3% of this subpopulation, the commonest being C9orf72 in 1.9-5% (Beck et al., 2013). 
Gene (mutation) Disease Inheritance Pointers Frequency 
C9orf72 (GGGGCC repeat) ALS/FTD AD   1.9-5% 
JPH3 (CTG/CAG repeat) HDL-2 AD African or Middle Eastern 1.3-4.5% 
VPS13A (chorein) Choreoacanthocytosis AR Acanthocytes, orofacial dyskinesia with tongue protrusion, lip biting 0.4-3% 
Mutations in mitochondrial DNA and nuclear 
DNA encoding mitochondrial proteins Mitochondrial disease - 
Myoclonus, dementia, muscle biopsy 
(ragged red fibres) 1.9% 
TBP (CAG/CAA repeat) SCA17 AD   0.5-1.8% 
FXN (GAA repeat) Friedreich’s ataxia AR Ataxia 0.4-1% 
CACNA1A SCA6, Episodic ataxia 2 AD   0.9% 
UBQLN2 ALS/FTD XLD   0.4% 
VCP ALS/FTD AD   0.4% 
PRNP (octapeptide rpt) HDL-1 AD   0.4% 
Table 1.1 Genetic HD phenocopies. 
AD – autosomal dominant, AR – autosomal recessive, ATN1 – atrophin 1, DRPLA – Dentatorubral-pallidoluysian atrophy, FTL – ferritin 
light chain, HDL-1/2 – Huntington’s disease like syndrome 1/2, JPH3 – Junctophilin 3, PRNP – prion protein, SCA – spinocerebellar 
ataxia, TBP – TATA box-binding protein, (Mariani et al., 2016, Wild et al., 2008, Wild and Tabrizi, 2007a, Wild and Tabrizi, 2007b). 
Group Disease Frequency 
Metabolic B12 deficiency 0.4% 
Immune Systemic lupus erythematosus (SLE), antiphospholipid syndrome  
Vascular Basal ganglia stroke  
Infection AIDS-related  
Post-infectious Sydenham’s chorea, PANDAS (paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection) 
 
Drugs Dopamine antagonists (neuroleptics, antiemetics), antiepileptics (phenytoin, carbamazepine, sodium valproate, gabapentin), benzodiazepines, oral contraceptive pill 
 
Cancer Paraneoplastic, basal ganglia metastases  
Table 1.2. Acquired HD phenocopies. 
(Mariani et al., 2016, Wild et al., 2008, Wild and Tabrizi, 2007a, Wild and Tabrizi, 2007b). 
1.2.7 Therapy 
Though many therapeutic targets have been identified, none have yet delivered treatments capable of modifying disease 
course in humans (Bates et al., 2015a, Hughes, 2014). However, many of symptoms are eminently treatable. 
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1.2.7.1 Motor 
Chorea is rarely the most disabling feature and many patients are unaware of its severity. If functionally restrictive, 
antichoreic medication is used sparingly as none are particularly effective and all can cause side effects. Sulpiride, 
olanzapine, risperidone and tetrabenazine are options, though the latter in particular carries a risk of depression. Later 
in the disease, chorea lessens and patients become more rigid and dystonic, at which point antispasticity drugs such as 
baclofen and clonazepam can be useful. Physiotherapy and walking aids can assist impaired voluntary movement and 
gait. Early referral to speech and language therapists is useful as exercises and communication aids can help dysarthria, 
and manoeuvres and modified diets can minimise aspiration from dysphagia. Levodopa may benefit juvenile-onset 
patients who have prominent parkinsonism (Wood, 2012). 
1.2.7.2 Psychiatric 
Current practice is largely anecdotal. Depression can be effectively treated with selective serotonin reuptake inhibitors 
(SSRI) such as citalopram and mirtazapine or cognitive behavioural therapy. Severe anxiety, aggression and impulsive 
behaviour may respond to newer antipsychotics, including risperidone, olanzapine and quetiapine. 
1.2.7.3 Cognition 
Patients are less able to care for themselves as the disease progresses, but a common problem is their lack of insight. 
Formal psychological, occupational and physical therapy assessment can advise on care. 
1.2.7.4 Palliative care 
Important issues around percutaneous feeding tubes, treatment of recurrent infections and end of life should be 
discussed early to allow patients to make informed decisions. 
1.2.7.5 Future treatments 
There are several potential therapeutic developments on the horizon. Reducing HTT expression involves nucleotide based 
suppression using RNA interference (RNAi) and antisense oligonucleotides (ASO), or transcriptional repression using zinc 
finger proteins (Wild and Tabrizi, 2014). The first medication trialled, IONIS-HTTRx, non-selectively suppresses both wild 
type and mutant HTT and is infused directly into the cerebrospinal fluid. I am currently a sub-investigator on the phase 
1b/2a clinical trial in patients with early manifest Huntington's disease (Trials, 2016). 
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Figure 1.1. Potential future therapeutic targets in Huntington's disease. 
The key on the right groups them by target. Adapted from Wild and Tabrizi (2014). 
Protein homeostasis targets include kinase inhibitors that modulate HTT phosphorylation (Atwal et al., 2011) and 
chaperone enhancers to reduce aggregate formation (Labbadia et al., 2012, Sontag et al., 2013). Autophagy enhancing 
strategies include mTOR inhibition (Renna et al., 2010) and the promotion of mHTT acetylation (Smith et al., 2014, 
Reilmann et al., 2014). Histone deacetylase inhibitors that regulate chromatin modification are targeting transcriptional 
dysregulation (Mielcarek et al., 2013). At the synapse, phosphodiesterase inhibitors aim to improve impaired cAMP 
signalling (Trials, 2015, Beconi et al., 2012) and MAPK signalling inhibitors have been found to be neuroprotective (Taylor 
et al., 2013, Apostol et al., 2008). BDNF replacement and agonism are being used to address the reduction found in HD 
brain (Jiang et al., 2013, Conforti et al., 2013, Todd et al., 2014, Simmons et al., 2013). Central and peripheral immune 
hyperactivity are being targeted with kynurenine 3-monooxygenase (KMO) inhibitors (Zwilling et al., 2011), laquinimod 
(Comi  et al., 2012), cannabinoid receptor agonists (Bouchard et al., 2012c) and excitatory amino-acid transporter 2 
(EAAT2) activators (Miller et al., 2008). Trials of antioxidants have so far been ineffective (Mrzljak and Munoz-Sanjuan, 
2015), but cellular metabolism is disrupted and modulation of PGC1α has ameliorated mouse models (Jin et al., 2013). 
Cell replacement has had promising results, but technical and ethical concerns limit its use (Kumar et al., 2016). 
1.2.8 Genetic modifiers of Huntington’s disease 
Motor onset correlates inversely with CAG repeat length, but is still highly variable and can differ by several decades in 
patients with the same repeat length, as measured in blood (Gusella et al., 2014, Keum et al., 2016). Age at cognitive and 
psychiatric onset (Keum et al., 2016), as well as age at death (Lanska et al., 1988), also correlate with CAG length, though 
to a lesser extent (Keum et al., 2016). 
The length of the repeat is the main influence on disease course, accounting for around 60% of variation in motor onset 
(Gusella et al., 2014), but up to 40% of the remaining variation is heritable and due to genetic differences elsewhere in 
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the genome (Wexler et al., 2004a). Interventions harnessing these mechanisms have the tantalising potential to influence 
disease course. 
 
Figure 1.2. Relationship between expanded CAG repeat length (x axis) and onset of diagnostic motor signs (y axis). 
Each open circle represents a single HD subject. The red line represents the best fit regression model. Reproduced from GeM-HD 
(2015). 
1.2.8.1 Candidate gene studies 
Numerous potential modifiers have been proposed (Djousse et al., 2003, Aziz et al., 2009, Lee et al., 2012d, Lee et al., 
2012a, Gusella et al., 2014, Rubinsztein et al., 1997, MacDonald et al., 1999, Cannella et al., 2004, Chattopadhyay et al., 
2003, Naze et al., 2002, Zeng et al., 2006, Lee et al., 2012c, Bates et al., 2014, Alberch et al., 2005, Taherzadeh-Fard et al., 
2009, Djousse et al., 2004, Li et al., 2006, Gayan et al., 2008). The length of the shorter HTT allele was thought to have an 
effect (Djousse et al., 2003, Aziz et al., 2009), but detailed statistical analysis found the longer allele was fully dominant 
(Lee et al., 2012d). Sequence variation in HTT can be used to define haplotypes, but none were found to significantly 
modify disease course (Lee et al., 2012a, Gusella et al., 2014). Notable studies of modifiers are listed in the table below, 
but none withstood statistical analysis. Rubinsztein et al. (1997) reported a TAA repeat polymorphism in the 3’ 
untranslated region of GRIK2 and this was supported by several subsequent studies (MacDonald et al., 1999, Cannella et 
al., 2004, Chattopadhyay et al., 2003, Naze et al., 2002, Zeng et al., 2006), but a larger study by Lee et al. (2012c) found 
no modifier effect. The p.V66M polymorphism in BDNF, a protein known to be functionally relevant in HD, was reported 
to modify age at onset (AAO) (Alberch et al., 2005), but others have consistently failed to replicate the result (Arning and 
Epplen, 2013). Taherzadeh-Fard et al. (2009) reported that rs7665116 in PPARGC1A, a key regulator of energy 
metabolism, modified AAO, but this single nucleotide polymorphism (SNP) was later shown to tag Southern European 
ancestry and patients from these regions are known to have significantly different AAO (Gusella et al., 2014). 
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Study type Proposed genetic modifier Function 
HTT variants 
Shorter CAG repeat (Djousse et al., 2004), CCG 
repeat, polymorphisms (Norremolle et al., 2009, 
Becanovic et al., 2015) 
 
Candidate gene studies 
GRIK2 (Lee et al., 2012b, Rubinsztein et al., 1997) Glutamate receptor subunit 
UCHL1 (Naze et al., 2002) Proteasome pathway 
BDNF p.V66M (Alberch et al., 2005) Neurotrophic factor 
HAP1 p.M441 (Metzger et al., 2008) Interacts with HTT, intracellular trafficking 
PPARGC1A (Taherzadeh-Fard et al., 2009) PGC-1a, regulator of mitochondrial energy metabolism 
ADORA2A c.C1976T (Dhaenens et al., 2009) Adenosine receptor 
ATG7 p.V471A (Metzger et al., 2010) Autophagy 
Linkage studies 
4p16 (Djousse et al., 2004)  
6q23-24, 18q22 (Li et al., 2006)  
2p25, 2q35, 6q22 (Gayan et al., 2008)  
Linkage studies in mice Mlh1 (Pinto et al., 2013a) DNA repair 
Table 1.3. Notable studies proposing genetic modifiers of Huntington’s disease. 
1.2.8.2 Linkage studies 
Linkage studies in sib-pairs and extended families identified potential modifier loci, though specific genes were not 
identified (Djousse et al., 2004, Li et al., 2006, Gayan et al., 2008). Linkage studies in the Hdh(Q111) knock in mouse model 
suggested MMR gene Mlh1 as a modifier (Pinto et al., 2013a). 
1.2.8.3 Genome-wide association studies 
The most recent approach to identifying genetic modifiers uses an unbiased genome-wide search. This strategy does not 
presuppose a pathogenic hypothesis, so findings are data driven. Through the great effort of the HD research community 
over the last two decades there are now large natural history studies and registries of patients available, along with their 
DNA samples, permitting the application of this strategy to large populations of HD patients. These include PHAROS 
(PHAROS, 2006), Predict-HD (Paulsen et al., 2006, Paulsen et al., 2008), TRACK-HD (Tabrizi et al., 2009a), EHDN REGISTRY 
(Orth et al., 2010, Orth et al., 2011) and COHORT (Dorsey, 2012). Importantly, HD populations may need many fewer 
subjects than traditional risk studies in order to show associated variation, because in the absence of mutant HTT these 
variants may not produce a selectable phenotype (Gusella et al., 2014). This means genetic modifiers may exist at 
relatively high frequency because they are not selected against in the general population. 
The Genetic Modifiers of Huntington’s Disease Consortium (GeM-HD) genome-wide association study (GWAS) of ~6000 
HD subjects of European descent identified two loci that influence age of motor onset (GeM-HD, 2015). The experience 
of the genetics community has emphasised the need for rigorous correction of significance thresholds due to genome-
wide testing, meaning a p value of 5x10-8 is often the criteria for significant association (Sveinbjornsson et al., 2016). At 
the chromosome 15 locus there were two independent signals; the minor allele at rs146353869 was associated with 6.1 
year earlier onset (p = 4.3x10-20) and at rs2140734 with 1.4 year later onset (p = 7.1x10-14). The second locus was on 
chromosome 8 and was associated with 1.6 year earlier onset (p = 2.7x10-8). The signals replicated in an independent 
cohort of 3319 European cases. rs35811129, the most significant variant in meta-analysis (p = 1.55x10-22) indexes 
rs2140734. The meta-analysis also identified a genome-wide significant signal on chromosome 3 driven by rs116483964 
(p = 8.84x10-9) and rs1799977 (p = 1.19x10-8). 
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Figure 1.3. Manhattan plot of meta-analysis from GeM GWAS of HD motor onset. 
Genome-wide significant peaks are seen on chromosome 15 and 8, and near-significant on chromosome 3. Reproduced from GeM-HD 
(2015). 
The chromosome 15 signals were in or near FANCD2/FANCI-Associated Nuclease 1 (FAN1), a DNA endo/exonuclease 
involved in DNA repair. FAN1 is highly expressed in the brain (GTEx, 2015) and the minor allele at rs2140734 is significantly 
associated with reduced expression in liver (p = 5.2 x 10-7), a tissue that also demonstrates somatic instability (Wheeler, 
1999, Mangiarini et al., 1997). At the chromosome 8 locus, the two main candidates are RRM2B and UBR5. RRM2B is an 
enzyme involved in dNTP synthesis (Pontarin et al., 2011), which is important during DNA replication and repair (Pontarin 
et al., 2012), as well as regulating mitochondrial DNA content (Bourdon et al., 2007) and suppressing the oxidative stress 
pathway (Kuo et al., 2012). UBR5 is a ubiquitin ligase that tags proteins for proteasomal degradation, and has been 
investigated for its role in polyglutamine protein aggregation (Ortega and Lucas, 2014). The chromosome 3 signal is likely 
underlain by MLH1 or LRRFIP2. MLH1 which is known to modify somatic instability in HD mice (Pinto et al., 2013a) and 
directly interacts with FAN1, lending further support to the chromosome 15 peak. Dominant loss of function mutations 
in MLH1 are associated with hereditary bowel cancer, in which tumours display instability of dinucleotide repeats (Pal et 
al., 2008). LRRFIP2 is involved in protein-protein interactions that regulate Wnt-signalling (Liu et al., 2005). 
DNA repair pathways were also associated with motor onset in the GeM gene set enrichment analysis (GSEA). The most 
significant repair pathway, GO:33683 nucleotide-excision repair, DNA incision (p = 1.69x10-6), contains FAN1. It also 
remained significant when FAN1 was excluded, thereby implicating the wider suite of DNA repair proteins in HD 
pathogenesis. 
Lee et al. (2017) extended the GeM-HD GWAS by genotyping a further 3,314 subjects, confirming the chromosome 15 
and 8 signals, and raising the chromosome 3 locus to genome-wide significance, suggesting MLH1 variation may delay 
onset by reducing expression. Bettencourt et al. (2016) showed that variants in DNA repair genes from the GeM-HD 
GWAS, including FAN1 and RRM2B, also influenced onset in the other polyglutamine diseases, suggesting a common 
mechanism operates in diseases caused by CAG repeat expansion (see Chapter 3). 
Hensman Moss et al. (2017b) derived a novel progression score based on principal component analysis of longitudinal 
motor, cognitive and imaging measures in 218 HD subjects from Track-HD. They conducted a GWAS in the Track-HD (n = 
216) and Registry (n = 1773) cohorts, identifying a chromosome 5 locus that slowed disease progression. The signal spans 
three genes; MSH3, DHFR and MTRNR2L2. rs557874766, the lead SNP in TRACK-HD, which was imputed, was genome-
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wide significant in the meta-analysis (p=1.58E-08) and encodes the amino acid change p.P67A in MSH3 (see Chapter 8). 
Colocalisation analyses with GTEx data suggested the SNPs driving this signal were eQTLs for both MSH3 and DHFR, 
reducing expression in brain and peripheral tissues. They conclude that the modifier effect could be due to functional or 
expression change in MSH3, DHFR or both. It is notable that MSH3 promotes somatic expansion in animal models of HD 
(Tome et al., 2013a, Dragileva et al., 2009, Williams and Surtees, 2015), DM1 (Nakatani et al., 2015b, Stevens et al., 2013, 
Du et al., 2013b, Seriola et al., 2011b, Nakatani et al., 2015c, Williams and Surtees, 2015, Kantartzis et al., 2012, Dragileva 
et al., 2009, Tome et al., 2013a, van den Broek et al., 2002, Foiry et al., 2006) and Friedreich’s ataxia (Bourn et al., 2012, 
Zhao et al., 2015b, Ezzatizadeh et al., 2012), as well as in DM1 patients (Morales et al., 2016), whereas DHFR does not. 
The study also identified the chromosome 15 signal at FAN1 and MTMR10, and the chromosome 3 signal at MLH1, which 
were just below the threshold of genome-wide significance. Their pathway analysis highlighted DNA repair, particularly 
mismatch repair. 
Genetic modifiers remain a priority in order to improve our understanding of pathogenesis, to enable clinical trials that 
stratify patients accounting for natural genetic variability, and to provide novel therapeutic targets. Though the natural 
modifying effect of a variant may be small, pharmacological manipulation of the pathway could result in a stronger effect. 
1.3 DNA repair 
1.3.1 The DNA damage response 
DNA is continually damaged, for example by UV sunlight, ionising radiation, chemical mutagens and, importantly in the 
central nervous system, by endogenous metabolic processes producing reactive oxygen species, all of which could result 
in cancer or cell death if unrepaired. The DNA damage response (DDR) is a series of overlapping signalling pathways that 
sense and set repair in motion. Mispaired bases are replaced with correct ones by mismatch repair (MMR), chemically 
altered bases are excised and replaced by base excision repair (BER), and more complex lesions like pyrimidine dimers 
are corrected by the removal of an oligonucleotide through nucleotide excision repair (NER) which is versatile because it 
senses structural distortions in DNA rather than specific base modifications. Covalent links between bases on different 
DNA strands are repaired by interstrand crosslink (ICL) repair, breaks in one DNA strand are repaired by single-strand 
break repair (SSBR), and double-strand breaks (DSB) are processed by either homologous recombination (HR), which 
during DNA replication uses the sister chromatid as a template, is precise and occurs in mitotic neural progenitor cells, 
or nonhomologous end joining (NHEJ), in which broken DNA ends are directly ligated, is error-prone and predominates 
in post-mitotic neurons (Ciccia and Elledge, 2010). Sensor proteins recognise specific DNA lesions, then the signal is 
amplified by phosphorylation of phosphatidylinositol 3-kinase-like protein kinases (PIKKs) such as ATM, ATR and DNA-PK, 
or poly(ADP-ribose) polymerases (PARPs) to recruit effector proteins through a cascade of various posttranslational 
modifications. Interestingly, even in the absence of DNA damage, tethering of sensor proteins to chromatin or 
compaction of chromatin itself are sufficient to activate the DDR (Ciccia and Elledge, 2010, Burgess et al., 2014). 
1.3.1.1 Mismatch repair 
1.3.1.1.1 Function 
During DNA replication, at microsatellites the template and daughter strands can dissociate and reanneal incorrectly, 
causing the number of repeat units on each strand to differ, with the unpaired nucleotide partially extrahelical in what is 
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known as an insertion-deletion loop (IDL). Together with base mismatches, which are caused by DNA polymerase errors 
that escape proofreading, these are repaired by the mismatch repair (MMR) system, which degrades the erroneous 
strand, allowing DNA polymerase to resynthesise an error free copy of the template. In the absence of MMR, IDLs and 
mismatches go uncorrected, leading to microsatellite instability (MSI) and eventually cancer (Jiricny, 2006). 
1.3.1.1.2 Bacterial mismatch repair 
Mismatch repair (MMR) proteins were named ‘Mut’ because inactivation in E. coli resulted in hypermutable strains. In E. 
coli the mismatch is recognised by MutS, which then forms a complex with MutL and MutH. The MutH endonuclease 
cleaves the newly synthesised unmethylated strand. MutL and MutS then act with an exonuclease and helicase to excise 
the DNA between the break and the mismatch, and the resulting gap is filled by DNA polymerase and ligase (Cooper, 
2000). 
1.3.1.1.3 Eukaryotic mismatch repair 
Eukaryotes, including humans, have a similar MMR system. Mammalian cells recognise the newly synthesised strand by 
the presence of single strand breaks (SSB) or insertion-deletion loops (IDL). Humans have two MutS homologues, MutSα 
(MSH2/MSH6) which targets a base mispair or 1-2 unpaired bases, and MutSβ (MSH2/MSH3) which targets small 
insertion-deletion loops (IDL) of 1-15 nucleotides, as well as DNA with a 3´ single-stranded overhang (Pearl et al., 2015, 
Iyer et al., 2015, Gupta et al., 2011b). ATP binding induces a conformational change which allows MutS to move along 
the DNA as a sliding clamp (Gradia et al., 1997). Three MutL homologues perform the function of prokaryotic MutL and 
MutH, cleaving the DNA of the lesioned strand, namely MutLα (MLH1/PMS2), MutLβ (MLH1/PMS1) and MutLγ 
(MLH1/MLH3). MutLα is the most active and endonucleolytically cleaves the lesioned strand near the mismatch in a 
PCNA, RFC and ATP-dependent process (Muro et al., 2015, Xiao et al., 2014). The MutS-MutL complex recruits PCNA and 
the endonuclease EXO1 to excise the cleaved strand, which is then resynthesised by DNA polymerase δ (POLD) and the 
repair process is completed by DNA ligase 1 (LIG1) (Muro et al., 2015). 
1.3.1.1.4 Disease 
Inactivation of MutS and L homologues by mutation or reduced expression of MutLa by promoter hypermethylation 
result in hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome), a relatively common inherited cancer 
syndrome (OMIM, 2015) causing tumours of colorectal, endometrial, ovarian, stomach, small bowel, hepatobiliary, 
urinary tract and skin tissue. Around 70-90% of cases are caused by mutations in MLH1 and MSH2, with MSH6 and PMS2 
mutations accounting for the remainder (Muro et al., 2015). MutSβ causes repeat instability, but evidence for MutSα is 
less consistent (Iyer et al., 2015). The phenotype of Msh6-/- mice is less severe compared to Msh2-/- animals because 
MutSβ can deal with most IDLs (de Wind et al., 1999). MSH3 mutation itself has not been linked to cancer in humans, but 
loss of MSH3 in tumour cells is correlated with increased microsatellite instability (Haugen et al., 2008), Msh3 knockout 
mice develop cancers only late in life, and Msh3/Msh6 double knockout increases cancer susceptibility more than single 
knockout of either gene (de Wind et al., 1999, Edelmann et al., 2000). Msh3-/- animals are not tumour prone, most likely 
because MutSα can initiate repair of most replication errors (Edelmann et al., 2000, Jiricny, 2006). 
1.3.1.1.5 Mismatch repair assays 
MMR deficient cells are resistant to methylating agents that generate O6-methylguanine (MeG), which pairs with C or T 
during replication. These mispairs are recognised by MMR machinery, but as the modified base is on the template strand, 
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MMR removes the normal base and the repair polymerase regenerates the mispair, repeatedly triggering MMR until the 
replication fork arrests. MMR-deficient cells do not attempt to process these mispairs, so survive at the cost of extensive 
mutagenesis (Jiricny, 2006). MMR-deficient cells are also tolerant to 6-thioguanine (6-TG), which is incorporated into 
DNA, methylated to 6-methythioguanine (6-MeTG), and acts in a similar way to MeG, being recognised predominantly by 
MutSα. Interestingly, MMR-deficient cells may also be more sensitive to ICL-induced cell death, suggesting functional 
interplay between these two repair pathways (Jiricny, 2006, Fiumicino et al., 2000). 
1.3.1.2 Base excision repair 
Bases damaged by oxidation, deamination or alkylation can cause mispairing and mutation. They are recognised and 
removed by DNA glycosylases, such as OGG1 which identifies 8-oxoguanine, forming apurinic/apyrimidinic (AP) sites. 
These are then cleaved by an AP endonuclease, resulting in a single-strand break that is processed by either short-patch 
repair, to replace a single nucleotide, or long-patch repair, to synthesise up to 10 nucleotides. Ogg1 deficient HD mice 
show reduced somatic expansion and delayed symptom onset, and treatment with a reactive oxygen species scavenger 
improves motor phenotype (Budworth et al., 2015). Fen1, which removes the 5’ flap generated during long patch BER, 
may also be involved in the generation of repeat expansions (Liu and Wilson, 2012). 
1.3.1.3 Interstrand crosslink repair 
ICLs are extremely toxic because they block progression of replication and transcription machinery, resulting in 
replication fork collapse, double strand breaks and chromosomal destabilisation (Noll et al., 2006, McCabe et al., 2009). 
Three models of ICL repair have been proposed (Raschle et al., 2008, Wang, 2007, Huang et al., 2013).  
1. In replication-coupled ICL repair, which involves the FA pathway, replication forks collide, either on one or both 
sides of an ICL. The FANCM-FAAP24-MHF complex recognises the stall and recruits the FA core complex of 8 
proteins (FANCA, B, C, E, F, G, L, and M). FANCM activates the ATR kinase, which phosphorylates the FA core 
complex and ID2 complex (FANCD2-FANCI). The FA core ubiquitinates the ID2 complex, which recruits structure-
specific nucleases, most likely SLX1, SLX4, XPF and ERCC1, to make single strand incisions either side to unhook 
the crosslink. Translesion synthesis (TLS) DNA polymerases can then bypass the lesion and the replication fork 
is restored by strand invasion and homologous recombination (Jin and Cho, 2017, Kee and D'Andrea, 2010, Kim 
and D'Andrea, 2012, Zhang and Walter, 2014, Huang and D'Andrea, 2010). The cross link is then removed by 
nucleotide excision repair (NER). 
2. In repair-independent replication, replication forks bypass the ICL without repair. The stalled fork is recognised 
by the FANCM/MHF complex translocase, which moves it past the lesion (Meetei et al., 2005, Huang et al., 2013). 
3. In the FA-independent pathway, the DNA glycosylase NEIL3 cleaves the N-glycosidic bond between bases and 
the sugar-phosphate backbone, allowing unhooking, then gap filling by TLS polymerases. This avoids double 
strand breaks, minimising the chance of chromosomal rearrangements (Rolseth et al., 2013, Wang et al., 2016). 
Fanconi anaemia is caused by a mutation in one of the 17 known FANC genes, leading to failure of ICL repair (Ceccaldi et 
al., 2016a). Cells are susceptible to ICL-inducing agents and most patients develop cancer, commonly acute myeloid 
leukaemia, as well as bone marrow failure, congenital defects, skin pigmentation and endocrine abnormalities. 
Inheritance is usually autosomal recessive. Treatment with androgens and haematopoietic growth factors can transiently 
help bone marrow failure, though long-term treatment involves bone marrow transplantation. 
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The role of the FA pathway in repeat instability has not yet been explored, though recently FAN1 was shown to protect 
against expansion in a fragile X mouse model (Zhao and Usdin, 2018). 
1.3.2 DNA repair and neurodegenerative disease 
1.3.2.1 Susceptibility of nervous system tissue to DNA damage 
DNA repair defects have long been linked to cancer syndromes, but many, for example those caused by mutations in 
components of NER like xeroderma pigmentosum, double strand break repair (DSBR) such as ataxia telangiectasia, or 
SSBR like ataxia with oculomotor apraxia-1 (AOA1), display neurodegeneration, including microcephaly, cognitive 
impairment, deafness, ataxia and neuropathy. This suggests the nervous system is especially sensitive to DNA damage, 
though the reason for selective vulnerability of postmitotic neurons remains unclear. 
1.3.2.2 Oxidative stress 
The nervous system is highly dependent on oxidative metabolism, which generates free radicals that can cause DNA 
strand breaks (McKinnon, 2009) and can promote repeat expansion (Kovtun et al., 2007, McMurray, 2008). The brain 
metabolises around 20% of consumed oxygen, but has a lower capacity than other tissues to neutralise reactive oxygen 
species and neurons are particularly vulnerable to oxidative stress (McKinnon, 2009, Canugovi et al., 2013). Increased 
levels of DNA damage such as strand breaks and oxidative lesions have been reported in human Alzheimer’s, Parkinson’s 
and amyotrophic lateral sclerosis (ALS) brain, and lower levels of DDR proteins are seen in AD, though it is unclear whether 
these are the cause or consequence of the primary neurodegenerative process. Oxidative lesions are primarily repaired 
by BER, and levels of glycosylases UDG1 and bOGG1, which recognise oxidised bases, are reduced in human AD brain 
(Canugovi et al., 2013). Genomic instability progressively increases with age due to decreasing DNA repair activity, the 
accumulation of irreversible mutations through erroneous repair of DNA lesions, and the failure of chromatin to return 
to its predamaged conformation, all of which could contribute to age-related neurodegeneration (Madabhushi et al., 
2014). 
1.3.2.3 Double strand breaks 
The role of DNA damage in the nervous system has long been studied in ataxia telangiectasia (AT), which is caused by 
mutations in ATM, a serine/threonine kinase recruited to double strand breaks (DSB) to coordinate repair. Compared to 
other lesions, DSBs are rare events, but they are extremely damaging because they can cause large chromosomal 
rearrangements leading to cell death or tumorigenesis (Jackson, 2002). AT is a multisystem disease with radiosensitivity, 
immunodeficiency and cancer, but it also causes cerebellar degeneration. The rare A-T like disease (ATLD) is a very similar 
syndrome caused by mutations in MRE11, which is involved in DSB repair. The similarities suggest defective DSB repair 
causes neurodegeneration, though the reason for selective vulnerability remains unclear (Madabhushi et al., 2014). DSBs 
are produced in neurons during normal physiological activity, though it is unclear whether these serve a purpose in 
learning new tasks or are the result of neuronal activity (Suberbielle et al., 2013). 
1.3.2.4 Single strand breaks 
Single strand breaks (SSB) are three times commoner than DSBs and can also provoke apoptosis, but whereas 
proliferating cells can repair these through HR during DNA replication, non-proliferating cells have fewer options 
available. Ataxia with oculomotor apraxia-1 (AOA1) involves cerebellar degeneration, cognitive impairment, low albumin 
and cholesterol and is caused by mutation in APTX, which processes DNA ends in SSBR and also interacts with DSB 
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machinery such as XRCC4 (Clements et al., 2004). Spinocerebellar ataxia with axonal neuropathy (SCAN1) is a rare disease 
of cerebellar degeneration and peripheral neuropathy caused by mutation in TDP1, a phosphodiesterase which acts on 
the DNA ends of SSBs and DSBs, leading to the accumulation of SSBs (El-Khamisy et al., 2005). These conditions 
demonstrate that failure of SSB repair can also result in neurodegeneration. 
1.3.2.5 Ageing 
With increasing age, DNA damage and mutations accumulate, and DNA repair activity declines (Lu et al., 2004). In mice, 
liver mutations almost quadruple with age (Dolle et al., 1997) and in adult human frontal cortex up to 40% of neurons 
have copy number variations (CNVs) (McConnell et al., 2013). Following DNA repair, chromatin may not return to its 
predamaged state, which may affect expression with age (Madabhushi et al., 2014). 
The DDR is important both during neural development and in mature neurons. Mutations in DNA repair factors cause 
severe neurodevelopmental disorders as well as age-related neurodegeneration. Postmitotic neurons are particularly 
vulnerable and acquire DNA damage such as oxidation and strand breaks with age, potentially because of declining repair 
activity. One of the greatest challenges in HD will be understanding how on the one hand DNA repair guards genomic 
stability, whilst on the other hand contributing to cell death (Jiricny, 2006). 
1.3.3 Modifiers of repeat stability 
1.3.3.1 DNA repair in Huntington’s disease 
Several DNA maintenance processes have been implicated in causing repeat expansion, including DNA replication, base 
excision repair, double strand break repair, nucleotide excision repair and recombination (Castel et al., 2010, Pearson et 
al., 2005a), but MMR is the strongest driver (Castel et al., 2010, Slean et al., 2008). DNA repair proteins appear to act on 
repeat sequences once they reach a threshold length. In Huntington’s disease mouse models, somatic expansion 
increases with age (Mangiarini et al., 1997, Wheeler, 1999, Ishiguro et al., 2001, Lee et al., 2011a), modifies disease course 
(Kovalenko et al., 2012, Wheeler, 2003), is exacerbated by oxidative DNA damage (Kovtun et al., 2007, Bogdanov et al., 
2001), depends on a functional mismatch repair system (Manley et al., 1999, Tome et al., 2013a, Pinto et al., 2013a), and 
can be ameliorated by manipulating DNA repair genes (Wheeler et al., 2003, Tome et al., 2013a, Kovtun et al., 2007). 
Knockout of MSH2 (Lopez Castel et al., 2010, Manley et al., 1999), MLH1 or MLH3 (Pinto et al., 2013a) completely ablates 
and knockout of MSH3 (Dragileva et al., 2009, Tome et al., 2013a) and PMS2 (Gomes-Pereira, 2004, Gomes-Pereira et al., 
2014b, Pinto et al., 2013b) reduces repeat expansion. CAG expansions are therefore driven by the mismatch repair 
complexes MutSβ (MSH2-MSH3), MutLα (MLH1-PMS2) and MutLγ (MLH1-MLH3). The inculpation of MutSβ, which deals 
with short insertion-deletion loops, suggests expansion may result from short incremental expansions rather than large 
jumps (Schmidt and Pearson, 2016, Williams and Surtees, 2015). Slip-outs may have unpaired or mispaired nucleotides 
at the junction, which could confuse the MMR system, potentially targeting repair to the incorrect strand and resulting 
in an expansion (Schmidt and Pearson, 2016). Knockout of OGG1, a base excision repair protein, also reduced expansion 
and delayed onset in HD mice (Budworth et al., 2015). 
It may not be necessary to completely inactivate MMR proteins, as subtle genetic variation also affects instability; 
germline and somatic instability were noted to differ between strains of HD mice (Tome et al., 2013a). This variability 
was mapped to variants in Msh3 that influenced its expression level. A genome-wide association study also identified 
Mlh1 as an influence on strain-specific variation in instability (Pinto et al., 2013a). Prognosis in human repeat expansion 
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diseases may, therefore, be tempered by the presence of variants in DNA repair genes. Elucidating a mechanism through 
which MMR could switch from expansion to contraction could have therapeutic potential (Lopez Castel et al., 2010). 
1.3.3.2 DNA repair in other repeat expansion diseases 
DNA repair is known to modify repeat instability in numerous repeat expansion diseases. In myotonic dystrophy, the 
MMR complex MutSβ (Msh2/Msh3) is required for expansion (Nakatani et al., 2015b, Stevens et al., 2013, Du et al., 
2013b, Seriola et al., 2011b, Nakatani et al., 2015c, Williams and Surtees, 2015, Kantartzis et al., 2012, Dragileva et al., 
2009, Tome et al., 2013a, van den Broek et al., 2002, Foiry et al., 2006) and MSH3 polymorphisms are associated with 
variation of somatic instability in patient blood (Morales et al., 2016). In SCA3, ERCC6, a base excision repair protein, is 
associated with intergenerational repeat expansion (Martins et al., 2014). In fragile X mice, Msh2 is required for 
expansion (Lokanga et al., 2014) and Fan1 is protective (Zhao and Usdin, 2018), and in fragile X patients, DNA repair genes 
are downregulated in blood (Xu et al., 2013). In Friedreich’s ataxia mice, Msh2, Msh3, Msh6 and Pms2 (Bourn et al., 2012, 
Zhao et al., 2015b, Ezzatizadeh et al., 2012) have been associated with expansion. 
1.3.3.3 Mechanisms underlying repeat instability 
Repetitive DNA sequences form unusual non-canonical structures, including slipped strands, hairpin loops, G-
quadruplexes and R-loops (Mirkin, 2007, Neil et al., 2017, McMurray, 2010), the stability of which correlates with 
expansion (Gacy et al., 1995). Hairpins contain an A:A base pair mismatch in the stem that is predicted in silico to result 
in a Z DNA structure, with double helix winding to the left instead of the right, perhaps with flipping out of the mismatched 
bases (Khan et al., 2015). Such structures could form substrates for the DNA mismatch repair machinery. In DM1 patients, 
for example, higher levels of slipped strand DNA are found in tissues with the most repeat instability, such as the heart 
(Axford et al., 2013). The disease process itself may also induce DNA damage, either through a direct effect of the 
expanded repeat or through mitochondrial dysfunction and excitotoxicity, which activate the DNA damage response 
(Shah and Mirkin, 2015). Processes involved in germline and somatic and instability may differ, with the former more 
related to DNA replication during cell division and the latter, which occurs in non-dividing neurons, associated with DNA 
repair, transcription and chromatin dynamics. 
1.4 FAN1 
FAN1 is a highly conserved DNA endo- and exonuclease originally described in 2010 by four groups (Kratz et al., 2010a, 
Liu et al., 2010b, MacKay et al., 2010b, Smogorzewska et al., 2010a). It is required for the Fanconi anaemia (FA) 
interstrand crosslink repair (ICL) pathway , acting in complex with some mismatch repair (MMR) proteins (MacKay et al., 
2010b, Kratz et al., 2010a, Liu et al., 2010b, Smogorzewska et al., 2010a), though its precise role in this process remains 
unclear (Thongthip et al., 2016, Lachaud et al., 2016a, Lachaud et al., 2016b). FAN1 is structure rather than sequence 
specific, binding and cleaving branched 5’ flap structures that occur as DNA repair intermediates (Kratz et al., 2010a, Liu 
et al., 2010b, MacKay et al., 2010b, Pennell et al., 2014, Liu et al., 2010c, MacKay et al., 2010a). It also has an independent 
role maintaining genomic stability and preventing chromosomal abnormalities, possibly through the regulation of 
replication fork dynamics (Lachaud et al., 2016a, Chaudhury et al., 2014). 
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1.4.1 Structure 
Four domains have been characterised. Through its N-terminal ubiquitin binding domain (UBZ), monoubiquitinated 
FANCD2 and FANCI of the FA pathway recruit it to nuclear ICL damage foci (Liu et al., 2010c, Smogorzewska et al., 2010a), 
hence its name (FANCD2 and FANCI Associated Nuclease 1). Its DNA binding (SAP) domain may be involved in recruiting 
FAN1 to ICL damage foci (Thongthip et al., 2016). The tetratricopeptide repeat (TPR) mediates protein-protein 
interactions and the assembly of multiprotein complexes. Finally, its nuclease domain, a viral replication and repair 
nuclease (VRR Nuc), has endonuclease activity at 5’ flap structures and 5’-3’ exonuclease activity (MacKay et al., 2010b). 
FAN1’s crystal structure has been determined bound to DNA substrates and suggests it may form a dimer to orient and 
nick DNA (Wang et al., 2014b, Zhao et al., 2014, Gwon et al., 2014, Yan et al., 2015). Interestingly, the bacterial and 
unicellular eukaryotic FAN1 lacks the UBZ domain (Jin and Cho, 2017). 
 
Figure 1.4. Schematic representation of FAN1. 
The UBZ (ubiquitin-binding zinc finger 4), SAP (SAF-A/B, Acinus and PIAS), TRP (tetratricopeptide repeat) and VRR Nuc (viral 
replication and repair nuclease) motifs of hFAN1 are indicated. Reproduced from Takahashi et al. (2015) 
A number of FAN1-DNA complex structures have been reported, all lacking the UBZ domain and binding DNA either as a 
monomer or dimer, but despite these, the mechanism of FAN1-mediated ICL repair remains unclear (Gwon et al., 2014, 
Wang et al., 2014a, Zhao et al., 2014, Shereda et al., 2010). FAN1 forms a bi-lobed structure with the N and C-terminal 
domains (NTD, CTD) positioned orthogonally. The NTD recognises the prenick duplex and the CTD interacts with the 
postnick duplex, but all domains are involved in binding DNA. The nuclease makes cuts at every third nucleotide of the 
flap, generating a 12 nt gap containing ssDNA, though it also has the ability to cleave between each third nucleotide too. 
FAN1 can assemble as a head-to-tail dimer in the presence of DNA through interaction between TPR and VRR domains 
of one molecule binding the SAP domain of another. The first molecule has the primary cleavage function, with the second 
involved in orientating the substrate. Monomeric and dimeric FAN1 can both cleave short DNA flaps, but the dimeric 
form is optimal for cleaving longer flaps (Rao et al., 2018). However, relative functions of the monomer and dimer are 
unknown (Zhao et al., 2014). 
1.4.2 Function 
1.4.2.1 Interstrand crosslink repair 
FAN1 is recruited to ICLs biphasically, with an initial rapid rise through the SAP domain directly binding DNA, followed by 
a steady build up mediated by the UBZ domain’s interaction with monoubiquitinated FANCD2 (Thongthip et al., 2016, 
Smogorzewska et al., 2010a, MacKay et al., 2010b). ICL repair involves the formation of double strand breaks and their 
repair by homologous recombination (HR) (Hanada et al., 2006, Hanada et al., 2007). Single stranded DNA is coated by 
replication protein A (RPA), which can be visualised as nuclear foci. During HR, RAD51 displaces RPA to generate strands 
that invade the sister chromatid (West, 2003). FAN1 depletion does not prevent the formation of RPA nuclear foci, but 
delays the disappearance of RAD51 suggesting a role in the completion of HR (MacKay et al., 2010a, Kratz et al., 2010b). 
g-H2AX binds double strand breaks (DSBs) to recruit DNA repair proteins (Niedernhofer et al., 2004, Rothfuss and 
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Grompe, 2004). FAN1 knockdown does not impair the formation of g-H2AX foci, but does delay their resolution (MacKay 
et al., 2010a, Kratz et al., 2010b), consistent with a role in resolving DSBs induced during ICL repair. These observations 
suggest that FAN1 participates in HR and its absence results in erroneous processing of ICLs, resulting in chromosomal 
aberrations (Kratz et al., 2010b, Raschle et al., 2008). 
FAN1 recognises and binds the ss/dsDNA junction of 5’ flap structures 3-4 nucleotides into the double stranded portion 
(Takahashi et al., 2015, Pizzolato et al., 2015), a region not covered by the RPA that stabilises ssDNA. It then makes an 
incision 2-4 nt into the dsDNA, successively cutting every third nucleotide (Wang et al., 2014b, Wang et al., 2014a), which 
may allow it to traverse an ICL in order to unhook it (Pizzolato et al., 2015). It has diverse nuclease activity, which would 
allow it to participate in several DNA repair processes, including ICL unhooking, trimming of unhooked strands and D-
loop incision during HR (Jin and Cho, 2017). 
However, FAN1 appears to act independently of the FA pathway, and may have additional functions in maintaining 
genomic stability. Lachaud et al. (2016a) showed that p.C44A/C47A UBZ domain mutant FAN1, which is unable to interact 
with ubiquitinated FANCD2, fully rescues ICL repair in FAN1 knockout cells, suggesting FA pathway-mediated FAN1 
recruitment is dispensable for ICL repair. FAN1 can be directly recruited to ICLs via its SAP DNA binding domain (Thongthip 
et al., 2016) and can also act alone to efficiently unhook ICLs in vitro (Wang et al., 2014a, Pizzolato et al., 2015). 
1.4.2.2 Replication fork recovery 
Though FAN1 is able to repair ICLs independent of the FA pathway, it appears that its interaction with FANCD2 is required 
for genomic stability (Chen et al., 2015, Schlacher et al., 2012). The pancreatic cancer-causing UBZ domain mutation 
p.M50R (Smith et al., 2016) impairs recruitment by FANCD2 and has normal ICL repair function, but cells develop 
chromosomal abnormalities (Lachaud et al., 2016a). FAN1 nuclease and UBZ domain mutants cannot protectively restrain 
stalled replication forks (Ray Chaudhuri et al., 2012, Ge and Blow, 2010, Lachaud et al., 2016a), potentially leading to 
replication fork reversal that has previously been implicated in repeat instability (Follonier et al., 2013, McMurray, 2010, 
Mirkin, 2007, Ray Chaudhuri et al., 2012). Replication forks can be stalled by ICLs, a lack of nucleotides, polymerase 
inhibition, abasic sites, modified bases, strand breaks or abnormal secondary structures on the template strand, such as 
G-quadruplexes (Porro et al., 2017). 
FANCD2 regulates FAN1 activity at stalled forks, protecting nascent DNA from nucleolytic degradation (Chaudhury et al., 
2014). In the presence of FANCD2, FAN1 is recruited to stalled replication forks and acts in concert with MRE11 and BLM 
to suppress firing of new origins and promote replication fork restart. In the absence of FANCD2, FAN1 is still recruited 
to stalled forks, but restart does not occur efficiently, new origins are triggered and uncontrolled FAN1 degrades nascent 
DNA strands behind the fork. Inappropriate incision such as this could cause genomic instability rather than protect 
against it. Therefore, FAN1 joins a group of fork restart proteins, including FANCD2, BRCA1, MRE11, XRCC3, RAD51, CTIP, 
and MUS81 (Chaudhury et al., 2014), all of which have been implicated in repair of double strand breaks by homologous 
recombination. The main role of FANCD2 may be to protect nascent DNA strands at replication forks and ICLs from 
nucleolytic degradation by loading them with RAD51 (Chaudhury et al., 2014). As a nuclease that can cleave several 
different DNA structures, FAN1 activity likely needs to be closely controlled (Porro et al., 2017). It seems that FAN1 is 
important for controlling the restart of replication forks stalled not only by ICLs, but by other lesions as well (Porro et al., 
2017, Zhao et al., 2014). 
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Porro et al. (2017) identified a PCNA interaction motif (PIP), which together with the UBZ domain recruits FAN1 to 
ubiquitylated PCNA at stalled replication forks, thereby preventing collapse and regulating fork progression. This PIP 
domain is not required for FAN1 recruitment to MMC-induced ICLs. 
1.4.2.3 Protein interactions 
FAN1 is known to directly interact with the ID complex (FANCD2 and FANCI), through which it is involved in ICL repair 
(Kratz et al., 2010a, Liu et al., 2010b, MacKay et al., 2010b, Smogorzewska et al., 2010a). However, it also interacts with 
mismatch repair complexes MutLα (MLH1 and PMS2) and MutLγ (MLH1/MLH3), which are required for repeat expansion, 
though the function of this interaction remains unknown (MacKay et al., 2010a, Kratz et al., 2010a, Liu et al., 2010c, 
Smogorzewska et al., 2010b). 
 
Figure 1.5. FAN1 interactome. 
Blue represents mismatch repair components, yellow is Fanconi anaemia pathway components, lines represent physical interactions. 
Prepared using GeneMANIA (Warde-Farley et al., 2010). 
1.4.2.4 Summary 
Taken together, a model is emerging in which abnormal DNA structures formed by the HTT CAG repeat could stall 
replication forks. Stalled forks are then bound by PCNA, FAN1 is recruited and its nuclease activity is involved in correct 
restart of the fork, with FANCD2 protecting nascent DNA from degradation. 
1.4.3 FAN1 depletion 
Loss of FAN1 sensitises cells to ICL-inducing agents, such as mitomycin C (MMC) and cisplatin, and results in 
chromosomal breaks reminiscent of FA patients (Kratz et al., 2010b, Liu et al., 2010c, MacKay et al., 2010b, Akkari et al., 
2000, MacKay et al., 2010a). Zhao and Usdin (2018) recently showed that FAN1 knockout in a fragile X mouse model 
accelerated CGG repeat expansion, particularly in liver and brain 
FAN1 mutations do not cause Fanconi anaemia, but homozygous loss of function mutations result in the recessive renal 
disease karyomegalic interstitial nephritis (KIN), characterised by renal fibrosis, tubular degeneration and polyploidy in 
multiple tissues (Zhou et al., 2012, Lachaud et al., 2016b, Thongthip et al., 2016). Heterozygous truncating mutations 
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have been linked to pancreatic (Smith et al., 2016) and hereditary colorectal cancers (Segui et al., 2015b). FAN1 lies in a 
2 Mb region of copy number variation (CNV) due to non-allelic homologous recombination of flanking repeats. Deletion 
and duplication of the region have been associated with intellectual disability, epilepsy, autism and schizophrenia (Ionita-
Laza et al., 2014). It is likely that chromosomal abnormalities due to failure of replication fork protection, as discussed 
above, underlie some of these conditions. 
Disease causing mutations near the active site, such as p.D960A, abolish nuclease activity and have been found in patients 
with KIN, pancreatic or colorectal cancer, and schizophrenia or autism (Zhao et al., 2014). Mutations on the surface of 
the protein, such as p.R507H and p.P894S, may affect protein-protein interactions. Mutations elsewhere may affect the 
protein structure or its interaction with DNA, such as p.R377W at the interface of the helical and CTD. Generally, the KIN-
causing mutations are clustered in the nuclease-containing CTD and those associated with cancer either affect the UBZ 
or nuclease domains (Zhao et al., 2014). 
1.5 MSH3 
1.5.1 Function 
MSH3 forms the neuronally expressed heterodimeric complex MutSb with MSH2, acting in the DNA mismatch repair 
(MMR) pathway, recognising base mismatches and small insert-deletion loops (IDL) (Tome et al., 2013a, Gonitel et al., 
2008). DNA repair pathways are highly interconnected and MutSb is implicated in at least three processes (Ashburner et 
al., 2000); repair of insertion-deletion loops, repair of double strand breaks by binding 3’ overhangs, and repair of single-
strand annealing (Lyndaker and Alani, 2009, Schmidt and Pearson, 2016). The MSH proteins are ATPases that possess the 
Walker ATP-binding motif, which is highly conserved in DNA repair proteins. ATP is not required for the initial recognition 
of mismatches (Jiricny, 2006), but it is subsequently required for the conformational change of the MutS complex, which 
allows it to release the mismatch and move along the DNA in the form of a sliding clamp. In the presence of a mismatch, 
the MutS heterodimer clamps around the DNA like a pair of praying hands (Jiricny, 2000). 
1.5.2 Structure 
1.5.2.1 Domains 
Eukaryotic MSH proteins have five domains homologous to the bacterial form, though unlike MSH2 and bacterial MutS, 
MSH3 and MSH6 also have a conserved 100-600 residue N-terminal region containing a motif for interaction with PCNA 
(Kunkel and Erie, 2005, Clark et al., 2007a). The MSH3 protein resembles a figure of eight, with the lower of the two 
channels penetrating the protein forming the DNA binding domain, and the dimerization interface and nucleotide binding 
domain at the opposite end of the molecule (Schofield and Hsieh, 2003). Domains I and IV bind DNA, with I directly 
contacting the mismatched base and IV forming jaws that clamp the protein to DNA (Schofield and Hsieh, 2003). Domain 
V, at the C-terminus, contains the dimerisation interface and the nucleotide binding site for ATP. Domain III provides a 
structural bridge between the ATPase domain and the DNA binding site. The crystal structure of MutSb in complex with 
DNA insertion-deletion loops shows it binds both DNA strands 5’ of the lesion through domain I, but only the loop-
containing strand 3’ of the lesion through domain IV (Gupta et al., 2011a). DNA binding is mediated by residues 245-246, 
and mutation of the homologous yeast residues leads to microsatellite instability (Schmutte et al., 2001). Tyr245 interacts 
with the normal strand 5’ in the double stranded region, whereas Lys246 contracts the loop strand. 
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1.5.2.2 Protein interactions 
MSH3 forms the heterodimeric MutSβ MMR complex by binding MSH2 through N-terminal residues 126-250 and C-
terminal residues 1050-1128 (Acharya et al., 1996). It also interacts with EXO1, an MMR exonuclease that excises 
mismatch-containing DNA tracts, through residues 75-297 (Schmutte et al., 2001). MSH3 contains an N-terminal PCNA 
interaction motif, Qxx(LI)xxFF (PIP box, which in MSH3 is encoded by QAVLSRFF at residues p.21-28) (Kleczkowska et al., 
2001, Clark et al., 2000, Flores-Rozas et al., 2000). PCNA is known to be involved in delivering MSH proteins to mismatches 
(Lau and Kolodner, 2003) and increases mismatch binding specificity (Flores-Rozas et al., 2000). It is a processivity factor 
for DNA polymerase, acting as a sliding clamp and participating in both DNA replication and MMR (Clark et al., 2000, 
Flores-Rozas et al., 2000, Kleczkowska et al., 2001, Goellner et al., 2015). The PCNA motif tends to be followed by a non-
conserved sequence containing basic amino acids and often prolines, which interacts with the interdomain connector 
loop (IDCL) of PCNA (Gulbis et al., 1996), the domain through which PCNA interacts with proteins (Kleczkowska et al., 
2001). PCNA-binding proteins can be divided into two groups based on the amino sequence in this region, one with a 
preponderance of basic residues and the other with proline residues (Zhang et al., 1999). MSH6 belongs to the former 
and MSH3 to the latter (Kleczkowska et al., 2001). Sequence analysis suggests these regions form short, flexible connector 
domains. The binding of MutSa to mismatch substrates leads to dissociation from PCNA. This suggests that MutSα and/or 
MutSβ may also be involved in DNA replication along with PCNA, but that they are handed over to the MMR machinery 
when a mismatch is detected (Lau and Kolodner, 2003, Jiricny, 2006). Mutational studies suggest the N-terminal 
interaction with PCNA is important for MMR (Schofield and Hsieh, 2003), with variants in the MSH3 or MSH6 PCNA 
binding motif strongly reducing PCNA binding (Clark et al., 2000, Flores-Rozas et al., 2000, Kleczkowska et al., 2001) and 
increasing mutation rates, though some MMR function is retained (Clark et al., 2000). 
 
Figure 1.6. Schematic representation of MSH3. 
Interaction domains are given in blue, and the 9 bp tandem repeat in red. 
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Figure 1.7. MSH3 protein interactions. 
Lines represent functional interaction. Line thickness represents the confidence of the interaction. Proteins are clustered into three 
groups (red, green, blue) by k-means. Generated in STRING. MutS and MutL protein complexes are marked with coloured ovals. 
1.5.2.3 MSH3 and DHFR share a promoter 
MSH3 is situated head-to-head with DHFR and they share a common promoter, but are divergently transcribed 
(Watanabe et al., 1996, Drummond, 1999). Induction of DHFR expression by methotrexate, a DHFR enzyme inhibitor, 
leads to a co-amplification of MSH3, and both genes are also upregulated in childhood acute lymphoblastic leukaemia 
(ALL) (Watanabe et al., 1996). DHFR upregulation is the main cause of methotrexate resistance in ALL. Some studies have 
suggested that the parallel increase in MSH3 may sequester MSH2 away from MutSa, thereby impairing base mismatch 
repair at the expense of IDL repair (Zhang et al., 1999, Drummond, 1999, Drummond et al., 1997, Marra et al., 1998, 
Pandit et al., 2001, Irving and Hall, 2001, Swann et al., 1996), resulting in methotrexate-induced hypermutability, though 
results of DNA repair assays have conflicted (Matheson et al., 2007). It is interesting that MSH3, a key MMR component, 
shares a promoter with DHFR, which can influence replication fidelity through the folate-dependent biosynthesis of 
purines (Drummond, 1999). The promoter contains sites for Sp1 and E2F transcription factors. Expression of both DHFR 
and MSH3 is influenced by cell cycle progression, increasing particularly during S phase with DNA replication, as well as 
at the onset of cell proliferation, with both genes expressed in parallel in most cases. The E2F site is close to the initiation 
site of DHFR and Sp1 is nearest the MSH3 initiation site, but there is no direct evidence for uncoupled expression of the 
two genes (Drummond, 1999). However, the existence of distinct transcription factor binding sites raises the possibility 
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of a more complex regulator mechanism. The genomic organisation linking DHFR and MSH3 may suggest communication 
between nucleotide synthesis and mismatch repair pathways. For example, variation in dNTP concentrations is known to 
influence the rate of mutation (Bebenek and Kunkel, 1990, Bebenek et al., 1992). The requirement for nucleotides rises 
during DNA replication, which is when mismatches are introduced and repaired, so the shared promoter arrangement 
may have arisen as an anticipatory mechanism to protect genome stability. 
Unlike MSH3, DHFR has not been implicated in HD pathogenesis. In the R6/1 transgenic mouse model of HD, coding 
variation in MSH3 that lowers its expression, as measured by western blot, reduces CAG repeat expansion (Tome et al., 
2013a). Tome et al. (2013a) identified 7 polymorphisms that resulted in non-synonymous amino acid changes in exons 2, 
3, 7, 8 and 10. Most residues were conserved, but only p.T321I was predicted damaging. This variant is not in a protein 
interaction domain, but may affect protein stability or conformation. One variant, p.A82S is within the Exo1 binding 
domain and is 54 amino acids downstream of the PCNA motif; the homologous human residue is p.S116. The mouse and 
human protein sequences are aligned below, and show 80% sequence identity (Blastp and Clustal2.1), differing mostly at 
the N-terminus. The authors postulated that MSH3 transcription was unaffected because its shared promoter and DHFR 
expression were undisrupted, and that instead the low MSH3 protein level may reflect its inability to form the MutSb 
protein complex with MSH2. Msh2 knockout in mice, for example, leads to undetectable levels of MSH3 (Tome et al., 
2013b). 
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Figure 1.8. Alignment of mouse and human MSH3 protein sequences. 
The PCNA interaction motif is shown in yellow (Kleczkowska et al., 2001, Clark et al., 2000, Flores-Rozas et al., 2000), the EXO1 
binding domain in cyan (Schmutte et al., 2001), the MSH2 binding domain in magenta (note EXO1 and MSH2 binding domains 
overlap. The residues forming salt bridges between MSH3 and MSH2 are in white on blue), the key DNA binding residues are in white 
on black (Gupta et al., 2011a), the ATP binding site in green, and the sites of the 7 coding variants from Tome et al. (2013a) are in red. 
Protein binding domains are relative to the human sequence. Sequence identity is 79% (Blastp) to 80.91% (Clustal2.1). 
mouse      MPRGKSASGGSTAAGPGPGRQTVLSRFFRSAGSLRSSASSTEPAEKVTEG---------- 50 
human      MSRRKPASGGLAASSSAPARQAVLSRFFQSTGSLKSTSSSTGAADQVDPGAAAAAAAAAA 60 
           * * * **** :*:. .*.**:******:*:***:*::***  *::*  *           
 
mouse      ------------------------DSRKRSLGNGGPTKKKARKVPEKEEENISVAAHHPE 86 
human      AAPPAPPAPAFPPQLPPHIATEIDRRKKRPLENDGPVKKKVKKVQQKEGGSDLGMSGNSE 120 
                                     :** * *.**.***.:** :**  .    : : * 
 
mouse      AKKCLRPRIVLKSLEKLKEFCCDSALPQNRVQTEALRERLEVLPRCTDFEDITLQRAKNA 146 
human      PKKCLRTRNVSKSLEKLKEFCCDSALPQSRVQTESLQERFAVLPKCTDFDDISLLHAKNA 180 
            ***** * * *****************.*****:*:**: ***:****:**:* :**** 
 
mouse      VLSEDSKSQANQKDSQF------GPCPEVF--QKTSDCKPFNKRSKSVYTPLELQYLDMK 198 
human      VSSEDSKRQINQKDTTLFDLSQFGSSNTSHENLQKTASKSANKRSKSIYTPLELQYIEMK 240 
           * ***** * ****: :      * .   .   :.: .*  ******:********::** 
 
mouse      QQHKDAVLCVECGYKYRFFGEDAEIAARELNIYCHLDHNFMTASIPTHRLFVHVRRLVAK 258 
human      QQHKDAVLCVECGYKYRFFGEDAEIAARELNIYCHLDHNFMTASIPTHRLFVHVRRLVAK 300 
           ************************************************************ 
 
mouse      GYKVGVVKQTETAALKAIGDNKSSVFSRKLTALYTKSTLIGEDVNPLIRLDDSVNIDEVM 318 
human      GYKVGVVKQTETAALKAIGDNRSSLFSRKLTALYTKSTLIGEDVNPLIKLDDAVNVDEIM 360 
           *********************:**:***********************:***:**:**:* 
 
mouse      TDTSTNYLLCIYEEKENIKDKKKGNLSVGIVGVQPATGEVVFDCFQDSASRLELETRISS 378 
human      TDTSTSYLLCISENKENVRDKKKGNIFIGIVGVQPATGEVVFDSFQDSASRSELETRMSS 420 
           *****.***** *:***::******: :***************.******* *****:** 
 
mouse      LQPVELLLPSDLSVPTEMLIQRATNVSVRDDRIRVERMNNTYFEYSHAFQTVTEFYAREI 438 
human      LQPVELLLPSALSEQTEALIHRATSVSVQDDRIRVERMDNIYFEYSHAFQAVTEFYAKDT 480 
           ********** **  ** **:***.***:*********:* *********:******::  
 
mouse      VDSQGSQSLSGVINLEKPVICALAAVIRYLKEFNLEKMLSKPESFKQLSSGMEFMRINGT 498 
human      VDIKGSQIISGIVNLEKPVICSLAAIIKYLKEFNLEKMLSKPENFKQLSSKMEFMTINGT 540 
           ** :*** :**::********:***:*:***************.****** **** **** 
 
mouse      TLRNLEILQNQTDMKTKGSLLWVLDHTKTSFGRRKLKNWVTQPLLKLREINARLDAVSDV 558 
human      TLRNLEILQNQTDMKTKGSLLWVLDHTKTSFGRRKLKKWVTQPLLKLREINARLDAVSEV 600 
           *************************************:********************:* 
 
mouse      LHSESSVFEQIENLLRKLPDVERGLCSIYHKKCSTQEFFLIVKSLCQLKSELQALMPAVN 618 
human      LHSESSVFGQIENHLRKLPDIERGLCSIYHKKCSTQEFFLIVKTLYHLKSEFQAIIPAVN 660 
           ******** **** ******:**********************:* :****:**::**** 
 
mouse      SHVQSDLLRALIVEAPELLSPVEHYLKVLNGPAAKVGDKTELFKDLSDFPLIKKRKNEIQ 678 
human      SHIQSDLLRTVILEIPELLSPVEHYLKILNEQAAKVGDKTELFKDLSDFPLIKKRKDEIQ 720 
           **:******::*:* ************:**  ************************:*** 
 
mouse      EVIHSIQMRLQEFRKILKLPSLQYVTVSGQEFMIEIKNSAVSCIPADWVKVGSTKAVSRF 738 
human      GVIDEIRMHLQEIRKILKNPSAQYVTVSGQEFMIEIKNSAVSCIPTDWVKVGSTKAVSRF 780 
            **..*:*:***:***** ** ***********************:************** 
 
mouse      HPPFIVESYRRLNQLREQLVLDCNAEWLGFLENFGEHYHTLCKAVDHLATVDCIFSLAKV 798 
human      HSPFIVENYRHLNQLREQLVLDCSAEWLDFLEKFSEHYHSLCKAVHHLATVDCIFSLAKV 840 
           * *****.**:************.****.***:*.****:*****.************** 
 
mouse      AKQGNYCRPTLQEEKKIIIKNGRHPMIDVLLGEQDQFVPNSTSLSQDSERVMIITGPNMG 858 
human      AKQGDYCRPTVQEERKIVIKNGRHPVIDVLLGEQDQYVPNNTDLSEDSERVMIITGPNMG 900 
           ****:*****:***:**:*******:**********:***.*.**:************** 
 
mouse      GKSSYIKQVALVTIMAQIGSYVPAEEATIGIVDGIFTRMGAADNIYKGRSTFMEELTDTA 918 
human      GKSSYIKQVALITIMAQIGSYVPAEEATIGIVDGIFTRMGAADNIYKGQSTFMEELTDTA 960 
           ***********:************************************:*********** 
 
mouse      EIIRRASPQSLVILDELGRGTSTHDGIAIAYATLEYFIRDVKSLTLFVTHYPPVCELEKC 978 
human      EIIRKATSQSLVILDELGRGTSTHDGIAIAYATLEYFIRDVKSLTLFVTHYPPVCELEKN 1020 
           ****:*: ***************************************************  
 
mouse      YPEQVGNYHMGFLVNEDESKQDSGDMEQMPDSVTFLYQITRGIAARSYGLNVAKLADVPR 1038 
human      YSHQVGNYHMGFLVSEDESKLDPGAAEQVPDFVTFLYQITRGIAARSYGLNVAKLADVPG 1080 
           * .***********.***** * *  **:** ***************************  
 
mouse      EVLQKAAHKSKELEGLVSLRRKRLECFTDLWTTHSVKDLHTWADKLEMEEIQTSLPH 1095 
human      EILKKAAHKSKELEGLINTKRKRLKYFAKLWTMHNAQDLQKWTEEFNMEETQTSLLH 1137 
           *:*:************:. :****: *:.*** *..:**:.*:::::*** **** * 
51 
 
Figure 1.9. Conservation of the MSH3 N-terminal domain between mouse and human. 
The PCNA interaction motif and Tome et al. (2013a) p.A82S variant are marked in red. Figure prepared in Jalview 2.10.4b1. 
1.5.3 MSH3 depletion 
Deficient MMR results in a mutator phenotype known as microsatellite instability (MSI), with length alterations at simple 
repeated sequences called microsatellites, which is the hallmark of Lynch syndrome, also known as hereditary non-
polyposis colorectal cancer (HNPCC) (Yamamoto and Imai, 2015). It is usually caused by mutations in MLH1 and MSH2, 
and less frequently in MSH6 and PMS2. Mutation of MSH3 has not been linked to cancer in humans, most likely because 
MutSα can also initiate repair at most replication errors (Edelmann et al., 2000, Jiricny, 2006), but loss of MSH3 is 
associated with increased microsatellite instability (Haugen et al., 2008), and Msh3 knockout further increases cancer 
susceptibility in Msh6 knockout mice (de Wind et al., 1999, Edelmann et al., 2000). 
1.6 The immune system in neurodegenerative disease 
1.6.1 Neurodegenerative disease 
Neurodegenerative diseases are characterised by synaptic loss and neuronal death resulting in cognitive decline and loss 
of motor function. These are attributed to aggregation of the pathogenic protein, which can occur spontaneously or due 
to inherited mutation. The diseases can be histologically classified by the pathological protein aggregate, which in 
amyloidoses such as CJD or Alzheimer’s disease is the prion protein or plaques of Aβ, in the tauopathies there are 
neurofibrillary tangles of the hyperphosphorylated microtubule-binding protein tau, also present in AD, in the 
synucleinopathies such as Parkinson’s disease aggregates of α-synuclein form as Lewy bodies, and aggregates of TDP-43 
form in amyotrophic lateral sclerosis (Dugger and Dickson, 2017). In aging and neurodegeneration there is evidence for 
increased number and activation of microglia in the CNS (Srinivasan et al., 2016). High levels of proinflammatory 
cytokines, including TNF, IL-1β and IL-6 are seen in brain, CSF and serum of AD, PD and HD patients (Heneka et al., 2014), 
which are thought to derive from microglia, rather than infiltrating adaptive immune cells (Crotti and Glass, 2015). 
1.6.2 Huntington’s disease 
The innate immune system shows prominent deficits in Huntington’s diseases. Microglia are activated in the brains of 
HD patient and mouse models, even before symptom onset (Tai et al., 2007b, Simmons et al., 2007), and complement 
components C1q, C4 and C3 are upregulated in the striatum (Singhrao et al., 1999). Several proinflammatory cytokines 
are increased in peripheral blood plasma and in the brain of HD patients, including IL-6 and IL-8 (Bjorkqvist et al., 2008), 
potentially driven by the upregulation of NFκB (Khoshnan et al., 2004). Reduction of IL-6 levels by antibody neutralisation 
or CB2 agonism in HD mice extends life span and suppresses motor deficits, synapse loss, and CNS inflammation 
(Bouchard et al., 2012a). α2-macroglobulin (α2M), an acute phase protein, is also increased in HD patient brain, mainly 
in reactive astrocytes (Dalrymple et al., 2007, Du et al., 1998). HD patient and mouse innate immune cells, including 
monocytes, macrophages and microglia, show impaired migration to an inflammatory stimulus (Kwan et al., 2012b), 
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which may be related to the increased IL-1β seen in brain and serum of HD patients and mice, even before symptom 
onset; knockout of the chemokine receptor Ccr2 in mice increases serum IL-1β and IL-6, leading to failure of macrophage 
and lymphocyte recruitment to inflammatory stimuli (Kurihara et al., 1997, Christensen et al., 2004, Rampersad et al., 
2011). 
Within the adaptive immune system, IL-4, an anti-inflammatory cytokine involved in tolerance and induction of regulatory 
T cells, is increased in HD patient and mouse brain and plasma (Bjorkqvist et al., 2008). Taken together, these results 
provide compelling evidence for immune upregulation, particularly of the innate immune system, in HD (Ellrichmann et 
al., 2013). 
1.6.3 Summary 
In summary, innate immune cells such as microglia can have both beneficial and damaging roles in the brain. We have 
currently only scratched the surface of the signalling pathways involved, but the study of neuroinflammation will be vital 
in understanding the pathogenesis of neurodegenerative disease. Risk genes have been identified relating to complement 
and microglial receptors, demonstrating a role for the immune system in AD pathogenesis. However, immune activity is 
complicated, with complement and peripheral immune cells having both beneficial and deleterious effects. While many 
immune components contribute to pathogenesis, it is unclear if they act cooperatively or independently. Innate immune 
pathways are amenable to pharmacological manipulation, so there is hope that a better understanding of the 
contribution of immune cells could lead to targeted therapies in the future.   
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Chapter 2 Materials and methods 
2.1 Cell lines 
2.1.1 HEK 293 
Human embryonic kidney cells derived from a healthy foetus in 1973 and transformed by adenovirus. 
2.1.2 SH-SY5Y 
Derived from a bone marrow biopsy from a four-year-old girl with neuroblastoma. 
2.1.3 HeLa 
Derived from cervical cancer cells from a patient named Henrietta Lacks in 1951. 
2.1.4 ReNcell neural stem cells 
The human neural ReNcell VM and CX progenitor cell lines were derived from 10-week-old foetal ventral mesencephalon 
and cerebral cortex, and immortalised by retroviral transduction with the v-myc oncogene by ReNeuron Group PLC 
(Guildford, UK). The CX line is clonal. The cell lines are commercially available from Millipore (cat #SCC008 and SCC007). 
They have a stable karyotype and can differentiate into neuronal and glial cells (Millipore, 2016, Donato et al., 2007). 
They grow as a monolayer with a doubling time of 20-30 hours. 
2.1.4.1 Lentiviral transduction with HTT exon 1 
ReNcell neural stem cells were transduced with HTT exon 1 containing 29, 71 or 129 CAG repeats in the Tabrizi lab. The 
p'HRsincpptUCOE+htt exon 1 IRES eGFP vector was generated by modifying A2UCOE, from Zhang et al. (2007), as 
described in Trager et al. (2014). Exon 1 human HTT-IRES-eGFP was ligated into the SalI-NdeI sites. The internal ribosome 
entry site (IRES) permits expression of both HTT and GFP from a single vector. Vector sequences are given in the Appendix. 
Transduced cells were FACS sorted (fluorescence-activated cell sorting) by GFP expression, which is contained within the 
A2UCOE plasmid. 
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Figure 2.1. p’HRsincpptUCOE+htt exon1 IRES eGFP 129CAG vector. 
Top – vector map showing sites of the exon 1 insertion, GFP and the ampicillin resistance gene. Below – linear representation. 
Expression of the 29, 71 and 129 CAG HTT exon 1 construct was demonstrated by fluorescence of GFP, which is expressed 
from the cassette through an IRES, and by western blot using antibodies to HTT. 
 
Figure 2.2. Micrographs of ReN VM cells transduced to express HTT exon 1 with 129 CAG repeats and GFP. 
Left – 40x magnification. Right – GFP fluorescence. 
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Neuronal ReN VM cells transduced to express HTT exon 1 with 71 or 129 CAG repeats show HD-relevant phenotypes, 
including HTT aggregates and mitochondrial respiratory chain deficits. Our group has conducted a baseline analysis of 
aggregate formation, size and location using a panel of validated antibodies to HTT, including S830 and MAB5492 
(Millipore), on the UCL Perkin Elmer Opera automated microscopy system (unpublished). 
2.1.4.2 Single cell cloning 
Cells were serially diluted and cultured in 20 µg/ml laminin-coated 96 well plates at either 1000, 100 or 10 cells/well in 
200 µL of NSC media (see below). Media was changed twice weekly. 
2.1.5 Track-HD patient-derived cell lines 
In the Track-HD cohort (Tabrizi et al., 2013, Tabrizi et al., 2012, Tabrizi et al., 2011a, Tabrizi et al., 2009a) our group 
developed a progression score that incorporated longitudinal imaging, cognitive and quantitative motor measures, and 
controlled for CAG repeat length (Hensman Moss et al., 2017b). Whole exome sequencing in the 25 fastest and 23 slowest 
progressing subjects identified several coding variants in FAN1 which were candidates for functional analysis. p.R507H 
(rs150393409), is a relatively rare SNP (MAF = 0.0028) in the DNA binding domain which was the third most significant 
variant in the GeM GWAS of HD, is associated with a 5.5 year early onset (p = 9.34E-18) (GeM-HD, 2015) and is predicted 
damaging in silico (SIFT and polyphen). It was observed in two fast progressing Track-HD subjects with onset 7.22 and 
10.31 years earlier than expected (mean 8.76 ± 1.54 years, progression scores 1.83 and 0.42 respectively). Their mean 
progression score was 1.12 (± 0.70), which is equivalent to an acceleration of up to 1.30 units on the UHDRS total motor 
score (TMS) and 0.37 units on the total functional capacity (TFC) per year (Hensman Moss et al., 2017b). Other variants 
include p.R145H (rs146408181, 10.1y early onset, progression score 2.11), p.E240K (rs150748572, 10.2y early onset, 
progression score 2.36) and p.829H (rs781332818, 9.3y early onset, progression score 2.27). In addition, two rare coding 
variants associated with slow progression were found; p.P894S (rs80120912), in the nuclease domain, was found in two 
subjects (progression scores -0.76 and -1.59), and p.R377W in one (rs151322829, progression score -1.25). 
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SNP id Ch:location (GRCh38.p7) 
Minor allele 
frequency 
(1000G) 
Consequence SIFT Polyphen 
n of het 
subjects in 
TrackHD 
Protein 
location 
Reference 
amino acid 
Alternative 
amino acid Domain 
Slope in GeM 
GWAS 
(years/minor 
allele) 
P-value in 
GeM 
GWAS 
Mean progression 
score (+/- sd) 
Mean residual 
AAO (years +/- 
sd) 
rs146408181 15:30905097 0.0002 missense variant tolerated benign 1 145 P H - - - 2.11 -10.1 
rs150748572 15:30905381 0.0012 missense variant tolerated benign 1 240 E K - - - 2.36 -10.2 
rs151322829 15:30905792 0.0014 missense variant deleterious benign 1 377 R W - - - -1.25 - 
rs150393409 15:30910758 0.0028 missense variant deleterious possibly damaging 2 507 R H SAP -5.55 9.34E-18 1.12 (+/- 0.70) -8.76 (+/- 1.54) 
rs781332818 15:30925938 0.0000 
missense 
variant, splice 
region 
deleterious possibly damaging 1 829 Q H - - - 2.27 -9.3 
rs80120912 15:30929290 0.0080 missense variant tolerated benign 2 894 P S VRR NUC - - -1.17 (+/- 0.42) 1.5 
Table 2.1. FAN1 variants identified by whole exome sequencing (WES) in fast and slow progressing subjects from TRACK-HD. 
SIFT and polyphen represent in silico functional prediction. 
Group Subject iD FAN1 variant Stage Predicted AAO 
Age at 
baseline AAO CAG 
Progression 
score Gender Control for 
Cases 
326-549-639 p.R145H Manifest HD 48.05 37.27 38 43 2.11 Male - 
850-476-675 p.E240K Manifest HD 52.22 44.16 42 42 2.36 Male - 
598-074-99X p.R377W Manifest HD 62.62 58.45 - 40 -1.25 Male - 
432-196-753 p.R507H Manifest HD 52.22 44.73 45 42 1.83 Female - 
135-074-011 p.Q829H Manifest HD 41.34 35.75 32 45 2.27 Female - 
826-350-503 p.P894S Premanifest 57.04 49.40 - 41 -1.59 Male - 
535-845-735 p.P894S Manifest HD 62.62 64.13 - 40 -0.76 Male - 
Controls 
841-795-617 - Premanifest 48.05 37.34 - 43 -1.71 Male 326-549-639 (p.R145H) 
147-577-839 - Premanifest 52.22 43.93 - 42 -1.52 Male 850-476-675 (p.E240K) and 432-196-753 (p.R507H) 
932-487-54X - Premanifest 52.22 53.17 - 42 -2.44 Female 432-196-753 (p.R507H) 
768-309-063 - Premanifest 41.34 34.96 - 45 -1.03 Female 135-074-011 (p.Q829H) 
Table 2.2. Track-HD patient-derived lymphoblastoid (LB) cell lines used in this study. 
AAO – age at motor onset, CAG – pathogenic HTT CAG repeat length. 
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Figure 2.3. Schematic representation of FAN1. 
Blue text – variants associated with fast progression, green text – variants associated with slow progression. The UBZ (ubiquitin-
binding zinc finger 4), SAP (SAF-A/B, Acinus and PIAS), TRP (tetratricopeptide repeat) and VRR Nuc (viral replication and repair 
nuclease) domains of FAN1 are indicated. 
Chapter 3 identifies FAN1 variants that also modify onset in other polyglutamine diseases (Bettencourt et al., 2016). 
rs3512 (g.30942802G>C), a common variant (MAF 0.19) in the 3’ untranslated region (UTR) of FAN1, which was associated 
with 1.3-year delayed onset in the GeM GWAS (p=5.28E-13) (GeM-HD, 2015), is associated with a 1.7-year delayed onset 
in the polyglutamine diseases (p = 1.52E10-05). rs3512 is in high LD (r2 = 0.85) with, rs2140734, the HD GWAS secondary 
peak at the FAN1 locus which was associated with 1.4-year late onset (p = 7.1E-14). Within the TRACK-HD cohort there 
are 18 homozygotes for the minor allele at rs3512, five of whom are amongst the slowest progressors. Skin biopsies have 
been collected from two of these. 
2.1.6 250Q lymphoblasts 
Dr Lara Cravo (Oxford University) shared lymphoblasts generated from a juvenile-onset HD subject with a 250 CAG repeat 
expansion (Nance et al., 1999). The subject had clinical onset aged 2.5 years with rigidity and cognitive decline, followed 
at 5 with seizures. He lived to 16, at which point he was mute with joint contractures and little spontaneous movement. 
His mother, from whom he likely inherited the mutation, died at 31 but had not been diagnosed with HD. Original sizing 
was based on a long smear on the PCR gel that was centred around 250 CAG. 
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Figure 2.4. CAG repeat sizing in 250Q lymphoblasts from Nance et al. (1999). 
Left – PCR amplification of genomic DNA. The 250Q subject is indicated by 19/250. The expanded allele appears as a broad smear on 
denaturing polyacrylamide (5%) gel. Right – Southern transfer, the 250Q subject is indicated by ‘patient A’. The densest region of the 
smear corresponds to approximately 250 CAG. 
2.1.7 73Q induced pluripotent stem cells 
Skin biopsies were collected at UCLH from three juvenile-onset HD siblings with 56, 67 and 73 CAG repeats, as well as 
their mother, an unaffected control, and used to generate fibroblasts. induced pluripotent stem cells (iPSC) were 
generated by Sendai virus reprogramming with the CytoTune-iPS 2.0 Sendai reprogramming kit by Prof Ali Brivanlou 
(Rockefeller University). iPSCs were verified by the expression of pluripotency markers, differentiation into all germ layers 
using a self-organisation assay, karyotyping, Sanger sequencing to confirm the CAG repeat length, and confirmation of 
the absence of exogenous Sendai virus. Three iPSC clones were generated from each subject. 
2.1.8 125Q juvenile-onset HD patient-derived cells 
2.1.8.1 Lymphoblastoid cells 
Blood was taken separately for the generation of lymphoblastoid cells and induced pluripotent stem cells. For the former, 
three CPDA yellow top blood tubes were drawn on 2/12/16 and sent at room temperature the same day to the European 
Collection of Authenticated Cell Cultures (ECACC) lab at Public Health England (PHE), Salisbury, where peripheral blood 
lymphocytes (PBL) were isolated and frozen ahead of Epstein–Barr virus (EBV) transformation. Once the cell line was 
generated, four ampoules were prepared and frozen in liquid nitrogen. Samples were quality assured by mycoplasma 
screening, sterility, cell count and viability against the source material (a blood spot card prepared at receipt) using STR-
PCR (short tandem repeat) profiling. 
2.1.8.2 Induced pluripotent stem cells (iPSC) 
4 vials of 6 ml whole blood were drawn on 19/9/17 in a BD Vacutainer cell preparation tube with sodium citrate (cat 
#362782). Two were shipped to Censo Biotechnologies, Midlothian, at room temperature the same day. The other two 
59 
vials were used to isolate peripheral blood mononuclear cells (PBMC) at UCL, which were stored in our lab. For the latter, 
the tube was mixed by gently inverting 8-10 times, then centrifuged for 30 min at 1700 xg at room temperature. After 
centrifugation, mononuclear cells and platelets were in a whitish layer just under the plasma layer. The entire contents 
of each tube above the gel were combined by pipetting into a 50 ml tube. PBS was added to bring the volume to 15 ml 
per vacutainer tube added i.e. 30 ml. Cells were mixed by inverting 5 times, then centrifuged at 300 xg for 15 min at room 
temperature. As much supernatant as possible was aspirated without disturbing the cell pellet, then 10 ml PBS was 
added, and the cells were resuspended by gently inverting the tube 5 times. Cells were centrifuged at 300 xg for 10 min 
at room temperature, then the supernatant was again aspirated without disturbing the cell pellet. 
 
Figure 2.5. BD vacutainer centrifugation. 
Freeze mix was prepared by adding 500 µL DMSO to 4.5 ml FBS and prechilled to 4°C. Cells were resuspended in 3 ml of 
freeze mix at 5.6E06 cells/ml, and 1 ml of cell suspension was added to each of 3 cryovials. These were placed in a Mr. 
Frosty freezing tub overnight at -80°C, then transferred to liquid nitrogen within 24 hours (PDG: 57399). One vial was 
subsequently shipped to Censo on 11/10/17, as cells from the fresh blood samples had been slow to establish. 
Censo reprogrammed PBMCs to pluripotent erythroid progenitor cells (EPCs) using the Sendai cytotune 2.0 method. Cells 
were cultured on Matrigel in mTESRTM1 medium, passaged using EDTA, and cryopreserved in Cryostor CS10 medium. 
They were quality assured for sterility, including mycoplasma, HIV-1, HIV-2, HBV, HCV and microbiological growth, were 
viable as evidenced by growth to confluency in <5 days, were karyotypically stable with no major abnormalities over 100 
kb detected on array-based Comparative Genomic Hybridization (aCGH), and qPCR for the Sendai backbone showed 
clearance of the viral vector. The cells had a typical morphology and consistent 4-5 day growth cycle. The line is capable 
of spontaneous differentiation with reduction of self-renewal markers (differentiation index -2.48) and a clear increase 
in germ layer gene expression for mesoderm (differentiation index 6.12) and endoderm (differentiation index 2.44), with 
ectoderm showing a small but positive shift in gene upregulation (differentiation index 0.33), likely indicating potential 
for ectodermal differentiation in a longer spontaneous or directed differentiation assay. Marker expression was 
consistent with morphology, with the majority of self-renewal markers showing expression levels typical of human iPSCs 
(TRA-1-60 94.58% positive, POU5F1 99.44% positive, SSEA-4 99.92% positive, SSEA-3 48.46% positive, NANOG 84.18% 
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positive, SSEA-1 3.48% positive). Though NANOG and SSEA-3 were low, the normal expression of other markers in 
conjunction with typical morphology and the line’s ability to differentiate, indicates a phenotype consistent with a 
pluripotent stem cell line. In summary, the expression profile and differentiation potential were typical of a human 
pluripotent stem cell line. 6 vials, each containing 1.0E06 cells at passage 9, were returned. 
 
Figure 2.6. Micrographs of 125Q pluripotent ESCs. 
2.1.9 109Q induced pluripotent stem cells (iPSC) 
Fibroblasts from a female juvenile-onset HD subject with 19/109 CAG repeats (Coriell, ND39258) originated from Johns 
Hopkins University under Russell Margolis’s IRB protocol #NA00018358. The iPSC line, gifted from Prof Nick Allen, Cardiff 
University, was generated at the Cedars-Sinai Medical Center and named CS09iHD109. Fibroblasts were reprogrammed 
into iPSCs by a non-integrating and virus-free method using the Amaxa Human Dermal Fibroblast Nucleofector Kit to 
express episomal plasmids with six factors: OCT4, SOX2, KLF4, L-MYC, LIN28 and p53 shRNA. Cedars-Sinai iPSC Core 
characterised the iPSCs, showing a normal karyotype, performed PCR to confirm the absence of episomal plasmids, and 
demonstrated pluripotency by immunostaining, RT-qPCR for endogenous pluripotency genes, gene-chip and 
bioinformatic PluriTest assays, and spontaneous embryoid body differentiation confirming the capacity to form all germ 
layers (Mattis et al., 2015, Consortium, 2017, Grima et al., 2017, Wiatr et al., 2018). 
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Figure 2.7. Representative light micrograph of 109Q iPSCs (5x). 
2.1.10 U20S Flp-In 
Munoz et al. (2014) shared the U20S Flp-In T-Rex osteosarcoma cell line in which endogenous FAN1 has been knocked 
out by a novel Cas9/CRISPR technique. Briefly, cells were transfected with a vector containing an FRT Flp recombinase 
target site, an ATG start codon and a zeocin resistance gene. They were then transfected with the pcDNA5/FRT/TO vector 
that contains tetracycline-inducible Cas9 nuclease and a hygromycin resistance gene lacking an ATG initiation site and 
embedded in an FRT site. 
 
Figure 2.8. pcDNA5/FRT/TO vector containing Cas9-Flag under a tetracycline-inducible promoter and a hygromycin resistance 
gene. 
Reproduced from Munoz et al. (2014) 
Transfection with pOG44, a Flp recombinase, leads to recombination between FRT sites which is conservative, preserving 
both sites. This inactivates the zeocin resistance gene, generating stable Cas9 expression and hygromycin resistance. 
Cells were transfected with sgRNA (single-guide RNA) which binds to its complementary sequence in FAN1. Cas9 is 
recruited to the sgRNA scaffold domain inducing a double strand break and non-homologous end joining leads to 
deletions and insertions, thereby disrupting FAN1. The Cas9 was then removed (flipped out) by reintroducing pOG44, 
which leads to recombination between the FRT sites. This disrupts hygromycin resistance and restores zeocin resistance. 
Cas9 was then removed from the pcDNA5/FRT/TO vector and replaced with GFP-labelled full length FAN1, into which 
variants can be inserted by mutagenesis. This allows the FAN1 knockout cells to be complemented with tetracycline-
inducible GFP-FAN1 containing our variants of interest. These cells, which have the advantage of an isogenic background 
lacking the endogenous wild type FAN1 allele, permit the study of FAN1 function. A line expressing endogenous FAN1 
was provided as a control (FAN1+/+). 
Human codon optimized Cas9PCMV 2X TetO2 NLS FlagHygromicin resistanceFRT
PCDNA5.1
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Figure 2.9. Light micrograph of U20S FAN-/- cells in culture. 
2.2 Cell culture 
2.2.1 Lymphoblastoid cells 
LB cells were cultured in RPMI medium (Thermo, cat #21870-076) supplemented with 15% non-heat inactivated fetal 
bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin. 
2.2.2 ReNcell 
2.2.2.1 Routine culture 
Cell proliferation is maintained in the presence of growth factors bFGF and EGF and their withdrawal results in 
differentiation into oligodendrocytes, astrocytes, and neurons within few days (Hoffrogge et al., 2006, Donato et al., 
2007). Undifferentiated cells were maintained on Thermo Nunc plasicware coated with 10 μg/ml laminin in NSC media; 
DMEM:F-12 (Gibco, #21331046) with the following additives (Wood-Kaczmar et al., 2008). Media was changed every 48-
72h. 
• 0.03% human albumin solution (Sigma # A9080) 
• 5 µg/ml transferrin (Sigma #T0665) 
• 16.2 µg/ml putrescine (Sigma #P5780) 
• 5 μg/ml insulin (Sigma #I9278) 
• 400 ng/ml L-thyroxine (T4, Sigma #T2376) 
• 337 ng/ml tri-iodo-thyronine (T3, Sigma #T2877) 
• 60 ng/ml progesterone (Sigma #P6149) 
• 40 ng/ml sodium selenite (Sigma #S9133) 
• 10 U/ml heparin (Sigma #H3149) 
• 40 ng/ml corticosterone (Sigma #46148) 
• 1x penicillin and streptomycin (Sigma #P4333) 
• 2 mM glutamine (Life technologies #25030-024) 
• 10 ng/ml bFGF (Peprotech, #100-18B) 
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• 20 ng/ml EGF (Peprotech, #AF-100-15). 
2.2.2.2 Differentiation 
Cells were seeded at 30,000 cells/cm2 and expanded to 80% confluence on Thermo Nunc plasicware coated with 20 μg/ml 
laminin. Differentiation was initiated (day 0) by changing to Initial differentiation medium that lacked the growth factors 
FGF and EGF, but was supplemented with 0.5 mM dibutyryl-cAMP (Calbiochem, #28745) and 2 ng/ml GDNF (Peprotech, 
#450-10). On day 6, media was changed to Mid-differentiation medium that lacked cAMP and GDNF. On day 15 they were 
changed into Differentiated medium, with 0.5 mM glutamine. This protocol, well established in the Tabrizi lab, generates 
a pan-neuronal culture (Wood-Kaczmar et al., 2008). 
 
Figure 2.10. Neuronal differentiation of ReN VM cells expressing HTT exon 1 with 129 CAG repeats. 
Light micrographs with days from initiation of differentiation shown. 
ReN CX cells expressing 129 CAG repeats rarely successfully differentiated without losing expression of HTT exon 1 (1/10 
differentiations). Representative micrographs from a sample differentiation are shown below. 
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Figure 2.11. Neuronal differentiation of ReN CX cells expressing HTT exon 1 with 129 CAG repeats. 
Light micrographs with days from initiation of differentiation shown. 
2.2.3 Stem cells 
2.2.3.1 Reagents 
• DMEM/F-12 (w/o glutamine)    Gibco cat no. 21331-046 
• Neurobasal      Gibco cat no. 21103-049 
• D-PBS       Gibco cat no. 14190-094 
• N2       Gibco cat no. 17502-048 
• B27 (w/o Vitamin A)     Gibco cat no. 12587-010 
• B27 (with Vitamin A)     Gibco cat no. 17504-044 
• L-Glutamine      Gibco cat no. 25030-024 
• β-mercaptoethanol     Gibco cat no. 21985-023 
• LDN193189      Sigma cat no. SML0559 
• SB431542      Cambridge Biosciences SM33-10 
• Dorsomorphin      Cambridge Biosciences SM03-10 
• Activin A      PeproTech cat no. AF-120-14E 
• Y27632, ROCK inhibitor     Sigma cat no. Y0503 
• BDNF       PeproTech cat no. AF450-02 
• GDNF       PeproTech cat no. AF-450-10 
• Fibronectin      Millipore cat no. FC010 
• Poly-D-lysine      Sigma cat no. P7280 
• Laminin       Trevigen cat no. 3400-010-02 
• Geltrex       Gibco cat no. A1413302 
d0 d7d3
d10 d26 d41
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• Essential 8 medium     Gibco cat no. A1517001 
• EDTA (0.5 mM)     Gibco cat no. 15575-020 
• EGF      Peprotech cat no. AF-100-15  
• bFGF      Peprotech cat no. 100-18B 
2.2.3.2 Routine culture 
This culture protocol was adapted from Shi et al. (2012). iPSCs were cultured on Geltrex-coated 6-well plates in E8+ media 
(10ml of 50X supplement added to 500 ml Essential 8 media, Thermo #A1517001). To coat the plates, 1 ml 1:100 
Geltrex:cold DMEM:F12 was used per well of a 6-well plate, and plates were incubated at 37°C for a minimum of 1 hour 
prior to use. Cells were passaged at 80-85% confluency at a split ratio of 1:6. Cells were washed in D-PBS, 1 ml of 0.5 mM 
EDTA in D-PBS added and then incubated at 37°C for 3 min. EDTA was aspirated, 2 ml of E8+ added and cells were gently 
triturated. Cells were diluted and added to a new plate. Generally, cells needed passage every 4-5 days. 
2.2.3.3 Thawing 
One vial of frozen iPSCs was thawed into one well of a 6-well plate. The vial was removed from liquid nitrogen and 
immersed in a water bath at 37°C. Once thawed, cells were transferred into a 15 ml tube and 10 ml of room temperature 
E8+ added. Cells were centrifuged at 200 xg for 5 mins, the supernatant discarded, and the pellet gently resuspended in 
2 ml of E8+. Geltrex solution was removed from the wells and the 2 ml iPSC suspension added dropwise around the edges. 
Media was changed daily until the first passage. 
2.2.3.4 Freezing 
To freeze iPSCs, the passage was conducted as above, but following aspiration of EDTA, 900 µL ice cold E8+ was added 
per well to triturate cells, the suspension was transferred to a cryovial, 100 µL DMSO added and the vial was frozen at -
80°C in a Mr FrostyTM Freezing Container (Nalgene). 24 h later it was transferred to liquid nitrogen. 
2.2.3.5 Medium spiny neuron (MSN) differentiation 
This differentiation protocol was adapted from Arber et al. (2015). N2B27 differentiation medium was prepared using 
2/3 DMEM:F12 and 1/3 Neurobasal, supplemented with 1:100 L-Glutamine, 1:150 N2, 1:150 B27 (without vitamin A up 
until day 26, and with vitamin A thereafter), and 0.1 mM β-mercaptoethanol. Cells were washed with D-PBS, then 2 ml 
of room temperature N2B27 differentiation medium, supplemented with SMAD inhibitors 100 nM LDN (1:5000), 10 µM 
SB431542 (1:1000) and 200 nM dorsomorphin (1:5000), was added. Half media was changed on alternate days. 
Between day 9 and 12, cells were passaged at a ratio of 2:3 onto fibronectin-coated 12 well plate. Plates were coated 
with 0.5 ml per well of 25 µg/ml fibronectin solution in D-PBS (1:40), incubated at 37°C for at least 1 h and washed with 
D-PBS before use. An hour before passage, media was removed from cells and replaced with 1.5 ml N2B27 differentiation 
medium supplemented with 25 ng/ml (1:4000) activin A and 10 µM ROCK inhibitor (1:1000), and incubated at 37°C. After 
1 h the conditioned media was reserved in a falcon tube and the cells washed in D-PBS. 0.5 ml 0.02% EDTA was added 
and cells incubated for 1 min at 37°C. EDTA was aspirated, 1 ml conditioned media added, and the surface scratched in 
pattern 1 with the tip of a 10 ml serological pipette to generate large clusters of cells. Cells were collected into a falcon 
tube and diluted with fresh N2B27 media with activin A and ROCK inhibitor, to an appropriate volume for a 2:3 split ratio. 
After removing PBS from the fibronectin-coated plates, 1.5 ml of the cell suspension was distributed dropwise around 
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the edge of each well. The following day 1 ml media was replaced with 1.5 ml N2B27 containing activin A but no ROCK 
inhibitor. Half media was changed on alternate days, thereby diluting out the ROCK inhibitor. 
 
Figure 2.12. Scratch pattern 1 for MSN differentiation passage 1. 
A second passage was conducted between days 19 and 22, at the neural progenitor stage when cultures were multi-
layered with occasional rosette formation. Cells were passaged at a ratio between 1:1 and 1:4 onto poly-D-lysine/laminin 
coated 6 or 12 well plates, or coverslips. To coat, 1 ml of 0.01% poly-D-lysine in dH2O was added per well of a 6-well plate 
(100 µL per coverslip) and the plate incubated at 37°C for at least 2 h. Plates were washed with sterile dH2O and 1 ml of 
20 µg/ml laminin diluted in cold DMEM-F12 was added (100 µL per coverslip) and incubated at 37°C for at least 1h. Cells 
were washed in D-PBS, then 0.5 ml 0.02% EDTA was added and incubated for 1-2 min at 37°C. EDTA was aspirated and 1 
ml of N2B27 medium with activin A was added to each well. The surface was scratched with the tip of a P1000 pipette 
tip, to generate small clusters of cells, as shown in scratch pattern 2. Cell clusters were collected into a falcon tube and 
resuspended by trituration with a 5 ml stripette. The cell suspension was diluted with an appropriate volume of N2B27 
medium with activin A, and 2 ml added around the edge of each well of a 6-well plate. Half volume media changes were 
carried out with N2B27 medium with activin A on alternate days. 
 
Figure 2.13. Scratch pattern 2 for MSN differentiation passage 2. 
At day 26, half media was changed to N2B27 supplemented with activin A (25 ng/ml), 20 ng/ml BDNF and 20 ng/ml GDNF. 
Thereafter half media was changed on alternate days. Arber et al. (2015) reported that by day 35, 80% of cells are 
neuronal (NeuN+), of which 50% display CTIP2 staining and 20-50% are DARPP32 positive. 
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Figure 2.14. Light micrographs of differentiated medium spiny neurons (MSN). 
Top row – 109Q MSNs, bottom row – 73Q clone 2 (QS3.2) MSNs, left column – 10x magnification, right column – 20x magnification. 
2.2.3.6 Maintenance of neural stem cells 
Cultures can be maintained in the neural stem cell (NSC) stage at MSN differentiation passage 2 on day 19-20 (Shi et al., 
2012). 6 well plates were coated with 20 µg/ml laminin in cold DMEM-F12 and incubated at 37°C for at least 1h. Cells 
were washed with D-PBS, then 0.5 ml Accutase was added and incubated at 37°C for 3-5 min. Cells were triturated gently 
with a P1000 pipette, transferred to a 15 ml falcon containing 10 ml D-PBS, then centrifuged at 300 xg for 3 min. The 
supernatant was removed, and the pellet resuspended in MSN NSC medium, prepared from N2B27 (without vitamin A) 
supplemented with 25 ng/ml activin A, 20 ng/ml bFGF and 20 ng/ml EGF. Having removed the laminin solution, 2 ml of 
cell solution was distributed into each well. Media was changed on alternate days and the cells passaged as required with 
either Trypzean or accutase. NSCs can re-enter MSN differentiation at the passage 2 stage by plating at 80% density on 
poly-D-lysine/laminin coated plates or coverslips, as above. 
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Figure 2.15. Light micrograph of 109Q neural stem cells. 
10x magnification. 
2.2.4 U20S cells 
U20S cells were cultured in DMEM GlutaMAX (Thermo, cat #10565018) supplemented with 10% fetal bovine serum (FBS), 
100 U/ml penicillin and 100 µg/ml streptomycin. 
2.3 Cell imaging 
2.3.1 Fixation 
1-24h before fixation, 1:100 Geltrex was added to media to aid attachment. 75% of media was removed, 150 µL 
prewarmed 4% formalin was added, then 100 µL of this solution was replaced with fresh formalin. Cells were incubated 
at room temperature for 15 min, then 75% of the formalin was removed and the cells gently washed in PBS, before adding 
100 µL PBS, containing 0.02% (w/v) sodium azide. 
2.3.2 Immunofluoresence 
Cells were permeabilised in 0.2% triton X100 diluted in PBS for 15 min at room temperature. They were incubated in 
blocking buffer containing 10% goat serum and 1% bovine serum albumin (BSA) diluted in PBS for 1 hour at room 
temperature. Primary antibodies were diluted in 1% BSA and added to cells, either for 2 hours at room temperature or 
overnight at 4°C. After five 5 min washes in PBS, secondary antibodies were added, diluted 1:1000 in PBS, for 2 hours at 
room temperature and protected from light. After three 5 min washes, cells were counterstained with Hoechst (Thermo, 
cat #33342), diluted 1:2000 in PBS, for 10 min. After three 5 min washes they were mounted in Dako fluorescence 
mounting medium (Agilent, cat #S3023). They were imaged on a Zeiss LSM 710 confocal microscope and analysed with 
Zen software. 
2.4 Genetics 
2.4.1 DNA extraction 
DNA was extracted using the QIAamp DNA mini kit (Qiagen, cat #51306), according to manufacturer instructions. Briefly 
cell pellets were resuspended in 200 µL PBS, then 20 µL proteinase K and 200 µL of buffer AL were added, vortexed and 
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incubated at 56 ˚ C for 10 min. 200 µL ethanol was added and the sample was transferred to the QIAamp mini spin column 
for centrifugation at 6000 xg for 1min. The filter was washed with buffer AW1 then AW2, and then DNA was eluted in 50 
µL of buffer AE. DNA concentration was measured by nanodrop. 
2.4.2 CAG repeat sizing 
The sizing assay, termed fragment analysis, involves amplification of the CAG repeat region by PCR using a fluorescently 
labelled forward primer located upstream of the CAG region, then sizing of the fragment by capillary electrophoresis, 
with sufficient resolution to separate alleles of one repeat difference. 
Two methods are used; triplet-repeat primed PCR (TP PCR) and CAGCCG PCR (Losekoot et al., 2013). TP-PCR is used for 
accurate sizing and includes a reverse primer that binds 5’ of the polyproline repeat. This chimeric reverse primer is 
located partially within the CAG region, and hybridises to multiple locations within the CAG repeat, creating a series of 
PCR products that differ in size by 1 CAG, giving a characteristic ladder on the capillary electrophoresis trace. These stutter 
peaks extend from the smaller allele and terminate with the larger allele. This enables the detection of large pathogenic 
repeats that cannot be amplified by flanking primers. Because the 5ʹ end of the reverse chimeric primer exactly matches 
the sequence 3ʹ of the CAG region, this product is preferentially amplified and the highest peak represents the true allele. 
Neither TP-PCR or CAGCCG PCR allows amplification of alleles over around 160 CAG, so without the TP-PCR reverse 
primer, traditional PCR would amplify only the normal allele and the subject would appear to be homozygous for the 
normal allele (Bean and Bayrak-Toydemir, 2014, Bates et al., 2014). 
In CAGCCG PCR, the reverse primer binds 3’ of the polyproline. This improves PCR amplification, but can lead to 
misclassification of alleles due to variability in the number of prolines. Most people have 7 (67%) or 10 prolines (30%), 
but up to 12 prolines have been observed (0.5%) (Andrew et al., 1994b). 
Sizing using both TP-PCR and CAGCCG PCR allows resolution of two same-sized non-pathogenic alleles by their 
heterozygosity for the polyproline repeat, thereby excluding failed amplification of a large pathogenic allele. 
Several variants have been described in or near the CAG repeat at a collective frequency of around 1% (Bean and Bayrak-
Toydemir, 2014, Gellera et al., 1996, Margolis et al., 1999). Depending on the stringency of the PCR conditions, alleles 
carrying a polymorphism in the primer binding sites may not be amplified, which could mimic homozygosity. 
2.4.2.1 Primers 
Numerous primers have been used over the years. 
6-FAM labelled forward primers 
• Hu4: ATGGCGACCCTGGAAAAGCTGATGAA (Quarrell et al. (2012)) 
• HD1: ATGAAGGCCTTCGAGTCCCTCAAGTCCTTC (Warner et al. (1993)) 
• HD344: CCTTCGAGTCCCTCAAGTCCTTC (Andrew et al. (1993)) 
• HD3F : CCTTCGAGTCCCTCAAGTCCTT (Teo et al. (2008)) 
• GBF: GAGTCCCTCAAGTCCTTCCAGCA (Gonitel et al. (2008)) 
TP PCR reverse primer 5’ of the polyproline repeat 
• HDE (HD3): GGCGGTGGCGGCTGTTGCTGCTGCTGCTGC (Warner et al., 1993) 
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CAGCCG reverse primers 3’ of the polyproline repeat 
• HD482: GGCTGAGGAAGCTGAGGAG (Andrew et al. (1993)) 
• HD5 Losekoot: GGCGGCGGCTGAGGAAGCTGAG (Losekoot et al. (2013)) 
• HD5 Mangiarini: CGGCTGAGGCAGCAGCGGCTGT (Mangiarini et al. (1996)) 
• GBR: GCCCAAACTCACGGTCGGT (Gonitel et al. (2008)) 
 
Figure 2.16. Primers for CAG repeat sizing. 
The sense, antisense and amino acid sequences are given for primers targeting the CAG repeat region in HTT exon 1. Primer are in 
purple, the polyglutamine tract is marked in red and the polyproline repeat in blue. 
For TP-PCR, optimal amplification was achieved the HD3F/HDE primer pair, and for CAGCCG PCR the HD3F/HD5 
Mangiarini primer pair were best. These pairs were used throughout this thesis. 
2.4.2.2 PCR 
2.4.2.2.1 Tabrizi lab protocol 
25 µL reactions were prepared containing 12.5 µL AmpliTaq Gold 360 Master Mix (Cat #4398876), 2.5 µL GC enhancer 
(Cat #4398848), 1 µL of each forward and reverse primer (stock 5 µM), 1µL of 50 ng/µL DNA and 7 µL water. The following 
cycling conditions were used. 
1. Initial denaturation 95°C 10 min 
2. Denature 95°C 30 sec 
3. Anneal 58°C 30 sec 
4. Extend 72°C 30 sec (90 sec for alleles >100Q) 
5. Cycle to step 2 total 30x 
6. Final extension 72°C 7 min 
7. Store 4°C 
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2.4.2.2.2 Bates lab protocol 
10 µL reactions were prepared containing 0.1 µL AmpliTaq (stock 5 U/µl), 1 µL of 2 mM dNTPs, 0.8 µL of each primer 
(stock 10 µM), 1 µL DMSO, 2mM AM buffer (including 0.0035 µL b-mercaptoethanol freshly added) and 2 µL of 50-100 
ng/µL DNA. The following cycling conditions were used. 
1. Initial denaturation 94°C 90 sec 
2. Denature 94°C 30 sec 
3. Anneal 65°C 30 sec 
4. Extend 72°C 90 sec 
5. Cycle to step 2 total 35x 
6. Final extension 72°C 10 min 
7. Store 4°C 
2.4.2.3 Capillary electrophoresis 
1 µL of PCR product was added to 10 µL Hi-Di formamide (Thermo #4311320) and the appropriate volume of size standard 
in a low profile non-skirted 96 well plate. For alleles <130 CAG repeats, 0.5 µL of the GeneScan™ 500 LIZ™ (Thermo 
#4322682) size standard was used. For alleles >130 CAG, either 0.1 µL of MapMarker ROX 1000 (Eurogentec #MW-0195-
80ROX), or 0.5 µL GeneScan™ 1200 LIZ™ (Thermo #4379950) was used. The sample was denatured at 95°C for 5 min, 
before cooling at 4°C for 5 min. The PCR products were resolved by capillary electrophoresis on an ABI Genetic Analyzer.  
2.4.2.4 Calculation of repeat size 
The resulting .fsa files were displayed in GeneMapper and appear as a cluster of peaks differing by one CAG unit due to 
PCR stutter and mosaicism within the tissue. Allele size is assigned to the highest (modal) peak in the cluster (Swami et 
al., 2009). Because the number of bases flanking the CAG repeat is known, it is straightforward to calculate the number 
of pure CAG repeats from the PCR product size. The polyglutamine tract in most cases terminates with CAACAG, meaning 
there are more glutamines than CAG repeats. By convention, the number of uninterrupted CAG repeats is used as the 
result of the genetic test because this has a larger effect on phenotype than the number of glutamines in the repeat tract 
(Losekoot et al., 2013, Bean and Bayrak-Toydemir, 2014, Bates et al., 2015c). The UCLH neurogenetics lab participate in 
quality control assessment and have adapted the calculation, below, based on the use of international standards. 
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Assay Forward primer Reverse primer 
Bases flanking 
pure CAG 
Calculation of pure CAG 
repeat length 
UCLH neurogenetics lab quality-
controlled protocol 
TP-PCR HD3F HDE 40 ((product – 40) / 3) ((product – 39) / 3) + 2 
CAG CCG HD3F HD5 Mangiarini 110 ((product – 110) / 3) ((product – 108) / 3) + 2 
Table 2.3. Calculation of CAG repeat size. 
2.4.2.5 Error limits 
American College of Medical Genetics (ACMG) define the measurement limits as ±2 for <50 CAG repeats, ±3 for 50-75, 
and ±4 for >75 (Bean and Bayrak-Toydemir, 2014). European Molecular Genetic Quality Network (EMQN) guidance advise 
±1 for £42 CAG and ±3 for alleles >42 CAG (Losekoot et al., 2013). 
The same DNA sample was run 12 times for induced pluripotent stem cells (iPSC) with 73 or 109 CAG repeats, ReNeuron 
VM neural stem cells with 129 CAG repeats, and patient-derived lymphoblastoid (LB) cells with 130 CAG repeats. Note, 
repeat instability means CAG length in these lines at the time of testing was 73, 121, 131 and 136 CAG repeats 
respectively. Error margins were comfortably within ACMG and EMQN guidance. 
 
Figure 2.17. Boxplot of variability in CAG sizing from cell lines with a range of repeat lengths. 
73 – 73Q iPSC, 109 – 109Q iPSC, 129 – ReNeuron VM 129Q, 130 – 130Q LB. Note, repeat instability re CAG length in these cell lines at 
the time of testing was 73, 121, 131 and 136 CAG repeats respectively. 
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  iPSC 73Q iPSC 109Q ReN VM 129Q LB 130Q 
Mean CAG repeat length 73 121 131 136 
SD 0.4 1.0 1.5 0.9 
SEM 0.17 0.40 0.51 0.38 
Table 2.4. Variability in CAG sizing from cell lines with a range of repeat lengths. 
Note, repeat instability means CAG length in these cell lines at the time of testing was 73, 121, 131 and 136 CAG repeats respectively. 
2.4.2.6 CAG expansion analysis 
2.4.2.6.1 Change in modal CAG repeat length 
The primary measure of repeat instability was change in modal CAG repeat number compared to the baseline or control 
sample. Secondary measures included the somatic instability index (SII) (Mollersen et al., 2010) and a proportional 
expansion analysis. Modal CAG repeat size, SII and the proportional expansion analysis were calculated using a custom R 
script, available at http://caginstability.ml:3838/app/, and confirmed manually. 
 
Figure 2.18. Change in modal CAG repeat length. 
CAG repeat PCR generates a normal distribution of amplicon fragments spaced three base pairs apart due to PCR stutter and 
mosaicism within the sample tissue. Repeat size is given as the modal peak height. Change in mode is difference between baseline 
mode (upper trace, 12 day tail) and the mode in the experimental sample (e.g. lower trace, 14 week liver). In the example above the 
change in mode is 11 repeats. 
2.4.2.6.2 Somatic instability index (SII) 
The SII calculates expansion relative to a control sample and is measured in CAG repeat units. Firstly, the modal peak in 
the baseline sample is identified. Peaks less than 20% this height are excluded to remove background signal. The 
normalised height of each peak is calculated as a proportion of the sum of the peak heights. The change in CAG length of 
each peak is calculated relative to the modal peak. Normalised peak height is multiplied by change in repeat length, and 
the sum of these values gives the somatic instability index. 
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Figure 2.19. Instability index calculation from Lee et al. (2010). 
Instability was quantified from GeneMapper traces. Threshold was set at 20% of the modal peak height. Peaks falling below this were 
excluded from analysis. Peak heights normalised to the total of all peak heights were multiplied by the change in CAG length of each 
peak relative to the modal peak in tail. These values were summed to generate an instability index. Striatum analysis is shown as an 
example (HdhQ111/+, 5 months). Open, blue, black, and red peaks represent background, contracted alleles, modal allele from tail 
analysis of same mouse, and expanded alleles, respectively. 
2.4.2.6.3 Proportional expansion analysis 
For the proportional expansion analysis, A is taken as the width of the distribution below the modal peak in the baseline 
tissue, and B as the width above the baseline modal peak. The modal point of the control sample is fixed, and A and B 
recalculated for each tissue or sample. B/(A+B) gives the proportion of the distribution that has expanded relative to the 
baseline sample. 
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Figure 2.20. Proportional expansion analysis. 
A is taken as the width of the distribution below the modal peak in the baseline tissue, and B as the proportion above the baseline 
modal peak. The modal point is fixed, and A and B recalculated using each tissue. B/(A+B) gives the proportion of the distribution that 
has expanded relative to the baseline sample. 
 
Figure 2.21. Representative example of fragment analysis traces from mouse #79 for the tissues and ages indicated (left). 
Modal CAG repeat length is given by red arrows. 20% threshold value for instability index is shown by yellow hashed line. Distribution 
widths for proportional expansion analysis are given below each trace in black. Instability index and proportional expansion measures 
are shown to the right. SL – left striatum, SR – right striatum, LIV – liver. Plots displayed in GeneMapper. 
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2.4.2.7 Statistical analysis 
2.4.2.7.1 Curve estimation 
Curve estimation was performed in R by producing regression statistics for different models with a custom script (see 
Appendix). Variance from the model and significance was measured by analysis-of-variance. 
2.4.2.7.2 Expansion rate 
Expansion rate was calculated from the slope of linear regression model fitted to change in modal CAG repeat length, 
and was expressed as number of days per change in modal CAG length (days/Q) +/- 95% confidence interval. Expansion 
rates were compared with control cells by analysis of variance between the slopes of the linear regression lines in SPSS 
(IBM). To compare expansion rates between treatments, the rate of CAG expansion was modelled as a linear regression 
of CAG expansion on the number of days since the start of treatment. Differences in rate of CAG expansion between 
treatments were modelled by the inclusion of a day*treatment interaction term in the regression, and the significance 
of this term determines the significance of CAG expansion rate differences between treatments. Correlations between 
multiple CAG expansion measurements from the same replicate cell line were modelled by including cell line specific 
random effects on CAG expansion rate in the analysis. Models were fitted using the lmer function in R. Initially, global 
differences in CAG expansion rate were tested between all treatments simultaneously. If this test was significant, post-
hoc tests were performed to characterise the differences. 
2.4.3 Sanger sequencing 
The target region was PCR amplified by adding 1 µL of template DNA at 200 pg/µL to 12.5 µL FastStart PCR Master mix 
(Sigma, cat #4710436001), 1 µL of each primer at 10 µM and 9.5 µL of water. Thermal cycling conditions were 95°C for 4 
min, then 30 touchdown cycles of 95°C for 30 sec, 62°C for 30 sec and reducing by 0.2°C each cycle (final 57°C), and 72°C 
for 2 min. Primers and nucleotides were degraded by adding 0.02 µL exonuclease I (Thermo, cat #EN0581), 0.08 µL FastAP 
(Thermo, cat #EF0654) and 0.3 µL water to each 1 µL of PCR product, then incubating at 37°C for 30 min and 80°C for 15 
min. The sequencing reaction was set up in a low profile, non-skirted 96 well plate by adding 1 µL of PCR product at 20 
ng/µL to 1 µL of BigDye (Thermo, cat #4337455), 5 µL Better buffer (Clent, cat #3BB-5), 0.4 µL of forward or reverse 
primer at 10 µM, 3.8 µL of betaine or Q solution and 3.8 µL of water. Thermal cycling conditions were 96°C for 1 min, 
then 25 cycles of 96°C for 10 sec, 50°C for 5 sec and 60°C for 4 min. DNA was precipitated by adding 3.75 µL of 0.125 M 
EDTA and 45 µL of ethanol, mixing, then incubating for 15 min at room temperature before centrifuging at 3000 xg for 
30 min at 4°C. The plate was then inverted and spun up to 185 xg for 30 sec. 60 µL of 70% ethanol was added and the 
plate was again centrifuged at 1650 xg for 15 min at 4°C before inverting it and spinning at 185 xg for 1 min. The plate 
was then covered to protect from light and left to dry at room temperature for 15 min or on a heat block at 37°C for 5 
min. 10 µL of Hi-Di formamide (Thermo, cat #4311320) was added to each well and at least 10 µL of water to any empty 
wells, then the plate was sealed, vortexed and pulse centrifuged ahead of incubation at 95°C for 2 min, then cooled to 
4°C for 2 min. Samples were sequenced on an ABI 3730 DNA analyzer. 
2.4.4 RNA extraction 
500 µL of TRIzol (ThermoFisher) was added to cells, which were triturated several times to homogenise, then incubated 
for 5 min. 100 µL chloroform (VWR) was added, and incubated for 5 min. The sample was centrifuged at 13,000 rpm for 
15 min. The aqueous phase was transferred to a new tube and an equal volume of 70% ethanol added. RNA was purified 
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as per the RNeasy Mini Kit protocol (QIAGEN, 74106). A 15 min genomic DNA digestion step (DNAse I, QIAGEN, 79254) 
was performed between the RW1 buffer washes. RNA was eluted with water and concentration was measured on a 
NanoDrop 1000. 
2.4.5 Quantative real time PCR (qPCR) 
RNA was reverse transcribed with an initial 12 µL reaction containing 10 µL of RNA at 1 µg/µL, 1 µL of 10 mM dNTPs 
(ThermoFisher), and 1 µL of 100 ng/µL random hexamers P21 (Eurofins), which was incubated at 65°C for 5 min. For the 
second 20 µL reaction 4µL of 5x first strand buffer, 2 µL of 100mM DTT (ThermoFisher),  1µL of RNasin (Promega) and 1 
µL of MMLV-RT (ThermoFisher) were added, then incubated at 25°C for 10 min, 37°C for 50 min and 70°C for 15 min(Benn 
et al., 2008a). The resulting cDNA was diluted to 1:10. 
2.4.5.1 Taqman 
15 µL qPCR reactions were set up in triplicate containing 7.5µL TaqMan Fast Advanced Master Mix (ThermoFisher), 3.75 
µL water, 3 µL cDNA and 0.75 µL of the appropriate probe set (ThermoFisher). PCR was quantified on the CFX 96 qPCR 
system (Bio-Rad) using the following thermal cycling conditions; 95°C for 40 sec, then 40 cycles of 95°C for 7 sec and 60°C 
for 20 sec. 
2.4.5.2 SYBR green 
25 µL reactions were set up in triplicate containing 12.5 µL SYBR green master mix (Thermo, cat #4309155), 0.75 µL of 
each primer at 5 µM, and 10 µL water. Standard cycling conditions were used; 94°C for 2 min, then 40 cycles of 94°C for 
15 sec and 60°C for 1 min. 
2.4.5.3 Comparative cycle threshold analysis 
The geometric mean (geomean) of housekeeping genes was used as a reference in order to determine the relative 
expression ratio of the genes of interest using the comparative Ct method (2-ΔΔCT) (Benn et al., 2008a). Briefly, 
expression level was corrected for the geomean of housekeeping genes (∆Ct), then expressed relative to the control or 
lowest expressing sample (ΔΔCt), and finally the fold change in expression was given by 2^-∆∆Ct. Data were analysed 
using a student’s t-test. 
2.4.6 DNA repair assays 
2.4.6.1 Interstrand crosslink repair 
ICL repair can be assayed by treating cultured cells with DNA crosslinking agents and assaying sensitivity (MacKay et al., 
2010b, Liu et al., 2010b). 
Mitomycin C (MMC) is an aziridine containing chemotherapeutic which potently crosslinks DNA by alkylating guanine 
nucleosides. Crosslinks are repaired by homologous recombination. Previous studies in HEK293 cells have used 0-60 
ng/ml for 24h (MacKay et al., 2010a, Kratz et al., 2010b, Liu et al., 2010c). Cells were treated for 16-24 hours with MMC 
at the indicated concentration. They were then washed in PBS and diluted in medium to 200 cells per well of a 96 well 
plate and viability was assessed after 10 days in culture by MTT assay. 
Cisplatin is a platinum containing cytotoxic. Platinum complexes react with DNA resulting in interstrand crosslinks, as 
well as intrastrand crosslinks and non-functional adducts. Previous studies in HEK293 cells used 0-1 μg/ml for 24h 
78 
(MacKay et al., 2010a, Kratz et al., 2010b). Cells were treated for 24 hours at the indicated concentration, then washed 
in PBS and cultured for 10 days before the MTT cell viability assay. 
For the γ-H2Ax assay, cells were treated with 200 ng/ml MMC or 1 µg/ml cisplatin for 2 h, then washed in PBS and cultured 
in medium for 24-72h. γ-H2Ax foci clearance was analysed as described in MacKay et al. (2010b). The proportion of cells 
in each population with more than 10 γ-H2AX foci at each time point (“γ-H2AX positive”) was determined. 
2.4.6.2 Mismatch repair 
6-thioguianine (6-TG) can be used to assay mismatch repair. It is converted to 6-methylthioguanine (6-MTG) which is 
incorporated into the genome in place of guanine and directs the insertion of thymine on the daughter strand, which is 
a mismatch and thus provokes MMR. Thymine is removed from the daughter strand but 6-MTG remains in place on the 
template strand. The cycle continues over and over, with unsuccessful repair attempts ultimately resulting in cell death. 
Cells lacking functional MMR are resistant (Karran and Attard, 2008, Swann et al., 1996). Cells were treated for 24 hours 
at the indicated concentration, then washed in PBS and cultured for 10 days before the MTT cell viability assay 
2.4.6.3 Single and double strand break repair 
Hydrogen peroxide (H2O2) oxidises bases and induces single and double strand breaks (Driessens et al., 2009). It was 
added to cells at the indicated concentration for 30 min, then cells were washed in PBS and cultured for 10 days before 
MTT cell viability assay. 
2.4.7 Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) is used to determine whether specific proteins are associated with particular DNA 
regions. DNA and its associated proteins are crosslinked, and the DNA-protein complexes are then sheared into roughly 
500 bp fragments by sonication. A protein-specific antibody was used to immunoprecipitate crosslinked DNA fragments 
which could then be quantified by qPCR or sequenced. 
Cells were collected washed in PBS then cross-linked with formaldehyde (1% final concentration) for 10 min at room 
temperature. Excess formaldehyde was quenched by adding glycine to a final concentration of 125 mM and incubating 
for 5 min. Cross-linked cells were pelleted, washed in PBS and frozen at -80°C or used directly. Cells were lysed in lysis 
buffer consisting of 15 mM Tris-HCL (pH7.5), 0.3 M Sucrose, 60 mM KCl, 15 mM NaCl, 5mM MgCl2, 0.1 mM EGTA, 0.5 mM 
DDT, 0.2% IGEPAL-CA, and supplemented with protease inhibitors. Nuclei were pelleted at 20,000 xg for 20 min. 
Supernatants were aspirated and nuclei were resuspended in sonication buffer, consisting of 50 mM Tris pH 8.0, 10 mM 
EDTA and 1 % SDS, supplemented with protease inhibitors. Chromatin was fragmented by 10 cycles of 30 sec sonication 
in a Bioruptor apparatus. Ice water was added to the sonication bath to ensure temperature was regulated during 
disruption. Insoluble material was cleared by centrifugation at 20,000 xg for 10 min. This sonicated fraction was used 
diluted 10-fold with dilution buffer, consisting of 16.7 mM Tris pH 8.0, 1.2 mM EDTA, 167 mM NaCl and 1% Triton X-100, 
supplemented with protease inhibitors. This was used as the ChIP input. Overnight Immunoprecipitation at 4°C used GFP-
Trap beads (ChromoTech) to capture GFP-FAN1 forms or an affinity purified FAN1 sheep polyclonal antibody (S420C) and 
protein G magnetic beads (20 µl of either bead per reaction). The isolated ChIP fractions were washed twice in Wash 
Buffer 1, consisting of 20 mM Tris-HCl pH 8.1, 50mM NaCl, 2mM EDTA, and 1% TX-100, 0.1% SDS, then once in Wash 
Buffer 2, consisting of 10 mM Tris.Cl pH 8.1, 150 mM NaCl, 1 mM EDTA, 1% NP40 and 1% Na deoxycholate, and then once 
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in Tris-EDTA. Bound material was eluted at 65°C for 30 min in 500 µL of 1% SDS and 500 µL of 0.1 M NaHCO3. Cross-links 
were reversed in ChIP and input fractions by adding NaCl to a final concentration of 250 mM and proteinase K (2 µl of 0.5 
mg/ml PK per reaction), then heating to 65°C for at least 4 h. DNA was purified using columns (Qiagen, cat #51306) and 
subjected to PCR using primers detailed below. DNA was quantified by SYBR Green qPCR with the indicated primers and 
a QuantStudio 5 real time qPCR machine. 
2.4.7.1 HTT primers 
Primer Sequence Start End 
g.5029F CCGCTCAGGTTCTGCTTTTA 29 48 
g.5057F CCAGAGCCCCATTCATTG 57 74 
g.5174R GCCTTCATCAGCTTTTCCAG 155 174 
HD3F forward (6-FAM, Teo et al 2008, UCLH) CCTTCGAGTCCCTCAAGTCCTT 174 195 
GB forward (6-FAM) GAGTCCCTCAAGTCCTTCCAGCA 179 201 
CAG repeat   197 253 
HDE reverse (UCLH) GGCGGTGGCGGCTGTTGCTGCTGCTGCTGC 241 270 
g.5310R CTGAGGAAGCTGAGGAGGC 286 304 
GB reverse (Gonitel et al, 2008) GCCCAAACTCACGGTCGGT 402 420 
g.5675F ATTCACCGAGGGGAGTCAC 669 687 
g.5773R CCCTGGTTTCTCGCAAATAA 748 767 
HTT con 1F TTTGCCCAGGGAATCTTTGC 25715 25734 
HTT con 1R TTGCAAGCGGAGAGAGAAGA 25847 25866 
HTT con 2F TGCCTTTCGAAGTTGATGCA 137819 137838 
HTT con 2R TGCCACCACGAATTTCACAA 138001 138020 
Table 2.5. HTT PCR primers. 
Start and end positions are relative to the genomic sequence, numbered from the start of the 5’UTR (Homo sapiens chromosome 4, 
GRCh38.p12 Primary Assembly, NCBI Reference Sequence: NC_000004.12). The location of the CAG repeat region is given for 
reference in red. 
 
Figure 2.22. Schematic representation of HTT primers on the genomic sequence. 
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Figure 2.23. HTT CAG repeat primers marked on the genomic sequence. 
The polyglutamine repeat is given in red. 
Primer Sequence Start End 
ATXN3 con F TATCCGTCTTGCAAGGTGGT   7359 7378 
ATXN3 con R CCCTGAATTGACGGCAGATG   7515 7534 
ATXN3 CAG F TTCAGACAGCAGCAAAAGCA   35564 35583 
CAG repeat   35582 35611 
ATXN3 CAG R AAAGTGTGAAGGTAGCGAACAT 35711 35732 
Table 2.6. ATXN3 PCR primers. 
Start and end positions are relative to the genomic sequence, numbered from the start of the 5’UTR (Homo sapiens chromosome 4, 
GRCh38.p12 Primary Assembly, NCBI Reference Sequence: NC_000014.9). The location of the CAG repeat region is given for reference 
in red. 
 
Figure 2.24. Schematic representation of ATXN3 primers on the genomic sequence. 
Primer Sequence Start End 
DMPK con F TGGGCCCAAAGACTCCTAAG 7722 7741 
DMPK con R TCTGAAGTCCTGTGGCTCTG 7874 7893 
CTG repeat   12294 12353 
Table 2.7. DMPK PCR primers. 
Start and end positions are relative to the genomic sequence, numbered from the start of the 5’UTR (Homo sapiens chromosome 4, 
GRCh38.p12 Primary Assembly, NCBI Reference Sequence: NC_000019.10). The location of the CTG repeat region is given for 
reference in red. 
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Figure 2.25. Schematic representation of DMPK primers on the genomic sequence. 
Primer Sequence Start End 
FXN GAA F CACTTTGGGAGGCCTAGGAA    1614 1633 
GAA repeat   1725 1742 
FXN GAA R CGCCCGGCTAACTTTTCTTT    1746 1765 
FXN con F AAGCGTGCATTTTGGATTCAA   19300 19320 
FXN con R TTTTCAATTCCCTCACTGTCCTT 19466 19488 
Table 2.8. FXN PCR primers. 
Start and end positions are relative to the genomic sequence, numbered from the start of the 5’UTR (Homo sapiens chromosome 4, 
GRCh38.p12 Primary Assembly, NCBI Reference Sequence: NC_000009.12). The location of the GAA repeat region is given for 
reference in red. 
 
Figure 2.26. Schematic representation of FXN primers on the genomic sequence. 
Primer Sequence Start End 
TBP con F  AAGAGTGTGCTGGAGATGCT 2605 2624 
TBP con R  ATGCCCTTCCTTGCCTTTTG 2812 2831 
TBP CAG F1 CAGCCAGCCTAACCTGTTTT 7421 7440 
TBP CAG F2 TGACCCCACAGCCTATTCAG 7517 7536 
TBP CAG R1 CTGCCTTTGTTGCTCTTCCA 7559 7578 
CAG repeat   7567 7689 
TBP CAG R2 TGGGACGTTGACTGCTGAA  7709 7727 
Table 2.9. TBP PCR primers. 
Start and end positions are relative to the genomic sequence, numbered from the start of the 5’UTR (Homo sapiens chromosome 4, 
GRCh38.p12 Primary Assembly, NCBI Reference Sequence: NC_000006.12). The location of the CAG repeat region is given for 
reference in red. 
 
Figure 2.27. Schematic representation of TBP primers on the genomic sequence. 
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2.4.7.2 qPCR analysis 
ChIP-qPCR data requires normalisation for sources of variability, including the amount of chromatin loaded, the efficiency 
of immunoprecipitation and DNA recovery. Data was normalised using the fold enrichment method (Scientific, 2018, 
Lacazette, 2017). The control immunoprecipitation (IP) without antibody signal is subtracted from the 
immunoprecipitation sample (dCt), then the fold enrichment is calculated as 2-dCt. This method assumes the background 
signal is reproducible between samples. 
2.5 Protein 
2.5.1 Western blotting 
Cells were washed in PBS before centrifugation at 13,000 G for 1 min and removal of supernatant. The pellet was 
resuspended in 200 μL of ice-cold lysis buffer, consisting of 0.1% Triton X-100, 0.1% sodium deoxycholate, 50 units/ml of 
benzonase, protease inhibitors, and incubated on ice for 20 min, agitating regularly. A small volume was removed for 
protein quantification assay using Bio-Rad assay. Proteins were precipitated overnight in 800 µL cold methanol, then 
centrifuged for 20 min at 12,000 rpm and 4°C and the supernatant removed. Pellets were dried, then resuspended in at 
a uniform concentration in SDS sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 12.5 
mM EDTA and 0.02% bromophenol blue), shaking at 95°C for 10 min to assist resuspension. Equal amounts of protein 
were loaded into the wells of a 9% SDS-polyacrylamide stacking gel (9% gel: 2.5 ml gel loading buffer, 6 ml of 30% 
acrylamide, 0.1% SDS, 10 µL of tetramethylethylenediamine (TEMED), 100 µL ammonium persulfate (APS), made up to 
10 ml with water, 1 mm plates. Stacking gel: 312.5 µL acrylamide, 312.5 µL stacking gel buffer, 0.1% SDS, 2.5 µL TEMED, 
125 µL APS, made up to 2.5 ml with water). The gel was run at 60 V for 10 min, until samples had run through the 
separating gel, then at 125 V for 1-2h in running buffer (25 mM Tris, 190 mM glycine, 0.1% SDS, pH 8.3). Samples were 
then transferred to nitrocellulose membrane in transfer buffer (25 mM Tris base, 190 mM glycine, 20% methanol, pH 
8.3). The membrane was blocked for 1h at room temperature or overnight at 4°C in Odyssey blocking buffer (Li-cor, #927-
40100). The appropriate concentration of primary antibody was added in blocking buffer and incubated overnight at 4°C. 
The membrane was washed five times in TBS-T (1x TBS, 900 ml water, 0.1% Tween 20), 5 min each wash, then incubated 
with secondary antibody in blocking buffer at room temperature for 1h. The membrane was then again washed three 
times in TBS-T (Goold et al., 2011), and imaged using an Odyssey Infrared Imager (LI-COR). 
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Chapter 3 DNA repair variants modify phenotype in polyglutamine diseases 
3.1 Background 
3.1.1 Polyglutamine diseases 
The 9 polyglutamine diseases are HD, SCA types 1, 2, 3 (Machado-Joseph disease, MJD), 6, 7 and 17, dentatorubral 
pallidoluysian atrophy (DRPLA), and spinal bulbar muscular atrophy X-linked type 1 (SMAX1, or SBMA). HD and SCA3 are 
the commonest, but the mean prevalence of all polyglutamine diseases is around 1/10,000 (Fan et al., 2014). All are 
dominantly inherited, with the exception of SBMA, which is X-linked. The protein in each case contains an expanded 
glutamine tract which leads to aggregation. In all, there is a negative correlation between repeat length and disease 
severity, all show anticipation, with the repeat tending to expand and cause more severe disease intergenerationally, all 
tend to begin in middle life, progress inexorably to death within around 15-20 years and have a predominantly 
neurological phenotype (Fan et al., 2014). 
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Polyglutamine 
disease Gene 
Prevalence 
(per 100,0000) 
Variance in AAO explained by repeat length 
(% that is heritable) 
Normal 
range 
repeat 
length 
Pathogenic 
range 
Somatic 
instability 
HD HTT 
3–10 (Wood, 2012, 
Rawlins, 2010, 
Bates et al., 2014, 
Warby et al., 2014) 
50–60% (Gusella et al., 2014, Persichetti et al., 
1994, Snell et al., 1993, Andrew et al., 1993, 
Duyao et al., 1993) (40–60% (Djousse et al., 
2003, Wexler et al., 2004b)) 
6–35 40–121 Yes 
SCA1 ATXN1 0.16 (Durr, 2010) 
64–76% (Ranum et al., 1994, Tezenas du 
Montcel et al., 2014, Globas et al., 2008, van de 
Warrenburg et al., 2002, van de Warrenburg et 
al., 2005) (no detected heritable component 
(van de Warrenburg et al., 2005))  
6–38 45–83 Yes 
SCA2 ATXN2 0.2 (Durr, 2010) 
50–80% (Giunti et al., 1998, Tezenas du 
Montcel et al., 2014, Velazquez Perez et al., 
2009, Globas et al., 2008, Hayes et al., 2000, 
Geschwind et al., 1997, Pulst et al., 2005, van 
de Warrenburg et al., 2002, van de Warrenburg 
et al., 2005, Lorenzetti et al., 1997) (17–59% 
(Pulst et al., 2005, van de Warrenburg et al., 
2005)) 
15–31 33–500 Yes 
SCA3 ATXN3 0.4 (Durr, 2010) 
45–80% (Tezenas du Montcel et al., 2014, 
Maruyama et al., 1995, Bettencourt and Lima, 
2011, Globas et al., 2008, Riess et al., 2008, van 
de Warrenburg et al., 2002, Durr et al., 1996, 
van de Warrenburg et al., 2005) (46% (van de 
Warrenburg et al., 2005)) 
12–44 52–87 Yes 
SCA6 CACNA1A 0.04 (Durr, 2010) 
26–52% (Tezenas du Montcel et al., 2014, 
Globas et al., 2008, Matsuyama et al., 1997, 
van de Warrenburg et al., 2002, van de 
Warrenburg et al., 2005) (no detected heritable 
component (van de Warrenburg et al., 2005)) 
4–18 20–33 Unknown 
SCA7 ATXN7 0.12 (Durr, 2010) 
71–88% (Tezenas du Montcel et al., 2014, 
David et al., 1998, van de Warrenburg et al., 
2002, van de Warrenburg et al., 2005) (no 
detected heritable component (van de 
Warrenburg et al., 2005)) 
3–19 37–460 Yes 
SCA17 TBP <0.02 (Durr, 2010) Unknown 25–40 49–66 Unknown 
DRPLA ATN1 
0.005–0.04 (Le Ber 
et al., 2003, Filla et 
al., 2000, Pujana et 
al., 1999, Silveira et 
al., 2002) 
50–68% (Wardle et al., 2009, Potter, 1996) 6–35 48–93 Yes 
SBMA AR 
0.65–2.00 (Udd et 
al., 1998, Spada, 
2014) 
29% (Sinnreich et al., 2004) 9–34 38–72 Yes 
Table 3.1. Characteristics of the polyglutamine diseases. 
Epidemiology and CAG repeat ranges of polyglutamine diseases. Prevalence is given per 100,000 European population. AAO = age at 
onset; HD = Huntington's disease; SCA = spinocerebellar ataxia; DRPLA = dentatorubral-pallidoluysian atrophy; SBMA = spinal and 
bulbar muscular atrophy. 
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Polyglutamine 
disease 
Phenotype 
HD 
Involuntary movements including chorea, and impaired voluntary movements with incoordination and 
bradykinesia (Bates et al., 2015c). Cognitive impairment in attention, mental flexibility, planning, initiation, lack 
of awareness, disinhibition (Duff et al., 2010) and impulsivity (Papoutsi et al., 2014). Neuropsychiatric features 
including depression, irritability, apathy and executive dysfunction. 
SCA1 
Ataxia, bulbar, somatosensory an oculomotor dysfunction, pyramidal signs, visual impairment, 
electrophysiological abnormalities (Subramony, 2012), executive dysfunction and verbal memory impairment 
(Burk et al., 2003, Kawai et al., 2009). 
SCA2 
Ataxia, slow eye movements, peripheral neuropathy, postural and action tremor, myoclonus and hyporeflexia, 
dementia with impaired attention, memory, frontal executive function (Kawai et al., 2009, Burk, 1999, Storey et 
al., 1999, Sokolovsky et al., 2010). 
SCA3 (MJD) Ataxia, pyramidal involvement, ophthalmoplegia, peripheral neuropathy, parkinsonism in some, cognitive dysfunction including attention difficulties (Burk et al., 2003, Maruff et al., 1996). 
SCA6 Ataxia, occasional extrapyramidal and sensory effects, impaired executive function and visual memory (Kawai et al., 2008, Globas et al., 2003, Sokolovsky et al., 2010). 
SCA7 Ataxia, retinal degeneration, ophthalmoplegia, seizures, and dementia with impaired executive function (Sokolovsky et al., 2010). 
SCA17 Ataxia, psychiatric features, extrapyramidal signs, seizures, dementia and apraxia (Schneider et al., 2006, Rolfs et al., 2003). 
DRPLA Ataxia, choreoathetosis, myoclonus, epilepsy, and dementia (Ikeuchi et al., 1995, Naito and Oyanagi, 1982, Warner et al., 1994). 
SBMA 
Male only. Progressive weakness, atrophy and fasciculations in limbs and bulbar musculature (Atsuta et al., 
2006, Kennedy et al., 1968, Rhodes et al., 2009), peripheral sensory neuropathy (Antonini et al., 2000), 
gynaecomastia, testicular atrophy and reduced fertility (Dejager et al., 2002). 
Table 3.2. Phenotypes of polyglutamine diseases. 
HD = Huntington's disease; SCA = spinocerebellar ataxia; DRPLA = dentatorubral-pallidoluysian atrophy; SBMA = spinal and bulbar 
muscular atrophy. 
3.1.2 Genetic modifiers 
A way of overcoming the complexity of the pathogenesis of repeat expansion disease is an unbiased search of the genome 
for loci that modify the course of the disease in a beneficial or damaging way. Drug manipulation of the identified 
biological pathway could have similarly beneficial effects on phenotype. In HD, the length of the CAG repeat in HTT 
explains around 56% of observed variation in age at onset (Gusella et al., 2014, Langbehn et al., 2004), but up to 40% of 
the remaining variability is heritable and due to genetic differences elsewhere in the genome (Wexler et al., 2004a).  
3.1.2.1 Age at onset 
Investigating these genetic modifiers, a GWAS of over HD 4000 patients identified three independent genome-wide loci 
significantly associated with age at motor onset; one on chromosome 8 and two close together on chromosome 15 (GeM-
HD, 2015). In any GWA, the location of significant variants does not immediately identify which gene underlies the effect; 
genotyping arrays designed for GWA studies use linkage disequilibrium to provide coverage of the entire genome by 
genotyping a subset of variants. They identify an association signal, or a region of linkage disequilibrium containing causal 
variants, which can contain hundreds of variants, spanning relatively large regions that encompass several genes (Bush 
and Moore, 2012, Spain and Barrett, 2015). The loci on chromosome 15 could be associated with FAN1, MTMR10 or the 
pseudogene HERC2P10. These lie in a region of copy number variation (CNV) due to non-homologous recombination of 
flanking repeats, and both deletion or duplication of the region have been associated with intellectual disability, epilepsy, 
autism and schizophrenia (Ionita-Laza et al., 2014). The highest priority candidate gene is FAN1, a nuclease that is involved 
in DNA interstrand crosslink (ICL) repair and interacts with MMR proteins including MLH1. The two chromosome 15 
signals were in opposing directions; the minor allele at rs146353869 was associated with 6.1 year earlier onset (p = 4.3x10-
20) and at rs2140734 with 1.4 year later onset (p = 7.1x10-14), suggesting FAN1 polymorphisms can be protective or 
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damaging in HD. These effect sizes are significant, representing up to 33% of disease duration and 30% of lifespan prior 
to diagnosis. The top coding SNP in FAN1, and third most significant overall, rs150393409 (pArg507His) in the DNA binding 
domain, is in strong linkage disequilibrium with the index SNP, rs146353869, and is associated with 6-year early onset (p 
= 9.34x10-18). Both these SNPs were imputed and either could be driving the deleterious GWAS signal. MTMR10 is 
involved in inositol-phosphate signalling. 
The role of FAN1 in the Fanconi anaemia ICL repair pathway remains unclear (Ceccaldi et al., 2016b). Rather than targeting 
specific DNA sequences, it is structure-specific, binding branched substrates that mimic DNA repair (Ceccaldi et al., 
2016b). Therefore, it is conceivable that FAN1 could target abnormal DNA structures formed by expanded repeats. Its 
mutation does not cause Fanconi anaemia, but loss-of-function mutations lead to the recessive renal syndrome 
karyomegalic interstitial nephritis (KIN) (Zhou et al., 2012) and heterozygous truncating mutations can cause hereditary 
colorectal cancer in a similar way to MMR mutations (Segui et al., 2015a). FAN1 may act directly at the repeat expansion 
to influence expansion. Alternatively, deficits in DNA repair could independently add, perhaps in an activity dependent 
manner (Madabhushi et al., 2015), to the selective neurodegeneration induced by the HTT CAG repeat expansion. 
The chromosome 8 association signal, driven by rs1037699 (p = 2.7E-08), contained RRM2B and UBR5. RRM2B is a subunit 
of the rate-limiting enzyme in deoxyribonucleotide triphosphate (dNTP) synthesis (Pontarin et al., 2011), which  is 
involved in DNA replication and repair (Pontarin et al., 2012), regulates mitochondrial DNA content (Bourdon et al., 2007) 
and reduces oxidative stress (Kuo et al., 2012). UBR5 is a E3 ubiquitin ligase involved in proteasome-mediated protein 
degradation, a function implicated in the accumulation of misfolded HTT fragments (Ortega and Lucas, 2014). 
A peak on chromosome 3 that did not reach significance in the GeM GWAS, but which a subsequent study with a larger 
cohort found genome-wide significant (Lee et al., 2017), was driven by rs144287831 (p = 2.2E-7) and centres on MLH1. 
MLH1 is known to interact with FAN1 (MacKay et al., 2010a, Kratz et al., 2010a, Liu et al., 2010c, Smogorzewska et al., 
2010b) and its inactivation in HD mice reduces somatic instability and improves disease phenotype (Pinto et al., 2013a). 
The pathway analysis found a substantial enrichment for the network of DNA repair genes, particularly nucleotide 
excision repair (p = 1.69E-06) and mismatch repair (p = 3.25E-06), independent of genome-wide significant individual 
SNPs. 
3.1.2.2 Progression 
A more recent GWAS identified a locus on chromosome 5 that was associated with the rate of HD progression (Hensman 
Moss et al., 2017b). This region included MSH3, DHFR and MTRNR2L2, and genome-wide significant variants were shown 
to influence DHFR expression in brain and peripheral tissues, and MSH3 expression in blood and fibroblasts. The lead 
single nucleotide polymorphism (SNP), rs557874766 (p = 1.58E-08), lies within a 9 bp tandem repeat sequence in exon 1 
of MSH3 (Nakajima et al., 1995) and was reported to result in the coding change Pro67Ala. The chromosome 15 locus 
implicated by the previous GWAS and likely underlain by FAN1 was just below genome-wide significance (p = 3.97E-4). 
Once again gene set analysis strongly enriched for DNA repair pathways, particularly mismatch repair (p = 8.88E-11). 
3.1.3 Summary 
Investigating the mechanism of repeat instability is complex and numerous processes appear to contribute. CAG repeat 
expansion requires mismatch repair proteins MSH2 (Savouret et al., 2004, Wheeler et al., 2003, Manley et al., 1999), 
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MSH3 (van den Broek et al., 2002) and PMS2 (Savouret et al., 2003). The long-term goal is to modulate instability level 
and direction, aiming to produce clinical benefit. It is likely that in answering these questions we will uncover novel 
genetic phenomena, and probably more questions. 
Genetic modifiers of Huntington’s disease have recently been found, highlighting parts of the DNA damage response such 
as mismatch repair, base excision repair and the Fanconi anaemia pathway. This raises questions about whether these 
processes also modify phenotype across all trinucleotide repeat diseases and if a common pathway underlies repeat 
instability. 
3.2 Aims 
Genetic variation in DNA repair proteins has been shown to influence age at motor onset and rate of progression in 
Huntington’s disease. The work presented in this chapter aims to determine whether DNA repair genes also modify 
disease course in the other polyglutamine diseases too. 
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3.3 Methods 
3.3.1 Patient cohorts 
Cohorts of subjects with all 9 polyglutamine diseases were gathered from the Neurogenetics Unit and Ataxia Centre of 
the National Hospital for Neurology and Neurosurgery (London, UK), TRACK-HD (Europe) (Tabrizi et al., 2013), the SPATAX 
network (France), the University of Athens Medical School/Eginition Hospital (Athens, Greece), the National Institute of 
Neurology and Neurosurgery, Manuel Velasco Suarez (Mexico), and the University of Azores (Ponta Delgada, Portugal). 
All polyglutamine patients willing to participate in research were enrolled regardless of CAG repeat length or age at onset 
(AAO). Very few DRPLA and SBMA samples were available, so these diseases were excluded from the analysis. 
Given the diverse range of phenotypes in polyglutamine diseases, AAO was recorded as the onset of motor symptoms in 
HD and as the first progressive symptom as reported by the patient for the other conditions. AAO was available for 1,462 
patients. 
Cohort Disease HD SCA1 SCA2 SCA3 SCA6 SCA7 SCA17 Total 
Athens, Greece 351 0 0 0 0 0 0 351 
Azores, Portugal 0 0 0 91 0 0 0 91 
London, UK 0 30 66 45 69 7 1 218 
Mexico 0 0 113 0 0 66 6 185 
SPATAX, France 0 147 115 261 0 0 0 523 
TRACK-HD, Europe 94 0 0 0 0 0 0 94 
Total 445 177 294 397 69 73 7 1,462 
% M 49.4 54.2 48.6a 52.6 60.9 56.2 85.7 51.8a 
Mean AAO ± SD 
(range) 
45 ± 12.1 
(6–82) 
37 ± 10.5 
(16–65) 
33 ± 12.9 
(8–73) 
39 ± 11.6 
(9–74) 
57 ± 10.5 
(18–76) 
35 ± 17.6 
(5–84) 
30 ± 13.4 
(8–44) 
 
Mean (CAG)n 
length ± SD 
(range) 
44 ± 5.0 
(37–92) 
48 ± 5.3 
(39–66) 
42 ± 4.5 
(33–64) 
71 ± 4.4 
(50–82) 
22 ± 0.9 
(21–26) 
48 ± 11.1 
(36–100) 
51 ± 6.4 
(42–58) 
 
Table 3.3. Cohort characteristics. 
HD = Huntington's disease; SCA = spinocerebellar ataxia; % M = percentage of males; AAO = age at onset; SD = standard deviation. 
aOne subject had no sex information. 
3.3.2 Selection of single nucleotide polymorphisms (SNPs) 
SNPs were selected from the most significant genes in DNA repair pathways that were significantly associated with AAO 
in the GeM GWAS (GeM-HD, 2015), as listed in their supplementary table S4. A small number of the most significant 
variants were selected in order to minimise the statistical limitations of multiple comparisons. These variants were not 
intended to comprehensively cover all DNA repair genes, but rather to have a likely influence on disease course based on 
their significance in the GeM GWAS (GeM-HD, 2015) or previous evidence of involvement in disease pathogenesis. MLH1, 
PMS1, PMS2, MSH3, FAN1, RRM2B, UBR5 and LIG1 have all be associated with age at onset or rate of progression in HD 
GWA studies (Lee et al., 2019, GeM-HD, 2015, Lee et al., 2017, Hensman Moss et al., 2017b). MLH1 (Pinto et al., 2013a), 
MLH3 (Pinto et al., 2013a), PMS2 (Gomes-Pereira, 2004, Gomes-Pereira et al., 2014b, Pinto et al., 2013b), MSH3 
(Dragileva et al., 2009, Tome et al., 2013a), MSH6 (Dragileva et al., 2009, van den Broek et al., 2002, Foiry et al., 2006) 
and LIG1 (Lopez Castel et al., 2009, Tome et al., 2011) are mismatch repair genes that are required for somatic instability 
in mouse models, and increased expression of PMS1 has been associated with later HD onset (Lee et al., 2019). RRM2B 
is involved in nucleotide synthesis, and UBR5 is a ubiquitin ligase previously investigated for a role in HTT aggregation 
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(Ortega and Lucas, 2014). ERCC3 is a helicase involved in nucleotide excision repair which was significantly associated 
with age at onset in GeM-HD (2015). 
For each gene, the most significant SNP was selected along with a small number of proxy SNPs that were in close linkage 
disequilibrium (r2 > 0.8) and were also associated with AAO. Where possible they were chosen to have a functional impact 
(1000 Genomes). In the case of FAN1, where there were two independent signals, the second signal was also included. 
This yielded 22 SNPs. 
SNP ID 
Chr:position 
(bp) 
(GRCh37/hg19) 
Gene 
symbol Functional annotation P GeM-HD) MAF* 
Genotype 
call rate* P (HWE)* 
rs1800937 2:48025764 MSH6 Stop_gained 0.0043 0.074 0.973 0.84 
rs4150407 2:128049631 ERCC3 Intron_variant 0.00046 0.479 0.964 0.003 
rs5742933 2:190649316 PMS1 NMD_transcript_variant 0.000949 0.205 0.972 1 
rs1799977 3:37053568 MLH1 Missense_variant 7.16E-07 0.28 0.966 0.354 
rs6151792 5:80056961 MSH3 Intron_variant 0.000209 0.117 0.978 0.706 
rs115109737 5:80102444 MSH3 Intron_variant 0.00045 0.041 0.98 0.489 
rs71636247 5:80118976 MSH3 Intron_variant 0.000255 0.034 0.976 1 
rs1805323 7:6026942 PMS2 Missense_variant 0.0304 0.043 0.975 0.736 
rs12531179 7:6028687 PMS2 Intron_variant 0.0000384 0.169 0.971 0.925 
rs3735721 8:103217695 RRM2B 3’_UTR_variant 5.68E-07 0.083 0.971 0.058 
rs1037700 8:103250775 RRM2B Intron_variant 5.03E-08 0.094 0.973 0.002 
rs5893603 8:103250839 RRM2B Frameshift_variant 4.28E-08 0.093 0.973 0.007 
rs1037699 8:103250930 RRM2B Missense_variant 2.7E-08 0.094 0.976 0.002 
rs16869352 8:103306033 UBR5 Synonymous_variant 4.01E-07 0.08 0.975 0.03 
rs61752302 8:103311153 UBR5 Synonymous_variant 0.00303 0.026 0.977 0.621 
rs72734283 14:75495059 MLH3 Intron_variant 0.00432 0.089 0.971 0.623 
rs175080 14:75513828 MLH3 Missense_variant 0.00772 0.435 0.971 0.447 
rs146353869 15:31126401 FAN1 Intron_variant 4.3E-20 0.017 0.973 1 
rs114136100 15:31197976 FAN1 Synonymous_variant 8.49E-16 0.019 0.976 0.423 
rs150393409 15:31202961 FAN1 Missense_variant 9.34E-18 0.013 0.975 1 
rs3512 15:31235005 FAN1 3’_UTR_variant 5.28E-13 0.283 0.973 1 
rs20579 19:48668830 LIG1 NMD_transcript_variant 0.00665 0.134 0.942 0.732 
Table 3.4. Characteristics of single nucleotide polymorphisms (SNPs) used in this study. 
SNPs were selected from the most significant genes (gene-wide p<0.1) in the “DNA repair pathway cluster” from the GeM-HD analysis 
(GeM-HD, 2015) (listed in Table S4 of GeM-HD). Genes annotated by the SNPs are indicated. *Refers to the current study. Chr = 
chromosome; MAF = minor allele frequency; HWE = Hardy–Weinberg equilibrium. 
3.3.3 Genotyping 
SNP assays were designed from sense or antisense sequences and genotyping was performed using custom fluorescence-
based KASP (Kompetitive allele specific PCR) assays at LGC Genomics (Hertfordshire, UK). Note, SNPs rs4150407, 
rs1805323, rs1037700, rs1037699, rs3512 and rs20579 were genotyped in reverse orientation, so the genotypes will also 
be complementary to HGVS nomenclature. 
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SNPs HGVS Names SNP to Chromosome Seed sense sequences for KASP assay design 
rs1800937 NC_000002.11:g.48025764C>T Forward TTGCCTGGCAGGTAGGCACAACTTA[C>T]GTAACAGATAAGAGTGAAGAAGATA 
rs4150407 NC_000002.11:g.128049631T>C Reverse AGTACACAATGGGAAGGTGGTCCAT[A>G]GACAAGAGCCTTCACCAGAAACTGA 
rs5742933 NC_000002.11:g.190649316G>C Forward GTAATTGCCTGCCTCGCGCTAGCAG[G>C]AAGGTAGTGTGGTGTGACTAACGGG 
rs1799977 NC_000003.11:g.37053568A>G Forward CTCAACCGTGGACAATATTCGCTCC[A>G]TCTTTGGAAATGCTGTTAGTCGGTA 
rs6151792 NC_000005.9:g.80056961C>T Forward TCACACAGCCATGTAAAATTAGGCC[C>T]GCAGACAATTCGAAGGAGGAGAAAA 
rs115109737 NC_000005.9:g.80102444G>A Forward GAATCACACAAGCTTATTTGCTATA[G>A]CATTATAATAACTTTTTACATCTGT 
rs71636247 NC_000005.9:g.80118976A>G Forward TGTATAAATATATGTGGAGAAAACC[A>G]TCTAGATAGAAGGCTTATTCCAAAA 
rs1805323 NC_000007.13:g.6026942G>T Reverse TCCAGTCACGGACCCAGTGACCCTA[C>A]GGACAGAGCGGAGGTGGAGAAGGAC 
rs12531179 NC_000007.13:g.6028687C>T Forward ATTTTTAGTAGAGACAGAGTTTCAC[C>T]GTGTTAGATAGTCTCGATCTCCTGA 
rs3735721 NC_000008.10:g.103217695A>G Forward GCTGGGGCCAGCTTAGTTGTAAGAA[A>G]AACTATTATTGTATATAATTGGACA 
rs1037700 NC_000008.10:g.103250775G>C Reverse GGCCTCAGGCCGGGGTGAGACTTAC[C>G]CCTGCGTTTATCCGCCTCACGCTCT 
rs5893603 NC_000008.10:g.103250839_103250840insG Forward TTGGCTGGCCCCGGGGCAGAGCAGC[->G]GAGCGGGACGCAAACCCAAAGTCAG 
rs1037699 NC_000008.10:g.103250930C>T Reverse AGGACAGGCCTGTCCGCCCGCCCTC[G>A]CCGCAGCCTGGCTTCGTCGTTGCGA 
rs16869352 NC_000008.10:g.103306033T>C Forward CAGCGTAAGGTAGCAATGCTTGGAA[T>C]ACACGCTTGCATTTTCCAATTGGCT 
rs61752302 NC_000008.10:g.103311153C>T Forward ACAATTTCAATATAAAATGAGCATT[C>T]GCCTTTCGATCCTTGGATTCTACTA 
rs72734283 NC_000014.8:g.75495059A>G Forward ATTATTTTATGATTTGACCTTGACA[A>G]CCCATCTAGCCAACTCCCATCCAGT 
rs175080 NC_000014.8:g.75513828G>A Forward GGTCATAGGACTTTCTCTCAAACTA[G>A]GCATCTGTTGTTCTAAACAATCTTC 
rs146353869 NC_000015.9:g.31126401C>A Forward AATGGTATGTATTAAAATGTGAATC[C>A]CAAGAGTGATGTGTCACTGTGCACT 
rs114136100 NC_000015.9:g.31197976C>T Forward GCTGCAATGGTCCTGGTCAAACAAC[C>T]GGTCATCCTTACTACCTTCGGAGTT 
rs150393409 NC_000015.9:g.31202961G>A Forward GCCTTTCTCAAATTGGCCAAACAGC[G>A]TTCAGTCTGCACTTGGGGCAAGAAT 
rs3512 NC_000015.9:g.31235005G>C Reverse ACAGAGAGCGTTAAAAGTAAAGGCA[C>G]TTCCAAGAGTAACACTGCTAATGCG 
rs20579 NC_000019.9:g.48668830G>A Reverse GCTGGACAGGAAGGGAGAATTCTGA[C>T]GCCAACATGCAGCGAAGTATCATGT 
Table 3.5. Seed sense sequences for SNP KASP assay design. 
Note that genotypes for SNPs in reverse orientation to chromosome given by KASP assays are complementary (reverse) to HGVS 
nomenclature. 
3.3.4 Statistical analyses 
AAO for each polyglutamine disease was corrected for repeat length to derive the residual AAO which was used as the 
primary phenotype (Lee et al., 2012d). For each individual disease a linear regression of ln(AAO) on expanded repeat 
length was performed, generating the coefficients given below. 
Disease Sample N A B p 
HD 445 6.120 -0.053 <2e-16 
SCA1 177 5.683 -0.044 <2e-16 
SCA2 294 5.799 -0.057 <2e-16 
SCA3 397 7.137 -0.049 <2e-16 
SCA6 69 5.967 -0.087 0.00268 
SCA7 73 4.643 -0.026 2.94e-5 
SCA17 7 2.387 0.017 0.7 
Table 3.6. Effects of repeat length of the expanded allele on age at onset. 
Results of fitting a linear regression ln(AAO) = A + B*(CAG)n. p value refers to the significance of the regression parameter (B) 
indexing the effect of repeat length. HD = Huntington's disease; SCA = spinocerebellar ataxia. 
These parameters were used to calculate expected AAO for each individual based on their pathogenic repeat length. This 
was subtracted from their actual AAO to give a residual. The association of each SNP with AAO was tested by performing 
a linear regression of these residuals on the number of minor alleles in the genotype in PLINK (Purcell et al., 2007). 
The primary analysis tested whether there was an overall association of all 22 SNPs with AAO. This was achieved by 
combining the association p values for each SNP using Brown (1975). Essentially, this is Fisher’s method for combining p 
values corrected for linkage disequilibrium between SNPs. 
The primary analysis used one-sided p values for association in the same direction as that observed in GeM-HD. In order 
to assess the overall directionality of the associations, the significance was compared to that obtained from a similar 
analysis using two-sided p values. 
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Analyses were performed on the following eight groups. Because of small sample size, SCA17 was not analysed 
independently, but was included in the analyses of all SCAs and HD+SCAs. p values were Bonferroni corrected for eight 
tests. 
1. All polyglutamine diseases (HD+SCAs) 
2. HD 
3. All SCAs 
4. SCA1 
5. SCA2 
6. SCA3 
7. SCA6 
8. SCA7 
3.4 Contributions 
The study was designed by Professors Tabrizi, Jones and Houlden. I was responsible for collection of phenotypic data on 
HD patients at the National Hospital for Neurology and Neurosurgery (London, UK). Data acquisition from other cohorts 
was performed by Conceicao Bettencourt, Davina Hensman, Sarah Wiethoff, Alexis Brice, Cyril Goizet, Giovanni Stevanin, 
Georgios Koutsis, Georgia Karadima, Marios Panas, Petra Yescas-Gomez, Lizbeth Esmerelda Garcia-Velazquez, Maria Elisa 
Alonso-Vilatela, Manuela Lima, Mafalda Raposo, Bryan Traynor and the SPATAX network. Statistical analyses were 
conducted by Professor Holmans. The work was supervised by Professors Holmans, Houlden, Tabrizi and Jones. These 
results were published in Bettencourt et al. (2016). 
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3.5 Results 
In the primary analysis which grouped all 22 SNPs, and corrected for multiple comparisons, there was significant 
association with age at onset (AAO) in HD+SCAs (p = 1.43E-5), HD (p = 1.94E-3), all SCAs (p = 1.07E-3), SCA2 (p = 3.50E-3) 
and SCA6 (p = 1.62E-3). These associations were more significant than an undirected test using two-sided SNP p values, 
indicating the effect direction for all SNPs is consistent with the GeM-HD GWAS (GeM-HD, 2015). The association with 
HD AAO also replicates the GeM-HD results in an independent cohort. 
Disease Group GeM-HD concordance? P (All SNPs) P (High LD SNPs removed) P (rs3512 removed) 
ALL (HD+SCAs) non directional 4.74E-04 * 2.26E-04 * 0.0049 * Same as GeM-HD 1.43E-05 * 6.98E-06 * 2.26E-04 * 
HD non directional 0.0226 0.0078 0.0364 Same as GeM-HD 0.0019 * 0.0005 * 0.0039 * 
SCAs non directional 0.0188 0.0236 0.0771 Same as GeM-HD 0.0011 * 0.0014 * 0.0067 * 
SCA1 non directional 0.3760 0.3860 0.4440 Same as GeM-HD 0.4160 0.2870 0.5240 
SCA2 non directional 0.0230 0.0629 0.0233 Same as GeM-HD 0.0035 * 0.0138 0.0044 * 
SCA3 non directional 0.1760 0.1140 0.3550 Same as GeM-HD 0.0809 0.0381 0.2050 
SCA6 non directional 0.0059 * 0.0735 0.0051 * Same as GeM-HD 0.0016 * 0.0340 0.0016 * 
SCA7 non directional 0.1550 0.2170 0.2970 Same as GeM-HD 0.0447 0.0885 0.1130 
Table 3.7. Analysis of combined SNPs. 
p values obtained by combining single-SNP p values using Brown (1975), allowing for LD between SNPs. Non-directional analysis 
combines two-sided p values. “Same as GeM-HD” analyses combine one-sided p-values in the same direction as the SNP effects 
observed in GeM-HD study(GeM-HD, 2015). In the “High LD SNPs removed” analysis, rs1037700, rs5893603 and rs16869352 were 
removed due to high LD (r2>0.8) with more significant SNPs in GeM-HD. * p values that satisfy Bonferroni correction for 8 disease 
group tests. Note that SCA17 was included in the “HD+SCAs” and “All SCAs” grouped analyses, but was not tested independently due 
to small sample size. HD – Huntington’s disease; SCA – spinocerebellar ataxia 
In a secondary analysis, association of individual SNPs with AAO was examined. Three of these associations were 
significant in the same direction as GeM-HD after Bonferroni correction for eight disease combinations and 22 SNPs; 
rs3512 (FAN1) with all SCAs and HD+SCAs, and rs1805323 (PMS2) with HD+SCAs. Correcting for 22 SNPs, five associations 
were significant in the same direction as GeM-HD; rs1805323 (PMS2) in HD and SCA1 and in RRM2B rs1037699, 
rs1037700 and rs5893603 were associated with SCA6. 
rs146353869, the most significant SNP in GeM was not replicated in this study, most likely because this small sample is 
less well powered to detect associations with rarer variants (rs146353869 MAF = 0.017). However, rs3512 is in strong 
linkage disequilibrium with the second GeM GWAS chromosome 15, associated with 1.4 later onset. 
Three SNPs (rs1037700, rs5893603, and rs16869352) were in high LD (r2 > 0.8) with more significant SNPs. Removing 
them reduced the combined SNP significance with SCAs, though they remained nominally significant (Table 6). Removing 
the most significant SNP in this study, rs3512, all combined SNP associations remained significant, suggesting the signal 
is not being driven by a single variant. 
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SNP Chr Pos 
A1 
(GeM-
HD) 
A2 
(GeM-
HD) 
MAF 
(GeM-
HD) 
Beta 
(GeM-
HD) 
P 
(GeM-HD) 
A1 
(All) 
A2 
(All) 
MAF 
(All) 
Beta 
(All) 
P 
(All) 
Beta 
(HD) p(HD) 
Beta 
(SCA1) P(SCA1) 
Beta 
(SCA2) 
P 
(SCA2) 
Beta 
(SCA3) 
P 
(SCA3) 
Beta 
(SCA6) 
P 
(SCA6) 
Beta 
(SCA7) 
P( 
SCA7) 
Beta 
(AllSCA) 
P 
(AllSCA) 
rs1800937 2 48025764 T C 0.092 0.820 4.30E-03 T C 0.074 0.490 4.75E-01 0.520 6.21E-01 -0.571 6.51E-01 -0.459 8.18E-01 2.455 4.47E-02 0.614 8.25E-01 -10.050 5.34E-01 0.438 6.13E-01 
rs4150407 2 128049631 C T 0.444 0.575 4.60E-04 G A 0.479 0.064 8.50E-01 -0.585 2.53E-01 -0.574 3.91E-01 1.384 1.03E-01 -0.013 9.85E-01 -2.129 2.55E-01 -2.702 3.83E-01 0.260 5.48E-01 
rs5742933 2 190649316 C G 0.206 -0.699 9.49E-04 C G 0.205 -0.725 9.59E-02 -0.732 2.49E-01 1.102 2.19E-01 -2.333 3.69E-02 -1.005 2.19E-01 0.939 6.76E-01 0.551 8.77E-01 -0.714 2.03E-01 
rs1799977 3 37053568 G A 0.319 0.847 7.16E-07 G A 0.280 -0.359 3.55E-01 0.531 3.39E-01 -0.241 7.58E-01 -2.555 2.20E-02 1.081 1.31E-01 -1.424 4.17E-01 -5.899 1.44E-01 -0.698 1.68E-01 
rs6151792 5 80056961 T C 0.099 -1.049 2.09E-04 T C 0.117 -0.662 2.16E-01 -1.395 7.99E-02 -0.436 7.30E-01 0.495 6.79E-01 -1.347 2.21E-01 -1.577 5.07E-01 -0.116 9.77E-01 -0.350 6.09E-01 
rs115109737 5 80102444 A G 0.060 -1.289 4.50E-04 A G 0.041 -2.095 1.81E-02 -3.014 2.10E-02 1.321 5.13E-01 -4.651 8.59E-02 0.100 9.50E-01 -5.197 1.41E-01 -5.756 2.87E-01 -1.726 1.28E-01 
rs71636247 5 80118976 G A 0.054 -1.398 2.55E-04 G A 0.034 -2.208 2.63E-02 -1.917 1.89E-01 -1.974 4.39E-01 -6.400 4.86E-02 0.324 8.52E-01 -3.813 2.82E-01 -7.123 2.49E-01 -2.329 6.76E-02 
rs1805323 7 6026942 T G 0.038 -0.950 3.04E-02 A C 0.043 -3.605 3.14E-05** -3.890 3.14E-04* -5.677 1.67E-03* -1.835 3.94E-01 -2.307 2.70E-01 -2.123 5.50E-01 -17.190 1.44E-01 -3.305 6.62E-03 
rs12531179 7 6028687 T C 0.147 0.938 3.84E-05 T C 0.169 0.579 2.16E-01 1.070 1.23E-01 0.039 9.67E-01 1.137 3.08E-01 0.083 9.32E-01 -0.320 8.83E-01 -0.798 8.07E-01 0.367 5.39E-01 
rs3735721 8 103217695 G A 0.085 -1.529 5.68E-07 G A 0.083 -0.389 5.25E-01 0.354 6.56E-01 0.692 5.13E-01 -3.278 6.32E-02 1.308 3.11E-01 -15.150 2.35E-03 -3.035 5.89E-01 -0.790 3.47E-01 
rs1037700 8 103250775 C G 0.097 -1.541 5.03E-08 G C 0.094 -0.817 1.54E-01 -0.012 9.87E-01 1.046 2.46E-01 -4.132 2.11E-02 0.863 4.72E-01 -14.250 5.47E-04* -8.021 1.55E-01 -1.235 1.11E-01 
rs5893603 8 103250839 G - 0.097 -1.548 4.28E-08 G - 0.093 -0.983 8.89E-02 -0.092 9.05E-01 0.914 3.13E-01 -4.189 1.84E-02 0.537 6.59E-01 -11.770 2.13E-03* -9.077 1.24E-01 -1.441 6.45E-02 
rs1037699 8 103250930 T C 0.096 -1.570 2.70E-08 A G 0.094 -0.819 1.53E-01 -0.006 9.94E-01 0.758 4.13E-01 -3.519 3.97E-02 0.896 4.55E-01 -14.260 4.86E-04* -9.077 1.24E-01 -1.228 1.11E-01 
rs16869352 8 103306033 C T 0.083 -1.528 4.01E-07 C T 0.080 -0.464 4.57E-01 0.691 3.98E-01 0.756 4.36E-01 -2.854 1.25E-01 0.681 6.27E-01 -10.850 3.24E-02 -7.745 1.64E-01 -1.067 2.09E-01 
rs61752302 8 103311153 T C 0.023 -1.671 3.03E-03 T C 0.026 -0.150 8.92E-01 -0.520 7.46E-01 0.567 7.10E-01 -1.045 6.76E-01 4.882 1.18E-01 -8.015 1.69E-01 NA NA 0.019 9.89E-01 
rs72734283 14 75495059 G A 0.099 0.858 4.32E-03 G A 0.089 0.898 1.40E-01 2.057 1.14E-02 1.585 1.82E-01 -1.099 5.41E-01 -0.650 5.88E-01 -1.686 5.59E-01 10.770 3.82E-02 0.318 6.98E-01 
rs175080 14 75513828 A G 0.466 -0.434 7.72E-03 A G 0.435 -0.671 5.66E-02 -1.245 1.61E-02 0.279 7.16E-01 -0.090 9.23E-01 0.397 5.62E-01 -0.927 5.84E-01 -4.356 1.66E-01 -0.405 3.70E-01 
rs146353869 15 31126401 A C 0.017 -6.107 4.30E-20 A C 0.017 -2.362 8.17E-02 -1.804 3.28E-01 1.980 5.64E-01 -8.999 3.81E-02 -1.537 4.94E-01 -3.496 5.52E-01 7.338 6.60E-01 -2.610 1.48E-01 
rs114136100 15 31197976 T C 0.018 -5.073 8.49E-16 T C 0.019 -2.101 9.20E-02 -1.188 4.88E-01 1.609 6.00E-01 -1.168 7.89E-01 -3.519 8.25E-02 -3.464 5.55E-01 6.909 6.73E-01 -2.521 1.27E-01 
rs150393409 15 31202961 A G 0.016 -5.765 9.34E-18 A G 0.013 -2.735 7.03E-02 -2.909 1.39E-01 -0.354 9.28E-01 -4.224 4.88E-01 -3.176 1.92E-01 -0.912 8.99E-01 7.443 6.57E-01 -2.551 2.17E-01 
rs3512 15 31235005 C G 0.309 1.325 5.28E-13 G C 0.283 1.680 1.52E-05** 1.297 2.94E-02 1.388 8.70E-02 1.020 3.03E-01 2.156 2.36E-03 0.886 6.37E-01 9.647 5.00E-03 1.809 2.22E-04** 
rs20579 19 48668830 A G 0.124 0.769 6.65E-03 T C 0.134 0.427 4.09E-01 0.119 8.82E-01 1.244 2.84E-01 0.412 7.55E-01 1.099 2.17E-01 -7.791 2.19E-02 -0.216 9.54E-01 0.515 4.28E-01 
Table 3.8. Individual SNP association with age at onset. 
Beta denotes the effect size – that is, the number of years added to or subtracted from the expected age at onset for each copy of the minor allele (A1). MAF denotes the frequency of the minor allele in 
GeM-HD(GeM-HD, 2015) (Column 6) and the present study (Column 11). p values highlighted bold and “*” satisfy Bonferroni correction for 22 SNPs; those highlighted bold and “**” satisfy Bonferroni 
correction for 8 disease groups and 22 SNPs. Note that for SNPs in reverse orientation (rs4150407, rs1805323, rs1037700, rs1037699, rs3512, and rs20579) are complementary to those in GeM-HD, 
which uses HGVS nomenclature. 
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A polygenic score was calculated using the sum of minor alleles at each locus, weighted by their effect size in the GeM 
GWAS. There was a positive correlation between increasing polygenic score and residual AAO, suggesting the variants 
are associated with delayed onset. However, the effect was relatively small, accounting for approximately 1% of the 
variance in residual AAO. 
 
Figure 3.1. Boxplot of residual age at onset across all samples against polygenic score. 
Polygenic score was calculated by summing minor alleles (weighted by effect on AAO in the GeM GWAS). Residual AAO for each 
quartile of risk score is plotted. Lower scores correspond to earlier than expected AAO (smaller residuals).   
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3.6 Discussion 
These data suggest a common mechanism operates in polyglutamine diseases in which variation in DNA repair genes 
modifies age at onset (AAO). The most significant variant in the present study, rs3512, is a common variant (MAF = 0.19) 
in the 3’ untranslated region (UTR) of FAN1 and has not previously been linked with disease. It was associated with 1.31 
year delayed onset in GeM (p = 5.28E-13). FAN1 is a DNA endo- and exonuclease involved in DNA repair (Kratz et al., 
2010a, Liu et al., 2010b, MacKay et al., 2010b, Smogorzewska et al., 2010a) that is highly expressed in the brain (GTEx, 
2015). It was originally identified as a key component in the Fanconi anaemia (FA) interstrand cross-link (ICL) repair 
pathway, though its mutation does not cause Fanconi anaemia. 
Significant association was also seen with PMS2 and RRM2B. PMS2 is a nuclease that heterodimerises with MLH1 to form 
MutLa. After MMR initiation by MutSa (MSH2-MSH6) or MutSb (MSH2-MSH3) binding to a mismatch, MutLa introduces 
a single strand break (SSB) near the mismatch, thereby generating new entry point for the exonuclease EXO1 to degrade 
the mismatch (Kadyrov et al., 2006, Borras et al., 2013). MutLa may also recruit DNA polymerase III to the mismatch site. 
PMS2 mutations are known to cause dominant and recessive hereditary bowel cancer (Online Mendelian Inheritance in 
Man, 2015). Its knockout in myotonic dystrophy and Friedreich’s ataxia mouse models significantly reduced repeat 
expansion (Gomes-Pereira et al., 2004, Bourn et al., 2012). RRM2B supplies dNTPs for DNA repair. It is widely expressed, 
including throughout the nervous system (GTEx, 2015), and its mutation can cause mitochondrial DNA depletion 
syndromes such as autosomal dominant progressive external ophthalmoplegia (McKusick, 2007), but it has not been 
linked with repeat instability. 
DNA repair has been implicated in several rare genetic diseases, all of which share a similar phenotype of 
neurodegeneration in the cerebellum or basal ganglia (Ross and Truant, 2017). Rare loss of function mutations in DNA 
repair genes are known to cause several recessive ataxias. ATM is a master regulator of DNA repair following double 
strand breaks. PNPK is a DNA-specific kinase involved in DNA repair. APTX interacts with PARP1 in the repair of single 
strand breaks. TDP1 mutations produce defects in single-strand break repair. It is not clear how these deficits in DNA 
repair result in cerebellar degeneration. However, there is evidence for ATM control being critical in cell division and 
apoptosis, which could lead to neuronal loss (Shiloh and Ziv, 2013). 
Repetitive DNA sequences form abnormal secondary structures, such as hairpin loops, which may be substrates of DNA 
repair proteins, and the process of repair may result in somatic instability (Holmans et al., 2017). MMR proteins, including 
MSH3, bind directly to slipped-strand DNA structures formed by CAG repeats (Pearson et al., 1997), processing them in 
complex with MSH2 and PMS2. Larger CAG repeats are associated with more severe pathology, earlier onset and faster 
progression, so somatic expansion provides a plausible mechanism by which DNA repair variation may act (Massey and 
Jones, 2018). 
Alternatively, aberrant DNA repair may lead to the accumulation of oxidative DNA damage in neurons, leading to 
mutation and epigenetic modification that alters expression. The nervous system is particularly vulnerable to oxidative 
stress because it has a relatively high metabolic rate, generates high levels of reactive oxygen species and is thought to 
have a lower ratio of anti- to pro-oxidant enzymes (Canugovi et al., 2013). Over time, these changes could lead to 
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neuronal dysfunction and ultimately, once a threshold level is crossed, apoptosis and neuronal loss could be triggered 
(Ross and Truant, 2017). 
This study had several limitations, including the relatively small sample size for several rare ataxias such as SCAs 6, 7 and 
17. Though the relationship between CAG length and AAO was modelled independently for each disease, there are likely 
to be other factors which differ between diseases that could not be accounted for, such as the presence of interruptions 
in the repeat tract which could provide protective stabilisation (Menon et al., 2013). Interruptions have been 
demonstrated in HD, SCAs 1-3 and 17, fragile X syndrome and Friedreich’s ataxia and myotonic dystrophy (Massey and 
Jones, 2018). They are known to reduce the stability of abnormal hairpin structures, thereby reducing repeat expansion. 
The next step is to repeat the analysis with larger samples and more DNA repair variants as this would be expected to 
increase the predictive power of the polygenic risk score (Dudbridge, 2013, Purcell et al., 2009, Consortium, 2014). 
3.7 Summary 
DNA repair genes modify age at onset (AAO) in polyglutamine diseases as a group, as well as independently in all SCAs, 
HD, SCA1 and SCA6, though the effect size is relatively small. This study replicates the results of the GeM GWAS in an 
independent cohort, with significant association of variation in FAN1 on chromosome 15, PMS2 on chromosome 7, and 
RRM2B on chromosome 8 with AAO. These results suggest a common mechanism operates in polyglutamine diseases, 
meaning therapeutic opportunities may be relevant across multiple diseases. Molecules targeting DNA repair have been 
developed to treat cancer. Such therapies may prove beneficial in polyglutamine diseases (Farmer et al., 2005, Jackson 
and Chester, 2015). A polygenic risk score may improve clinical trial design by enabling stratification of patients by genetic 
variability. When the pathogenic trinucleotide repeat expansions causing these diseases were first discovered, the 
research focus was on the mutation itself; having subsequently explored an array of downstream pathogenic 
mechanisms, focus is now returning to the DNA level. 
3.8 Publications relating to this chapter 
The work relating to this chapter was published in: 
DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. Bettencourt, 
C.*, Moss, D. H.*, Flower, M.*, Wiethoff, S., Brice, A., Goizet, C., Stevanin, G., Koutsis, G., Karadima, G., Panas, M., Yescas-
Gomez, P., Garcia-Velazquez, L. E., Alonso-Vilatela, M. E., Lima, M., Raposo, M., Traynor, B., Sweeney, M., Wood, N., 
Giunti, P., network, Spatax, Durr, A., Holmans, P.#, Houlden, H. #, Tabrizi, S. J. # and Jones, L. # Ann Neurol, 2016 
Jun;79(6):983-90. doi: 10.1002/ana.24656. 
* These authors should be regarded as joint first authors. 
# These authors jointly supervised the work. 
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Chapter 4 Transcriptional dysregulation in Huntington’s disease patient 
blood 
4.1 Background 
4.1.1 Huntington’s disease causes widespread pathology 
HD research has traditionally focused on the brain due to the presence of characteristic mutant huntingtin protein 
aggregates (Bates et al., 2015c) and because the prominent symptoms and signs can be linked to neurodegeneration in 
the basal ganglia and cerebral cortex (van der Burg et al., 2009). However, mutant HTT is ubiquitously expressed (Trottier 
et al., 1995) and mounting evidence suggests it has direct effects in peripheral tissues (van der Burg et al., 2009, Carroll 
et al., 2015), though whether these effects are distinct, or parallel those in the brain remains unclear. 
HD patients demonstrate peripheral immune dysfunction presymptomatically (Tai et al., 2007a, Bjorkqvist et al., 2008, 
Kwan et al., 2012c, Träger et al., 2015), as well as weight loss that leads to cachexia with advancing disease (Carroll et al., 
2015). There is progressive muscle wasting (Busse et al., 2008), endocrine dysfunction (Saleh et al., 2009), liver 
impairment (Carroll et al., 2015) and cardiac dysfunction (Lanska et al., 1988, Mihm et al., 2007, Pattison et al., 2008). 
Mutant HTT (mHTT) protein aggregates can be found in the peripheral tissues of HD mice (Orth et al., 2003), as well as 
advanced patients (Turner et al., 2007). These peripheral features may contribute to CNS pathology, disease progression 
and mortality (Carroll et al., 2015, van der Burg et al., 2009), and strongly suggest that HD is a systemic disorder. 
Patient-derived tissue is the most physiologically relevant system in which to study pathogenesis. The peripheral 
phenotype provides an opportunity to study HD pathogenic mechanisms. In contrast to brain tissue, availability of which 
is limited and from post-mortem subjects with end-stage disease (Montanini et al., 2013, Tomita et al., 2004), peripheral 
tissues can be sampled minimally invasively and inexpensively from living patients, enabling longitudinal study 
throughout disease course. 
4.1.2 Transcriptional dysregulation in Huntington’s disease 
4.1.2.1 Transcriptional dysregulation in the brain 
Transcriptional dysregulation is an early and central feature of HD (Seredenina and Luthi-Carter, 2012, Hodges, 2006). 
Suggested mechanisms include the sequestration of transcription factors in intracellular aggregates or their direct 
inhibition by mutant HTT (mHTT). The transcription factor CBP, for example, is found in polyglutamine aggregates 
(McCampbell et al., 2000, Nucifora et al., 2001), whereas Sp1 has a higher affinity for mutant than wild type HTT (Dunah 
et al., 2002, Li et al., 2002, Shimohata et al., 2000). Expansion of the polyglutamine stretch in HTT reduces its affinity for 
the transcriptional repressor REST, which the wild type protein retains in the cytoplasm, resulting in repression of 
neuronal genes such BDNF (Zuccato et al., 2007, Zuccato et al., 2003). mHTT can also affect proteasomal degradation of 
transcription factors, decreasing levels of CBP, for example (Cong et al., 2005). Transcriptional activity is influenced by 
chromatin structure; cell and animal models have found histone hypoacetylation in HD (Sadri-Vakili et al., 2007, Hazeki 
et al., 2002), and HDAC inhibitors have been shown to be neuroprotective, improving the HD-like phenotype (Ferrante 
et al., 2003, Sadri-Vakili et al., 2007, Steffan et al., 2001, Hockly et al., 2003, Thomas et al., 2008). HTT itself can bind DNA, 
altering the activity of transcription factors (Benn et al., 2008b), and is found in P-bodies, which are involved in RNA-
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mediated transcriptional regulation (Eulalio et al., 2007, Savas et al., 2008). miRNA expression is dysregulated in HD 
cortex (Johnson et al., 2008, Packer et al., 2008, Johnson and Buckley, 2009, Lee et al., 2011b, Strand et al., 2005), with 
notable reduction of those regulated by REST (Marti et al., 2010, Packer et al., 2008). By grouping genes into biologically 
relevant pathways several process have been reproducibly implicated, including neuronal signalling, synaptic proteins, 
transcription factors, chromatin remodelling, metabolic regulators and inflammation (Seredenina and Luthi-Carter, 
2012). 
Neueder and Bates (2014) applied weighted gene correlation network analysis (WGCNA) (Langfelder and Horvath, 2008) 
to the Hodges et al. (2006) microarray brain expression data set of 44 human HD and 36 matched control brains. They 
generated networks for four brain regions; the caudate nucleus (CN), BA4 region of the frontal cortex, which has motor 
function (FC-BA4), BA9 region of the frontal cortex, involved in association and cognitive functions (FC-BA9), and 
cerebellum (CB).  
In the cerebellum they identified 2504 downregulated and 2230 upregulated genes. The modules CBpos4, CBpos5 and 
CBneg4 were also dysregulated in frontal cortex, and CBpos5 and CBneg2 were dysregulated in both frontal cortex and 
caudate. CBneg1 hub genes were involved in synaptic function. Other negatively correlated cerebellar modules enriched 
for mitochondrial and proteasomal genes. Positively correlated cerebellum modules enriched for genes involved in 
transcriptional regulation, chromatin binding and protein folding. Notably, there was no immune dysregulation in the 
cerebellum. 
In the frontal cortex, there was no transcriptional dysregulation in Brodmann area 9 (dorsolateral and medial prefrontal 
cortex), but significant changes were found in Brodmann area 4 (primary motor cortex). Most modules dysregulated in 
BA4 were also dysregulated in caudate and cerebellum. In addition to the signal shared with cerebellum, there was 
upregulation of inflammatory response and NFκB/IκB genes, and angiogenesis, and there was downregulation of 
synaptic, mitochondrial, protein transport and proteasomal genes. 
The largest changes were seen in the caudate, with 3798 (30.4%) of genes negatively and 5349 (42.8%) of genes positively 
dysregulated. Caudate modules were better preserved in the frontal cortex than the cerebellum. Positively correlated 
modules were involved in the inflammatory response, transcriptional regulation and mRNA processing, and negatively 
correlated ones in synaptic, mitochondrial, DNA repair and proteasomal function. They found preservation of caudate 
modules in other neurodegenerative diseases, including AD, ALS, MS, PD and myotonic dystrophy, with a high enrichment 
for inflammatory pathway genes. HD mouse models mimicked some of the transcriptional dysregulation, but aspects 
such as the inflammatory response were poorly reflected. 
Labadorf et al. (2015) analysed the transcriptome of human postmortem prefrontal cortex Brodmann area 9 (BA9) from 
20 HD subjects and 49 controls using next-generation high throughput sequencing, identifying dysregulation of immune 
and developmental genes. They found significant differential expression in HD including proinflammatory genes of the 
NFkB family and cytokine receptors. Dysregulated pathways enriched for genes involved in the immune response, 
development, cell growth and transcriptional regulation. However, none of the expression changes were significantly 
associated with disease burden or age at onset. 
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4.1.2.2 Peripheral transcriptional dysregulation 
In R6/2 mice, brain and muscle have been shown to be concordant (Luthi-Carter et al., 2002, Strand et al., 2005), and this 
profile may be consistent with HD patient muscle too (Strand et al., 2005). However, studies of gene expression changes 
in HD blood have been inconsistent. Using microarray technology, Borovecki et al. (2005) identified 12 upregulated 
transcripts, seven of which were also upregulated in brain. However, subsequent studies did not replicate these results 
(Runne et al., 2007, Lovrecic et al., 2009, Mastrokolias et al., 2015). 
Gene names Protein Function 
ANXA1 Annexin A1 Inflammatory regulator 
AXOT Axotrophin Ubiquitin-protein ligase 
CAPZA1 Capping protein (Actin filament) muscle Z-line, alpha 1 Structural protein that binds actin filaments 
HIF1A Hypoxia-inducible factor 1, alpha subunit Transcriptional regulator of the adaptive response to hypoxia 
JJAZ1 (SUZ12) Polycomb protein SUZ12 Transcriptional repressor 
P2Y5 (LPAR6) Lysophosphatidic Acid Receptor 6 G-protein coupled receptor 
PCNP PEST proteolytic signal-containing nuclear protein Cell cycle regulation 
ROCK1 Rho-associated protein kinase 1 Protein kinase that regulates actin cytoskeleton 
SF3B1 Splicing factor 3b, subunit 1 Pre-mRNA splicing 
SP3 Transcription factor Sp3 Transcription factor 
TAF7 Transcription initiation factor TFIID subunit 7 Transcription factor 
YIPPEE (YPEL5) Yippee Like 5 Innate immune system 
Table 4.1. 12 genes significantly upregulated in HD blood from Borovecki et al. (2005). 
Using tag-based serial analysis of gene expression (SAGE), Mastrokolias et al. (2015) found 170 genes differentially 
expressed by motor score, 40 of which had previously been reported in at least one microarray study. 
Gene Protein B Expression level Adjusted p Protein Function 
HYAL2 Hyaluronoglucosaminidase 2 0.4 2.6 1.0E−03 Hydrolyzes hyaluronic acid 
LMO2 LIM domain only 2 0.3 6.6 1.0E−03 Yolk sac hematopoiesis 
MARC1 Mitochondrial amidoxime reducing C1 0.4 5 5.0E−03 N-hydroxylate prodrug conversion 
NT5DC2 5ʹ-Nucleotidase domain containing 2 0.4 2.8 9.0E−03 Hydrolase and metal ion binding 
RNF135 Ring finger protein 135 0.3 5.8 9.0E−03 DDX58 Ubiquitination~IFN-β 
PROK2 Prokineticin 2 0.5 7.9 1.0E−02 Circadian clock—GI contraction 
RPN1 Ribophorin I 0.3 5.5 1.0E−02 26S Proteasome ubiquitin binding 
CYSTM1 Cysteine-rich transmembrane module 1 0.4 6 1.0E−02 Stress tolerance 
VCAN Versican 0.3 8.2 1.6E−02 Intercellular signaling Binds hyal. acid 
NCF4 Neutrophil cytosolic factor 4 0.3 8.9 1.8E−02 NADPH-oxidase component 
ARL4C ADP-Ribosylation factor-like 4C −0.3 8.2 1.0E−03 Microtubule vesicular transport 
TMEM109 Transmembrane protein 109 (Mg23) −0.3 7 6.0E−03 UVC αB-Crystallin protection 
MACF1 Microtubule-actin crosslinking factor 1 −0.2 7.2 6.0E−03 Actin-microtubule stabilization 
MDN1 Midasin homolog −0.2 5.3 7.0E−03 AAA-ATPase(dynein) 
PTPN4 Protein tyrosine phosphatase NR type 4 −0.3 5.1 9.0E−03 Glutamate receptor signaling 
PRF1 Perforin 1 −0.4 9.5 1.0E−02 Cytolysis 
CD3G CD3g Molecule gamma −0.3 7.5 1.0E−02 CD3 complex signal transduction 
NMT2 N-Myristoyltransferase 2 −0.3 3.4 1.0E−02 N-terminal Myristoylation 
KLRD1 Killer cell lectin receptor subfamily D 1 −0.4 6.1 1.0E−02 Recognition of MHC class I HLA-E 
GPR56 G Protein-coupled receptor 56 −0.4 7.3 1.0E−02 Brain cortical patterning 
Table 4.2.Top 10 up and downregulated genes in HD blood from Mastrokolias et al. (2015). 
B – coefficient of gene expression change per motor score unit, multiplied by average motor score. Expression level – average log2 
gene expression. 
Miller et al. (2016) identified transcriptional dysregulation in HD monocytes. Patient-derived primary monocytes were 
cultured with and without proinflammatory stimulus. In their basal, unstimulated state there was significant 
transcriptional dysregulation, including increased expression of proinflammatory cytokines such as IL-6. Their pathway 
analysis enriched for proinflammatory genes regulated by the NFĸB pathway. These results suggest peripheral HD 
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myeloid cells have a proinflammatory phenotype in resting state, consistent with them being primed by mHTT. This leads 
to an exaggerated inflammatory response once they encounter a stimulus. 
4.1.3 RNA-Seq 
Prior to next-generation sequencing (NGS), large scale gene expression was studied with microarrays. Thousands of DNA 
probes profiled transcripts, but gave limited coverage of only known and common alleles, and lacked coverage of variant 
transcripts. RNA-Seq utilises NGS and is not dependent on prior sequence knowledge, sequencing every transcript in the 
sample, known and unknown. This allows the identification of structural variations, such as gene fusions and alternative 
splicing, as well as novel genes and transcripts. It is more sensitive at detecting low abundance transcripts, can 
differentiate isoforms, and accurately determines expression level, differential splicing and allele-specific expression. It 
gives an absolute measure of transcript levels and structure (Wang et al., 2009, Blekhman et al., 2010). 
4.2 Aim 
Analyse the whole blood transcriptome of a cohort of Huntington’s disease subjects using RNA sequencing (RNA-Seq), 
correlate this with disease severity and compare it to transcriptional dysregulation seen in the brain in HD and other 
neurodegenerative diseases. 
4.3 Methods 
4.3.1 Cohorts 
The Track-HD cohort consisted of 54 premanifest gene carriers, 63 manifest HD subjects and 23 controls. These were 
selected as a representative sample from the Track-HD study to ensure a wide range of disease risk and severity. Control 
subjects were age and gender matched to individuals in the premanifest and manifest groups, and selected from spouses 
or partners to ensure consistency of environments. Track-HD enrolled participants at four study sites in London (UK), 
Paris (France), Leiden (Netherlands), and Vancouver (BC, Canada) (Tabrizi et al., 2009b). Manifest subjects demonstrated 
motor abnormalities that were unequivocal signs of HD, as evidenced by total motor scores (TMS) over 5 on the Unified 
Huntington’s Disease Rating Scale (UHDRS). Premanifest gene carriers had a burden of pathology score (age x [CAG – 
36.5]) (Penney et al., 1997) greater than 250, a TMS of 5 or lower and a diagnostic confidence score (DCS) less than 4 on 
the UHDRS (Group, 1996), indicating no substantial motor signs (Tabrizi et al., 2009b). Age and clinical scores considered 
for the analysis were at the time of blood collection. 
The Leiden cohort (Mastrokolias et al., 2015) consisted of 18 premanifest gene carriers, 56 manifest HD subjects and 27 
age and gender-matched controls. Motor onset was determined by an experienced neurologist using the same UHDRS 
standard as in TRACK-HD. All premanifest carriers showed no substantial motor signs, with a TMS of 5 or less and a UHDRS 
diagnostic confidence level less than 4. All controls were free of known medical conditions. Blood sample collection and 
analysis methods, described below, were identical for the two cohorts.  
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Cohort Group n Mean age, y 
± SD (range) 
Gender 
(male/female) 
Mean (CAG)n length 
± SD (range) 
Mean TMS 
± SD (range) 
Mean TFC 
± SD (range) 
Track-HD   Premanifest 50 42 ± 9 (22-64) 24/26 43 ± 3 (39-52) 2 ± 2 (0-8) 13 ± 0 (12-13) 
  Manifest 62 48 ± 10 (23-64) 26/36 44 ± 3 (39-59) 23 ± 11 (5-45) 11 ± 2 (7-13) 
HD 112 46 ± 10 (22-64) 50/62 44 ± 3 (39-59) 14 ± 13 (0-45) 12 ± 2 (7-13) 
Control 22 45 ± 5 (34-53) 9/13 - - - 
Leiden   Premanifest 18 46 ± 10 (29-63) 5/13 42 ± 2 (39-47) 3 ± 2 (0-5) 12 ± 1 (10-13) 
  Manifest 56 55 ± 11 (35-79) 29/27 44 ± 3 (39-53) 42 ± 30 (6-102) 7 ± 5 (0-13) 
HD 74 53 ± 11 (29-79) 34/40 44 ± 3 (39-53) 32 ± 31 (0-102) 8 ± 5 (0-13) 
Control 27 43 ± 11 (26-65) 13/14 - - - 
Combined HD 186 48 ± 11 (22-79) 84/102 44 ± 3 (39-59) 21 ± 24 (0-102) 10 ± 4 (0-13) 
Control 49 44 ± 9 (26-65) 22/27 - - - 
Table 4.3. Track-HD and Leiden cohorts for RNA-Seq analysis. 
Manifest subjects demonstrated motor abnormalities that were unequivocal signs of HD. Premanifest gene carriers had a total motor 
score of 5 or lower and a diagnostic confidence score (DCS) less than 4 on the UHDRS, indicating no substantial motor signs. The HD 
group consists of the combined premanifest and manifest subjects. Controls were matched for age and gender. Age and clinical 
scores considered for the analysis were at time of blood collection. SD – standard deviation; TFC – Total Functional Capacity; TMS – 
Total Motor Score. 
4.3.2 Sample collection 
Whole blood was collected in two PAXGene Blood RNA tubes (PreAnalytix, Qiagen/BD Company) per subject, and 
immediately placed upright at room temperature. They were checked at 5 hours for incomplete mixing or separation, 
and any showing separation were remixed with a further 10 inversions. Tubes were stored overnight at -20°C and 
transferred to -80°C the following morning. They were sent on dry ice to Biorep within 30 days. 
4.3.3 RNA preparation 
Total RNA extraction was performed using the PAXGene Blood RNA kit (cat #762174; PreAnalytix, Qiagen/BD Company), 
following the supplier’s instructions. Each solution in the kit was divided into aliquots to process batches of 12 samples. 
Replicate tubes for each subject were processed on different days. RNA was stored at -80oC before proceeding with the 
quality measurements and further use. RNA was collected by centrifugation, washing with 70% ethanol, and resuspended 
in buffer. Quality measurements of total RNA were made using spectrophotometric analysis (Nanodrop), 260/280 ratio 
denaturing agarose gel, and the RNA 6000 Nano kit for the Agilent Bioanalyzer (cat # 5067-1511, Agilent Technologies). 
Samples were globin reduced using the GLOBINclearTM method (cat #AM1980, ThermoFisher Scientific). Quality control 
measures were made on globin-reduced samples on the Bioanalyzer RNA 6000 Nano kit (cat #5067-1511, Agilent 
Technologies). 
4.3.4 Sequencing 
Indexed cDNA sequencing libraries were prepared using the TruSeqTM Poly-A mRNA method (Illumina). In short, poly-A 
mRNA transcripts were captured from total RNA using poly-T beads and cDNA generated using random hexamer priming 
(Illumina, 2014). Paired-end sequencing of indexed cDNA libraries on a HiSeq 2500 generated at least 50 M reads per 
sample. Sequencing was performed using SBS and cluster kits from Illumina. Indexed samples were demultiplexed and 
FASTQ files were generated. 
4.3.5 Quality control 
Sequencing failed for six Track-HD samples, including four premanifest, one manifest and one control subject. Quality 
control analysis was performed using the RNA-SeQC package (DeLuca et al., 2012), ensuring measures including rRNA 
rate, mapping rate, concordance mapping rate and uniqueness rate were within acceptable ranges. Globin depletion was 
checked by inspecting read counts mapped to HBB, HBA1 and HBA2, confirming they made up less than 2% of reads for 
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all samples. Four Track-HD and six Leiden samples failed quality control for duplication rate over 75%, GC bias or 5’ bias, 
and were removed, leaving 48 premanifest, 61 manifest and 21 control subjects in the Track-HD cohort and 15 
premanifest, 54 manifest and 26 control subjects in the Leiden cohort. 
4.3.6 Gene expression analysis 
RNA-Seq data were aligned to the human reference genome hg19 using TopHat2 (Kim et al., 2013). Read counts were 
summarized using HTSeq, keeping any duplicates and using the Ensembl transcript/gene database 
(http://www.ensembl.org/info/data/ftp/index.html, obtained in gtf format, genome build GRCh38.3, gene build updated 
in June 2015). To remove residual batch effects the R package svaseq was used (Leek, 2014). Using the cleaned count 
data, differential expression analysis was conducted using the R package DESeq2 (Love et al., 2014). Outlier counts were 
removed using a Cooks distance cutoff of 5 in DESeq2. After filtering by the mean of normalised counts, 18,257 transcripts 
were detected. Age and gender were used as covariates in the analysis. 
4.3.7 Pathway analysis 
Enrichment of differential expression among gene sets corresponding to biological hypotheses (pathways) was tested 
using the Gene Set Enrichment Analysis (GSEA) method (Subramanian et al., 2005). Rather than defining a list of 
significant genes, GSEA ranks all genes in order of their differential expression statistic, and tests whether the genes in a 
particular gene set have a higher rank overall than would be expected by chance. The analysis is weighted by the 
differential expression statistic, thus giving more weight to more significant genes. Significance of enrichment was 
obtained by randomly permuting gene-wide association statistics among genes. One-sided p-values were calculated 
separately for differential upregulation and downregulation of expression in HD, and these were then converted into the 
corresponding chi-square statistic for use in the GSEA analysis. To avoid making a priori assumptions, a large pathway set 
was collated from publicly available pathway databases, including Gene Ontology (GO) (Consortium, 2016), Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (KEGG, 2016), Mouse Genome Informatics (MGI) (MGI, 2016), PANTHER 
(PANTHER, 2016), BioCarta (BioCarta, 2016), REACTOME (REACTOME, 2016) and NCI (Institute, 2012). This resulted in a 
total of 14,706 functional gene sets, many with overlapping members, containing between 3 and 500 genes. To correct 
for multiple testing of pathways, GSEA p-values were converted into q-values (Storey and Tibshirani, 2003), which can be 
interpreted as the minimum false discovery rate at which that q-value would be counted as significant. 
4.3.8 Gene co-expression networks 
Weaknesses of relying on public databases to provide pathways for analysis include their restriction to prior biological 
knowledge and the poor annotation of many genes. To overcome this annotation gap, we also tested the following sets 
of gene co-expression modules for enrichment of dysregulation: 
1. The set of 124 HD brain expression modules derived by Neueder and Bates (2014), who applied weighted gene 
correlation network analysis (WGCNA) (Langfelder and Horvath, 2008) to the Hodges et al. (2006) microarray 
brain expression data set of 44 human HD and 36 matched control brains. They generated networks for four 
brain regions; the caudate nucleus (CN), the BA4 region of the frontal cortex, which has motor function (FC-
BA4), the BA9 region of the frontal cortex, involved in association and cognitive functions (FC-BA9), and 
cerebellum (CB). 
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2. A set of 117 co-expression modules derived from the Gibbs et al. (2010) dataset, comprising microarray 
expression data from 150 control individuals measured in four brain regions: cerebellum (CB), frontal cortex 
(FC), caudal pons (Pons) and temporal cortex (TCTX). Modules were generated using WGCNA as described in 
(International Genomics of Alzheimer's Disease, 2015). 
3. A novel set of 213 co-expression modules were generated from Braineac (2016), which consists of microarray 
expression data for 12 brain regions from 134 control brains; occipital cortex, frontal cortex, temporal cortex, 
hippocampus, intralobular white matter, cerebellar cortex, thalamus, putamen, substantia nigra, and medulla 
(inferior olivary nucleus). For each brain region, the array data was normalised in the R statistical-programming 
environment using the RMA algorithm (Carvalho and Irizarry, 2010). Principal Component Analysis (PCA) and 
hierarchical clustering were used to identify single outlier arrays for removal. In addition, small outlier clusters 
(<6 arrays) that were distinct from most of the other arrays were removed (i.e. small clusters appearing at the 
top of the dendrogram). Once outlier arrays were removed, the arrays were re-normalised and inspected again 
and re-processed if necessary until a homogenous dataset was produced. WGCNA was performed using the R 
package to derive modules (Langfelder and Horvath, 2008). Multiple probesets of the same gene were collapsed 
to a single value using the collapseRows() function, using default settings and based on gene annotation 
provided by Affymetrix (Affymetrix, 2016). Scale independence and mean connectivity were plotted to derive a 
soft threshold power of 6. Networks were unsigned. 
4. The set of 111 co-expression modules from Zhang et al. (2013), generated using microarray expression data on 
1,647 postmortem samples from three brain regions of late-onset Alzheimer’s disease (LOAD) and control 
subjects; prefrontal cortex (BA9), primary visual cortex (BA17), and cerebellum. 
4.3.9 Concordance of fold change in gene expression between datasets 
Labadorf et al. (2015) analysed the transcriptome of human postmortem prefrontal cortex Brodmann area 9 (BA9) from 
20 HD subjects and 49 controls using next-generation high throughput sequencing, identifying dysregulation of immune 
and developmental genes. Of the 15,834 genes common to both the combined Track-HD and Leiden blood dataset and 
the Labadorf et al. (2015) prefrontal cortex dataset, 8447 had a fold change >1 (i.e. upregulated) in blood and 7860 in 
cortex. Thus, if fold changes in the two datasets were assumed to be unrelated, the expected probability that a gene 
would show concordant fold change is equal to ((8447/15834)x(7860/15834))+((7387/15834)x(7974/15834)) = 0.4997. 
The number of genes with concordant fold change in the absence of a relationship between the datasets is thus 
distributed as a binomial (15834, 0.4997) distribution. In the actual data, 8425 genes were observed to have concordant 
direction of fold change, significantly higher than the number expected by chance (7912). 
A similar method was used to test for concordance of fold change in genes between the Track-HD and Mastrokolias et al. 
(2015) datasets. 
4.4 Contributions 
The study was conceived and designed by Professor Sarah Tabrizi. RNA was prepared by Davina Hensman and sequenced 
at Biorep. Alignment and read counts were performed by Kitty Lo and Vincent Plagnol. Gene expression and pathway 
analyses were performed by Professor Peter Holmans. Data interpretation and presentation was conducted by Michael 
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Flower. Figures were prepared by Timothy Stone and Michael Flower. Michael Flower wrote the manuscript, Hensman 
Moss et al. (2017a).  
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4.5 Results 
4.5.1 Differential expression 
Attempting to identify both HD specific and stage-specific changes in gene expression (mRNA) level, premanifest, 
manifest and control subjects were compared, whilst controlling for age and gender. Premanifest gene carriers had a 
mean total motor score (TMS) of 2 and total functional capacity (TFC) of 13, indicating no substantial motor signs. 
Manifest subjects demonstrated motor abnormalities that were unequivocal signs of HD. 
No transcripts were significantly differentially expressed (FDR < 0.05) between premanifest and manifest HD in either the 
TRACK-HD (Tabrizi et al., 2009b) or the independent Leiden cohort, or when these cohorts were combined (results not 
shown). As expression changes did not differ significantly between disease stages, all mutant HTT gene carriers were 
combined to increase the analytical power in a comparison of HD and controls. Once again there were no individually 
significant transcripts in independent or combined cohorts. The top 10 genes from the differential expression analysis in 
the combined cohort are given below, and a complete list is provided in Hensman Moss et al. (2017a). 
Entrez gene ID Gene Symbol p (diffexp) q (diffexp) log2(FC) 
722 C4BPA 7.81E-06 1.41E-01 1.371 
2297 FOXD1 9.09E-05 7.02E-01 -0.785 
3805 KIR2DL4 1.93E-04 7.02E-01 0.651 
196394 AMN1 2.11E-04 7.02E-01 0.208 
94137 RP1L1 2.47E-04 7.02E-01 -1.350 
158248 TTC16 2.67E-04 7.02E-01 -0.347 
100422824 MIR3128 2.86E-04 7.02E-01 0.930 
5797 PTPRM 3.12E-04 7.02E-01 -0.359 
84692 CCDC54 4.79E-04 9.58E-01 2.532 
889 KRIT1 7.30E-04 9.58E-01 -0.081 
Table 4.4. Top 10 genes from the differential expression analysis in the combined Track-HD and Leiden cohort. 
4.5.2 Pathway analysis 
Genes were combined into networks with similar functional annotation, then expression was investigated in HD relative 
to controls. Pathway annotations were collated from publicly available gene ontology databases to form a set of generic 
pathways using the same method as the recent HD genome-wide association study (GWAS) of age at onset (GeM-HD, 
2015, Hensman Moss et al., 2017a). 
The number of pathways significantly dysregulated in both Track-HD and Leiden blood datasets was significantly higher 
than would be expected by chance. This indicates shared biology between the two independent cohorts despite 
differences in demographic and disease stage; Leiden subjects were on average 7 years older and had correspondingly 
higher TMS (mean 32 versus 14 in Track-HD) and lower TFC (mean 8 versus 12 in Track-HD). The significance of the overlap 
was greatly increased in analyses specifying the direction of dysregulation (increased or decreased expression) (see table 
below). Therefore, directional analyses were used in the combined dataset as the primary analysis.  
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Reference 
dataset 
Comparison 
dataset 
Direction of 
dysregulation in HD 
Number of pathways significant in both datasets (p value) 
Generic pathways HD brain modules Control brain modules 
Leiden Track-HD 
Nondirectional 69 (4.6E-02) - - 
Downregulated 130 (<1.0E-03) 4 (1.1E-01) 24 (<1.0E-03) 
Upregulated 219 (<1.0E-03) 9 (<1.0E-03) 23 (<1.0E-03) 
Track-HD Leiden 
Nondirectional 69 (1.4E-01) - - 
Downregulated 130 (1.7E-02) 4 (3.5E-02) 24 (<1.0E-03) 
Upregulated 217 (<1.0E-03) 10 (<1.0E-03) 21 (<1.0E-03) 
Table 4.5. Overlap analysis of Track-HD and Leiden cohorts shows that a significant excess of pathways are associated with HD (p 
< 0.05) in both datasets. 
Significance of overlap is greatest when directionality is taken into account. There is an excess of significantly enriched pathways and 
modules in the reference dataset conditional on the pathway being enriched (p < 0.05) in the comparison dataset. The generic 
pathways gene set is collated from publicly-available databases including GO and KEGG. HD brain modules are derived from Neueder 
and Bates (2014). Control brain modules are from the Braineac (2016) and Gibbs et al. (2010) expression datasets. 
Gene set enrichment analysis (GSEA), with a false discovery rate (q-value) threshold of q < 0.05 to correct for multiple 
testing, identified 53 upregulated and 14 downregulated pathways that are at least nominally significant in both cohorts. 
Multiple immune-related pathways were upregulated, and RNA processing, ATP metabolism and DNA repair were 
notably downregulated. The 10 most significant pathways for each direction of dysregulation are given in in the table 
below and the full list of significant pathways is available in Hensman Moss et al. (2017a). 
Direction of 
dysregulation in 
HD 
Pathway Number of 
dysregulated 
genes 
p 
(combined) 
q 
(combined) 
p 
(Track-HD) 
p 
(Leiden) 
Description 
Upregulated 
MGI: 2419 434 3.03E-10 4.32E-06 5.10E-05 3.01E-05 Abnormal Innate Immunity                                                                                                                                                                                 
MGI: 3009 432 5.78E-09 4.13E-05 5.96E-06 1.65E-04 Abnormal Cytokine Secretion                                                                                                                                                                              
GO: 50792 117 2.59E-08 1.23E-04 1.12E-02 7.24E-05 Regulation Of Viral Process                                                                                                                                                                              
GO: 9615 208 1.22E-07 4.36E-04 3.06E-02 5.34E-06 Response To Virus                                                                                                                                                                                        
MGI: 2451 278 1.68E-07 4.80E-04 1.26E-02 9.51E-06 Abnormal Macrophage Physiology                                                                                                                                                                           
GO: 19221 308 2.38E-07 5.45E-04 4.60E-05 1.71E-04 Cytokine-Mediated Signaling Pathway                                                                                                                                                                      
GO: 2252 365 3.10E-07 5.45E-04 7.01E-03 1.14E-04 Immune Effector Process                                                                                                                                                                                  
MGI: 5025 406 3.44E-07 5.45E-04 5.91E-05 2.02E-04 Abnormal Response To Infection                                                                                                                                                                           
MGI: 1793 372 4.33E-07 5.82E-04 5.93E-05 2.42E-04 Altered Susceptibility To Infection                                                                                                                                                                      
MGI: 8568 305 4.49E-07 5.82E-04 4.79E-05 6.25E-05 Abnormal Interleukin Secretion                                                                                                                                                                           
Downregulated 
GO: 8380 282 5.22E-08 7.45E-04 4.25E-05 7.24E-05 RNA splicing                                                                                                                                                                                             
GO: 6397 359 2.38E-07 1.70E-03 1.48E-04 4.14E-04 mRNA processing                                                                                                                                                                                          
GO: 16887 329 1.37E-06 5.48E-03 1.96E-04 3.34E-02 ATPase activity                                                                                                                                                                                          
GO: 6200 333 1.54E-06 5.48E-03 2.42E-04 3.36E-02 ATP catabolic process                                                                                                                                                                                    
GO: 46034 361 5.36E-06 1.53E-02 1.74E-04 4.45E-02 ATP metabolic process                                                                                                                                                                                    
GO: 16607 144 9.06E-06 2.15E-02 4.68E-04 4.61E-03 Nuclear speck                                                                                                                                                                                            
GO: 6281 356 1.66E-05 2.75E-02 2.00E-03 1.18E-04 DNA repair                                                                                                                                                                                               
GO: 16604 271 2.08E-05 2.75E-02 5.59E-03 2.46E-03 Nuclear Body                                                                                                                                                                                             
GO: 4386 135 2.12E-05 2.75E-02 2.83E-02 4.81E-02 Helicase Activity                                                                                                                                                                                        
GO: 375 184 2.40E-05 2.86E-02 1.14E-03 2.05E-03 RNA splicing, via transesterification reactions                                                                                                                                                          
Table 4.6. The 10 most significantly up and downregulated ‘generic’ pathways in HD versus control blood GSEA. 
A total of 14,706 Generic pathways, each containing between 3 and 500 genes, were collated from publicly-available databases 
including GO and KEGG. Pathways are significantly dysregulated after multiple testing correction (q < 0.05). Enrichment p values in 
the current study for the Track-HD, Leiden and combined datasets are shown.  
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Figure 4.1. Upregulated pathways in HD versus control blood. 
Schematic representation of pathways collated from publicly available databases that are significantly upregulated in HD versus 
controls after correction for multiple testing (q < 0.05). Modules with similar gene content and functional annotation have been 
consolidated. Nodal shading is inversely proportional to false discovery rate threshold (q value); deep shades have low q values and 
pale shading is close to the 5% threshold. The weight of connecting lines is proportional to the number of genes shared between 
pathways. 
 
Figure 4.2. Downregulated pathways in HD versus control blood. 
Schematic representation of pathways collated from publicly available databases that are significantly downregulated in HD versus 
controls after correction for multiple testing (q < 0.05). Modules with similar gene content and functional annotation have been 
consolidated. Nodal shading is inversely proportional to false discovery rate threshold (q value); deep shades have low q values and 
pale shading is close to the 5% threshold. The weight of connecting lines is proportional to the number of genes shared between 
pathways. 
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The 10 most dysregulated genes (p < 0.01) from the significantly up or downregulated generic pathways (q < 0.05) are 
shown below, and a complete list of genes (p < 0.05) in all nominally significant pathways (p < 0.05) is given in Hensman 
Moss et al. (2017a). Notably, the significantly upregulated pathways contain some of the most differentially expressed 
individual transcripts, with several more contained in pathways reaching nominal significance (p < 0.05) for dysregulation. 
Genes highlighted by MGI pathways appear distinct from other pathway databases, likely because they are based on 
knockout studies in mice. 
Direction Entrez 
gene ID 
Gene 
Symbol 
p 
(Comb) 
log2FC 
(Comb) 
p 
(Track-
HD) 
log2FC 
(Track-
HD) 
p 
(Leiden) 
log2FC 
(Leiden) 
Pathway membership (q < 0.05) 
Genes in 
upregulated 
pathways 
722 C4BPA 7.81E-06 1.371 1.29E-01 0.437 7.36E-01 0.187 GO:2252, GO:2253, GO:5773, GO:31347, GO:44437, GO:50778 
8763 CD164 9.53E-04 0.098 2.97E-01 0.083 5.57E-03 0.101 GO:323, GO:5764, GO:5765, GO:5773, GO:44437 
597 BCL2A1 1.06E-03 0.423 8.85E-02 0.319 1.20E-02 0.393 MGI:1793, MGI:2419, MGI:2462, MGI:2463, MGI:5025 
4940 OAS3 1.12E-03 0.688 5.14E-02 0.602 6.45E-02 0.455 
GO:2252, GO:9615, GO:19221, 
GO:34340, GO:43903, GO:45069, 
GO:45071,GO:48525, GO:50792, 
GO:60337, GO:71345, GO:71357, 
KEGG:5164, 
REACTOME:287,REACTOME:587, 
REACTOME:589 
49 ACR 1.13E-03 1.237 7.54E-03 1.417 1.79E-01 0.768 GO:5773, GO:44437 
9262 STK17B 1.19E-03 0.132 4.42E-02 0.134 3.56E-02 0.136 
MGI:1844, MGI:2425, MGI:2444, 
MGI:3009, MGI:5000, MGI:5005, 
MGI:8568 
164668 APOBEC3H 1.98E-03 -0.323 1.41E-01 -0.208 4.33E-03 -0.476 
GO:2252, GO:9615, GO:43903, 
GO:45069, GO:45071, GO:48525, 
GO:50792 
79026 AHNAK 2.12E-03 -0.169 1.48E-02 -0.201 1.27E-01 -0.106 MGI:1793, MGI:2406, MGI:2444, MGI:3009, MGI:5025, MGI:8568 
6614 SIGLEC1 4.39E-03 0.634 3.58E-01 0.291 9.79E-02 0.552 MGI:2459, MGI:8195 
875 CBS 4.42E-03 0.592 1.15E-01 0.439 2.38E-02 0.681 MGI:8469, MGI:8713, MGI:8835 
Genes in 
downregulated 
pathways 
9262 STK17B 1.19E-03 0.132 4.42E-02 0.134 3.56E-02 0.136 MGI:5094 
54957 TXNL4B 1.65E-03 0.088 2.99E-02 0.088 2.67E-02 0.090 GO:5681, GO:6397, GO:8380 
375757 SWI5 1.68E-03 0.114 3.22E-02 0.112 2.67E-02 0.130 GO:6281 
146713 RBFOX3 1.86E-03 -0.434 3.81E-02 -0.396 7.65E-02 -0.357 GO:6397, GO:8380 
79026 AHNAK 2.12E-03 -0.169 1.48E-02 -0.201 1.27E-01 -0.106 MGI:5094 
29890 RBM15B 2.67E-03 -0.055 9.18E-02 -0.048 8.98E-02 -0.044 GO:6397, GO:8380 
9987 HNRNPDL 3.38E-03 -0.078 2.98E-02 -0.088 9.41E-03 -0.098 GO:5681 
23499 MACF1 3.72E-03 -0.120 4.52E-03 -0.172 2.15E-01 -0.068 GO:6200, GO:16887, GO:46034 
146754 DNAH2 4.04E-03 -0.621 1.82E-01 -0.415 2.39E-02 -0.723 GO:6200, GO:16887, GO:46034 
10236 HNRNPR 5.92E-03 -0.069 1.15E-01 -0.053 5.62E-02 -0.074 GO:375, GO:377, GO:398, GO:5681, GO:6397, GO:8380 
Table 4.7. Top genes in top pathways. 
The 10 most dysregulated genes (p < 0.01) from the significantly up or downregulated generic pathways (q < 0.05). p – corrected 
significance in the indicated dataset. Log2FC – Log2 fold change in expression.  
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Group Pathway Description p 
(blood combined) 
Group 1 
Abnormal 
innate 
immunity 
MGI: 2419 abnormal innate immunity 3.03E-10 
MGI: 2451 abnormal macrophage physiology 1.68E-07 
MGI: 2462 abnormal granulocyte physiology 4.09E-05 
MGI: 2463 abnormal neutrophil physiology 9.20E-05 
MGI: 2498 abnormal acute inflammation 1.01E-04 
Group 2 
Abnormal 
cytokine 
secretion 
MGI: 3009 abnormal cytokine secretion 5.78E-09 
MGI: 8568 abnormal interleukin secretion 4.49E-07 
MGI: 8835 abnormal intercellular signaling peptide or protein level 8.31E-06 
MGI: 8713 abnormal cytokine level 1.35E-05 
MGI: 8469 abnormal protein level 2.68E-05 
MGI: 10210 abnormal circulating cytokine level 8.70E-05 
MGI: 8704 abnormal interleukin-6 secretion 1.54E-04 
MGI: 8705 increased interleukin-6 secretion 2.00E-04 
Group 3 
Regulation 
of viral 
process 
GO: 50792 regulation of viral process 2.59E-08 
GO: 48525 negative regulation of viral process 6.05E-07 
GO: 45069 regulation of viral genome replication 1.21E-06 
GO: 45071 negative regulation of viral genome replication 2.30E-06 
GO: 43903 regulation of symbiosis, encompassing mutualism through parasitism 4.28E-05 
GO: 9615 response to virus 1.22E-07 
GO: 2252 immune effector process 3.10E-07 
Group 4 
Cytokine-
mediated 
signalling 
pathway 
GO: 19221 cytokine-mediated signaling pathway 2.38E-07 
REACTOME 287 REACT:CYTOKINE SIGNALING IN IMMUNE SYSTEM 8.59E-07 
GO: 71345 cellular response to cytokine stimulus 1.15E-06 
REACTOME 589 REACT:INTERFERON SIGNALING 3.02E-05 
GO: 60337 type I interferon-mediated signaling pathway 4.20E-05 
GO: 71357 cellular response to type I interferon 4.20E-05 
REACTOME 587 REACT:INTERFERON ALPHA BETA SIGNALING 6.00E-05 
GO: 34340 response to type I interferon 8.95E-05 
KEGG 5164 KEGG INFLUENZA A 1.14E-04 
Group 5 
Abnormal 
response to 
infection 
MGI: 5025 abnormal response to infection 3.44E-07 
MGI: 1793 altered susceptibility to infection 4.33E-07 
MGI: 2406 increased susceptibility to infection 6.87E-06 
Group 6 
Abnormal 
myeloid 
leukocyte 
morphology 
MGI: 8250 abnormal myeloid leukocyte morphology 6.46E-07 
MGI: 8251 abnormal phagocyte morphology 3.12E-06 
MGI: 8195 abnormal antigen presenting cell morphology 1.94E-05 
MGI: 2441 abnormal granulocyte morphology 3.42E-05 
MGI: 8248 abnormal mononuclear phagocyte morphology 4.39E-05 
MGI: 2446 abnormal macrophage morphology 5.88E-05 
Group 7 
Regulation 
of cytokine 
production 
GO: 1817 regulation of cytokine production 2.76E-06 
GO: 31347 regulation of defense response 4.73E-06 
GO: 50778 positive regulation of immune response 7.29E-06 
GO: 2253 activation of immune response 2.92E-05 
Group 8 
Abnormal T-
cell 
physiology 
MGI: 2444 abnormal T cell physiology 1.14E-05 
MGI: 2459 abnormal B cell physiology 1.11E-04 
Group 9 
Abnormal 
self 
tolerance 
MGI: 5005 abnormal self tolerance 1.21E-05 
MGI: 1844 autoimmune response 1.28E-05 
MGI: 5000 abnormal immune tolerance 1.63E-05 
MGI: 2425 altered susceptibility to autoimmune disorder 7.94E-05 
Group 
10 Vacuole 
GO: 5773 vacuole 1.36E-05 
GO: 323 lytic vacuole 1.41E-05 
GO: 5764 lysosome 1.41E-05 
GO: 44437 vacuolar part 4.50E-05 
GO: 5765 lysosomal membrane 4.97E-05 
Table 4.8. Groups of pathways upregulated in HD blood vs controls. 
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Group Pathway Description p 
(blood-
combined) 
Group 1 mRNA splicing 
GO: 8380 RNA splicing 5.22E-08 
GO: 6397 mRNA processing 2.38E-07 
GO: 375 RNA splicing, via transesterification reactions 2.40E-05 
GO: 377 RNA splicing, via transesterification reactions with bulged adenosine as 
nucleophile 
6.25E-05 
GO: 398 mRNA splicing, via spliceosome 6.25E-05 
GO: 5681 spliceosomal complex 7.29E-05 
Group 2 ATPase activity 
GO: 16887 ATPase activity 1.37E-06 
GO: 6200 ATP catabolic process 1.54E-06 
GO: 46034 ATP metabolic process 5.36E-06 
Ungrouped terms 
GO: 16607 nuclear speck 9.06E-06 
GO: 6281 DNA repair 1.66E-05 
GO: 16604 nuclear body 2.08E-05 
GO: 4386 helicase activity 2.12E-05 
MGI: 5094 abnormal T cell proliferation 4.60E-05 
Table 4.9. Groups of pathways downregulated in HD blood vs controls. 
4.5.3 Pathway dysregulation overlap with HD myeloid cells 
With RNA-Seq, Miller et al. (2016) identified transcriptional dysregulation in unstimulated monocytes from HD cases 
relative to controls. Their GSEA used the same set of generic pathways used here. A significant excess of pathways were 
found to be significantly (p<0.05) enriched for dysregulation in both Miller et al. (2016) and the combined TRACK-HD and 
Leiden whole blood data. This overlap was attributable to a significant excess of pathways enriched for upregulation in 
both datasets. Overlap in downregulated pathways was not significantly larger than expected by chance. The top 10 
pathways significantly (p<0.05) enriched for upregulation in both myeloid and whole blood are given in the table below, 
and the full list of up and downregulated pathways is listed in Hensman Moss et al. (2017a). Pathways that are 
significantly enriched for upregulation are predominantly immune-related, which is unsurprising given Miller et al. (2016) 
isolated monocytes from blood. 
Direction of 
dysregulation in HD 
Number of pathways significant in both datasets 
(p value) 
Nondirectional 132 (0.009) 
Downregulated 36 (0.113) 
Upregulated 339 (<1.0E-03) 
Table 4.10. Overlap between HD blood and myeloid cells. 
A significant excess of pathways were found to be significantly (p<0.05) enriched for dysregulation in both Miller et al. (2016) and the 
combined TRACK-HD and Leiden whole blood data.  
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Pathway Number 
of genes 
p 
(blood: 
London+Leiden) 
p 
(myeloid-
unstimulated) 
p 
(blood and myeloid 
combined) 
Description 
MGI: 2419 434 3.03E-10 3.77E-08 4.44E-16 abnormal innate immunity 
MGI: 3009 432 5.78E-09 4.26E-07 8.54E-14 abnormal cytokine secretion 
GO: 31347 430 4.73E-06 8.96E-09 1.35E-12 regulation of defense response 
GO: 9615 208 1.22E-07 9.68E-07 3.64E-12 response to virus 
MGI: 2451 278 1.68E-07 1.83E-06 9.16E-12 abnormal macrophage physiology 
GO: 2252 365 3.10E-07 1.95E-06 1.76E-11 immune effector process 
MGI: 1793 372 4.33E-07 2.30E-06 2.85E-11 altered susceptibility to infection 
MGI: 8568 305 4.49E-07 3.26E-06 4.13E-11 abnormal interleukin secretion 
MGI: 5025 406 3.44E-07 4.42E-06 4.28E-11 abnormal response to infection 
MGI: 8835 258 8.31E-06 1.92E-07 4.49E-11 abnormal intercellular signaling peptide or 
protein level 
Table 4.11. Top 10 upregulated pathways that overlap between HD blood and myeloid cells. 
Pathways significantly (p<0.05) enriched for up and downregulation in both myeloid and whole blood. 
4.5.4 Gene co-expression modules 
4.5.4.1 HD blood 
A limitation of using curated pathways from databases is the incomplete or incorrect annotation. One way to overcome 
this is to use gene co-expression, because genes that are co-expressed often have related functions. WGCNA identifies 
clusters (modules) of genes with highly correlated expression, constructing original, unbiased gene co-expression 
networks based on observed data (Gibbs et al., 2013). HD brain expression modules were generated by Neueder and 
Bates (2014), who applied WGCNA to Hodges et al. (2006) data and annotated each module that was associated with HD 
disease status. To further fill the annotation gap and better define functional biological pathways, novel co-expression 
modules were generated for control brain from the Braineac (2016) and Gibbs et al. (2010) datasets. 
GSEA for brain co-expression modules was applied to the combined Track-HD and Leiden blood expression dataset. 
Immune and inflammatory-related brain modules were upregulated in HD blood, and notable downregulated modules 
included synaptic function, proteasomal degradation, mitochondrial function and transcription, as shown in the table 
below. Also given below is a table of the top 10 genes from the modules that are themselves nominally significantly 
dysregulated (p < 0.05) in the combined dataset, and the full list is provided in Hensman Moss et al. (2017a). In addition 
to reinforcing the biological conclusions from the previous pathway analysis, the significantly dysregulated modules also 
share genes with the top pathways above. 
  
112 
Direction Brain 
expression 
gene set 
Module Brain region Annotation Number of 
genes 
p 
(Combined) 
p 
(Track-
HD) 
p 
(Leiden) 
 Cor 
(HD) 
BH 
(HD) 
Upregulated HD 111 FC_BA9 Immune response 514 7.81E-12 1.27E-04 7.53E-05 - - 
HD 69 (FC4pos1) FC_BA4 Inflammatory response 712 3.77E-08 3.05E-05 1.32E-03 0.61 3.77E-03 
Control (B) 712 TCTX Inflammatory response 213 1.41E-07 3.40E-05 8.14E-04 - - 
HD* 48 (CNpos2)* CN Lipid metabolism/regulation of transcription 1785 2.03E-07 3.85E-03 6.33E-03 0.72 2.21E-11 
Control (B) 110 FCTX  Inflammatory response 173 8.94E-07 1.04E-03 2.50E-03 - - 
Control (B) 909 White Matter Activation of immune response 265 2.12E-06 1.24E-03 2.48E-02 - - 
Control (B) 610 Substantia 
Nigra 
Inflammatory response 178 1.21E-05 8.56E-04 5.57E-04 - - 
Control (B) 811 Thalamus Inflammatory response 142 1.61E-05 3.94E-03 2.89E-03 - - 
Control (G) 56 Pons Lipoprotein/ immune response /GTPase regulator activity 207 1.97E-05 2.44E-04 4.19E-02 - - 
Control (B) 911 White Matter Inflammatory response 159 3.00E-05 8.42E-04 1.39E-02 - - 
HD 28 CB Immune response 209 3.11E-05 1.07E-02 1.19E-02 - - 
Control (B) 713 TCTX Activation of immune response 171 4.02E-05 2.39E-02 4.67E-02 - - 
HD 33 CB Immune response 255 4.34E-05 1.08E-02 1.37E-02 - - 
Control (B) 505 Putamen Ether lipid metabolism 500 6.28E-05 3.16E-03 2.06E-02 - - 
HD 68 (CNpos5) CN Cilium 1268 1.09E-04 3.05E-02 5.00E-02 0.54 7.74E-06 
Control (B) 516 Putamen Cellular response to cytokine stimulus 133 3.07E-04 1.44E-02 1.71E-02 - - 
HD 64 (CNpos6) CN Inflammatory response 114 3.13E-04 1.18E-02 3.80E-02 0.46 2.28E-04 
HD 124 FC_BA9 NA 1176 2.91E-03 1.19E-02 2.37E-02 - - 
Downregulated Control (G) 22 CB Pro-rich region 831 1.83E-08 2.49E-03 2.06E-02 - - 
Control (G) 28 FC  Intra-cellular transport/mitochondrion 3178 2.10E-08 6.30E-04 7.66E-05 - - 
Control (B) 304 Medulla mRNA metabolic process 1811 2.91E-08 5.00E-15 4.01E-02 - - 
HD* 66 
(CNneg1)* 
CN Synapse/ion channels 2645 2.71E-07 1.51E-04 2.13E-02 -0.80 6.03E-15 
Control (B) 804 Thalamus Regulation of cell morphogenesis 857 1.31E-06 4.03E-02 4.13E-04 - - 
Control (B) 522 Putamen Regulation of RNA splicing 64 4.44E-06 6.26E-03 2.66E-04 - - 
Control (G) 74 Pons Transcription/acetylation/protein transport 1183 9.22E-06 3.85E-08 7.44E-04 - - 
Control (B) 702 TCTX Antigen processing: ubiquitination and proteasome degradation 4602 3.87E-04 1.22E-03 2.47E-02 - - 
Control (G) 48 FC Transcription corepressor/cell morphogenesis 648 4.65E-04 7.83E-03 2.05E-02 - - 
Control (B) 202 Hippocampus Mitochondrial membrane 2737 4.75E-04 1.16E-07 1.54E-02 - - 
HD 19 CB Protein binding 155 7.44E-04 2.66E-02 2.26E-02 - - 
Control (B) 906 White Matter Uridyltransferase activity  416 1.12E-03 2.53E-02 1.12E-02 - - 
Control (G) 93 Pons Mitochondrion/nuclear lumen 317 1.30E-03 9.85E-03 8.74E-04 - - 
Control (B) 812 Thalamus Transport of mature transcript to cytoplasm 114 1.42E-03 1.99E-02 4.70E-02 - - 
HD 102 FC_BA9 Cytoplasm 1908 1.47E-03 7.57E-03 1.31E-04 - - 
Control (B) 706 TCTX Microtubule organising center 481 1.93E-03 3.70E-05 3.80E-03 - - 
Control (G) 52 Pons Acetylation/fatty acid metabolism 1590 3.28E-03 2.23E-02 1.31E-02 - - 
HD 3 (CBneg2) CB mitochondrion 1164 3.19E-02 2.56E-02 1.29E-05 -0.45 1.66E-03 
Control (G) 25 CB RNA binding 648 8.02E-01 1.72E-04 3.62E-02 - - 
Table 4.12. WGCNA brain expression modules in HD versus control blood. 
P values for dysregulation in the combined blood sample are corrected for multiple testing (q < 0.05). HD brain modules were defined 
by Neueder and Bates (2014), and Control brain modules were generated from Braineac (2016) and Gibbs et al. (2010). Neueder and 
Bates (2014) module identifiers are given in brackets where available. * denotes the caudate modules that were highly positively or 
negatively correlated with HD in their study. BH – Benjamini-Hochberg correction for false discovery rate; CN – caudate nucleus; FC – 
frontal cortex; FC BA4 – BA4 region of the frontal cortex; FC BA9 – BA9 region of the frontal cortex; CB – cerebellum; TCTX – temporal 
cortex. 
  
113 
Entrez gene 
ID 
Gene Symbol p 
(Comb) 
log2FC 
(Comb) 
p 
(Track-HD) 
log2FC 
(Track-HD) 
p 
(Leiden) 
log2FC 
(Leiden) 
Module 
membership 
2297 FOXD1 9.09E-05 -0.785 1.10E-02 -0.685 1.69E-03 -1.014 
HD 48 
(CNpos2), HD 
111 
3805 KIR2DL4 1.93E-04 0.651 2.57E-03 0.823 1.52E-02 0.533 CTRL (B) 702 
196394 AMN1 2.11E-04 0.208 1.87E-02 0.205 9.25E-03 0.195 CTRL (B) 202, CTRL (B) 702 
5797 PTPRM 3.12E-04 -0.359 5.26E-03 -0.381 2.82E-03 -0.448 
CTRL (B) 202, 
CTRL (B) 702, 
CTRL (B) 904, 
HD 66 
(CNneg1) 
889 KRIT1 7.30E-04 -0.081 1.59E-02 -0.097 7.86E-02 -0.057 
CTRL (B) 304, 
CTRL (G) 28, 
HD 102 
22979 EFR3B 8.17E-04 0.494 6.02E-03 0.603 2.07E-02 0.496 
CTRL (B) 702, 
CTRL (B) 904, 
HD 66 
(CNneg1) 
56934 CA10 8.42E-04 2.036 1.21E-02 2.020 8.42E-02 1.945 
CTRL (B) 702, 
CTRL (B) 902, 
HD 66 
(CNneg1), HD 
102 
8763 CD164 9.53E-04 0.098 2.97E-01 0.083 5.57E-03 0.101 HD 68 (CNpos5) 
597 BCL2A1 1.06E-03 0.423 8.85E-02 0.319 1.20E-02 0.393 
CTRL (B) 110, 
CTRL (B) 217, 
CTRL (B) 516, 
CTRL (B) 610, 
CTRL (B) 712, 
CTRL (B) 811, 
CTRL (B) 
911,HD 33, HD 
68 (CNpos5), 
HD 69 
(FC4pos1), HD 
111 
4940 OAS3 1.12E-03 0.688 5.14E-02 0.602 6.45E-02 0.455 CTRL (B) 702, CTRL (B) 902 
Table 4.13. Top 10 genes in WGCNA modules. 
Genes from the modules that are themselves nominally significantly dysregulated (p < 0.05) in the combined dataset. 
4.5.4.2 Comparison of blood with HD striatum 
Neueder and Bates (2014) derived 124 HD brain expression modules in four brain regions by applying WGCNA to the 
Hodges et al. (2006) microarray expression dataset of 44 human HD and 36 matched control brains. The table below gives 
modules that were significantly dysregulated (after correcting for multiple testing of modules) in both HD brain (Neueder 
and Bates, 2014) and in the combined Track-HD and Leiden blood expression dataset. The direction of dysregulation in 
brain is shown by the correlation between the module eigengene and HD status (with a positive correlation 
corresponding to upregulation in the HD brain). Notably, two of the most significantly dysregulated modules in HD 
caudate (Neueder and Bates, 2014) were also significantly dysregulated in the same direction in blood, not only in the 
combined dataset, but in each of the Track-HD and Leiden datasets independently; these being module 48 (CNpos2), 
which is upregulated in HD, and module 66 (CNneg1), which is downregulated.  
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Module Brain 
Region 
Module 
name 
Number of 
genes 
p 
(combined) 
p 
(TRACK) 
p 
(Leiden) 
cor 
(HD brain) 
p 
(HD brain) 
Description 
69 FC_BA4 FC4pos1 712 3.77E-08 3.05E-05 1.32E-03 0.610 3.77E-03 Inflammatory response  
48 CN     CNpos2  1785 2.03E-07 3.85E-03 6.33E-03 0.724 2.21E-11 Lipid metabolism/regulation of transcription 
64 CN     CNpos6  114 3.13E-04 1.18E-02 3.80E-02 0.463 2.28E-04 Inflammatory response  
66 CN     CNneg1  2644 2.71E-07 1.51E-04 2.13E-02 -0.800 6.03E-15 Synapse            
Table 4.14. Brain expression modules significantly dysregulated both in HD brain and HD blood. 
All modules in this table are significantly dysregulated after correction for multiple testing (q < 0.05) in the combined blood sample, 
and are nominally significantly dysregulated (p<0.05) in both Track-HD and Leiden datasets separately. Cor(HD brain) – the 
correlation between module eigengene and HD status observed by Neueder and Bates (2014) in brain expression data, with a positive 
correlation corresponding to upregulation in HD. p(HD brain)  is the p-value for that correlation (corrected for multiple testing of 
modules). CN – caudate nucleus, FC_BA4 – BA4 region of the frontal cortex. 
The module membership (kME) of a gene is measured by the correlation of its expression with the eigengene, which is 
representative of all gene expression profiles in the module (Langfelder and Horvath, 2008); highly connected ‘hub’ genes 
have high kME values. Interestingly, among genes in module 48 (CNpos2), the Neueder and Bates (2014) HD caudate 
module that was also significantly upregulated in blood, there was a significant (p = 7.6 x 10-4) correlation between 
dysregulation p-value in the direction of interest (positive) in HD blood and degree of module membership (kME) 
(Neueder and Bates, 2014). This suggests that highly connected “hub” genes in this module may play a role in 
transcriptional dysregulation in HD. A similar, although much stronger, effect was noted in caudate (Neueder and Bates, 
2014). There was no significant correlation in module 66 (CNneg1). The top 10 genes in module 48 (CNpos2) that are 
dysregulated (p < 0.05) in both blood and caudate are shown in below, ranked by their kME value, and the full list is given 
in Hensman Moss et al. (2017a). 
Gene Entrez kME log2FC (blood) 
Directional p 
(blood) 
log2FC 
(caudate) 
p 
(caudate) 
RAB13 5872 0.877 0.138 3.11E-02 0.761 8.07E-10 
RAB31 11031 0.858 0.118 4.82E-02 0.503 6.25E-09 
MT2A 4502 0.833 0.237 1.40E-02 0.640 1.98E-06 
S100A6 6277 0.810 0.121 2.37E-02 0.776 3.13E-09 
DDIT4 54541 0.781 0.193 9.64E-03 0.827 4.82E-05 
PFKFB3 5209 0.780 0.286 5.78E-03 0.568 1.39E-06 
TSPO 706 0.772 0.170 3.30E-03 0.452 6.60E-08 
DDAH2 23564 0.762 0.087 4.48E-02 0.375 4.04E-09 
ITGA7 3679 0.758 0.151 4.38E-02 0.287 1.21E-04 
PLEKHF2 79666 0.742 0.067 3.34E-02 0.370 1.16E-06 
Table 4.15. Top 10 genes in module 48 (CNpos2) that are dysregulated (p < 0.05) in both blood and caudate, ranked by their kME 
value. 
Module membership (kME) of a gene is measured by the correlation of its expression with the eigengene, which is representative of 
all gene expression profiles in the module; highly connected ‘hub’ genes have high kME values. 
4.5.4.3 Comparison of blood with HD prefrontal cortex 
Labadorf et al. (2015) identified dysregulated expression of immune and developmental genes in human HD postmortem 
prefrontal cortex (Brodmann area 9). Fold changes in expression of individual genes in the combined Track-HD and Leiden 
data were compared to those observed in Labadorf et al. (2015), and were found to be in the same direction for 8,425 
out of the 15,834 genes present in both datasets. This is a highly significant (p < 2.2x10-16) excess (see Methods), 
suggesting some concordance in signal at the individual gene level. 
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Furthermore, a significant excess of generic pathways was found to be significantly (p < 0.05) dysregulated in both 
datasets, most markedly in the positive (p < 0.001) direction, but also negative (p = 0.028), thus showing an overlap in 
biological signal. The top 10 pathways up and downregulated in HD blood and prefrontal cortex are given in the table 
below, and the full list is available in Hensman Moss et al. (2017a). Pathways significantly upregulated in both datasets 
are mainly related to immune response. 
Direction Pathway Number of 
dysregulated 
genes 
Blood p 
(Combined) 
Brain p 
(Labadorf) 
Description 
Upregulated 
MGI: 2459 402 1.11E-04 1.39E-13 abnormal B cell physiology 
MGI: 2419 434 3.03E-10 2.05E-12 abnormal innate immunity 
MGI: 1800 361 5.45E-04 2.58E-12 abnormal humoral immune response 
MGI: 8195 412 1.94E-05 8.78E-12 abnormal antigen presenting cell morphology 
MGI: 2490 333 8.00E-04 3.52E-11 abnormal immunoglobulin level 
MGI: 8250 462 6.46E-07 4.04E-11 abnormal myeloid leukocyte morphology 
MGI: 4939 381 3.31E-03 1.68E-10 abnormal B cell morphology 
GO: 50778 403 7.29E-06 2.11E-10 positive regulation of immune response 
MGI: 8251 387 3.12E-06 3.29E-10 abnormal phagocyte morphology 
MGI: 3009 432 5.78E-09 5.24E-10 abnormal cytokine secretion 
Downregulated 
GO: 5874 327 4.97E-05 8.10E-05 microtubule 
GO: 86 120 8.11E-03 1.70E-04 G2/M transition of mitotic cell cycle 
GO: 48812 455 3.45E-02 2.20E-04 neuron projection morphogenesis 
PAN-PW 29 120 4.80E-02 2.67E-04 Huntington disease 
GO: 15631 187 4.14E-04 2.84E-04 tubulin binding 
GO: 7017 372 7.94E-04 4.13E-04 microtubule-based process 
MGI: 1828 233 1.66E-04 7.14E-04 abnormal T cell activation 
REACTOME 214 68 3.16E-03 1.12E-03 REACT:centrosome maturation 
REACTOME 952 68 3.16E-03 1.12E-03 REACT:recruitment of mitotic centrosome proteins and 
complexes 
REACTOME 636 59 1.87E-03 1.48E-03 REACT:loss of nlp from mitotic centrosomes 
Table 4.16. Top 10 pathways dysregulated (p < 0.05) in both HD prefrontal cortex (Labadorf et al., 2015) and blood. 
The pattern of immune upregulation is also observed in the brain co-expression modules. The top 10 modules in HD 
prefrontal cortex and blood are given in the table below, and the full list is available in Hensman Moss et al. (2017a). 
Notably, several modules related to the synapse and neuron projection are downregulated in both datasets. The two HD-
related caudate modules from Neueder and Bates (2014) that were significantly dysregulated in blood were also 
significantly dysregulated in the same direction in Labadorf et al. (2015). Module 48 (CNpos2), which enriches for 
transcriptional regulators, was significantly upregulated (p < 1x10-16) and module 66 (CNneg1), enriched for synaptic 
genes, was significantly downregulated (p < 1x10-16), as are several other significant modules from Neueder and Bates 
(2014).  
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Direction Brain expression 
gene set 
Module Brain Region Number of 
dysregulated 
genes 
Blood p 
(combined) 
Brain p 
(Labadorf) 
Cor(HD) p (HD) Annotation 
Upregulated 
HD        111 FC BA9 514 7.81E-12 0.00E+00 - - Immune response 
HD        69 
(FC4pos1) 
FC BA4 712 3.77E-08 0.00E+00 0.610 3.77E-03 inflammatory response 
HD        48 (CNpos2) CN     1785 2.03E-07 0.00E+00 0.724 2.21E-11 regulation of transcription 
Control (Braineac)   803 Thalamus             870 1.18E-03 0.00E+00 - - Inflammatory response 
HD        124 FC BA9 1176 2.91E-03 0.00E+00 - - protein binding 
HD        4 (CBpos6) CB     781 6.17E-03 0.00E+00 0.309 4.79E-02 metallothionein 
Control (Braineac)   705 Temporal Cortex      494 1.09E-02 1.17E-15 - - Inflammatory response 
Control (Braineac)   908 White Matter         359 3.48E-02 2.55E-15 - - Activation of immune response 
Control (Gibbs)      49 Frontal Cortex       446 6.83E-03 3.50E-15 - - oxidoreductase 
Control (Braineac)   106 Frontal Cortex       430 2.53E-03 3.94E-15 - - activation of immune response 
Downregulated 
HD        66 (CNneg1) CN     2644 2.71E-07 0.00E+00 -0.8 6.03E-15 synapse 
Control (Braineac)   602 Substantia Nigra     2374 1.07E-03 0.00E+00 - - mitochondrial envelope 
Control (Braineac)   103 Frontal Cortex       855 4.01E-02 0.00E+00 - - Neuron projection morphogenesis 
HD        98 
(FC4neg5) 
FC BA4 1359 1.97E-04 5.55E-17 -0.445 0.03354 glycolysis 
Control (Braineac)   802 Thalamus             3342 5.39E-03 1.11E-16 - - Neuron projection 
Control (Braineac)   4 Cerebellar 
Cortex    
973 2.26E-05 1.14E-13 - - neuron projection 
Control (Braineac)   407 Occipital Cortex     432 1.10E-02 6.71E-12 - - Transmission across Chemical Synapses 
Control (Braineac)   302 Medulla              1911 2.63E-05 1.69E-11 - - Cellular respiration 
Control (Braineac)   708 Temporal Cortex      414 6.81E-03 3.86E-11 - - Autophagy 
HD        2 (CBneg4) CB     408 1.22E-02 3.44E-10 -0.388 0.01111 mitochondrion 
Table 4.17. Top 10 modules dysregulated (p < 0.05) in both HD prefrontal cortex (Labadorf et al., 2015) and blood. 
4.5.5 Association with disease severity 
4.5.5.1 Individual transcripts 
To look for an effect on disease severity, gene expression was correlated with UHDRS total motor score (TMS). After 
correcting for multiple testing, expression of phosphatidylcholine transfer protein (PCTP) was significantly positively 
correlated with TMS. However, this gene was not found to be significantly correlated with TMS by Mastrokolias et al 
(Mastrokolias et al., 2015). 
Entrez 
gene ID 
Gene Symbol p 
(corr-TMS) 
q 
(corr-TMS) 
log2(FC) 
58488 PCTP 1.82E-06 3.25E-02 8.00E-03 
51060 TXNDC12 4.42E-05 1.79E-01 5.30E-03 
57096 RPGRIP1 4.64E-05 1.79E-01 1.25E-02 
9258 MFHAS1 5.12E-05 1.79E-01 -8.40E-03 
3667 IRS1 6.73E-05 1.79E-01 -1.37E-02 
158293 FAM120AOS 6.88E-05 1.79E-01 3.80E-03 
84263 HSDL2 7.01E-05 1.79E-01 6.30E-03 
56925 LXN 1.01E-04 2.22E-01 1.05E-02 
118881 COMTD1 1.12E-04 2.22E-01 -8.10E-03 
597 BCL2A1 1.44E-04 2.35E-01 1.44E-02 
Table 4.18. Top 10 genes with expression in correlation with disease severity (total motor score). 
4.5.5.2 Gene sets 
Generic pathways that were significantly enriched for up or downregulated genes (Table 4.6), also enriched for genes 
correlated with TMS in the expected direction using a similar method to that previously used to test for enrichment of 
differentially expressed genes. The top 10 up and downregulated pathways are given in the table below and the full list 
is in Hensman Moss et al. (2017a). Several immune related pathways were positively correlated with TMS, including 
MGI:2419, the most significantly dysregulated pathway in HD blood (Table 6). Downregulated pathways that correlated 
with TMS were related to ATP metabolism and DNA repair.  
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Direction Pathway p 
(combined-
diffexp) 
p 
(TRACK-
diffexp) 
p 
(TRACK-
TMS) 
Description 
Upregulated 
MGI: 2419 3.03E-10 5.10E-05 2.18E-03 abnormal_innate_immunity 
GO: 10942 8.79E-02 4.70E-02 3.21E-03 positive regulation of cell death 
MGI: 2462 4.09E-05 6.48E-04 6.39E-03 abnormal_granulocyte_physiology 
MGI: 8556 6.85E-04 8.68E-03 7.91E-03 abnormal_tumor_necrosis_factor_secretion 
MGI: 2463 9.20E-05 2.79E-03 8.99E-03 abnormal_neutrophil_physiology 
MGI: 8704 1.54E-04 4.76E-03 9.56E-03 abnormal_interleukin-6_secretion 
GO: 5773 1.36E-05 7.03E-03 1.62E-02 vacuole 
GO: 50792 2.59E-08 1.12E-02 1.64E-02 regulation of viral process 
MGI: 5351 6.95E-03 2.20E-02 2.76E-02 decreased_susceptibility_to_autoimmune_disorder 
GO: 44437 4.50E-05 6.10E-04 3.48E-02 vacuolar part 
Downregulated 
GO: 45786 8.92E-04 1.88E-02 3.23E-05 negative regulation of cell cycle 
MGI: 706 9.70E-02 1.11E-02 9.09E-05 small_thymus 
MGI: 2364 6.81E-02 1.14E-02 2.57E-04 abnormal_thymus_size 
MGI: 5018 6.50E-04 5.94E-03 2.70E-04 decreased_T_cell_number 
MGI: 2435 1.95E-04 6.87E-03 2.79E-04 abnormal_effector_T_cell_morphology 
MGI: 8081 1.48E-03 5.61E-03 3.83E-04 abnormal_single-positive_T_cell_number 
MGI: 2145 1.19E-03 5.67E-03 8.68E-04 abnormal_T_cell_differentiation 
MGI: 2444 3.61E-04 7.95E-03 8.74E-04 abnormal_T_cell_physiology 
MGI: 2432 6.45E-04 3.48E-02 1.01E-03 abnormal_CD4-positive_T_cell_morphology 
MGI: 6387 8.81E-05 4.95E-03 1.31E-03 abnormal_T_cell_number 
Table 4.19. Top 10 pathways enriched for up and downregulation in HD blood that also enriched for genes correlated with disease 
severity (TMS) in the same direction. 
4.5.5.3 Co-expression modules 
Similarly, modules dysregulated in HD blood relative to controls (Table 4.12) were also correlated with TMS in the 
expected direction. As shown in the table below, many modules significantly correlated with TMS, including 68 (CNpos5; 
p=5.52x10-7) and 66 (CNneg1; p=1.05x10-7), which were also dysregulated in the HD caudate (Neueder and Bates, 2014).  
118 
Direction Brain 
expression 
gene set 
Module Brain region Annotation Number of 
dysregulated 
genes 
p 
(Combined-
diffexp) 
p 
(TRACK-
diffexp) 
p 
(TRACK-
TMS) 
 Cor 
(HD) 
BH 
(HD) 
Upregulated 
HD 68 (CNpos5) CN Cilium 1268 1.09E-04 3.05E-02 5.52E-07 0.54 7.74E-06 
Control (B) 909 White Matter Activation of immune response 265 2.12E-06 1.24E-03 8.22E-04 - - 
Control (B) 713 TCTX Activation of immune response 171 4.02E-05 2.39E-02 1.69E-03 - - 
HD 111 FC_BA9 Immune response 514 7.81E-12 1.27E-04 3.75E-03 - - 
Control (G) 56 Pons Lipoprotein/ immune response /GTPase regulator activity 207 1.97E-05 2.44E-04 7.72E-03 - - 
HD 28 CB Immune response 209 3.11E-05 1.07E-02 8.70E-03 - - 
Control (B) 505 Putamen Ether lipid metabolism 500 6.28E-05 3.16E-03 6.43E-02 - - 
Control (B) 911 White Matter Inflammatory response 159 3.00E-05 8.42E-04 7.75E-02 - - 
HD 124 FC_BA9 NA 1176 2.91E-03 1.19E-02 9.14E-02 - - 
Control (B) 110 FCTX  Inflammatory response 173 8.94E-07 1.04E-03 1.34E-01 - - 
HD 33 CB Immune response 255 4.34E-05 1.08E-02 1.52E-01 - - 
Control (B) 610 Substantia Nigra Inflammatory response 178 1.21E-05 8.56E-04 2.00E-01 - - 
HD 64 (CNpos6) CN Inflammatory response 114 3.13E-04 1.18E-02 2.22E-01 0.46 2.28E-04 
Control (B) 811 Thalamus Inflammatory response 142 1.61E-05 3.94E-03 2.28E-01 - - 
Control (B) 712 TCTX Inflammatory response 213 1.41E-07 3.40E-05 2.35E-01 - - 
Control (B) 516 Putamen Cellular response to cytokine stimulus 133 3.07E-04 1.44E-02 4.16E-01 - - 
HD 69 (FC4pos1) FC_BA4 Inflammatory response 712 3.77E-08 3.05E-05 5.22E-01 0.61 3.77E-03 
HD* 48 (CNpos2) CN Lipid metabolism/regulation of transcription 1785 2.03E-07 3.85E-03 6.14E-01 0.72 2.21E-11 
Downregulated 
Control (B) 304 Medulla mRNA metabolic process 1811 2.91E-08 5.00E-15 6.11E-16 - - 
Control (B) 702 TCTX Antigen processing: ubiquitination and proteasome 
degradation 
4602 3.87E-04 1.22E-03 2.04E-13 - - 
Control (B) 202 Hippocampus Mitochondrial membrane 2737 4.75E-04 1.16E-07 1.44E-09 - - 
Control (G) 28 FC  Intra-cellular transport/mitochondrion 3178 2.10E-08 6.30E-04 4.16E-09 - - 
HD* 66 (CNneg1) CN Synapse/ion channels 2645 2.71E-07 1.51E-04 1.05E-07 -0.80 6.03E-15 
Control (G) 52 Pons Acetylation/fatty acid metabolism 1590 3.28E-03 2.23E-02 1.30E-07 - - 
Control (G) 74 Pons Transcription/acetylation/protein transport 1183 9.22E-06 3.85E-08 1.19E-05 - - 
Control (G) 22 CB Pro-rich region 831 1.83E-08 2.49E-03 7.72E-05 - - 
Control (B) 804 Thalamus Regulation of cell morphogenesis 857 1.31E-06 4.03E-02 8.29E-05 - - 
Control (B) 706 TCTX Microtubule organising center 481 1.93E-03 3.70E-05 3.00E-04 - - 
Control (G) 48 FC Transcription corepressor/cell morphogenesis 648 4.65E-04 7.83E-03 7.14E-04 - - 
HD 102 FC_BA9 Cytoplasm 1908 1.47E-03 7.57E-03 9.26E-03 - - 
Control (B) 906 White Matter Uridyltransferase activity  416 1.12E-03 2.53E-02 1.34E-02 - - 
Control (B) 812 Thalamus Transport of mature transcript to cytoplasm 114 1.42E-03 1.99E-02 1.36E-02 - - 
HD 19 CB Protein binding 155 7.44E-04 2.66E-02 2.18E-02 - - 
HD 3 (CBneg2) CB mitochondrion 1164 3.19E-02 2.56E-02 6.17E-02 -0.45 1.66E-03 
Control (G) 93 Pons Mitochondrion/nuclear lumen 317 1.30E-03 9.85E-03 1.24E-01 - - 
Control (B) 522 Putamen Regulation of RNA splicing 64 4.44E-06 6.26E-03 2.52E-01 - - 
Control (G) 25 CB RNA binding 648 8.02E-01 1.72E-04 9.99E-01 - - 
Table 4.20. Modules dysregulated in HD blood that also correlated with disease severity (TMS) in the same direction. 
Control (B) – co-expression modules generated from Braineac (2016), Control (G) – co-expression modules generated from Gibbs et al. 
(2010). 
4.5.5.4 Overlap with an independent HD cohort 
Mastrokolias et al. (2015) listed 170 genes significantly associated with TMS, of which 142 passed quality control in our 
RNA-Seq data. These were tested for correlation between TMS in gene positive subjects from the Track-HD cohort. The 
top 10 genes in Track-HD are given below and the full list is available from Hensman Moss et al. (2017a). 14 genes were 
nominally significant (p < 0.05), which is significantly higher than expected by chance (p = 7.89x10-3). Using the same 
method as for concordance with Labadorf et al. (2015) (see Methods), fold changes in expression of individual genes 
were compared between Track-HD and Mastrokolias et al (Mastrokolias et al., 2015). Strikingly, 101 genes showed 
consistent direction of effect, as measured by log(FC), significantly greater than expected by chance (p=4.78x10-7). Thus, 
the analysis of TMS in the Track-HD cohort broadly supports the associations reported in Mastrokolias et al. (2015).  
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Ensembl gene ID Entrez 
gene ID 
Gene name log(FC)-
Mastrokolias 
p 
(Mastrokolias) 
log(FC)-
TRACK 
p 
(TRACK) 
ENSG00000119471 84263 HSDL2 7.00E-03 4.86E-02 6.00E-03 7.01E-05 
ENSG00000110422 10114 HIPK3 7.00E-03 3.77E-02 -6.00E-03 9.52E-03 
ENSG00000177542 79751 SLC25A22 -7.00E-03 3.58E-02 -3.00E-03 1.14E-02 
ENSG00000103569 366 AQP9 1.20E-02 4.68E-02 7.00E-03 1.41E-02 
ENSG00000185803 79581 SLC52A2 -8.00E-03 4.60E-02 -3.00E-03 1.50E-02 
ENSG00000188322 388228 SBK1 -7.00E-03 4.54E-02 -5.00E-03 1.56E-02 
ENSG00000101096 4773 NFATC2 -1.10E-02 1.69E-02 -8.00E-03 1.83E-02 
ENSG00000171051 2357 FPR1 9.00E-03 2.77E-02 6.00E-03 2.39E-02 
ENSG00000112159 23195 MDN1 -6.00E-03 9.10E-03 -5.00E-03 2.45E-02 
ENSG00000008869 54497 HEATR5B -7.00E-03 4.68E-02 -3.00E-03 2.69E-02 
Table 4.21. Top 10 differentially expressed genes from Mastrokolias et al (Mastrokolias et al., 2015) that correlated with disease 
severity (TMS) in Track-HD blood. 
4.5.6 Comparing the HD transcriptomic signature with Alzheimer’s disease brain 
In Alzheimer’s disease, an early inflammatory response involving microglia contributes to pathogenesis (Gomez-Nicola et 
al., 2013, Olmos-Alonso et al., 2016, Hong et al., 2016a). Given the upregulation of immune-related gene sets in HD, co-
expression modules dysregulated in Alzheimer’s disease (AD) brain were tested to see if they are also disrupted in HD 
blood. The International Genomics of Alzheimer’s Disease Consortium (IGAP) identified four modules from the Gibbs et 
al. (2010) brain co-expression network that showed enrichment of signal in the GWAS of >70,000 late-onset Alzheimer’s 
disease (LOAD) and control subjects (International Genomics of Alzheimer's Disease, 2015). These four modules, each 
derived from a different brain region, are all involved in the immune response and were all significantly upregulated in 
the combined HD blood dataset; they are given in the table below. Module 56, derived from pontine data, was also 
significantly enriched in both Track-HD and Leiden datasets independently. IGAP identified 151 genes that were present 
in two or more of these modules and showed the most significant enrichment with LOAD GWAS signal (International 
Genomics of Alzheimer's Disease, 2015). These 151 genes were also significantly enriched for upregulation in the 
combined HD blood dataset (p = 2.50 x 10-4). 
Module Brain Region Number of 
genes 
p 
(IGAP) 
p 
(Comb) 
p 
(Track-HD) 
p 
(Leiden) 
Module Description 
34 Frontal Cortex 109 1.00E-05 1.45E-03 7.06E-03 9.48E-02 GO:0006955 immune response 
99 Temporal Cortex 145 4.00E-05 2.22E-04 5.25E-03 9.13E-02 GO:0006955 immune response 
56 Pons 207 6.00E-05 1.97E-05 2.44E-04 4.19E-02 GO:0006955 immune response 
5 Cerebellum 135 6.80E-04 1.09E-03 4.24E-02 8.15E-02 GO:0006955 immune response 
Table 4.22. Modules from Gibbs et al. (2010) that are dysregulated in both Alzheimer’s disease brain (International Genomics of 
Alzheimer's Disease, 2015) and HD blood. 
Comb – combined TRACK-HD and Leiden bHD blood dataset. 
Zhang et al. (2013) identified co-expression modules that were differentially connected between LOAD and controls. Ten 
of these were also significantly enriched for upregulation in the HD blood expression dataset (given in the table below) 
after correction for multiple testing (q < 0.05), with their most significant module, yellow, being particularly highly 
enriched (combined Track-HD and Leiden p < 1x10-16). Notably, this module has immune and microglia-specific functions 
(Zhang et al., 2013). This enrichment for modules from the IGAP GWAS (International Genomics of Alzheimer's Disease, 
2015) and Zhang et al. (2013) in the HD blood transcriptome suggests a shared immune-related mechanism between 
different neurodegenerative diseases, at least including HD and Alzheimer’s disease. 
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Module Rank 
(Zhang)  
Annotation Brain 
region 
Number of 
genes 
p 
(Comb) 
q 
(Comb) 
p 
(Track-HD) 
p 
(Leiden) 
Yellow 1 Immune functions    PFC 867 <1.00E-16 3.32E-15 1.55E-11 4.93E-11 
Cyan 5 Vasculature development    VC 487 2.71E-11 4.49E-10 4.65E-08 1.33E-05 
Gold 25 Immune functions    CB 318 1.09E-10 1.21E-09 1.28E-04 1.85E-04 
Light cyan 11 Immune functions    VC 434 2.14E-09 1.77E-08 1.95E-05 5.36E-04 
Forestgreen 24 Immune functions    CB 200 9.86E-06 6.54E-05 3.23E-05 1.12E-02 
Red 9 Nerve ensheathment (myelination)   PFC 701 2.04E-04 1.13E-03 4.50E-02 8.89E-03 
Violet red 21 Nitric oxide and human cancer VC 124 3.14E-04 1.49E-03 1.10E-02 8.24E-02 
Navy 15 Regulation of cell growth  CB 200 1.55E-03 6.44E-03 3.68E-02 5.56E-03 
Turquoise 13 NAD(P) homeostasis    VC 909 6.30E-03 2.32E-02 5.87E-02 4.38E-03 
Green yellow 8 Unfolded protein    PFC 478 1.02E-02 3.38E-02 7.42E-02 3.67E-01 
Table 4.23. Top 10 co-expression modules from Alzheimer’s disease brain(Zhang et al., 2013) that are dysregulated in HD blood. 
Significance was corrected for multiple testing (q < 0.05). PFC – prefrontal cortex, VC – visual cortex, CB – cerebellum. 
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4.6 Discussion 
HD research has focused on the brain because the most conspicuous clinical features are clearly linked to progressive 
degeneration of specific brain regions (van der Burg et al., 2009, Bates et al., 2015c). However, HD is a systemic condition 
with peripheral expression of mutant huntingtin directly driving abnormalities such as immune dysfunction, metabolic 
derangement and transcriptional dysregulation that contribute to onset, progression, quality of life and mortality (van 
der Burg et al., 2009, Carroll et al., 2015). 
In this chapter, RNA-Seq of whole blood was conducted in two independent cohorts of HD patients. Using gene set 
enrichment analysis (GSEA) with publicly-available pathway databases and WGCNA modules from HD and control brain 
datasets, gene sets were found to be dysregulated in blood that replicated in both independent cohorts and correlated 
with clinical motor signs (TMS). These correspond to the most significantly dysregulated modules in caudate nucleus, the 
most prominently affected region in HD brain. This suggests mutant huntingtin drives a pathogenic signature that is 
common to both blood and brain. 
4.6.1 Individual transcripts 
RNA-Seq more comprehensively and accurately quantifies mRNA than hybridisation-based microarrays or tag-based 
methods (Costa et al., 2010). Expression of phosphatidylcholine transfer protein (PCTP) significantly correlated with TMS 
(Table 4.18). This protein transports phospholipids across intracellular membranes, which is of interest given the 
upregulation of modules representing lipid metabolism in both HD blood (Table 4.12) and brain (Neueder and Bates, 
2014). Phospholipid levels are altered in in mouse models and human postmortem HD brain, HTT carrying an expanded 
polyglutamine tract can disrupt lipid bilayers, and HTT phospholipid binding is altered in HD, which may be involved in its 
aggregation (Kegel-Gleason, 2013). However, PCTP was not significantly correlated with TMS in Mastrokolias et al. (2015). 
It is perhaps unsurprising that there was limited differential expression of individual transcripts by disease state (Table 4) 
or severity in either the independent or combined cohorts; the major cell types known to contribute to HD symptoms 
are not present in blood and the haematogenous cells known to be dysfunctional in HD, such as monocytes and 
macrophages (Bjorkqvist et al., 2008, Wild et al., 2011), constitute only a small proportion of circulating cells (Whitney et 
al., 2003). There is considerable variation of gene expression in blood with age, gender, cell type and time of day, which 
also likely limited sensitivity (Whitney et al., 2003, Horvath et al., 2012). Our results are consistent with previous studies 
that have shown weak correlation at the transcript level between blood and brain (Cai et al., 2010). 
4.6.2 Gene sets 
4.6.2.1 Immune upregulation 
Despite these limitations, gene set enrichment analysis identified significantly overlapping dysregulated pathways in the 
Track-HD and Leiden HD blood datasets, even though they differed in age and disease severity. Therefore, through 
grouping transcripts into biologically relevant pathways and co-expressed transcripts, it was possible to highlight areas 
of dysfunctional biology in HD. The observed upregulation of immune-related pathways (Table 4.6) and modules (Table 
4.12) is consistent previous transcriptional and functional studies (Mastrokolias et al., 2015, Carroll et al., 2015, van der 
Burg et al., 2009). HD patients are known to have immune dysfunction, both in the central nervous system (CNS) with 
microglial activation (Tai et al., 2007a), and peripherally with elevated proinflammatory cytokines in premanifest carriers 
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up to 16 years before predicted onset (Bjorkqvist et al., 2008, Wild et al., 2011). The migration of phagocytic cells is 
impaired in HD (Kwan et al., 2012c, Träger et al., 2015) and patient-derived monocytes are hyperactive on stimulation, 
an effect reduced by HTT lowering (Bjorkqvist et al., 2008). Modulation of the peripheral immune system with a type 2 
cannabinoid receptor (CB2) agonist (Bouchard et al., 2012b) or bone marrow transplantation (Kwan et al., 2012a) can 
increase lifespan and reduce motor deficits and synaptic loss in HD mouse models. 
4.6.2.2 RNA processing 
RNA processing modules (Table 4.12) were downregulated, which is consistent with disruption of splicing, miRNA 
expression and processing (Seredenina and Luthi-Carter, 2012) in HD brain by dysregulation of splicing factors such as 
PTBP1 (Lin et al., 2016), and the disruption of nuclear mRNA export in mouse models (Gasset-Rosa et al., 2017). 
4.6.2.3 Energy metabolism 
Pathways (Table 4.6) and modules (Table 4.12) involved in mitochondrial function and energy metabolism were 
downregulated in HD blood, which is consistent with prominent deficits in energy metabolism, particularly mitochondrial 
function, seen in HD patients and animal models. In patients, glucose consumption is reduced and there is ATP depletion, 
particularly in the basal ganglia but also throughout the body, even in presymptomatic carriers, and the lactate-pyruvate 
ratio in CSF is elevated (Acuña et al., 2013, Mochel and Haller, 2011, Jodeiri Farshbaf and Ghaedi, 2017). Proposed 
mechanisms include impaired oxidative phosphorylation due to respiratory chain deficiencies, increased oxidative stress, 
as evidenced by increased reactive oxygen species, oxidative DNA damage and the induction of oxidative defence 
mechanisms in HD brain, and impaired trafficking and biogenesis of mitochondria. PGC-1α, a member of the 
downregulated ATP metabolic process pathway (Table 4.6), is a key protective regulator of mitochondrial genes and 
biogenesis. It has previously been shown to be reduced in HD patient and mouse brain and muscle (Chaturvedi et al., 
2009, Cui et al., 2006, Chaturvedi et al., 2010), its knockout in mice leads to selective striatal lesions (Lin et al., 2004), and 
HD striatal neurons expressing exogenous PGC-1α are resistant to 3-nitropropionic acid (3-NP) (Weydt et al., 2006). 
4.6.2.4 DNA repair 
DNA repair pathways were downregulated in HD blood and correlated with disease severity (TMS). GO:6281 includes 
terms for all major DNA repair pathways, and may represent the downregulation of protective factors such as FAN1, 
which is included as part of the ICL repair group (Consortium, 2016). These pathways are likely to be relevant to somatic 
expansion that may influence disease onset and progression (Jonson et al., 2013b, Massey and Jones, 2018, Holmans et 
al., 2017). 
4.6.2.5 Disease severity 
The signature of pathway dysregulation identified in HD whole blood correlates with TMS in HD subjects from Track-HD. 
It also significantly overlaps with that recently found in unstimulated HD monocytes (Miller et al., 2016). This enrichment 
was driven primarily by upregulation of immune pathways, as might be expected given that Miller et al. (2016) isolated 
myeloid cells. 
4.6.2.6 Comparison with HD brain 
To overcome the annotation gap commonly observed with publicly-derived pathway databases and to investigate 
whether gene expression changes from HD brain are also present in blood, GSEA was performed using brain co-
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expression networks derived from HD (Neueder and Bates, 2014) and control (Gibbs et al., 2010, Braineac, 2016) subjects. 
Several HD brain modules were significantly dysregulated in HD blood, suggesting a common signature of transcriptional 
dysregulation between blood and brain. 
Brain modules upregulated in blood were enriched for immune-related genes, confirming the results of the pathway 
analysis. Strikingly, two of the modules most significantly dysregulated in HD caudate, 48 (CNpos2) and 66 (CNneg1), 
were also significantly dysregulated in the same direction in both independent blood datasets. Compared with other 
brain regions, the caudate has the largest number of expression changes and the highest correlation with HD (Neueder 
and Bates, 2014). Module 48 (CNpos2), the second most significantly upregulated module in caudate, is enriched for 
transcriptional regulators, chromatin modifiers and genes involved in mRNA processing (Neueder and Bates, 2014). It is 
also significantly enriched for immune response genes, giving further support to the pathway results. 
Module 66 (CNneg1), the most significantly downregulated module in caudate, contains genes involved in neuronal 
function, particularly synaptic function and plasticity, and ion channels. Around half of its hub genes are implicated in 
synaptic function and all were significantly downregulated in Hodges et al. (2006). Though synapses are not present in 
blood, synaptic genes may be dysregulated in circulating cells without significant pathogenic impact, or alternatively they 
may serve distinct functions in blood cells. Indeed, Cai et al. (2010) found that the synaptic module was well preserved 
between brain and blood. 
In addition, gene expression and pathway dysregulation from HD prefrontal cortex (Labadorf et al., 2015) was replicated 
in HD blood. The high degree of overlap increases confidence in the shared signal between blood and brain. A significant 
proportion of the modules dysregulated in HD blood correlated with TMS. 
Mina et al. (2016) performed WGCNA on the Leiden blood sample, finding modules related to immune response that 
were associated with TFC and TMS. Furthermore, by comparing biological annotations of their HD blood modules with 
those they derived from Hodges et al. (2006) brain expression data, they showed a common signature between blood 
and caudate related to immune response. These analyses, using different methodology to those presented here, lend 
further support to the results above. 
The demonstration of a transcriptional signature common to both HD blood and brain supports the use of blood cells to 
study aspects of HD biology. HD model systems, such as mice, only recapitulate aspects of disease and must be compared 
to the relevant data in human tissue (Morton and Howland, 2013, Ehrnhoefer et al., 2009). Access to brain tissue is very 
limited and tends to be from post-mortem subjects with advanced disease, which affects RNA integrity (Montanini et al., 
2013, Tomita et al., 2004). Blood, by contrast, is readily available and can be obtained longitudinally from HD subjects. 
4.6.3 Comparison with Alzheimer’s disease brain 
In AD, amyloid plaques are surrounded by chronically activated microglia (Gomez-Nicola et al., 2013, Olmos-Alonso et 
al., 2016) and GWA studies have identified immune-related genes as risk factors for LOAD (Wyss-Coray and Rogers, 2012). 
Hong et al. (2016a) showed that early in the disease process, before plaque formation, microglia and complement 
activation drive synaptic loss, a process that may reflect reactivation of developmental synaptic pruning (Hong et al., 
2016b).  
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In this chapter, in HD blood there was significant upregulation of all four immune modules associated with AD brain in 
the IGAP GWAS (International Genomics of Alzheimer's Disease, 2015), as well as the most significant immune and 
microglia-related modules from the Zhang et al. (2013) study of AD brain. In a co-expression network generated from 
prefrontal cortex of 194 HD patients, Zhang et al. (2013) found that their most significant immune and microglia module 
was not significantly dysregulated in HD prefrontal cortex and did not correlate with CAG repeat length. This may be 
because cortex shows less severe pathology and transcriptional dysregulation than caudate (Hodges, 2006). 
4.7 Summary 
This chapter investigated transcriptional dysregulation in peripheral HD blood of two independent cohorts from Track-
HD (Tabrizi et al., 2009b) and Leiden, and compared it to datasets generated from brain in HD and Alzheimer’s. There 
was significant dysregulation of brain Weighted Gene Correlation Network Analysis (WGCNA) modules in the same 
direction in blood, as well as significant dysregulation of pathways. The transcriptional signature replicated dysregulation 
seen in HD brain, particularly the caudate which is the tissue most vulnerable to the disease. Immune gene sets were 
notably upregulated in all analyses and this signal overlapped with the transcriptional signature of Alzheimer’s disease 
(AD) brain. Overlapping immune upregulation in HD and AD suggests these two distinct neurodegenerative diseases share 
some common pathogenic mechanisms, including macrophage function (Hong et al., 2016a).  The strong immune signal 
is consistent with transcriptional studies in numerous neurodegenerative diseases, indicating a key role for inflammation 
in neuronal degeneration. 
4.8 Publications relating to this chapter 
The work presented in this chapter was published in: 
Huntington’s disease blood and brain show a common gene expression pattern and share an immune signature with 
Alzheimer’s disease. Hensman Moss, Davina J.*, Flower, Michael D.*, Lo, Kitty K., Miller, James R. C., van Ommen, Gert-
Jan B., ’t Hoen, Peter A. C., Stone, Timothy C., Guinee, Amelia, Langbehn, Douglas R., Jones, Lesley, Plagnol, Vincent, van 
Roon-Mom, Willeke M. C., Holmans, Peter# and Tabrizi, Sarah J.# Scientific Reports, 2017 Mar 21;7:44849. doi: 
10.1038/srep44849. 
* These authors should be regarded as joint first authors. 
# These authors jointly supervised the work. 
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Chapter 5 Cell models of HTT CAG repeat instability 
5.1 Background 
5.1.1 Repeat instability 
The pathogenic CAG repeat in HTT is inherently unstable, and tends to expand over time, particularly in the striatum 
(Kennedy et al., 2003, Shelbourne et al., 2007b, Swami et al., 2009). Expansion produces an increasingly toxic 
polyglutamine protein, and is correlated with earlier onset and increasingly severe disease (Lee et al., 2012d, Telenius et 
al., 1994, Gomes-Pereira et al., 2001, Fortune et al., 2000, Kennedy and Shelbourne, 2000, Swami et al., 2009), suggesting 
it is a mechanism underlying the tissue-specific, progressive nature of the disease (Goula et al., 2012, Wheeler et al., 
1999, Shelbourne et al., 2007a). Several modifiers of repeat stability have been identified (Wheeler et al., 2007) including 
environmental stress (Chatterjee et al., 2015), chemical inducers (Gomes-Pereira and Monckton, 2004a) and DNA repair 
genes, particularly the mismatch repair pathway (Kovalenko et al., 2012). Knockout of Msh2 or Msh3 significantly reduces 
somatic expansion in HD (Manley et al., 1999, Kovtun and McMurray, 2001, Wheeler et al., 2003, Owen et al., 2005), 
DM1 (van den Broek et al., 2002, Savouret et al., 2003) and fragile X (Lokanga et al., 2014, Zhao et al., 2015b, Zhao et al., 
2016) mouse models, suggesting repeat expansion is a result of DNA repair activity, particularly MutSb (MSH2/MSH3). In 
HD (Kennedy et al., 2003) and DM1 (Ashizawa et al., 1993) patients and transgenic mouse models (Lia et al., 1998, Fortune 
et al., 2000, Mangiarini et al., 1997, Kennedy and Shelbourne, 2000), there is no significant link between somatic 
expansion rate and the proliferative capacity of the tissue, implying expansion occurs during transcription or repair, 
rather than DNA replication. Integrating somatic mosaicism and transcriptomic data in HD transgenic mice showed a 
negative correlation between cell cycle pathways and tissue-specific instability, consistent with a cell-cycle independent 
mechanism (Lee et al., 2010). Whilst DNA replication is limited to S-phase, DNA repair occurs at all stages of the cell cycle 
and is a strong candidate as the driver of expansion. 
The mechanisms that give rise to repeat instability in patients are not yet fully understood, but significant evidence 
implicates the formation of abnormal DNA secondary structures and DNA damage induced by oxidative stress. Slipped-
strand DNA structures may occur when DNA is unwound during transcription or repair (Lopez Castel et al., 2011), though 
the involvement of DNA replication in proliferative tissues is also possible. In HD, DM1 and SCA7 (Freudenreich et al., 
1997, Kang et al., 1995, Liu et al., 2010a, Panigrahi et al., 2002, Cleary et al., 2010, Nenguke et al., 2003), contractions 
occur when the CTG repeat is on the lagging strand template and expansions when it is CAG, suggesting CAG repeats 
have a higher propensity to form DNA slip outs or are processed differently by DNA repair machinery. Slipped DNA 
structures are likely more prone to forming on the lagging strand template because it remains single stranded for 
relatively long ~300 nt stretches prior to Okazaki fragment synthesis (Hay and DePamphilis, 1982, Anderson and 
DePamphilis, 1979). Slip outs have been found at CTG repeat tracts in non-mitotic DM1 patient tissue that show somatic 
expansion, including brain, muscle and heart (Axford et al., 2013), suggesting they are stable, and not merely transient 
mutagenic intermediates. 
HD patient striatum shows more oxidative lesions (Browne et al., 1997), and mouse models accumulate oxidative damage 
in tissues affected by CAG repeat expansion, such as the liver and brain (Kovtun et al., 2007), specifically at CAG repeat 
DNA, in a length dependent manner (Bogdanov et al., 2001, Goula et al., 2009). Knockout of the BER glycosylase OGG1, 
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which removes 8-oxoG, reduces somatic expansion in R6/1 mice (Kovtun et al., 2007). In Friedreich’s ataxia, where GAA 
repeats are also unstable and the absence of MMR components Msh2 or Msh6 accelerates expansion in mouse models 
(Bourn et al., 2012, Lai et al., 2014, Krasilnikova and Mirkin, 2004), frataxin deficiency is directly associated with increased 
cellular oxidative stress in patients (Calabrese et al., 2005, Armstrong et al., 2010).  
The existence of rare DM1, HD and SMBA families with consistent contractions rather than expansions, the bias towards 
contraction in CAG and CTG expansion models where MMR factors such as MSH2 and MSH3 have been inactivated 
(Dragileva et al., 2009, Foiry et al., 2006, Kovtun et al., 2004, Manley et al., 1999, Savouret et al., 2003, Savouret et al., 
2004, van den Broek et al., 2002, Wheeler et al., 2003), and the prevalence of CTG contractions through the female 
germline of LigI deficient DM1 mice all suggest the mechanisms underlying expansion and contraction may be distinct 
(Slean et al., 2016). 
5.1.2 Cell models of repeat instability 
5.1.2.1 Huntington’s disease 
Few cell models of robust and significant HTT CAG repeat instability in the absence of genotoxic stress are available. 
Kovtun et al. (2007) exposed patient-derived fibroblasts (FB) and lymphoblasts (LB) with 69 CAG repeats to H2O2 up to 
three times over nine days and showed an increase of 1 CAG. Cannella et al. (2009) cultured 58 HD patient-derived LB 
lines with repeat lengths between 39 and 120 CAG for 6-12 months. Those with over 64 CAG expanded by an average 3 
repeats over 6 months (53.22 ± 16.29 days/Q). They found that treatment with the DNA intercalator ethidium bromide, 
the GC/AT modifier ethylmethanesulphonate (EMS), or the interstrand crosslinker mitomycin C (MMC), narrowed the 
traces and induced some negative skew in two lines with 74 and 80 CAG repeats. 
Jonson et al. (2013a) generated pluripotent embryonic stem cells with 127 CAG repeats from R6/1 HD mice and showed 
that exposure to chronic oxidative stress with H2O2, which induces single and double strand breaks, accelerated CAG 
repeat expansion up to threefold. In undifferentiated cells, expansion rate increased from 2 to 5 CAG repeats over 12 
passages (5 weeks), and in differentiating cells it increased from 0.8 to 1.5 repeats over 12 days. Potassium bromide 
(KBrO3), which generates oxidative DNA damage, particularly 8-oxoG (Ballmaier and Epe, 2006), induced a more modest 
acceleration. Methyl methanesulfonate (MMS), an alkylating agent that methylates DNA (Sanderson and Shield, 1996), 
had no effect, suggesting that oxidative rather than alkylating damage promotes expansion. 
Jacquet et al. (2015) showed that human HD embryonic stem cells with 38-43 CAG repeats are stable in culture and during 
cardiomyocyte differentiation, whereas Mollica et al. (2016) reported that 44Q patient-derived fibroblasts showed a 
small positive skew in the electrophoresis trace over 35 days, which was reduced by the DNA methyltransferase inhibitor 
5-azacytidine. 
5.1.2.2 Myotonic dystrophy 
5.1.2.2.1 Lymphoblastoid cells 
Repeat instability appears to occur more readily in myotonic dystrophy type 1 (DM1) cells, with patient-derived 
lymphoblasts (LB) having long been known to show expansion in culture (Ashizawa et al., 1996, Bidichandani et al., 1999, 
Ashizawa et al., 1993). 
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5.1.2.2.2 Artificial cell models 
Human fetal lung fibroblasts stably transfected with a CTG repeat-containing plasmid which was not expressed due to a 
5’ transcription terminator showed expansion that was accelerated when transcription was activated by Cre-mediated 
excision of the terminator, suggesting transcription could contribute to instability (Nakamori et al., 2011). Experiments 
in HEK 293 cells transfected with CTG-containing plasmids suggested 5’ oxidative damage increased instability and 3’ 
lesions led to contraction (Lai et al., 2013). In human fibrosarcoma cells transfected with an 800 CTG plasmid, knockdown 
of MSH2 and MSH3 reduced expansion (Nakatani et al., 2015a). In a human foetal astrocytic line, knockdown of MSH3 or 
inactivation of its ATPase activity reduced expansion of a non-pathogenic CTG repeat, whereas MSH3 overexpression 
increased it (Keogh et al., 2017). 
5.1.2.2.3 Stem cells 
Human embryonic stem cells (hESC) derived from DM1 patients with 370 or 1800 repeats showed instability that was 
stabilised by outer plexiform layer (OPL) differentiation and downregulation of MMR genes, but HD lines were stable 
(Seriola et al., 2011a, De Temmerman et al., 2008). In another study, DM1 iPSCs showed instability at a rate that 
correlated with repeat length and was reduced by shRNA-mediated MSH2 knockdown or differentiation into embryoid 
body or neurospheres, whereas once again HD iPSCs were stable (Du et al., 2013a). 
5.1.2.2.4 Animal cells 
In cells derived from a transgenic DM1 mouse, there was no correlation between expansion and mitotic rate, suggesting 
DNA replication is insufficient to drive expansion (Gomes-Pereira et al., 2014a, Gomes-Pereira and Monckton, 2004b, 
Gomes-Pereira et al., 2001). When the cell cycle was chemically or genetically arrested, the repeat continued to expand 
at the same rate, supporting a cell division-independent mutational pathway. 
5.1.2.2.5 Friedreich’s ataxia 
HEK 293 cells stably transfected with a GAA construct showed expansion in culture, which was decreased by reducing 
transcription (Ditch et al., 2009) or knockdown of MSH2 or MSH3 (Halabi et al., 2012a). In patient-derived LBs, the BER-
inducing alkylating agent temozolomide led to GAA contraction (Lai et al., 2014). In fibroblasts, ectopic expression of 
MSH2 and MSH3 led to expansion and shRNA-mediated knockdown of either reduced it (Halabi et al., 2012b). FRDA iPSCs 
showed instability (Du et al., 2012a, Ku et al., 2010) which was reduced by MSH2 (Du et al., 2012b, Ku et al., 2010), MSH3 
(Ku et al., 2010) or MSH6 (Du et al., 2012b, Ku et al., 2010) knockdown and differentiation into neural stem cells (Du et 
al., 2012b, Ku et al., 2010). 
5.1.2.2.6 SCA10 
LB cells derived from SCA10 patients show instability (Lin and Ashizawa, 2003), and when HeLa cells were complemented 
with an ATTCT repeat they demonstrated length dependent expansion (Liu et al., 2007). 
5.1.3 Stem cells 
HD patient-derived stem cells are a valuable system in which to study pathogenesis because they can be expanded 
indefinitely, retain the potential to differentiate into neurons, and can generate specified cell populations, including 
DARPP-32 positive striatal MSNs, thereby providing a physiologically-relevant model of HD (Aubry et al., 2008). They 
show a robust phenotype with expression, electrophysiological, metabolic and cellular adhesion changes that correlate 
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with pathogenic HTT CAG repeat length and recapitulate aspects of cellular phenotypes found in HD patients and mice 
(Consortium, 2012, Consortium, 2017). Human-derived stem cells are also currently the focus of cell replacement 
therapies for HD, having shown improvement in neurogenesis, immune dysfunction, mitochondrial function and cell 
survival in animal models (Rosser and Bachoud-Levi, 2012, Maucksch et al., 2013, Connor, 2018). 
5.1.3.1 Medium spiny neurons 
GABAergic medium-sized spiny neurons (MSN) are the principal projection neurons of the striatum which specifically 
degenerate early in HD (Lange et al., 1976, Reiner et al., 1988, Gerfen, 1992, Ouimet et al., 1984), and therefore represent 
the most physiologically relevant cell model in which to study repeat expansion. In vivo, they derive from the lateral 
ganglionic eminence (LGE), likely driven by activin A, a TGFβ family protein that induces forebrain neurogenesis (Arber et 
al., 2015). 
The Arber et al. (2015) MSN differentiation protocol induces expression of striatal MSN markers including CTIP2, DARPP-
32, NOLZ1, GSX2, FOXP2, DLX2, ARPP21, CALB1, PENK, TAC1, GAD1, DRD1 and DRD2. Straccia et al. (2015) assessed 
human foetal WGE (whole ganglionic eminence, the striatal priodrium) and cortex, and adult caudate, putamen and 
motor cortex for expression of a panel of genes involved in striatal development. WGE was distinguished by high 
expression of DLX1, DLX5, DLX6, EBF1, LHX6, NKX2-1, and SIX3. In mature striatal neurons there was specific upregulation 
of ADORA2A, CALB1, DRD1, DRD2, PENK, and TAC1, with comparably increased expression of GAD2 and OPRM1 also 
occurring in foetal WGE, and downregulation of WGE markers DLX1, DLX5, DLX6, EBF1, LHX6, and SIX3. They concluded 
that direct (TAC1, DRD1) and indirect (PENK, DRD2) striatal pathway genes were the most specific markers for adult 
MSNs, together with CALB1 and ADORA2A. DARPP-32 (PPP1R1B) expression is often used to identify MSNs, but 
interestingly whilst it was increased, it was not a reliable marker of mature striatal neurons. CTIP2 (BCL11B), another 
traditional MSN marker, actually decreased relative to foetal WGE, which parallels data in the Human Brain Atlas (Sunkin 
et al., 2013). Therefore, CTIP2 and DARPP-32 expressing neurons may represent the foetal stage of striatal development, 
which would explain their classification as an MSN markers in studies where foetal brain tissue or differentiated stem 
cells were analysed (Delli Carri et al., 2013). 
5.2 Aims 
Somatic instability cannot be monitored longitudinally in human brain cells, but age-dependent, expansion-biased, tissue-
specific somatic mosaicism has been replicated in transgenic mouse models of HD (Kennedy and Shelbourne, 2000, 
Mangiarini et al., 1996, Mollersen et al., 2010, Gonitel et al., 2008, Kovtun and McMurray, 2001) and DM1 (Seznec et al., 
2000). Animal studies of somatic instability are limited by the complex nature of tissues, which are made up of multiple 
cell types with differing proliferative capacities, and the inability to determine the replicative history of any given cell in 
vivo (Gomes-Pereira et al., 2014a). Biochemical studies have largely used cell-free extracts or purified DNA repair proteins 
to study activity at trinucleotide repeats, though it is not possible to recapitulate the complex interactions of the DNA 
repair network in cell free systems (Stevens et al., 2013). Cell models have the advantage of lower complexity than animal 
models and facilitate the modulation of DNA repair proteins (Nakatani et al., 2015a). Current HD cell models lack 
significant expansion, requiring long periods in culture or chronic genotoxic insult to produce subtle repeat length change, 
which has limited our understanding of the molecular basis of repeat instability (Gomes-Pereira et al., 2014a). 
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To explore the role of DNA repair in mediating instability, this chapter sets out to a generate cell culture models that 
reliably reproduce the time-dependent and expansion biased repeat instability seen in HD patients and mouse models. 
Once established, it investigates the effect of genotoxic stress and the role of DNA repair proteins in repeat stability in 
different cell types and differentiation states. 
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5.3 Methods 
5.3.1 Cell viability assays 
Cell death was measured either by LDH cytotoxicity kit (Promega cat #G1780) or MTT assay 24 h following stress.  
5.3.1.1 Cytotoxicity kit 
Cells were diluted to the appropriate concentration, added to a 96 well plate and exposed to genotoxic stress at the 
indicated concentration in a 100 µL volume per well. Cells were washed, 100µL fresh media added, and then incubated 
at 37°C for 24 h. 10 µL of 10X lysis solution was added to positive control wells and incubated for 45 min at 37°C. 50 µL 
aliquots of media from all wells were transferred to a clear bottom plate and 50 µL of CytoTox reagent added to each. 
The plate was covered to protect from light and incubated at room temperature for 30 min. 50 µL of Stop solution was 
added to each well and the absorbance was measured at 490 nm on a Tecan sunrise absorbance microplate reader. The 
average values of the negative control (medium only) wells was subtracted from all wells, then percentage cytotoxicity 
was calculated relative to positive control wells. 
5.3.1.2 MTT assay 
The MTT assay is a colorimetric readout of cellular metabolic activity used to measure cytotoxicity by loss of viable cells. 
Cellular oxidoreductase enzymes reduce the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) to insoluble formazan, which is purple. Cells were cultured in a 96 well plate at 10,000 cells per well in 
100 μL of medium overnight to adhere. The selected genotoxin was added at the appropriate concentration and duration. 
Media was changed and MTT added at 5 mg/ml in PBS. Cells were incubated at 37°C for 1 h, then media was removed 
and formazan crystals were dissolved by the addition of 50 μL of DMSO and incubation at room temperature for 30 min. 
The plate was read on a microplate absorbance reader at 570 nm. 
5.3.2 Oxidative stress 
Hydrogen peroxide (H2O2), which oxidises bases and induces single and double strand breaks (Driessens et al., 2009), was 
added to media at the required concentration by serial dilution from a 1000 µM stock and incubated for 30 min (Jonson 
et al., 2013a), then washed once with PBS and normal culture media added. 
5.3.3 shRNA-mediated FAN1 knockdown 
An shRNA hairpin targeting endogenous FAN1 (target sequence GTAAGGCTCTTTCAACGTA), synthesised by GeneArt, was 
subcloned into the pSUPER.retro.puro vector (see Appendix) and transfected into Phoenix Ampho packaging cells using 
Lipofectamine LTX (Gandhi et al., 2009, Wood-Kaczmar et al., 2008). After 16h, 8 ml fresh media was added, then media 
containing mature retrovirus was harvested 48h post transfection. This was filtered and frozen at -80°C or used directly. 
It enabled the long term, stable knockdown needed to test FAN1 involvement in CAG repeat instability in culture and 
during neuronal differentiation. 
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Figure 5.1. Cloning FAN1 shRNA into the pSUPER.retro.puro vector. 
Top left – pSUPER.retro.puro vector map showing HindIII, EcoR1 and NheI restriction sites. Top right – ligation of shRNA 
oligonucleotide into pSUPER.retro.puro. The shRNA used in this study is indicated by ‘02’. The insert of around 280 bp was excised by 
HindIII and EcoR1 cuts from the GeneArt synthesised plasmid (pMA) and pSUPER.retro.puro clones. Ligation was confirmed by PCR 
using forward primer ACGGCACCTTTAACCGAGAC within pSUPER and reverse primer AGGCTCTTTCAACGTATCTCTTGA within the 
shRNA oligo, giving a 338 bp product. Bottom – GeneArt fragment sequence showing shRNA region, and HindIII and EcoR1 sites. 
Media containing retrovirus that encodes shRNA targeting FAN1 or empty vector was mixed one to one with normal iPSC 
media and supplemented with polybrene (8 μg/ml). This media was added to iPSCs at approximately 70% confluence and 
incubated for 16 h. Cells were washed with PBS and fresh media added for 48h prior to selection with puromycin (1 
μg/ml). Media was changed on at least alternate days, monitoring to minimise the number of dead cells in the culture. 
Colonies of transduced cells were detected after 10-14 days. Untreated cells were cultured alongside the selected cells 
and used as controls in subsequent experiments. A similar protocol was trialled three times with 125Q lymphoblastoid 
(LB) cells, but none survived selection, indicating failure of transduction. 
5.3.4 Immunofluoresence 
Antibodies used in this study are given in the table below. 
Antibody Target Manufacturer Cat # Type Species Dilution 
Primary 
DARPP-32 Santa Cruz sc-11365 (H-62) Polyclonal IgG Rabbit 1:200 
CTIP2 Abcam ab18465 (25B6) Monoclonal IgG2a Rat 1:200 
βIII tubulin Abcam ab107216 Polyclonal IgG Chicken 1:500 
Secondary 
Goat anti-Rabbit Alex Fluor 488 Invitrogen A-11008 Polyclonal IgG Goat 1:1000 
Goat anti-Rat Alexa Fluor 568 Invitrogen A-11077 Polyclonal IgG Goat 1:1000 
Goat anti-Mouse Alex Fluor 647 Invitrogen A-21236 Polyclonal IgG Goat 1:1000 
Table 5.1. Antibodies for immunofluorescence. 
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5.3.5 Quantative real time PCR (qPCR) 
The following Taqman probes (Thermo) were used to assess FAN1 knockdown and MSN differentiation in iPSC lines. 
Housekeeping genes used in the 2^-ΔΔCt analysis were ACTB, ATP5B, EIF4A2 and SDHA. 
Gene Probe 
ACTB Hs01060665_g1 
ADORA2A Hs00169123_m1 
ATP5B Hs00969569_m1 
BCL11B (CTIP2) Hs01102259_m1 
CALB1 Hs01077197_m1 
DRD1 Hs00265245_s1 
DRD2 Hs00241436_m1 
EIF4A2 Hs00756996_g1 
FAN1 Hs00429686_m1 
GAD2 Hs00609534_m1 
HTT Hs00918174_m1 
OPRM1 Hs01053957_m1 
PENK Hs00175049_m1 
PPP1R1B (DARPP-32) Hs00259967_m1 
PPP1R1B (DARPP32) Hs00259967_m1 
SDHA Hs00188166_m1 
TAC1 Hs00243225_m1 
Table 5.2. Taqman qPCR probes. 
5.4 Contributions 
ReNeuron neural stem cells (NSC) were transduced with the 129Q vector as described in Trager et al. (2014), and baseline 
characterisation of cellular phenotype was conducted by Rhia Ghosh (UCL) and Alison Wood-Kaczmar (UCL). shRNA 
vector cloning and western blotting was conducted by Rob Goold (UCL). Blood sampling and peripheral blood 
mononuclear cells (PBMC) preparation were performed by Michael Flower. 125Q lymphoblastoid (LB) cell transformation 
was conducted by European Collection of Authenticated Cell Cultures (ECACC) lab at Public Health England (PHE), 
Salisbury, and iPSCs were generated by Censo Biotechnologies, Midlothian. All cell culture, cloning, retroviral 
transduction, genotoxic stress, CAG repeat sizing, immunofluorescence, microscopy and data analysis was conducted by 
Michael Flower. These results have been published in Goold et al. (2018). 
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5.5 Results 
5.5.1 ReNcell neural stem cells 
5.5.1.1 ReNcell VM 129Q 
5.5.1.1.1 Hydrogen peroxide titration 
ReNcell VM neural stem cells were lentivirally transduced with HTT exon 1 containing either non-pathogenic 29, or 
pathogenic 71 or 129 CAG repeats. Each line was neuronally differentiated as in Donato et al. (2007), with mitotic neural 
stem cells cultured in parallel. Those expressing 129 repeats were found to be more sensitive to oxidative stress during, 
rather than after differentiation with 25% cell death induced by approximately 25 µM or 250 µM hydrogen peroxide 
respectively. 
 
Figure 5.2. Oxidative stress in ReNeuron VM 129Q cells. 
Left – cells 3d into the differentiation protocol stressed with the indicated H2O2 concentration for 30 min. Right – differentiated cells 
17 days from neuronal induction. 3 independent replicates for each data point, error bars represent SEM. Cell death measured by LDH 
cytotoxicity assay 24h after stress. 
5.5.1.1.2 CAG repeat sizing 
Differentiation experiments were performed at least in triplicate and samples taken serially for CAG repeat sizing. At 
baseline, cells transduced with the 29Q vector were sized at 30.8 ± 0.0028Q, the 71Q vector at 70.3 ± 0.13Q and the 
129Q vector at 132.1 ± 1.46Q. There was no significant change in modal CAG repeat length, proportional expansion 
analysis or somatic instability index, either in culture as NSCs or during neuronal differentiation over 8 weeks. 
Representative fragment analysis traces are given below. 
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Figure 5.3. Representative CAG repeat sizing from ReN VM neural stem cells (NSC) differentiated for 56 days. 
Top – NSC at baseline. Middle – neuronally differentiated for 42 and 56 days. Bottom – NSC cultured in parallel for 56 days. Left – 
ReN VM transduced with non-pathogenic 29Q HTT exon 1. Middle – 71Q HTT exon 1. Right – 129Q HTT exon 1. Modal CAG repeat 
length at baseline is given as a red dotted line. Modal CAG length at other times represented by red arrow. Q – modal CAG length. 
HTT exon 1 
repeat length Treatment Modal CAG length 
Change in modal 
CAG 
Proportional 
expansion Instability index 
71Q 
NSC baseline 70.1 (± 0) 0 (± 0) 0.485 (± 0.004) 0 (± 0) 
NSC d56 70.75 (± 0.37) 0.65 (± 0.367) 0.675 (± 0.012) 0.785 (± 0.02) 
Differentiated d56 70.15 (± 0.04) 0.05 (± 0.041) 0.505 (± 0.102) 0.32 (± 0.261) 
129Q 
NSC baseline 130.53 (± 1.35) 0 (± 0) 0.557 (± 0.09) 0 (± 0) 
NSC d56 128.63 (± 0.68) -1.9 (± 1.429) 0.590 (± 0.072) 0.867 (± 1.38) 
Differentiated d56 130.5 (± 1.5) -0.033 (± 0.984) 0.613 (± 0.07) 1.11 (± 0.582) 
Figure 5.4. Repeat expansion analysis in ReN VM cells cultured as neural stem cells (NSC) or differentiated (MSN) for 56 days. 
Change in modal CAG is given relative to baseline. For proportional expansion, 0.5 represents a normal distribution with a mode 
equal to the baseline mode. The maximum is 1.0 (the entire distribution is greater than the control mode) and minimum is 0.0 (the 
entire distribution is less than the control mode). Instability index is given relative to baseline and is measured in CAG units. NSC – 
neural stem cell. Differentiated – neuronal differentiation. Values are the mean of at least 3 replicates (± SEM). 
NSCs and differentiating or differentiated neurons were then exposed to chronic oxidative stress with H2O2. Sublethal 
doses were used, aiming to kill less than 10% of cells, given that longitudinal sampling from post-mitotic cultures is 
required (see Methods). Differentiating cells received either 0, 6.25 or 12.5 µM H2O2 for 30 min weekly and samples were 
taken for CAG sizing at 48d form neuronal induction. Differentiated cells were challenged with 0, 75 or 150 µM H2O2 for 
30 min weekly from day 15 after neuronal induction and samples were taken at 44d from induction. NSCs were cultured 
and stressed in parallel, and all experiments were conducted in triplicate. There was no significant change in modal CAG 
repeat length or somatic instability index in any group. 
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Figure 5.5. Representative CAG repeat sizing from ReN VM 129Q neural stem cells (NSC) chronically stressed with H2O2 during 
differentiation for 48 days. 
Top – NSC at baseline. Lower 3 traces – stressed for 30 min once weekly with the indicated H2O2 concentration during neuronal 
differentiation for 48d. Modal CAG repeat length at baseline is given as a red dotted line. Q – modal CAG length. 
ReN VM 129Q NSC stress during 
differentiation 
Modal CAG length Change in modal CAG length Proportional expansion Instability index 
Baseline NSC 132.33 (± 0.55) 0 (± 0.549) 0.358 (± 0.002) 0 (± 0.152) 
Differentiated 48d + 0µM H2O2 130 (± 1.88) -2.33 (± 1.877) 0.335 (± 0.03) -1.186 (± 0.511) 
Differentiated 48d + 75µM H2O2 130.12 (± 1.32) -2.211 (± 1.322) 0.376 (± 0.019) 0.256 (± 0.136) 
Differentiated 48d + 150µM H2O2 129.81 (± 1.7) -2.521 (± 1.697) 0.389 (± 0.007) -0.166 (± 0.407) 
Table 5.3. Repeat expansion analysis in ReN VM 129Q NSCs chronically stressed with H2O2 during differentiation for 48 days. 
Change in modal CAG, proportional expansion and instability index are given relative to baseline. NSC – neural stem cell. 
Differentiated – neuronal differentiation. Values are the mean of at least 3 replicates (± sem). 
 
Figure 5.6. Representative CAG repeat sizing from ReN VM 129Q NSCs 44d after initiation of differentiation, chronically stressed 
with H2O2 from day 15. 
Top – NSC at baseline. Lower 3 traces – stressed for 30min once weekly with the indicated H2O2 concentration from day 15. Modal 
CAG repeat length at baseline is given as a red dotted line. Q – modal CAG length. 
Baseline NSC
Differentiated 48d
+ 0 µM H2O2
Differentiated 48d
+ 6.25 µM H2O2
Differentiated 48d
+ 12.5 µM H2O2
132Q
ReN VM 129Q oxidative stress during differentiation
131Q
Baseline NSC
Differentiated 44d
+ 0 µM H2O2
Differentiated 44d
+ 75 µM H2O2
Differentiated 44d
+ 150 µM H2O2
ReN VM 129Q oxidative stress after differentiation
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ReN VM 129Q NSC stress after 
differentiation 
Modal CAG length Change in modal 
CAG length 
Proportional 
expansion 
Instability index 
Baseline NSC 131.33 (± 0.61) 0 (± 0.606) 0.331 (± 0.021) 0 (± 0.274) 
Differentiated 44d + 0µM H2O2 130.66 (± 0.51) -0.672 (± 0.512) 0.415 (± 0.008) 1.461 (± 0.209) 
Differentiated 44d + 75µM H2O2 132.83 1.50 0.44 1.41 
Differentiated 44d + 150µM H2O2 131.4 (± 1.33) 0.07 (± 1.33) 0.4 (± 0.031) 0.825 (± 0.493) 
Table 5.4. Repeat expansion analysis in ReN VM 129Q NSCs 44d after initiation of differentiation, chronically stressed with H2O2 
from day 15. 
Values are the mean of at least 3 replicates (± SEM), except 75 µM where repeat sizing failed for two replicates. 
5.5.1.2 ReNcell CX 129Q 
ReN CX NSC electrophoresis traces show a broad, multimodal distribution, with dominant peaks at 83 and 127Q. In the 
first instance cells were differentiated using the Donato et al. (2007) protocol. Differentiated neurons were chronically 
stressed with 100 µM H2O2 weekly from day 15 and samples taken for repeat sizing at day 49 from neural induction. 
Over 7 weeks the smaller peak at 82.8Q increased by 0.96 repeats (proportional expansion +0.15, instability index 
+1.05Q) and 1.04 repeats (proportional expansion +0.36, instability index +1.34Q) in the absence and presence of chronic 
oxidative stress respectively. 
The larger peak at 126.8Q appeared to increase with differentiation in the absence or presence of oxidative stress by 
39.1 repeats (proportional expansion +1.0, instability index +24.43Q) and 37.3 repeats (proportional expansion +1.0, 
instability index +30.6Q), with none of the original modal allele remaining. The change at the broad 127Q peak is 
suggestive of expansion, but may represent the selective loss of cells expressing shorter alleles, perhaps because CAG 
expansion reduces HTT expression, thereby providing a selection advantage (Dragatsis et al., 2009). Over the 7 weeks, 
the smaller 83Q peak showed a increased by 1Q in both mode and instability index. 
 
Figure 5.7. Representative CAG repeat sizing in ReN CX 129Q cells differentiated in the presence of chronic oxidative stress. 
Top – baseline neural stem cells (NSC). Middle – neuronally differentiated for 49 days. Bottom – neuronally differentiated with 100 
µM H2O2 stress for 30 min weekly from day 15. Modal CAG repeat length at baseline is given as a red dotted line. Q – modal CAG 
length. 
However, the ReN CX cells rarely successfully differentiated without losing HTT exon 1 expression, demonstrating the 
toxicity of exon 1 fragment. A later successful differentiation in a sample expressing a peak at 116.3Q baseline is shown 
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below. At day 5 it had increased by 0.71Q (proportional expansion -0.05, instability index -0.10Q) and at day 14 had 
increased by 1.00Q (proportional expansion +0.08, instability index +0.91Q). 
 
Figure 5.8. Representative CAG repeat sizing in ReN CX 129Q cells differentiated for 14 days. 
Top – baseline neural stem cells (NSC). Middle – neuronally differentiated for 5 days. Bottom – neuronally differentiated for 14 days. 
Red dotted lines represent the modal CAG length at baseline (116Q), and the modal CAG lengths observed in previous differentiations 
(127Q and 166Q). Modal CAG length at other times represented by red arrow. Q – modal CAG length. 
5.5.1.3 ReN VM 129Q single cell cloning 
To increase sensitivity in the expansion analysis, the polyclonal ReN VM 129Q cells were single cell cloned by serial 
dilution at 100 or 10 cells/well in 96 well plates (see Chapter 2). Cultures derived from 100 cell/well dilutions contained 
several distinct peaks, but those from the 10 cell/well dilution produced a single narrow, normally distributed peak. 23 
clones were generated from 10 cell/well dilution, two of which were cultured and the CAG repeat sized. Notably both 
had CAG repeat lengths derived from the top 5% of the original polyclonal distribution (mean 142.3 ± 1.36Q), again 
suggesting positive selection for longer repeat length. The mean width of the CAG traces was successfully reduced from 
39.34 ± 1.40Q to 8.09 ± 4.32Q. 
116Q
Baseline NSC
Differentiation d5
Differentiation d14
117Q
117Q
127Q 166Q
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Figure 5.9. CAG repeat sizing in ReN VM 129Q single cell clones (SCC). 
Top left – first is the original polyclonal line, in the middle is cloning with a dilution of 100 cells/well and finally dilution at 10 
cells/well. Top right – modal CAG repeat length. Bottom right – width of the CAG repeat distribution on capillary electrophoresis. 
Note this includes several distinct peaks in the polyclonal and 100 cells/well dilution. Values given are mean ± SEM. ReN VM 129Q – 
original polyclonal population. SCC– single cell cloning by serial dilution to 100 or 10 cells/well in a 96 well plate format. Bottom left – 
CAG repeat sizing from a ReN VM 129Q single cell clone in culture and during neuronal differentiation. First is baseline neural stem 
cells (NSC), second is neuronally differentiated from day 0 and sized at day 23, third is NSC in culture for 117 days, and at the bottom 
are NSC in culture for 135 days. Modal CAG repeat length at baseline is given as a red dotted line. Modal CAG length on other dates 
are represented by red arrows. Q – modal CAG length, SCC1– single cell clone number 1.  
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Single cell 
clone 
Treatment Modal CAG length Change in modal 
CAG 
Proportional 
expansion 
Instability index 
SCC1 
NSC baseline 140.79 0.00 0.52 0.00 
Differentiated d23 143.11 2.32 0.74 1.82 
NSC d117 145.36 4.57 0.88 4.29 
NSC d135 146.45 5.66 1.00 5.22 
SCC2 NSC baseline 141.31 0.00 0.43 0.00 NSC d14 143.23 1.92 1.00 3.59 
Table 5.5. CAG repeat sizing analysis for two single cell clones in culture and during differentiation. 
SCC – single cell clones 1 and 2. 
 
Figure 5.10. CAG expansion analysis of ReN VM 129Q single cell clones. 
Top left – modal CAG repeat length over time. Top right – change in modal CAG repeat length relative to NSC at baseline. Bottom left 
– proportional expansion analysis relative to baseline. Bottom right – instability index relative to baseline, measured in CAG repeat 
units. SCC – single cell clones 1 and 2, NSC – neural stem cell. Neurons – neuronal differentiation. 
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5.5.2 Track-HD patient-derived lymphoblastoid cells 
Cannella et al. (2009) demonstrated HTT CAG repeat expansion in patient-derived lymphoblasts (LB) with at least 64 CAG 
repeats cultured for 6 months. Jonson et al. (2013a) found that chronic oxidative stress with 50 or 150 µM hydrogen 
peroxide (H2O2), which induces an array of DNA damage including oxidised bases and DNA strand breaks (Spencer et al., 
1995, Spencer et al., 1996), for 30 min before each passage accelerated expansion of a 127Q HTT exon 1 CAG repeat in 
R6/1 mouse embryonic stem cells in a dose dependent manner (Mangiarini et al., 1996). 
5.5.2.1 Hydrogen peroxide titration 
HD LBs with 43 CAG repeats, assayed using the MTT method, showed around 25% cell death at 50 µM and 50% at 150 
µM H2O2. 
 
Figure 5.11. Oxidative stress in HD lymphoblastoid (LB) cells. 
43 CAG repeat LB cells were exposed to the indicated H2O2 concentration for 30 min before cell viability measurement by MTT assay 
24 h later. Each data point is the mean of 6 replicated ± SEM. 
5.5.2.2 CAG repeat sizing 
In the first instance, a panel of LB cell lines, including a 43Q, 44Q and 52Q line, and one from a fast progressing Track-HD 
subject with the p.R507H variant (see Methods), were cultured and exposed to either 50 or 150 µM H2O2. None of the 
lines with 42-44 CAG repeats showed significant change in modal CAG repeat length or instability index in culture over 
17 weeks, or with chronic oxidative stress over 6 weeks. The 52Q line did not show expansion in routine culture, and did 
not survive treatment with 150 µM H2O2, but those exposed to 50 µM may have shown a small expansion, with modal 
CAG length increasing at a rate of 113.96 ± 6.32 days/Q (p = 0.0034) and instability index at a rate of 90.22 ± 5.55 days/Q 
(p = 0.0043), though this was based on an increase of <1Q. 
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Figure 5.12. Representative CAG repeat sizing in lymphoblastoid (LB) cells chronically stressed with the indicated H2O2 
concentration. 
Modal CAG repeat length at baseline is indicated by a red dotted line. The 44Q and 52Q LB lines exposed to 150 µM H2O2 died out 
after 7d and 2d respectively. 
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Figure 5.13. Repeat expansion analysis in a 43Q, 44Q, 52Q and p.R507H LB lines chronically exposed to oxidative stress. 
Left column – modal CAG repeat length, middle column – change in modal CAG repeat length, right column – instability index, 
measured in CAG units. 
5.5.3 250Q lymphoblasts 
LBs derived from a juvenile-onset subject, originally estimated to have 250 CAG repeats by PCR and Southern blot, were 
cultured. The triplet repeat-primed PCR (TP-PCR) capillary electrophoresis trace consistently showed stutter in 3 bp units, 
with exponential decay as amplification efficiency declines with increasing product size (Jama et al., 2013). This 
characteristic ladder of stutter peaks is due to the chimeric reverse primer, which is located partially within the CAG 
region, hybridising to multiple locations within the CAG repeat. As the main allele, at around 250 CAG repeats (Nance et 
al., 1999), is too large to amplify, it is not possible to accurately assign an allele size by this method. The largest resolved 
peak was at 136Q, which is the size this allele was called by the UCLH neurogenetics lab. 
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Figure 5.14. CAG repeat sizing in 250Q lymphoblasts (LB) by TP-PCR capillary electrophoresis. 
5.5.4 73Q induced pluripotent stem cells 
Three clones of induced pluripotent stem cells (iPSC), generated by Sendai reprogramming of fibroblasts from a juvenile-
onset HD subject with 73 CAG repeats, were studied for repeat stability. 
5.5.4.1 Hydrogen peroxide titration 
iPSCs derived from juvenile-onset HD patients with 73 or 109 CAG repeats (QS3.2 and 109Q iPSC respectively) were 
assayed using the cytotoxicity kit. QS3.2 were more sensitive than 109Q iPSCs, with 50% cell death at around 70 µM and 
250 µM H2O2 respectively. 
 
Figure 5.15. Oxidative stress in QS3.2 and 109Q iPSCs. 
QS3.2 – clone 2 of iPSCs derived from a juvenile-onset HD subject with 73 CAG repeats. 109Q iPSCs – derived from a juvenile-onset HD 
subject with 109 CAG repeats.  
5.5.4.2 FAN1 knockdown 
Expression of FAN1 was significantly reduced in 73Q QS3.2 iPSCs and 109Q iPSCs by the introduction of shRNA, with 
transcript levels reduced by 41% and 59% (p = 2.17E-06), and protein by 76% (p = 0.014) and 84% (p = 1.87E-05) 
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respectively. Transcript levels of HTT, MSH3 and MLH1 were unchanged (see Figure 5.26). FAN1 knockdown was 
maintained throughout differentiation. 
 
Figure 5.16. shRNA mediated FAN1 knockdown in QS3.2 and 109Q iPSCs. 
Left – western blot. Middle – densitometric quantification of western blot in ImageJ. Right – qPCR of FAN1 relative expression. QS3.2 
– clone 2 of iPSCs derived from a juvenile-onset HD subject with 73 CAG repeats. 109Q iPSCs – derived from a juvenile-onset HD 
subject with 109 CAG repeats. 
5.5.4.3 CAG repeat sizing 
At baseline, the CAG length differed between clones, with QS3.1 measuring 74, QS3.2 at 76 and QS3.3 at 75 CAG repeats. 
Additionally, QS3.1 consistently showed a bimodal distribution, all of which suggest repeat instability during 
reprogramming.  
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Figure 5.17. Baseline CAG repeat sizing in QS3 iPSCs. 
Left – representative CAG repeat sizing in three clones of QS3 iPSCs derived from a juvenile-onset HD patient with 73 CAG repeats. 
The left panel of this shows triplet-repeat primed PCR (TP-PCR) using the HDE reverse primer for accurate CAG sizing. Note the 
characteristic ladder of PCR stutter peaks extending from the non-pathogenic allele (out of crop) to the pathogenic allele (shown). The 
right panel shows CAGCCG PCR using the HD5 reverse primer for optimal amplification. Note increased peak height on the scale 
relative to TP-PCR. Top right –HDE triplet-repeat primed PCR (TP-PCR) for accurate repeat sizing, HD5 CAGCCG PCR for optimal 
amplification. Error bars represent SEM. Bottom right –Mean, standard deviation (SD) and standard error of the mean (SEM) are 
given. Note QS3.3 was sized only once using the HDE primers for TP-PCR. 
Clones 1 and 2 (QS3.1 and 3.2) were cultured under control conditions long term, differentiated to neural stem cells (NSC) 
or medium spiny neurons, chronically exposed to oxidative stress and FAN1 was stably knocked down by shRNA. Chronic 
oxidative stress was induced by exposure to 25 µM or 100 µM H2O2 for QS3.2 and 109Q iPSC respectively for 30 min 
before each passage, aiming to kill around 25% of cells. 
QS3.1 and QS3.2 cells cultured in control conditions for 100 days, under chronic oxidative stress for 20 days or 
differentiated to NSCs and maintained in culture for 43 days did not show any significant change in modal CAG repeat 
length, instability index or proportional expansion analysis. For iPSCs differentiated into medium spiny neurons (MSNs), 
the modal CAG repeat number did not significantly increase over 193 days, but instability index increased at a rate of 
88.42 ± 13.82 days/Q (p = 1.01E-03) and proportional expansion showed a nominal increase (slope = 0.001 ± 5.01E-04, p 
= 0.081). However, this slow rate is equivalent to an increase of only 2 CAG units over the course of the 28 week 
experiment. 
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Figure 5.18. CAG expansion analysis in QS3 iPSCs in culture, chronic oxidative stress and differentiation as NSCs or MSNs. 
Top left – representative CAG repeat sizing traces from clone 1. Top right– clone 2. Bottom – change in modal CAG length from 
baseline (left), instability index (middle), and proportional expansion analysis (right). QS3 – data from clones 3.1 and 3.2 grouped 
together for analysis. H2O2 – chronic exposure to 25 µM hydrogen peroxide for 30 min before each passage. NSC – iPSCs 
differentiated along the MSN protocol until passage 2, then maintained as mitotic neural stem cells (NSC). MSN – medium spiny 
neurons. FAN1 KD – shRNA-mediated stable FAN1 knockdown. 
5.5.5 125Q patient-derived cells 
5.5.5.1 Lymphoblastoid cells 
Whole blood DNA, LB cells and pluripotent erythroid progenitor cells (EPC) were generated from a juvenile-onset HD 
patient with 125 CAG repeats. Comparing blood samples in 2014 and 2017, there was no significant change in CAG repeat 
size, within the ± 3-4 CAG error margin of the assay at this repeat length (Bean and Bayrak-Toydemir, 2014, Losekoot et 
al., 2013). 
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Figure 5.19. CAG repeat sizing of whole blood from a 125Q HD subject sampled 3 years apart. 
Top – representative CAG sizing. Baseline modal CAG repeat length is given by the dotted red line. Bottom left – modal CAG repeat 
length, middle – instability index, bottom right – proportional expansion analysis. 
At baseline, the LB cells had an average modal CAG repeat length of 136.4 ± 0.58 CAG repeats, meaning the repeat had 
expanded by 11 CAG during generation of the line. Electrophoresis traces showed a broad distribution of peaks across 
72.00 ± 3.86 CAG. In each of five independent cultures the traces became bimodal, before a clonal population arose after 
around 40 days, as evidenced by the CAG distribution width narrowing to 44.23 ± 5.64 CAG. Consistent with results from 
single cell cloning in ReN VM NSCs, clones always originated from the higher repeat lengths in the distribution, with an 
average modal CAG length of 161.2 ± 3.06. 
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Figure 5.20. CAG repeat sizing of lymphoblasts (LB) from a subject with 125 CAG repeats at baseline and following the emergence 
of a clone. 
Left – representative CAG repeat sizing in control or chronic oxidative stress conditions. Note the initially broad distribution width at 
baseline, before a bimodal distribution develops (d11-32) and the emergence of a clonal population after around 40 days. The repeat 
length in clonal cells then continues to expand. Chronic oxidative stress with 100 µM H2O2 for 30 min before every third passage was 
applied to cells in parallel. Top right – modal CAG repeat length at baseline and in clonal populations after around 40 days. Bottom 
right – width of the CAG repeat trace on capillary electrophoresis. 
The development of a bimodal distribution confounds expansion analysis by modal CAG repeat length, which appears to 
suddenly increase up to 30 CAG as the longer repeat becomes dominant. However, the instability index and proportional 
expansion analysis show a smooth, apparently linear, expansion over time. 
Three cultures were exposed to chronic oxidative stress with 100 µM H2O2 for 30 min before every third passage, aiming 
for a sublethal stress that permits long term culture (see Methods). There was no significant change in repeat expansion 
relative to control conditions. However, stress was applied before clonality was achieved, and cultures would rarely 
survive longer than 40 days. An acceleration in expansion may be detectable were oxidative stress to be applied after 
clonality at around day 40. 
Focussing on the clonal cells, which increases the sensitivity and resolution of expansion analyses, data was combined 
from 5 cultures after a clone had emerged. Modal CAG repeat length expanded at a rate of 6.75 ± 0.66 days/Q (p non-
zero = 3.44E-09), proportional expansion analysis increased (p = 8.55E-09), and instability index expanded at a rate of 
3.91 ± 0.27 days/Q (p = 3.07E-12). 
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Figure 5.21. CAG repeat expansion analysis in 125 CAG LB cells. 
Top row – 5 independent cultures under control conditions. Note the apparent sudden increase in modal CAG length (top left) around 
day 30 as cultures become bimodal. Note the linearity of instability index expansion (top middle). On the proportional expansion 
analysis, expansion is again linear, though this measure reaches its maximum, 1.0, within around 60 days, once the entire distribution 
becomes larger than the baseline modal CAG length. Middle row – cultured under chronic oxidative stress. 100 µM H2O2 for 30 min 
before every third passage was applied to cells in parallel to cultures 1, 4 and 5. There was no significant difference in expansion 
between control and oxidative stress conditions. Bottom row – clonal 125Q LB cells. Data from 5 cultures following clonality at 
around 40 days have been combined. 
5.5.5.2 Induced pluripotent stem cells (iPSC) 
Pluripotent erythroid progenitor cells (EPC) generated from the same subject also showed CAG repeat instability on 
initial characterisation, with modal CAG repeat length expanding at a rate of 25.77 ± 3.82 days/Q (p = 4.57E-03), 
proportional expansion analysis increasing significantly (p = 0.010) and instability index increasing at a rate of 26.17 ± 
4.71 days/Q (p = 0.010). These cells will form the basis of further investigation of the role of DNA maintenance in 
somatic instability in MSNs. 
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Figure 5.22. CAG repeat sizing in 125Q iPSCs. 
DNA extracted from the source blood sample was sized (top), then serial samples were assayed from iPSCs in culture over 64 days. 
Modal CAG repeat length at baseline is shown by a dotted red line and modal CAG at other timepoints by a red arrow. 
5.5.6 109Q induced pluripotent stem cells 
5.5.6.1 CAG repeat expansion 
iPSCs derived from a juvenile-onset HD patient with 109 CAG repeats were assessed for instability. At baseline, they sized 
at 121 CAG repeats, indicating expansion from the original length. In three independent cultures the modal CAG repeat 
length expanded exponentially (r2 = 0.989, p = 7.65E-26). If it is assumed this curve can be extrapolated to the past, then 
we observe that the cells have been in culture for 192 days (6 months) since they were derived from the donor 109Q 
subject. The mean intersection of the exponential functions from three cultures was at 109Q, at an average day -210. 
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ln(CAG) = (5.473e-04 * d) + 4.797 
Figure 5.23. Exponential model of modal CAG repeat expansion in 109Q iPSCs. 
Day 0 represents the start of culture, the dotted line at 109 CAG represents the repeat length measured in blood of the subject from 
which the cells were derived. d – day of culture  r2 = 0.9882, p = 7.651e-26. 
Culture 
# 
Duration 
(d) a k r2 p 
Intersection Mean intersect 1 2 3 
1 295 121.10 ± 0.23 5.47E-04 ± 1.20E-05 0.988 7.65E-26 - -250.86d, 105.57Q 
-209.20d, 
108.00Q 
-209.69d, 
108.83Q 2 196 129.78 ± 0.36 8.23E-04 ± 3.20E-05 0.981 1.56E-12 
-250.86d, 
105.57Q - 
-169.00d, 
112.93Q 
3 64 136.20 ± 0.48 1.11E-03 ± 1.04E-04 0.983 8.66E-03 -209.20d, 108.00Q 
-169.00d, 
112.93Q - 
Table 5.6. Exponential modelling of modal CAG expansion in 109Q iPSCs. 
Culture 1 – began 16/1/17 on receipt of the cell line, cultured for 295 days. Culture 2 – cells from culture 1 frozen on 22/5/17 (d127, 
130Q), thawed on 2/1/18 and cultured for 196 days. Culture 3 – cells from culture 2 frozen on 1/3/18 (d59, 136Q), thawed on 7/5/18 
and cultured for 64 days. 
5.5.6.2 Oxidative stress 
In a pilot experiment, 109Q iPSCs were exposed to chronic oxidative stress in triplicate with 100 µM H2O2 for 30 min 
before each passage, aiming to kill around 25% of cells (see Methods). Over the short 20 day experiment there was no 
significant difference in expansion rate between control and oxidative stress conditions, but a longer exposure would be 
required to definitively determine whether there is an effect. 
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Figure 5.24. CAG repeat expansion in 109Q iPSCs exposed to chronic oxidative stress. 
Cells were cultured in control conditions or exposed to 100 µM H2O2 for 30 min before each passage over the course of 20 days. Data 
is generated from duplicate cultures. Left – change in modal CAG repeat length, right – instability index. 
5.5.6.3 FAN1 knockdown 
Long term, stable FAN1 knockdown in 109Q iPSCs was achieved by retrovirally mediated shRNA transduction (see 
Methods). In iPSCs, knockdown at the protein level was 60.26 ± 6.18% relative to empty vector (p = 0.0118) and at the 
transcript level was 59.34 ± 16.52% relative to control cells (p = 5.67E-03). 
An established differentiation protocol, adapted from Arber et al. (2015), was used to generate medium spiny neurons 
(MSN) from control and retrovirally transduced iPSC lines. qPCR demonstrated significantly increased expression of a 
panel of mature striatal MSN markers, including genes in the direct (TAC1, DRD1) and indirect (PENK, DRD2) striatal 
pathway, as well as BCL11B (CTIP2), OPRM1, PENK, GAD2 and CALB1. Immunofluorescence confocal microscopy 
demonstrated expression of βIII tubulin (79.56 ± 4.82%), DARPP32 (13.15 ± 2.19%) and CTIP2 (31.29 ± 5.23%) in neuronal 
cells with typical spiny dendritic morphology (Arber et al., 2015). 
FAN1 knockdown was maintained throughout differentiation, with protein level reduced by 88.91 ± 11.42% relative to 
empty vector (p = 0.0112) and transcript level reduced by 50.86 ± 2.96% relative to control (p = 4.68E-03) in MSNs. FAN1 
knockdown did not alter expression of HTT, DARPP-32 or CTIP2, or DNA mismatch repair components MLH1 and MSH3. 
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Figure 5.25. Immunofluorescence confocal microscopy of differentiated 109Q medium spiny neurons (MSNs) treated with either 
FAN1 knockdown, empty vector or in control conditions. 
Top row – control conditions, bottom left – empty vector, bottom right – shRNA-mediated FAN1 knockdown. Primary antibodies are 
CTIP2 (red), DARPP-32 (green), bIII tubulin (white) and Hoescht (blue). Range bars indicate 20 µM. 
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Figure 5.26. Stable shRNA-mediated FAN1 knockdown in 109Q iPSCs and MSNs. 
Top left – western blot of FAN1 and MLH1 in 109Q iPSCs and differentiated MSNs in control, empty vector or FAN1 knockdown 
conditions. Top right – densitometric quantification of western blot in ImageJ. Data for FAN1 represents the mean of two replicates. 
Middle left – qPCR of FAN1, HTT, MSH3 and MLH1 in 109Q iPSCs and differentiated MSNs in control, empty vector or FAN1 
conditions. Data represents the mean of 5-6 biological replicates for iPSCs and 2 replicates for MSNs. Expression of each gene is 
relative to the mean of control 109Q iPSCs (blue). Middle right – proportion of cells in MSN cultures positive for DARPP-32 and CTIP2 
immunofluorescence staining, expressed relative to Hoescht. Data represents the mean ± SEM of 6 fields for each condition. Bottom – 
expression of a panel of MSN markers from Straccia et al. (2015). Data represents the mean of 5-6 biological replicates for iPSCs and 
2 replicates for MSNs. Expression of each gene is relative to control 109Q iPSCs. Error bars represent SEM. Con – control cells, empty – 
empty vector, FAN1 KD – shRNA targeting FAN1, MSN d35 – medium spiny neurons at the end of the differentiation protocol. 
In iPSCs, CAG repeat length expanded at a similar rate in control and empty vector treated cells. The rate of change in 
modal CAG repeat length was 13.95 ± 0.31 days/Q and 16.00 ± 0.72 days/Q respectively (p = 0.383), and instability index 
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increased at 13.55 ± 0.34 days/Q and 13.33 ± 0.59 days/Q respectively (p = 0.912). Knockdown of FAN1 increased 
expansion rate of modal CAG repeat length to 9.81 ± 0.27 days/Q and instability index to 9.50 ± 0.28 days/Q, a significant 
acceleration relative to control and empty vector treated cells (p mode = 3.15E-15, p index = 4.71E-13 respectively). These 
results suggest FAN1 protects against expansion of the endogenous HTT CAG repeat, at least in mitotic cells. 
To assess if this mechanism also operates in non-dividing cells, the CAG repeat was measured in differentiated MSNs. In 
control and empty vector treated MSNs, it again expanded at a similar rate; modal repeat length increased at 15.46 ± 
0.70 days/Q and 17.00 ± 1.99 days/Q respectively (p = 0.430) and instability index expanded at 16.74 ± 0.75 days/Q and 
15.01 ± 3.72 days/Q respectively (p = 0.641). The rate was equivalent to iPSCs in control and empty vector conditions (p 
mode = 0.275 and 0.635). FAN1 knockdown accelerated expansion of modal CAG length to 10.71 ± 0.77 days/Q and 
instability index to 9.24 ± 0.56 days/Q, which are significant increases relative to control and empty vector treated cells 
(p mode = 4.15E-04, p index = 3.28E-08). Once again, expansion rate in FAN1 knockdown MSNs and iPSCs was equivalent 
(p mode = 0.357). These results suggest FAN1 restrains CAG repeat expansion in cultures containing a high proportion of 
post-mitotic differentiated striatal neurons. 
 
 Figure 5.27. Comparison of exponential expansion models in 109Q iPSC, NSC and MSNs. 
Representative CAG repeat sizing from a sample culture of iPSCs (blue), neural stem cells (NSC, orange) or differentiated medium 
spiny neurons (MSN, magenta). Left – change in modal CAG repeat length. Right –instability index. Exponential models have been 
fitted for 109Q iPSC (ln(CAG) = (1.043e-02 * d) + 0.5844; r2 = 0.7934, p = 2.580e-19), NSC (ln(CAG) = (5.996e-03 * d) + 1.396; r2 = 
0.9434, p = 2.126e-27), and MSN (ln(CAG) = 1.795e-02 * d) – 0.202; r2 = 0.916, p = 1.106e-09) 
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Figure 5.28. CAG repeat expansion in 109Q iPSCs and MSNs following shRNA-mediated FAN1 knockdown. 
Linear regression models have been fit. Top row – iPSCs, bottom row – differentiated medium spiny neurons (MSN), left column – 
change in modal CAG repeat length, right column – instability index. Blue – control untreated conditions, orange – empty vector 
treated, purple – shRNA-mediated FAN1 knockdown. For iPSCs, data is generated from 9 replicates of control conditions, 2-4 
replicates from each of two empty vector transductions, and 3-7 replicates from each of three FAN1 shRNA transductions. For MSNs 
in each condition, data is from 2 replicates of three serial differentiations from each of two independent transductions. 
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5.5.7 Comparison of CAG expansion rates 
No cell lines with up to 76 CAG repeats showed significant instability in culture. In 109Q iPSCs, expansion was exponential, 
suggesting expansion rate positively correlates with CAG repeat length. This is supported by lines derived from the 
juvenile-onset HD subject with 125 CAG repeats, as her iPSCs at baseline expanded at a rate of 26 days/Q, but her clonal 
LB cells, at 161 repeats, expanded faster than any other cell line, at 6.75 days/Q. Comparing across different cell types 
the relationship between CAG repeat length and expansion rate was less clear, with 109Q iPSCs expressing 131 repeats 
expanding at 14 days/Q, but ReN VM neural stem cell single cell clones (SCC) carrying a longer 142 repeat expanding 
more slowly at 28 days/Q. Expansion rate was not clearly related to mitotic rate; doubling time in iPSCs was approximately 
half that of LB cells, though their expansion rate was slower, suggesting the mechanism underlying repeat instability is 
independent of DNA replication. 
 
Figure 5.29. Comparison of CAG repeat expansion rate in HD cell lines. 
Left – rate of change in modal CAG repeat length, expressed as days per CAG unit (days/Q). Cell lines sorted in order of CAG repeat 
length at the point of rate measurement (note this usually differs from original founder repeat length). Right – doubling time of cells 
in culture. LB – lymphoblastoid cell, p.R507H – FAN1 variant associated with fast disease progression, QS3/109Q/125Q – iPSCs 
derived from juvenile-onset HD patients with 73, 109 and 125 CAG repeat respectively, ReN VM – ReNeuron neural stem cells, 125Q 
LB clonal – LBs derived from a juvenile-onset HD patient with 125 CAG repeats following the emergence of a clonal population. 
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5.6 Discussion 
Pathogenic repeat expansions, such as the CAG in HTT exon 1, are unstable somatically and through the germline in a 
process that is age-dependent, expansion biased and tissue-specific. In HD (Wheeler et al., 1999, Goula et al., 2012, 
Shelbourne et al., 2007a), DM1 (Anvret et al., 1993, Wong et al., 1995, Ashizawa et al., 1993, Lopez Castel et al., 2011) 
and Friedreich’s ataxia (FRDA) (De Biase et al., 2007, Clark et al., 2007b), expansion occurs in the tissues most prominently 
affected by the condition. The mechanism driving it remains unclear, but expansion occurs in postmitotic cells and 
requires DNA repair factors, particularly the mismatch repair pathway, suggesting it happens during DNA repair, rather 
than replication. Recent genetic studies have identified DNA repair genes FAN1 (GeM-HD, 2015, Bettencourt et al., 2016) 
and MSH3 (Hensman Moss et al., 2017b) as modifiers of HD motor onset and disease progression respectively. Though 
several artificial and patient-derived cell models of DM1 repeat instability exist, no HD cell models currently show 
significant repeat expansion within an observable timeframe that would allow measurement of changes in expansion 
rate induced by manipulation of DNA repair factors. In the present study, 11 human cell lines, including ectopic expression 
systems and patient-derived lymphoblastoid (LB) and stem cells, were evaluated for robust and quantifiable HTT CAG 
repeat expansion that could form the basis of an investigation of DNA repair. 
5.6.1 ReNeuron neural stem cells 
ReN VM neural stem cells (NSC) transduced to express HTT exon 1 containing either 71 or 129Q did not show significant 
expansion in routine culture or when exposed to chronic oxidative stress. Though the 129Q repeat in ReN CX cells 
appeared to expand during differentiation and when exposed to chronic oxidative stress, this may have represented 
clonal selection rather than true repeat expansion. Their poor retention of HTT exon 1 expression through differentiation 
precluded evaluation of longitudinal change in repeat length. 
ReNcell lines expressing 129Q HTT exon 1 show a broad, often multimodal distribution of CAG repeat lengths on the 
capillary electrophoresis trace, which limits the ability to detect repeat expansion. ReN VM 129Q cells were single cell 
cloned by serial dilution, producing cell lines with significantly narrower, normally distributed traces. Clones tended to 
arise from cells expressing the longest repeat lengths in the original population, averaging 142Q, suggesting a positive 
selection pressure for larger alleles. Whilst increasing CAG repeat length produces a protein with a more toxic 
polyglutamine tract, it reduces protein expression levels (Persichetti et al., 1996) and there may be a threshold repeat 
length above which expansion is beneficial to cell survival (Dragatsis et al., 2009). Clonal ReN VM cells showed CAG 
expansion, with modal repeat length increasing at a rate of 27.86 ± 4.12 days/Q (p = 0.029). 
5.6.2 Track-HD patient-derived lymphoblastoids 
Cannella et al. (2009) found lymphoblastoid cells (LB) with at least 64Q showed modest expansion in culture averaging 
an increase of 3 repeats over 6 months (53.22 ± 16.29 days/Q), and Jonson et al. (2013a) found that chronic oxidative 
stress can accelerate CAG repeat expansion in transgenic mouse embryonic stem cells. A panel of LB cells from Track-HD 
patients with repeat lengths ranging from 43 to 52 CAG, and including a fast progressing subject heterozygous for the 
p.R507H FAN1 variant associated with early onset (GeM-HD, 2015), showed no significant repeat length change in culture. 
52Q LBs appeared to show modest expansion with oxidative stress over 6 weeks, equivalent to a rate of 113.96 ± 6.32 
days/Q (p = 0.0034). Electrophoresis traces from a 250Q LB line derived from a juvenile-onset HD subject showed 
characteristic exponentially decaying triplet repeat-primed PCR (TP-PCR) stutter peaks. Whilst these can be used to 
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diagnose the presence of an expanded allele, this method does not permit accurate sizing and therefore precludes 
longitudinal repeat expansion analysis. 
5.6.3 73Q patient-derived stem cells 
Three clones of iPSCs generated from fibroblasts of a juvenile-onset HD patient with 73 CAG repeats were evaluated. At 
baseline the repeat length of each clone had changed to between 74 and 76 CAG, and one clone, QS3.1, showed a bimodal 
distribution with a secondary peak at 64Q, all of which suggest repeat instability during reprogramming. However, during 
routine culture and with chronic oxidative stress, there was no significant change in the CAG repeat length of these iPSCs. 
With differentiation into medium spiny neurons (MSN) there was a significant increase in instability index (p = 1.01E-03), 
with a trend towards increasing modal CAG repeat length and proportional expansion, though the rate was slow, 
equivalent to an increase of only 2 CAG repeats in 28 weeks. 
5.6.4 109Q and 125Q patient-derived cell lines 
iPSCs generated from a juvenile-onset HD subject with 109 CAG repeats were initially sized at 121Q, showing expansion 
from the original source, and in long term culture the repeat expanded exponentially. LB cells generated from a juvenile-
onset HD subject with 125Q showed a broad, multimodal distribution of CAG lengths on repeat sizing. A clonal line arose 
within 40 days, once again from the longer repeat lengths of the founder population. The clones averaged 161Q, then 
continued to expand rapidly at a rate of 6.75 ± 0.66 days/Q (p = 3.44E-09). Pluripotent erythroid progenitor cells (EPC) 
generated from the same subject also demonstrated repeat expansion, though at the slower rate of 25.77 ± 3.82 days/Q 
(p = 4.57E-03). 
5.6.5 FAN1 protects against CAG repeat expansion 
Retroviral transduction of iPSCs with shRNA targeting FAN1 lowered its transcript level by 60% and protein by 60-80% 
relative to control cells and those treated with empty vector. A limitation of dividing cell cultures is the opportunity for 
cell selection effects, which can confound the interpretation of results (Gomes-Pereira et al., 2014a), but using 
differentiated cultures circumvents this and more accurately reflects the post-mitotic neuronal tissue in which the HTT 
CAG expands and which prominently degenerates in vivo. The iPSCs were therefore differentiated into MSNs, showing 
significantly increased expression of a panel of MSN and neuronal markers by immunofluorescence, qPCR and western 
blot. FAN1 knockdown was maintained throughout differentiation, and did not affect the expression of HTT, MSN markers 
or mismatch repair genes, including MSH3 and MLH1. 
In 109Q iPSCs, modal CAG expansion rate was equivalent in iPSCs and differentiated MSNs under control conditions, at 
13.95 ± 0.31 days/Q and 15.46 ± 0.70 days/Q respectively. FAN1 knockdown significantly accelerated expansion by the 
same degree in iPSCs and MSNs, increasing the rate to 9.81 ± 0.27 days/Q and 9.24 ± 0.56 days/Q respectively. This 
suggests that FAN1 is protective, stabilising the CAG repeat in both mitotic iPSCs and post-mitotic medium spiny neurons. 
FAN1 was knocked down to the same level in the 73Q iPSC line, but still no expansion was observed during the course of 
the 102 day experiment. Retroviral transduction of 125Q LB cells was unsuccessful, with no cells surviving selection, and 
the 125Q iPSC line is currently undergoing characterisation. Once baseline repeat expansion and medium spiny neuron 
differentiation has been fully characterised, the 125Q iPSCs will provide an independent line in which to assess the effect 
of FAN1 knockdown on repeat stability. 
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Collectively, these results show CAG repeat expansion proceeded at the same rate in iPSCs and non-mitotic differentiated 
MSNs, and was accelerated by knockdown of the nuclease FAN1, favouring DNA repair as the source of repeat instability, 
rather than DNA replication. Comparing the unstable cell lines, there was no significant correlation between mitotic rate 
and CAG repeat expansion, also supporting a replication-independent mechanism. Excluding the ReN VM single cell 
clones, longer repeat lengths were associated with faster expansion rate. 125Q iPSCs expanded at a rate of 26 days/Q, 
for example, whereas the same patients’ LB cells, which have a longer doubling time than other iPSC lines but a repeat 
length of 161Q, expanded at a rate of 6.75 days/Q. These findings tally with results from DM1 cell models, where cell 
proliferation rate was not associated with expansion (Gomes-Pereira et al., 2001) and mitotic inhibition did not affect 
expansion rate (Gomes-Pereira et al., 2014a). It will be interesting to determine whether chemical or genetic arrest of 
the cell cycle in 109Q and 125Q iPSCs has similarly little effect on CAG repeat instability. 
Other DNA repair proteins, particularly those of the mismatch repair pathway such as MutSβ (MSH2-MSH3) (Dragileva et 
al., 2009, Tome et al., 2013a, Lopez Castel et al., 2010, Manley et al., 1999), MutLα (MLH1-PMS2) (Gomes-Pereira, 2004, 
Gomes-Pereira et al., 2014b, Pinto et al., 2013b) and MutLγ (MLH1-MLH3) (Pinto et al., 2013a), have been strongly linked 
to CAG repeat expansion and recently genetic variation in MSH3 has been shown to influence disease progression in HD 
patients (Hensman Moss et al., 2017b). A natural progression of this work is to assess the impact of knockdown of each 
on expansion rate in the cell models developed here, beginning with MSH3. One would predict from results in animal 
studies that inactivation of mismatch repair would reduce expansion (Dragileva et al., 2009, Tome et al., 2013a, Lopez 
Castel et al., 2010, Manley et al., 1999). 
5.7 Summary 
In this chapter several cell models of CAG repeat expansion have been generated, including patient-derived LB and iPSCs, 
and neural stem cells ectopically expressing HTT exon 1. These recapitulate the time and repeat length dependent 
expansion observed in vivo (Kennedy et al., 2003, Shelbourne et al., 2007b, Swami et al., 2009, Mangiarini et al., 1997). 
Expansion rate appears comparable over the course of this experiment in both mitotic cells and differentiated medium 
spiny neurons (MSN), the cells showing prominent somatic expansion in HD patients and which selectively degenerate 
early in the disease course. Knockdown of FAN1 accelerated repeat expansion in both iPSCs and MSNs, suggesting a 
common DNA repair mechanism in both dividing and non-dividing cells, in which FAN1 protectively stabilises the repeat. 
5.8 Publications relating to this chapter 
The work presented in this chapter was published in: 
FAN1 modifies Huntington's disease progression by stabilising the expanded HTT CAG repeat. Goold, R.*, Flower, M.*, 
Moss, D. H., Medway, C., Wood-Kaczmar, A., Andre, R., Farshim, P., Bates, G. P., Holmans, P., Jones, L. and Tabrizi, S. J. 
Hum Mol Genet, 2018 Oct 24. doi: 10.1093/hmg/ddy375. 
* These authors should be regarded as joint first authors. 
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Chapter 6 FAN1 activity at HTT CAG repeat DNA 
6.1 Background 
6.1.1 FAN1 is a genetic modifier of Huntington’s disease 
The HTT CAG repeat translates into an expanded polyglutamine tract at the N-terminus of the protein which confers 
toxicity. Longer CAG repeats cause more severe disease with earlier onset and faster progression (Bates et al., 2015c). 
CAG repeat tracts are inherently unstable and tend to expand both somatically and intergenerationally through the 
germline. Expansion results in a longer polyglutamine tract which increases toxicity. Somatic instability likely plays an 
important role in HD pathogenesis, with CAG repeat length increasing over time in the tissues most affected by HD, 
particularly the striatum, and correlating with disease onset (Swami et al., 2009). Despite the correlation of repeat length 
with disease course, onset can still differ by several decades in patients with the same CAG repeat length, as measured 
in blood (Gusella et al., 2014, Langbehn et al., 2010). CAG repeat length accounts for around 56% of variation in onset 
(Gusella et al., 2014), but up to half of the remaining variability is heritable and therefore due to genetic differences 
elsewhere in the genome (Wexler et al., 2004a). Processes that influence onset or progression may offer tractable 
therapeutic targets. 
Recent genome-wide association studies (GWAS) have identified genetic variation that influences HD age at onset (AAO) 
at a chromosome 15 locus, likely underlain by FAN1, with at least two independent signals; one advancing and the other 
delaying onset (GeM-HD, 2015). The most significant coding SNP, and third most significant of all variants, encodes 
p.R507H, which was associated with onset 6 years earlier than predicted (GeM-HD, 2015). It produces an amino acid 
change in the DNA binding domain that is predicted damaging in silico (Kumar et al., 2009, Adzhubei et al., 2013). Pathway 
analysis showed sets of DNA repair genes were associated with disease onset, even when FAN1 was excluded, suggesting 
FAN1 may be part of a DNA damage response (DDR) network that modulates HD pathogenesis (GeM-HD, 2015). The 
chromosome 15 locus was replicated in a GWAS of HD progression (Hensman Moss et al., 2017b), and FAN1 variants 
from the HD studies were also shown to influence age at onset in the other polyglutamine diseases too (see Chapter 3) 
(Bettencourt et al., 2016). Fan1 was recently found to protect against CGG repeat expansion in a mouse model of Fragile 
X syndrome (Zhao and Usdin, 2018). Similar stabilisation of the HTT CAG repeat would reduce somatic expansion and 
could underlie the association of FAN1 variation with disease course. 
6.1.2 FAN1 function 
Functional redundancy is common in the DDR, with components participating in multiple independent pathways (Peng 
et al., 2014, Zhao et al., 2009). Interaction between mismatch repair (MMR) and interstrand crosslink (ICL) DNA repair 
pathways has been reported (Peng et al., 2014), with FAN1 capable of partially compensating for loss of EXO1 MMR 
activity (Desai and Gerson, 2014). Therefore, FAN1 and MMR components may influence HD disease course through a 
shared mechanism. A stable physical interaction between FAN1 and MutLα components MLH1 and PMS2 further 
supports this hypothesis (MacKay et al., 2010b). Gel filtration has shown a large proportion of FAN1 co-migrates with 
MLH1 in a high molecular weight complex that includes PMS2, but not ID complex proteins FANCD2 and FANCI in the 
absence of crosslinking (MacKay et al., 2010b). This suggests the complex with MutLα plays an important, but as yet 
unidentified role in FAN1 function. There is significant evidence from mouse models that MMR components are required 
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for somatic instability (Pinto et al., 2013a, Tome et al., 2013a), and MMR pathways were found to be associated with age 
at onset in the large GWAS of HD patients (GeM-HD, 2015). MMR components MSH3 and MLH1 were recently identified 
as modifiers of disease progression in HD patients (Hensman Moss et al., 2017b, Lee et al., 2017). As both FAN1 (Zhao 
and Usdin, 2018) and MMR (Zhao et al., 2015a, Schmidt and Pearson, 2016) regulate repeat stability, interactions 
between these components suggests they contribute to a common pathway (Zhao et al., 2015b, Zhao and Usdin, 2018, 
Schmidt and Pearson, 2016). 
FAN1 is a DNA endo/exonuclease that was originally identified as a component of the Fanconi anaemia (FA) interstrand 
crosslink (ICL) repair pathway, though its mutation does not result in Fanconi anaemia (Kratz et al., 2010a, Liu et al., 
2010b, MacKay et al., 2010b, Smogorzewska et al., 2010a). Rather, mutations have been associated with the recessive 
renal syndrome karyomegalic interstitial nephritis (KIN) (Zhou et al., 2012, Lachaud et al., 2016b, Thongthip et al., 2016), 
pancreatic (Smith et al., 2016) and colorectal cancers (Segui et al., 2015b), and autism and schizophrenia (Ionita-Laza et 
al., 2014). Independent of its ICL repair function, FAN1 is also involved in maintaining genomic stability by regulating 
recovery of stalled replication forks (Chaudhury et al., 2014, Lachaud et al., 2016a). These functions require FAN1 
nuclease activity, which resides in the C-terminal VRR Nuc (viral replication and repair nuclease) domain. It is structure 
specific, binding branched DNA forms such as 5’ flaps and then cutting at every third nucleotide. Its crystal structure has 
been determined bound to artificial DNA substrates, but DNA binding and its endogenous substrate specificity have not 
been demonstrated in cell systems. FAN1 knockout sensitises cells to ICLs and delays the resolution of double strand 
breaks (DSB) induced during the repair (MacKay et al., 2010a, Kratz et al., 2010b), though its role in repair process remains 
unknown. 
6.2 Aims 
Genetic variation in FAN1 has been linked to disease course in HD patients, and in a fragile X mouse model Fan1 was 
shown to protect against CGG repeat expansion. This chapter aims to characterise the effect of FAN1 genetic variation 
and expression on DNA repair activity and CAG repeat stability. The synthetic cell systems developed also provide an 
isogenic background on which to investigate the CAG length-dependence of repeat stability. In synthetic and patient-
derived cell lines, experiments look for a novel interaction between FAN1 and HTT CAG repeat DNA. 
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6.3 Methods 
6.3.1 FAN1 knockdown in HEK 293 cells 
Two siRNA oligonucleotides (Dharmacon) targeted the FAN1 sequences given below (Liu et al., 2010b). siRNA was 
transfected into cells at 100 nM using Lipofectamine (Thermo, cat #11668-019) according to manufacturer instructions. 
• siRNA 1: AAACCGTACTTGAGAATGA 
• siRNA 2: GTAAGGCTCTTTCAACGTA 
6.3.2 Transfection of HEK 293 cells with Myc-tagged FAN1 
Full length Myc-tagged FAN1 constructs were designed with six silent mutations at the siRNA target sites that render 
them resistant to knockdown. These were subcloned into the mammalian expression vector pcDNA3.1(+)hygro and used 
to transiently and stably transfect HEK293T cells. 
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Table 6.1. Full length Myc-tagged FAN1 construct. 
Four variants associated with fast progression (blue), siRNA target sequences (red) and silent mutations that confer siRNA resistance 
(grey) are highlighted. 
6.3.3 Complementation of U20S cells with FAN1 constructs 
U20S FAN1-/- cells were complemented with full length WT or variant FAN1, as described in Munoz et al. (2014). Variants 
were first introduced into the pcDNA5/FRT/TO vector (see Appendix) by site directed mutagenesis (SDM). 
6.3.3.1 Site directed mutagenesis 
FAN1 mutants were generated by site directed mutagenesis (SDM) of the pcDNA5-GFP-FAN1/FRT/TO vector using the 
QuickChange XL kit (Agilent, cat #200521) according to manufacturer’s instructions. Complimentary primers containing 
the desired mutation were generated. 
p.R145H 
FAN1_WT and snps: double siRNA resistant r.e., kozac, start, MYC 
 
 
        1 GGTACCGCCA CCATGGAACA GAAACTGATC TCTGAAGAAG ACCTGATGAT GTCAGAAGGG  
       61 AAACCTCCTG ACAAAAAAAG GCCTCGTAGA AGCTTATCAA TCAGCAAGAA TAAGAAAAAA  
      121 GCATCTAATT CTATTATTTC GTGTTTTAAC AATGCACCAC CTGCTAAACT TGCCTGCCCC  
      181 GTTTGCAGTA AAATGGTGCC TAGATATGAC TTAAACCGGC ACCTTGATGA AATGTGTGCT  
      241 AACAATGACT TCGTTCAAGT GGATCCAGGG CAGGTTGGCT TAATAAATTC AAATGTGTCT  
      301 ATGGTAGATT TAACCAGTGT TACCTTAGAA GATGTAACAC CTAAGAAGTC ACCACCACCA  
      361 AAGACAAATT TAACCCCTGG CCAAAGTGAT TCAGCAAAAA GGGAAGTAAA GCAGAAGATC  
      421 AGTCCCTACT TTAAAAGTAA TGATGTGGTG TGCAAAAATC AAGATGAGCT GAGAAATCGT 
                                                      R145H         A     
      481 AGTGTGAAAG TCATTTGTTT GGGAAGCCTA GCATCTAAAT TGTCCAGAAA ATACGTAAAG  
      541 GCTAAAAAAT CAATAGATAA GGATGAAGAA TTTGCCGGTT CTAGTCCACA GAGTTCCAAA  
      601 TCCACAGTTG TTAAGAGCCT GATTGATAAC TCTTCAGAAA TTGAGGACGA GGATCAAATT  
      661 TTGGAGAACA GTTCTCAAAA AGAAAACGTG TTTAAATGTG ATTCTCTAAA GGAAGAGTGC  
      721 ATTCCTGAAC ATATGGTAAG AGGAAGTAAA ATAATGGAAG CCGAAAGCCA AAAGGCTACC 
        E240K   A  
      781 CGGGAATGTG AGAAATCAGC CCTCACCCCT GGATTCTCAG ATAATGCGAT CATGTTATTC  
      841 TCACCAGATT TCACTCTTAG GAATACATTA AAGTCTACTT CAGAAGACAG TCTTGTAAAG  
      901 CAAGAGTGTA TCAAAGAAGT GGTTGAAAAA CGTGAGGCAT GTCATTGTGA AGAAGTAAAA  
      961 ATGACTGTTG CTTCAGAAGC TAAAATACAG CTGTCAGATT CAGAGGCAAA ATCTCATAGT  
     1021 TCTGCAGATG ATGCTTCTGC ATGGAGTAAC ATCCAAGAGG CTCCTCTGCA GGATGACAGT  
     1081 TGCTTAAACA ATGATATCCC TCACAGCATT CCTTTGGAGC AGGGGTCAAG CTGCAATGGT  
     1141 CCTGGTCAAA CAACCGGTCA TCCTTACTAC CTTCGGAGTT TCCTTGTGGT GCTGAAGACA  
     1201 GTGCTCGAAA ACGAAGATGA TATGTTGCTC TTTGATGAGC AGGAGAAGGG AATTGTAACT  
     1261 AAATTTTATC AGTTATCAGC TACTGGTCAG AAGTTATATG TCAGACTATT CCAGCGGAAA  
     1321 TTAAGCTGGA TTAAGATGAC CAAATTAGAG TATGAAGAGA TTGCCTTAGA CTTAACACCT  
     1381 GTGATTGAAG AATTGACGAA TGCAGGCTTT CTACAGACAG AATCTGAGTT GCAAGAACTC  
     1441 TCTGAAGTGC TTGAACTCCT TTCTGCTCCT GAACTAAAAT CCCTAGCCAA GACCTTCCAC  
     1501 TTGGTGAATC CCAATGGACA GAAACAGCAG CTGGTGGACG CCTTTCTCAA ATTGGCCAAA  
     1561 CAGCGTTCAG TCTGCACTTG GGGCAAGAAT AAGCCTGGAA TTGGTGCAGT GATTTTAAAA  
    A  R507H 
     1621 AGAGCCAAAG CCTTGGCTGG ACAGTCAGTA CGAATCTGTA AAGGCCCCAG GGCTGTGTTT  
     1681 TCCCGCATCT TGCTACTGTT TTCGTTGACC GACTCAATGG AAGATGAAGA CGCCGCTTGT  
     1741 GGAGGTCAGG GACAGCTTTC AACAGTCCTG TTGGTCAACC TCGGCCGAAT GGAGTTTCCT  
     1801 AGTTACACCA TCAATCGGAA AACCCACATC TTCCAAGACA GAGATGATCT TATCAGATAT  
     1861 GCAGCAGCCA CGCACATGCT GAGTGACATT TCTTCCGCAA TGGCCAATGG GAACTGGGAA  
     1921 GAAGCTAAGG AGCTCGCTCA GTGTGCAAAA AGGGATTGGA ACAGACTGAA AAACCACCCT  
     1981 TCTCTGAGAT GCCACGAAGA TTTACCACTC TTCCTGCGGT GTTTCACTGT TGGGTGGATT  
     2041 TATACAAGGA TTTTGTCTCG GTTTGTGGAA ATACTGCAGA GACTTCACAT GTATGAGGAA  
     2101 GCCGTCAGAG AACTTGAAAG CCTTTTGTCT CAGAGAATTT ATTGTCCTGA CAGCAGAGGC  
     2161 CGATGGTGGG ATCGACTGGC CCTTAATTTA CACCAGCACT TGAAGCGCCT GGAACCGACT  
     2221 ATCAAGTGCA TCACAGAGGG GCTGGCGGAT CCGGAAGTCA GAACGGGACA CCGCCTTTCA  
     2281 CTGTATCAGC GAGCCGTGCG CCTGCGAGAG TCTCCGAGCT GTAAAAAGTT CAAGCACCTC  
     2341 TTCCAGCAGC TCCCAGAAAT GGCTGTGCAA GATGTGAAAC ACGTGACCAT CACAGGCAGG  
     2401 CTGTGCCCAC AGCGTGGGAT GTGCAAGTCT GTGTTTGTGA TGGAGGCCGG GGAGGCCGCT  
     2461 GACCCCACCA CGGTCCTGTG CTCTGTGGAG GAGCTGGCAC TGGCCCATTA CAGACGCAGC  
     2521 GGTTTTGACC AGGGGATTCA TGGCGAAGGG TCCACCTTCA GCACCCTGTA TGGCCTCCTC  
  Q829H     C 
     2581 CTGTGGGACA TCATCTTCAT GGATGGGATT CCGGATGTCT TCAGAAACGC CTGTCAGGCA  
     2641 TTCCCCCTGG ACTTGTGCAC AGACAGCTTC TTCACAAGCA GACGCCCAGC CCTTGAGGCC  
     2701 AGGCTGCAGC TGATTCATGA TGCCCCCGAG GAGAGCCTGC GGGCCTGGGT GGCAGCCACG  
     2761 TGGCATGAGC AGGAAGGCAG AGTGGCTTCC CTTGTCAGCT GGGATCGCTT CACGTCTCTT  
     2821 CAGCAAGCTC AGGATCTTGT CTCCTGCCTG GGGGGCCCTG TGCTCAGTGG TGTGTGCAGG  
     2881 CACCTGGCTG CTGACTTTCG ACACTGTCGA GGGGGCCTCC CCGACCTGGT GGTGTGGAAC  
     2941 TCCCAGAGCC GTCACTTTAA GCTGGTGGAA GTTAAAGGCC CCAATGATCG TCTTTCACAT  
     3001 AAGCAGATGA TCTGGCTGGC TGAACTGCAG AAGCTGGGGG CTGAAGTAGA AGTCTGCCAT  
     3061 GTGGTTGCAG TTGGAGCTAA GAGCCAAAGC CTTAGCTAAT AACTCGAG  
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• Sense  5'-AAATCAAGATGAGCTGAGAAATCATAGTGTGAAAGTCATTTGTTTGG-3' 
• Antisense 5’-CCAAACAAATGACTTTCACACTATGATTTCTCAGCTCATCTTGATTT-3' 
• Target TGCAAAAATCAAGATGAGCTGAGAAATC[G>A]TAGTGTGAAAGTCATTTGTTTGGGAAGCC 
p.E240K 
• Sense  5'-AAGTAAAATAATGGAAGCCAAAAGCCAAAAGGCTACCCG-3' 
• Antisense  5’-CGGGTAGCCTTTTGGCTTTTGGCTTCCATTATTTTACTT-3’ 
• Target AAGAGGAAGTAAAATAATGGAAGCC[G>A]AAAGCCAAAAGGCTACCCGGGAATGTGAGA 
p.R377W 
• Sense 5’-CGGTCATCCTTACTACCTTTGGAGTTTCCTTGTGG-3’ 
• Antisense 5’-CCACAAGGAAACTCCAAAGGTAGTAAGGATGACCG-3’ 
• Target CCTGGTCAAACAACCGGTCATCCTTACTACCTT[C>T]GGAGTTTCCTTGTGGTGCTGAAAACC 
p.R507H 
• Sense  5’-CAAATTGGCCAAACAGCATTCAGTCTGCACTTGGG-3' 
• Antisense 5'-CCCAAGTGCAGACTGAATGCTGTTTGGCCAATTTG-3' 
• Target CGCCTTTCTCAAATTGGCCAAACAGC[G>A]TTCAGTCTGCACTTGGGGCAAGAATAAGCCTG 
p.D960A (Liu et al., 2010b) 
• Sense 5’-GGGCCTCCCCGCCCTGGTGGTGT-3’ 
• Antisense 5’-ACACCACCAGGGCGGGGAGGCCC-3’ 
• Target TTTCGACACTGTCGAGGGGGCCTCCCCG[A>C]CCTGGTGGTGTGGAACTCCCAGAGCCGTCAC 
p.Q829H 
• Sense 5’-CGCAGCGGTTTTGACCACGGGATTCATGGC-3’ 
• Antisense 5’-gccatgaatcccgtggtcaaaaccgctgcg-3‘ 
• Target TGGCCCATTACAGACGCAGCGGTTTTGACCA[G>C]GGGATTCATGGCGAAGGGTCCACCT 
p.P894S 
• Sense 5’-CTGATTCATGATGCCTCCGAGGAGAGCCTGC-3’ 
• Antisense 5’-GCAGGCTCTCCTCGGAGGCATCATGAATCAG-3’ 
• Target GGCCAGGCTGCAGCTGATTCATGATGCC[C>T]CCGAGGAGAGCCTGCGGGCCTGGGTG 
Reactions were set up containing 5 µL of 10x reaction buffer, 10 ng of the vector, 125 ng of each primer, 1 µL of dNTP 
mix, 3 µL of QuikSolution, made up to 50 µL with water, the 1µL of PfuTurbo DNA polymerase (2.5 U/μl) was added. 
Cycling conditions were 95°C for 1 min, then 18 cycles of 95°C for 50 sec, 60°C for 50 sec, 68°C for 1 min/kb of plasmid 
(8 min 30 sec in this case), and then a final extension phase of 68°C for 7 min. 
Parental methylated DNA was digested by addition of 0.5 µL DpnI (10 U/µL) and incubation at 37°C for 1 h. The product 
was run on an agarose gel to confirm amplicon size. Bacterial transformation of the PCR product repairs nicks in the DNA 
and amplifies the product. 45 µL XL10-Gold ultacompetent cells were aliquoted into a 14 ml tube, 2 µL β-ME was added 
and the cells incubated on ice for 10 min before 2 µL of the DpnI treated DNA was added. The samples were heat pulsed 
at 42°C for 30 sec, then incubated on ice for 2 min. 500 µL of 42°C SOC medium (Thermo, cat #15544034) was added, 
then incubated at 37°C overnight, shaking at 225-250 rpm. The reaction was then transferred to ampicillin agar plates 
and incubated at 37°C for 24 h. 
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Colonies were picked and grown up in Luria-Bertani (LB) broth with ampicillin (Thermo, cat #10855001) overnight at 30°C. 
Colony screening by BamHI digestion identified candidates for sequencing. BamHI cuts the pcDNA5-GFP-FAN1/FRT/TO 
vector at two sites producing two products. 1 µL of template DNA was added to 0.5 µL of BamHI (NEB, cat #R0136S), 2 
µL of CutSmart buffer and 16.5 µL water. It was incubated at 37°C for 1h, then run on an agarose gel. 
 
Figure 6.1. Colony screening by restriction digest. 
pcDNA5-GFP-FAN1/FRT/TO has two BamHI sites and one SmaI site. WT – wild type vector, i – p.R145H, ii – p.E240K, iii – p.R507H, Iv –
p.Q829H. 
The plasmids were isolated using the QIAprep spin miniprep kit (Qiagen, cat #27104) according to the manufacturer’s 
instructions. The mutations were confirmed by Sanger sequencing using the following primers. 
Primer Primer sequence Product (bp) 
R145H/E240K sense CGGACTCGGATCTATGATGTCA - 
R145H antisense CTGAGAATCCAGGGGTGAGG 782 
E240K antisense CTGGTGAGAATAACATGATCGCA 809 
R377W sense CTCTGCAGGATGACAGTTGC - 
R377W antisense TCCCTTCTCCTGCTCATCAA 188 
R507H sense TGCAGGCTTTCTACAGACAGA - 
R507H antisense TGGGGCCTTTACAGATTCGT 269 
D960A sense CACGTCTCTTCAGCAAGCTC - 
D960A antisense GAAAGACGATCATTGGGGCC 186 
Q829H sense TTCCAGCAGCTCCCAGAAAT - 
Q829H antisense TCCTGAGCTTGCTGAAGAGA 494 
P894S sense CTGGACTTGTGCACAGACAG - 
P894S antisense GAGCTTGCTGAAGAGACGTG 186 
Table 6.2. Sequencing primers to confirm SDM. 
6.3.3.2 Transfection of U20S FAN1-/- cells 
First, the Cas9-Flag was flipped out. The reaction mix was made by adding 1 ml Opti-MEM media (Thermo, #31985062) 
and 60 μL GeneJuice (Millipore, #70967), then vortexing and incubating at room temperature for 10 min (Munoz et al., 
2014). 10 μg of pOG44 (MRC PPU, #DU13162) was added, then agitated and incubated for 10 min at room temperature. 
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The reaction mix was added to cells and incubated for 48h. Zeocin selection was applied at 200 μg/ml (InvivoGen, # 
11006-33-0) for 5 days. 
The Cas9-Flag flip out cells were then transfected with the pcDNA5/FRT/TO vector encoding FAN1. The transfection mix 
was made by adding 1ml Opti-MEM and 60 μL GeneJuice, which was then vortexed and incubated at room temperature 
for 10 min. 9 μg of pOG44 and 1 μg of vector were added, then agitated and incubated for 10 min at room temperature. 
The transfection mix was added to the cells which were incubated for 48h. Then selection with puromycin (Thermo, 
#A1113802) at 1.5 μg/ml was applied. All variants were then confirmed by Sanger sequencing. 
6.3.4 Lentiviral transduction of U20S cells with HTT exon 1 
HTT exon 1 constructs with 30, 70, 97 or 118 CAG repeats were stably introduced into U20S cells by lentiviral transduction. 
p’HRsincpptUCOE+htt IRES eGFP human HTT exon 1 lentiviral plasmids were previously described in Trager et al. (2014). 
For transient expression, cells were transfected directly using GeneJuice, according to manufacturer instructions (Merck, 
cat #70967). For stable integration, it was packaged in lentiviral particles. HEK 293T cells were transfected with packaging 
vectors and p’HRsincpptUCOE+htt IRES eGFP using Lipofectamine LTX (Thermo, cat #15338500). After 16 h, media was 
changed, then at 48 h media containing mature lentivirus was harvested. This was filtered and either used directly or 
frozen at -80°C. U20S media was mixed 1:1 with lentiviral media, supplemented with 8 µg/ml polybrene and added to 
U20S cells for 24 h. Media was then changed and tetracycline added. For repeat expansion experiments, this was 
considered the start of the time course. Once at 80-90% confluence, cells were passaged using TrypZean (Lonza, cat 
#BE02034E). At each passage excess cells were washed by centrifuging at 1000 xg for 1 min, resuspending in PBS, then 
centrifuged again at 1000 xg for 1 min. PBS was removed and the semi-dry pellet was stored at -80°C ahead of DNA 
extraction. 
6.3.5 Antibodies 
FAN1 
• S420C sheep polyclonal antibody to human full length FAN1 (MRC PPU)(MacKay et al., 2010b) 
• FS2 sheep polyclonal antibody to human full length FAN1 (MRC PPU, CHDI) 
• Ab68572 mouse polyclonal antibody to human full length FAN1 (Abcam) 
• Ab95171 rabbit polyclonal antibody to a synthetic peptide corresponding to the N-terminal 50 amino acids of 
human FAN1 (Abcam) 
Myc 
• PB11 Myc-Tag mouse monoclonal antibody against a synthetic peptide corresponding to residues 410-419 of 
human c-Myc (Cell signaling, #2276). 
FANCD2 
• Ab2187-50 rabbit polyclonal antibody to N-terminal fusion protein fragment of human FANCD2 
(Abcam)(MacKay et al., 2010b). 
• NB100-182 rabbit polyclonal antibody to N-terminal fusion protein of human FANCD2 (Novus), used for 
immunofluorescence(MacKay et al., 2010b). 
MLH1 
• Anti-MLH1 mouse monoclonal antibody to full length human MLH1 (BD Pharminigen, #554073) 
HTT 
• 4C9 monoclonal antibody raised against the proline-rich region (amino acids 65-84) of human HTT (Landles et 
al., 2010, Weiss et al., 2012). 
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• 2B7 mouse monoclonal antibody raised against the N-terminal portion of human HTT (Weiss et al., 2012). 
GAPDH 
• Rabbit polyclonal antibody raised against amino acids 1-335 representing full length GAPDH of human origin 
(Santa Cruz, #sc-47724) 
GFP 
• Rabbit polyclonal raised against amino acids 1-238 representing full length GFP (Santa Cruz, #sc-8334) 
γ-H2Ax 
• A300-081A rabbit polyclonal antibody 
6.4 Contributions 
U20S FAN1 knockout cells were provided by Prof John Rouse of the MRC Protein Phosphorylation Unit, University of 
Dundee. HEK 293 FAN1 knockdown and transfection with FAN1 constructs, site directed mutagenesis, complementation 
of U20S cells with FAN1 variant forms, cell culture and DNA repair assays were conducted by Michael Flower under the 
supervision of Rob Goold. HTT exon 1 constructs were generated as detailed in Trager et al. (2014), transfected into U20S 
cells by Rob Goold, cultured by Michael Flower and Rob Goold, and CAG repeat sizing and analysis were conducted by 
Michael Flower. Immunoprecipitation was conducted by Rob Goold and qPCR by Michael Flower. The work presented in 
this chapter has been published in Goold et al. (2018). 
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6.5 Results 
6.5.1 FAN1 interstrand crosslink repair function 
6.5.1.1 HEK 293 cells 
6.5.1.1.1 Transfection with Myc-tagged FAN1 
Generating clones stably expressing FAN1 constructs proved difficult, with most colonies surviving selection being false 
positives. Only lines expressing wild type and p.R507H FAN1 were established. Similar results were obtained in HeLa and 
SH-SY5Y cells (results not shown). Parallel experiments using a Myc-PSMB5 construct in pcDNA3.1, the same vector, 
generated plenty of positive clones suggesting that exogenous overexpression of FAN1 may be toxic. 
 
Figure 6.2. Transient transfection of HEK293 cells with full length Myc-tagged FAN1 variants. 
Blots are probed with antibodies as shown. Anti-FAN1 antibody S420C, Con – control, WT – wild type. Molecular weights are given in 
KDa. B actin was used as the loading control 
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Figure 6.3. Stable transfection of HEK293 cells. 
Left – immunoblot of HEK293 single cell clones transfected with FAN1 variants. Few clones were found to express significant levels of 
FAN1. Control transfection with Myc-PSMB5 in the same vector provided good expression. Right – confocal immunofluorescence 
shows HEK 293 cells expressing Myc-tagged constructs. Transient transfection with FAN1 WT (upper left) and stable transfection with 
FAN1 WT (upper right), Myc-PSMB5 vector control (lower left) or FAN1 p.R507H (lower right). Green – PB11 anti-Myc; Blue – DAPI 
nuclear stain. 
6.5.1.1.2 Interstrand crosslink repair 
HEK 293 cells stably transfected with Myc-tagged wild type and p.R507H FAN1 formed normal nuclear DNA repair foci 
that colocalise with FANCD2 after induction of interstrand crosslink (ICL) lesions by MMC. 
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Figure 6.4. Confocal immunofluorescence shows Myc-tagged FAN1 is expressed in the nucleus and forms repair foci that colocalise 
with FANCD2 following MMC. 
Green – PB11 anti-Myc, Red – Anti-FANCD2, Blue – DAPI nuclear stain. 
6.5.1.1.3 FAN1 knockdown 
Two siRNA oligonucleotides were used to knockdown endogenous FAN1 in the HEK293 cells. Transfection with either 
gave around 60% FAN1 knockdown relative to control. FAN1 knockdown increased sensitivity to MMC-induced 
interstrand crosslinks (ICL). Expression of the Myc-tagged constructs was unaffected due to silent mutations at the siRNA 
target sequences.  
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Figure 6.5. siRNA mediated knockdown of endogenous FAN1 in HEK293 cells stably transfected with Myc-tagged p.R507H FAN1. 
HEK293 were exposed to either oligonucleotide 1, 2 or mock (M). Cells were harvested after 24h and lysates prepared. Left – 
representative blot probed with 9B11 anti-Myc and S420C anti-FAN1 antibodies. B actin was used as a loading control. Myc-tagged 
FAN1 constructs are resistant to knockdown (top panel). Middle – quantification of immunoblots. Endogenous FAN1 levels were 
reduced to by 53.8 ± 2.5% (middle panel). Right – siRNA mediated knockdown of FAN1 in HEK293 cells stably transfected with wild 
type FAN1 increases sensitivity to MMC in an MTT survival assay. Cells were exposed to MMC at the indicated concentration and 
survival was assayed at 24h using MTT. Values are the mean of three knockdown experiments, error bars represent SEM. 
6.5.1.2 Lymphoblastoid cells 
6.5.1.2.1 Interstrand crosslink repair 
Patient-derived lymphoblasts from fast progressing Track-HD subjects with coding variants in FAN1, along with their 
matched HD positive controls, were exposed to MMC to assess resistance to ICLs. Two lines, p.R507H and WT1 (control 
for p.R145H), showed increased resistance. However, these two lines also expressed FAN1 at a higher level, which may 
account for their apparent MMC resistance.  
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Figure 6.6. Patient-derived LB cell MMC sensitivity. 
Left – LB resistance to MMC as determined by MTT assay at 7-10 days. p.R507H and the WT1 lines demonstrated increased resistance 
(n=3, ± SD). Right – Immunoblot to quantify FAN1 expression level in HD LB cells. Lysates were prepared from p.R145H, p.E240K and 
p.R507H subjects and their matched controls. The lower panel shows the blot probed with the S420C anti-FAN1 antibody. GAPDH was 
used as a loading control. In the lower panel the blot was quantified by densitometry in ImageJ and represented graphically as a ratio 
of FAN1/GAPDH. 
6.5.1.2.2 Effect of rs3512 on FAN1 expression 
To assess whether the rs3512 FAN1 variant, the most significant SNP from Bettencourt et al. (2016) which was also 
associated with delayed onset in the GeM GWAS (B = 1.31 years/minor allele, p = 5.28E-13), affects FAN1 expression 
level, western blots were prepared from patient-derived HD lymphoblasts of Track-HD subjects. LB cell lines were 
cultured from three homozygous variant (GG), two heterozygotes and six homozygous wild type (CC) Track-HD patients. 
Note, the genotyping assay for this variant was designed in reverse, meaning the wild type allele is C and the variant is 
G. In this small cohort, rs3512 genotype did not significantly affect FAN1 expression level. 
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Figure 6.7. Immunoblot for FAN1 expression in HD lymphoblasts from subjects with the given rs3512 genotype. 
As the reverse strand was genotyped, C is ancestral and G is variant. Samples were loaded with progression rank decreasing from left 
to right in each genotype (faster to the right). The upper panel shows the blot probed with S420C FAN1 antibody. 
6.5.1.3 U20S cells 
6.5.1.3.1 Site directed mutagenesis to introduce FAN1 variants 
FAN1 variants were introduced into the pcDNA5-GFP-FAN1/FRT/TO vector by site directed mutagenesis (SDM), then 
these were used to complement U20S Flp-In FAN1-/- cells, selected using puromycin, and Sanger sequencing confirmed 
successful transfection. These U20S cells stably expressing the variants permit the assay of GFP-tagged FAN1 function on 
an isogenic background. p.R507H was the FAN1 coding variant most significantly associated with HD motor onset in the 
GeM-HD GWAS (GeM-HD, 2015), p.R145H, p.E240K and p.829H are FAN1 coding variants found in fast progressing Track-
HD patients, and p.D960A is a mutation in the active site that completely ablates nuclease activity (Kratz et al., 2010a, Liu 
et al., 2010b). 
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Figure 6.8. Sanger sequencing confirming SDM of the pcDNA5/FRT/TO FAN1 vector. 
From top to bottom, p.R145H, p.E240K, p.R507H, p.Q829H and p.D960A are presented along with the wild type (WT) vector 
sequencing at each locus. Variants are marked in red boxes. 
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6.5.1.3.2 Titration of FAN1 expression 
U20S cells express GFP-FAN1 at approximately physiological levels in the absence of induction, whereas tetracycline at 
the 1 µg/ml suggested by Munoz et al. (2014), induced massive overexpression. Expression at such a high level appears 
toxic to cells, sensitising them to MMC-induced ICLs to the same degree as FAN1 knockout. 
 
Figure 6.9. Tetracycline induction reverses the protective effect of GFP-FAN1. 
Left – confocal immunofluorescence of U20S cells transfected with wild type GFP-FAN1. Anti-GFP antibody (white), nuclei are stained 
with DAPI (blue). Cells have been treated with MMC (top panel), tetracycline (middle panel) or both (bottom panel). Top right – 
viability of U20S cells expressing wild type (WT) GFP-FAN1 following exposure to MMC at the indicated doses. FAN1 knockout (blue) 
sensitises cells to MMC, an effect reversed by complementation with wild type GFP-FAN1 (red). Tetracycline at 1 µg/ml induces 
overexpression of wild type GFP-FAN1 (grey), which reduced viability to knockout levels. Bottom right – immunoblot of tetracycline-
induced GFP-FAN1 expression. Control U20S cells (FAN1+/+) and FAN1 knockout (-/-) are shown. GFP-WT is expressed at 
approximately physiological levels in the absence of tetracycline, but tetracycline induces overexpression of both p.R507H and wild 
type (WT) GFP-FAN1. Blots are probed with S420C anti-FAN1 antibody and anti-GFP antibody. Heat shock protein 90 (HSP90) is used 
as a loading control. 
A dose titration assessed toxicity at lower doses, but even tetracycline concentrations as low as 0.06 μg/ml had a 
detrimental effect on viability following MMC exposure. 
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Figure 6.10. Tetracycline dose titration in p.R507H FAN1 U20S cells exposed to MMC. 
Top left –immunoblot probed with the indicated antibodies, shows GFP-FAN1 expression level increases with tetracycline dose. Top 
right – viability of U20S cells induced with the indicated dose of tetracycline and exposed to the increasing concentrations of MMC. 
Bottom – viability of U20S cells exposed to 30 ng/ml MMC and induced with increasing concentrations of tetracycline. 
6.5.1.3.3 Nuclear interstrand crosslink repair foci 
Cisplatin induces ICLs, repair of which involves the induction of double strand breaks that can be visualised as nuclear 
foci of phosphorylated histone H2AX (γ-H2AX) (Niedernhofer et al., 2004, Rothfuss and Grompe, 2004). Foci normally 
peak at 24 h then clear by 48 h (MacKay et al., 2010b). In U20S cells, FAN1 knockout did not affect the appearance of foci 
but did prevent their clearance at 72h. Reconstituting cells with either wild type or p.R507H GFP-FAN1 restored γ-H2AX 
clearance. 
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Figure 6.11. γ-H2AX assay following cisplatin exposure in U20S cells. 
Left – confocal images of FAN1 knockout (-/-) U20S cells and those complemented with wild type (WT) or R507H GFP-FAN1. 
Immunofluorescence for γ-H2AX foci (red) and counterstaining with DAPI nuclear stain (blue). Scale bar 50 μM. Right – quantification 
of nuclei showing >10 γ-H2AX foci (results from two separate experiments). 
6.5.1.3.4 Interstrand crosslink sensitivity 
FAN1 knockout sensitises U20S cells to MMC-induced ICLs, and expression of wild type, p.R145H, p.E240K, p.R507H or 
p.Q829H GFP-FAN1 constructs restored resistance. As expected, the nuclease inactivated p.D960A mutation (Kratz et al., 
2010a, Liu et al., 2010b), either on a WT or p.R507H FAN1 background, compromised ICL repair function. 
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Figure 6.12. FAN1 knockout sensitises U20S cells to MMC-induced interstrand crosslinks (ICL) and expression of wild type or variant 
GFP-FAN1 restores resistance. 
Top left – viability assay in U20S cells exposed to MMC for 20 h. Cells express endogenous FAN1 (+/+), wild type or variant FAN1, or 
have FAN1 knocked out (-/-). Viability was determined by MTT assay after 10 days. Bottom left – immunoblot of U20S knockout (-/-) 
cells and those complemented with FAN1 constructs in the absence of tetracycline induction. Blots are probed with the S420C FAN1 
antibody and GAPDH is used as a loading control. Quantification is corrected for GAPDH loading control and given relative to WT. Top 
right – viability assay in U20S cells with the variants indicated, exposed to MMC for 20 h. The p.D960A nuclease mutant sensitises 
cells to MMC. Bottom right – immunoblot showing FAN1 levels in U20S cells reconstituted with catalytically active or nuclease dead 
WT or p.R507H variant FAN1 forms. The FAN1-/- line is shown for comparison. Quantification is corrected for GAPDH loading control 
and given relative to WT. Note the p.R507H forms are expressed at a higher level. 
6.5.1.3.5 Genotoxins 
Similar results were found for cisplatin, which also induces ICLs. However, FAN1 knockout and p.R507H expression did 
not influence sensitivity to 6-TG, which invokes the MMR pathway, or hydrogen peroxide, which causes single and double 
strand breaks. 
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Figure 6.13. Genotoxin assays in U20S cells. 
Cell viability determined by MTT assay. Top left – U20S cells exposed to MMC at the indicated concentration for 24 h, cell viability 
assay 10 d later. Bottom left – U20S cells exposed to cisplatin at the indicated concentration for 24 h, cell viability assay 10 d later. 
Top right – U20S cells exposed to 6-TG at the indicated concentration for 24 h, cell viability assay 10 d later. Bottom right – U20S cells 
exposed to H2O2 at the indicated concentration for 30 min, cell viability assay 10 d later. 
6.5.2 CAG repeat instability 
6.5.2.1 FAN1 expression level 
The 118Q repeat in U20S FAN1-/- cells expanded exponentially in culture (r2 = 0.9264, p = 8.892e-27).  
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ln(CAG) = (7.818e-04 * d) + 4.766 
Figure 6.14. Model of U20S FAN1-/- 118Q exponential expansion. 
r2 = 0.9264, p = 8.892e-27. The exponential model is represented by a solid line, and the 95% confidence interval by dotted lines. 
A linear model fit almost as well (r2 = 0.9248, p = 1.435E-26), giving an expansion rate of 10.69 ± 0.44 days/Q. The CAG 
repeat was stabilised in cells expressing endogenous FAN1 (FAN1+/+) or complemented with wild type GFP-FAN1, with 
the expansion rate slowed to 17.70 ± 1.36 days/Q (p = 2.69E-04) and 14.83 ± 1.10 days/Q respectively (p = 2.57E-04). 
Overexpression of FAN1 by induction with 0.1 µg/ml tetracycline further slowed expansion to 21.28 ± 1.84 days/Q (p = 
9.86E-05). These results show increasing FAN1 expression slows CAG expansion rate. 
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Figure 6.15. FAN1 protects against U20S 118Q CAG repeat expansion in a dose-dependent manner. 
Top left – modal CAG repeat length in FAN1-/- and FAN1+/+ cells stably transduced with 118Q HTT exon 1. Data from 6x FAN1-/- and 5x 
FAN1+/+ cultures are combined. Top right – modal CAG repeat length in FAN1-/- or FAN1GFP-WT cells (± 0.1 µg/ml tetracycline induction) 
stably transduced with 118Q HTT exon 1. Data from 5x FAN1-/- and 5x FAN1WT and 11x FAN1WT +Tet cultures are combined. Error bars 
represent SEM. Bottom left – representative repeat sizing in U20S FAN1-/- cells stably expressing 118Q HTT exon 1, samples are taken 
on the days indicated following transduction. Bottom right – Cell lysates for SDS-PAGE from U20S FAN1+/+, FAN1-/-, and FAN1GFP-WT, 
with or without induction of expression by 0.1 µg/ml tetracycline (Tet). Antibodies to GFP, FAN1 (S420C) and actin are shown. In the 
absence of Tet, low levels of GFP-FAN1 are expressed, close to endogenous expression levels seen in FAN1+/+ cells. Tetracycline 
induces FAN1 overexpression. 
6.5.2.2 CAG length dependence 
30 and 70Q HTT exon 1 fragments were stable in U20S FAN1-/- cells throughout 8 weeks in culture. The modal CAG length 
of the 97Q construct expanded exponentially (r2 = 0.8795, p = 1.690E-08), though again fit almost as well to a linear model 
(r2 = 0.8793, p = 1.711E-08) with an expansion rate of 18.41 ± 1.55 days/Q. This was significantly slower than the 118Q 
construct (p = 1.38E-05). These results show CAG expansion is detectable over a relatively short time in culture, provided 
long repeat lengths are used, and suggests expansion rate is CAG length dependent. 
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ln(CAG) = (5.516e-04 * d) + 4.576 
Figure 6.16. Model of U20S FAN1-/- 97Q exponential expansion. 
r2 = 0.8795, p = 1.690e-08. The exponential model is represented by a solid line, and the 95% confidence interval by dotted lines. 
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Figure 6.17. CAG repeat expansion in U20S FAN1-/- cells is length dependent. 
Panels show modal CAG repeat length in FAN1-/- cells stably transduced with HTT exon 1 containing the indicated CAG repeat length. 
30 and 70Q are stable over the 40-day culture. 118Q expands, as shown above. 97Q also expands, though at a slower rate than 
118Q. Data from 3 cultures for each repeat length are combined, error bars represent SEM. 
 
Figure 6.18. Change in modal CAG repeat length of U20S FAN1-/- cells expressing HTT exon 1 with 29-118Q. 
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The 118Q exponential model (p = 8.892E-27) predicts the 30Q construct would expand at 41.38 days/Q and the 70Q 
construct at 18.37 days/Q in the absence of FAN1. The 97Q exponential model (p = 1.690E-08) predicts they would expand 
at 58.64 and 26.04 days/Q respectively. Both 30Q and 70Q constructs were cultured for 8 weeks without identifiable CAG 
repeat length change, suggesting further data over a longer time period is required to improve the accuracy of 
exponential models. 
 
Figure 6.19. Overlay of U20S FAN1-/- exponential expansion. 
The indicated exponential model was used to offset culture start date for each cell line. Exponential model predictions are indicated 
by a solid line and the 95% confidence interval by the shaded area. Orange – 30Q, green – 70Q, blue – 97Q, purple – 118Q. 
Top left – exponential model of U20S FAN1-/- 97Q; ln(CAG) = (5.516e-04 * d) + 4.576; r2 = 0.8795, p = 1.690e-08. Top right – 
exponential model of U20S FAN1-/- 118Q; ln(CAG) = (7.818e-04 * d) + 4.766; r2 = 0.9264, p = 8.892e-27. Bottom –118Q exponential 
model with the 97Q model overlain. 
The p.R507H DNA binding domain variant did not significantly alter CAG expansion rate relative to FAN1WT (p = 0.0878). 
The p.D960A nuclease dead mutant, either alone or with p.R507H, did not affect the rate of expansion relative to FAN1WT 
or FAN1R507H (p = 0.331 and p = 0.882 respectively), suggesting the nuclease domain is not required for FAN1 to stabilise 
the HTT CAG repeat. 
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Figure 6.20. FAN1 nuclease and p.R507H variants do not modify CAG repeat expansion rate. 
Modal CAG repeat size in FAN1-/- cells reconstituted with the FAN1 forms as indicated and stably transduced with 118Q HTT exon 1. 
Linear trend lines have been fitted. Data combined from 6x FAN1-/-, 12x WT, 3x D960A (nuclease inactivated), 7x R507H and 4x 
R507H+D960A cultures, error bars represent SEM. Expression levels of each variant line are shown above, note p.R507H forms are 
expressed at a higher level. 
6.5.3 FAN1-DNA interaction 
To investigate for an interaction between FAN1 and HTT DNA, chromatin fractions were prepared from HD cell lines. 
Endogenous FAN1 was immunoprecipitated using the S420C antibody and the presence of HTT CAG DNA was assayed by 
qPCR. 
6.5.3.1 U20S cells 
U20S FAN1-/- and cells expressing wild type FAN1 were transiently transfected with 70Q HTT exon 1, aiming to introduce 
high copy numbers of plasmid DNA. FAN1 expression was induced by tetracycline in order to optimise conditions for 
detecting an interaction. PCR detected low, but reproducible levels of CAG repeat DNA in ChIP fractions and amplified 
both the normal and expanded HTT CAG alleles. qPCR primers spanning the HTT CAG repeat demonstrated an enrichment 
in U20S FAN1WT ChIP fractions relative to the control immunoprecipitation (IP) without antibody, and as expected there 
was no significant enrichment in FAN1-/- cells. This suggests a novel interaction between FAN1 and CAG repeat DNA, and 
demonstrates the specificity of the ChIP pull down. However, primers targeting HTT DNA near (HTT con 1, intron 3-4) and 
far from the CAG repeat (HTT con 2, exon 49) also showed enrichment in ChIP fractions, suggesting FAN1 binds DNA but 
does not specifically target the CAG repeat. 
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Figure 6.21. FAN1 binds HTT CAG repeat DNA. 
U20S FAN1-/- cells and those reconstituted with WT FAN1 were transiently transfected with 70Q HTT exon 1. ChIP with the sheep 
S420C antibody was used to isolate FAN1. Left – agarose gel of input and ChIP fractions amplified with HD3F/HD5 primers which span 
the CAG repeat. Negative (water) and positive (70Q HTT exon 1 plasmid) are shown. The smaller band represents the endogenous 
HTT allele and the larger is 70Q exon 1. Right – SYBR green qPCR of ChIP fractions using the primers indicated. Enrichment is given 
relative to the control IP without antibody (dotted line). GBF/5310R and HD3F/HDE span the CAG, HTT con 1 primers are 25 kb 3’ of 
the CAG repeat, between exons 3 and 4, and HTT con 2 primers are 138 kb 3 of the repeat’, at exon 49. All samples run in triplicate, 
error bars represent SEM of independent runs. 
6.5.3.2 Patient-derived induced pluripotent stem cells (iPSC) 
ChIP fractions were prepared from 109Q and 125Q iPSCs, which are homozygous for wild type FAN1 and contain unstable 
HTT CAG repeats. Once again PCR amplified both the normal and pathogenic CAG repeat. qPCR showed significant 
enrichment of HTT CAG repeat DNA (p 109Q = 0.0208, p 125Q = 1.672E-03), but also enriched for distal regions of HTT (p 
109Q = 3.068E-03) and the CAG repeat DNA of ATXN3 and TBP.  
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Figure 6.22. FAN1 interacts with endogenous HTT DNA of 109Q iPSCs. 
Left – 109Q iPSC input, FAN1 ChIP and no antibody control fractions were PCR amplified with a primer pair spanning the CAG repeat 
(HD3F/HD5) and a pair at the 3’ end of the HTT gene (HTT con 2), then run on an agarose gel. Input (5%) and ChIP fractions are 
shown. The two bands seen in CAG PCR are from the normal and pathogenic alleles. Middle – SYBR green qPCR with primer pairs 
spanning the CAG repeat (GBF/GBR and GBF/5310R) and a pair at the 3’ end of the HTT gene (HTT con 2). Enrichment is given relative 
to the control IP without antibody (dotted line). Right – qPCR with primer pairs spanning the CAG repeats in ATXN3 and TBP. All 
samples run in triplicate, two independent experiments for HTT qPCR, error bars represent SEM. 
 
Figure 6.23. FAN1 interacts with endogenous HTT DNA of 125Q iPSCs. 
SYBR green qPCR with primer pairs spanning the CAG repeat (GBF/GBR and GBF/5310R), and pairs distal to the repeat; HTT con 1 
primers bind between exons 3 and 4, and HTT con 2 primers bind at exon 49. Enrichment is given relative to the control IP without 
antibody (dotted line). All samples run in triplicate, 2-4 independent experiments for CAG repeat qPCR, error bars represent SEM. 
6.5.3.3 Patient-derived lymphoblastoid cells 
FAN1 ChIP fractions were prepared from two lymphoblastoid (LB) cell lines either homozygous for wild type FAN1 or 
heterozygous for the p.R507H variant. PCR with primers spanning the CAG repeat showed amplification of both the short 
and long alleles. qPCR with primers spanning the HTT CAG repeat showed enrichment in ChIP fractions from both wild 
type and p.R507H lines (p WT = 0.0158, p R507H = 0.0316). There was also significant enrichment for two HTT primer 
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pairs distal to the CAG repeat (p HTT con 1 = 0.0155, p HTT con 2 = 0.0129) and for primers targeting trinucleotide repeat 
and control regions of ATXN3, DMPK, FXN and TBP genes. There was no significant difference in enrichment at any of the 
targets between wild type and p.R507H lines. 
 
Figure 6.24. FAN1 interacts with endogenous HTT DNA of HD lymphoblasts (LB). 
Left – input, FAN1 ChIP and no antibody control fractions from HD lymphoblasts derived from patients homozygous for wild type 
FAN1 or heterozygous for the p.R507H variant were PCR amplified by primers spanning the CAG repeat (HD3F/HD5), then run on an 
agarose gel. Input (5%) and ChIP fractions are shown. The two bands seen in CAG PCR are from the normal and pathogenic alleles. 
Middle – SYBR green qPCR with primers spanning the CAG repeat (GBF/5310R) and pairs distal to the repeat; HTT con 1 primers are 
between exons 3 and 4, and HTT con 2 primers are at exon 49. Enrichment is given relative to the control IP without antibody (dotted 
line). Right – qPCR with primer pairs spanning trinucleotide repeat and control regions of ATXN3, DMPK, FXN and TBP. Samples in 
triplicate, each run 2-7 times independently, error bars represent SEM. 
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6.6 Discussion 
6.6.1 Interstrand crosslink repair 
As expected, siRNA-mediated FAN1 knockdown in HEK 293 cells increased sensitivity to MMC-induced interstrand 
crosslinks (ICL). Stably expressed Myc-tagged full length wild type or p.R507H FAN1 formed nuclear DNA repair foci after 
ICL induction, demonstrating that the artificial constructs are functional in ICL repair, but that the DNA binding domain 
variant, which is associated with early HD onset, does not affect FAN1 localisation to ICL lesions. A HD patient-derived 
lymphoblastoid line heterozygous for the p.R507H variant appeared resistant to MMC-induced ICLs, relative to most 
control lines, though this may have been due to its increased FAN1 expression level. FAN1 knockout in U20S cells 
sensitised them to ICLs and delayed resolution of double strand breaks (DSB) formed during ICL repair, but did not affect 
mismatch repair function. Complementation with p.R145H, p.E240K, p.R507H or p.Q829H FAN1 restored resistance to 
wild type levels, again demonstrating full functionality of the variant lines in ICL repair. 
6.6.2 Repeat instability 
6.6.2.1 FAN1 stabilises the HTT CAG repeat 
U20S cells stably transduced with 118Q HTT exon 1 show repeat expansion that is significantly accelerated by FAN1 
knockout (FAN1-/-, p = 2.57E-04). Increasing FAN1 expression incrementally slowed CAG expansion rate, suggesting its 
stabilising effect is dose-dependent. This is consistent with a recent study that showed Fan1 knockout accelerates CGG 
repeat expansion in a mouse model of fragile X syndrome. The p.R507H variant did not significantly alter expansion rate 
relative to wild type FAN1 in U20S cells. 
FAN1 is likely to play a key role in a network of DNA damage response (DDR) proteins, as suggested by GWAS pathway 
analyses finding significant association of DNA repair gene sets with onset (GeM-HD, 2015). These include mismatch 
repair components MSH3 and MLH1, inactivation of which in HD mouse models abrogates somatic expansion and 
ameliorates the HD phenotype (Pinto et al., 2013a, Tome et al., 2013a). The in vitro cell models presented here suggest 
FAN1 also contributes to this mechanism, protecting against CAG expansion. 
6.6.2.2 CAG length dependence 
A non-pathogenic 30Q and a pathogenic 70Q CAG repeat were stable in the U20S FAN1-/- system, which is consistent with 
observations in iPSCs derived from an HD patient with 73Q, which were stable in long term culture (chapter 5). A 97Q 
repeat expanded exponentially in culture, though at a slower rate than the 118Q repeat (p = 1.38E-05). This suggests 
that, in this system and over the short 6 week culture, CAG repeat expansion is repeat length-dependent, with a trigger 
between 70 and 97 CAG repeats. 
Repeat instability likely involves the formation of unusual DNA structures such as hairpin loops (Gacy et al., 1995), with 
high complementarity of the repeating sequence leading to slippage or mis-hybridisation (Pearson et al., 2005b). These 
structures are recognised by DNA repair proteins, particularly the MMR pathway, which may trigger attempts at repair 
that lead to the incorporation of additional CAG units. Longer CAG repeats are more unstable and prone to increased 
rates of expansion (Pearson et al., 2005b), features which are recapitulated in the U20S CAG repeat series and 109Q iPSCs 
(Chapter 5). Cells with more typical pathogenic CAG repeat lengths, up to 73Q, remained stable in culture, which may 
reflect the rarity of expansion events in shorter repeats, and it may be that expansion could be detected in longer term 
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culture or in cell types other than U20S. HD typically manifests in midlife, which may reflect slow expansion of the CAG 
repeat over decades until a toxic threshold is reached, after which time the polyglutamine tract confers toxicity in 
vulnerable cells, such as striatal medium spiny neurons, resulting in clinical onset (Kaplan et al., 2007, Kennedy et al., 
2003, Swami et al., 2009). 
6.6.2.3 Nuclease activity 
The p.D960A active site mutation completely inactivates FAN1 nuclease function, as demonstrated by increased 
sensitivity of U20S FAN1D960A cells to MMC-induced ICLs to the same degree as FAN1 knockout. However, this mutation 
did not affect CAG expansion rate in U20S cells expressing 118Q HTT exon 1, relative to wild type FAN1. This suggests the 
nuclease activity is not required for FAN1 to stabilise the HTT CAG repeat. All FAN1 functions identified to date, including 
ICL repair (MacKay et al., 2010b, Kratz et al., 2010a, Liu et al., 2010b, Smogorzewska et al., 2010a, Thongthip et al., 2016) 
and replication fork recovery (Lachaud et al., 2016a, Chaudhury et al., 2014, Porro et al., 2017), depend on its nuclease 
activity, suggesting a novel mechanism underlies CAG repeat stabilisation. 
6.6.3 FAN1-DNA interaction 
Chromatin immunoprecipitation (ChIP) suggests FAN1 binds at or near the HTT CAG repeat, potentially recognising 
unusual DNA structures (McMurray, 2010). However, FAN1 also bound other DNA regions, suggesting it does not 
preferentially interact with expanded CAG repeats. These results were consistent across synthetic and patient-derived 
cell lines, showing FAN1 also interacts with the endogenous HTT CAG repeat. There was no significant difference in 
enrichment between wild type and p.R507H FAN1, suggesting this variant does not alter its binding to these DNA 
substrates. 
6.6.4 FAN1 function 
The mechanism by which FAN1 protects against CAG repeat expansion is unknown, but three models can be postulated. 
Firstly, FAN1 may bind CAG DNA, blocking access of other DNA repair proteins such as MSH3 and preventing error-prone 
repair. Secondly, as MutLα (MLH1/PMS2) independently binds FAN1 and MutSβ (MSH2/MSH3) (MacKay et al., 2010b), 
FAN1 could sequester MLH1 that would otherwise act with MSH3 to promote repeat expansion. Finally, FAN1 could act 
on the CAG repeat, promoting accurate repair either directly or as a scaffold for a repair complex. Supporting this, the 
FAN1 interactome includes several modifiers of CAG repeat stability, including MutL components (MLH1, MLH3, and 
PMS2) and PCNA (MacKay et al., 2010b, Porro et al., 2017). FAN1 is recruited to stalled replication forks by ubiquitinated 
PCNA (Porro et al., 2017), but no function has yet been identified for the interaction with MLH1, despite evidence 
indicating this complex is stable and comprises a substantial proportion of the cellular FAN1 and MLH1 under steady state 
conditions (MacKay et al., 2010b). FAN1 has the potential DNA binding and nuclease activity to act directly at CAG repeat 
DNA (Kratz et al., 2010a, Liu et al., 2010b, MacKay et al., 2010b, Smogorzewska et al., 2010a), but results presented in 
this chapter suggest FAN1 activity to stabilise CAG repeats is independent of its nuclease activity. 
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Figure 6.25. Potential mechanisms by which FAN1 may protect against CAG repeat expansion. 
A) MutSβ (MSH2/MSH3, orange) and MutLα (MLH1/PMS2, blue) misidentify abnormal secondary structures formed by CAG repeat 
DNA (red), such as hairpins, invoking mismatch repair, during which out of register alignment introduces repeat expansion. B) FAN1 
(green) may bind CAG repeat DNA, prohibiting access by MutSβ. C) FAN1 may sequester MutLα (MLH1/PMS2) away from MutSβ, 
preventing MMR. D) FAN1 may act directly at the CAG repeat, promoting accurate repair. 
6.7 Summary 
FAN1 is a nuclease involved in DNA interstrand crosslink (ICL) repair that has recently been shown to stabilise CGG repeat 
DNA in a mouse model of Fragile X syndrome. The results presented here validate FAN1 involvement in ICL repair and 
show that FAN1 expression reduces HTT CAG repeat expansion. Expansion is CAG repeat length and FAN1 concentration 
dependent, but does not require its nuclease activity. FAN1 binds HTT CAG repeat DNA, but is not specifically targeted to 
it. These data provide new mechanistic insights into how FAN1 acts to alter disease progression. The known FAN1 
interactome suggests it acts in concert with other DNA damage response (DDR) proteins, potentially sequestering MLH1 
that would otherwise act with MSH3 to promote repeat expansion. 
Preliminary results in cells expressing p.R507H (rs150393409), the most significant FAN1 coding SNP in the GeM GWAS 
of HD onset (GeM-HD, 2015), do not find any functional changes that could explain its effect on disease course. ICL repair 
was unaffected by its heterozygous expression in patient-derived lymphoblastoid (LB) cells or by its expression in U20S 
FAN-/- cells. CAG expansion rate in U20Sp.R507H did not differ significantly from FAN1WT cells and ChIP-qPCR showed no 
significant alteration in its interaction with HTT CAG repeat DNA. However, the semi-quantitative nature of these assays 
and the relatively high levels of FAN1 expressed in U20S cells may obscure subtle differences in activity conferred by 
p.R507H, especially given the strong effect of expression level on expansion rate. 
Further work will investigate the molecular mechanism by which FAN1 modifies CAG repeat stability, and whether this is 
a potential therapeutic target in HD. It will study the effect of FAN1 variation on DNA binding and repeat expansion in 
U20S cells, look for differential binding of the short and long HTT CAG allele by tapestation or bioanalyzer analysis of 
ChIP-qPCR products, probe the protein interactions of FAN1 by immunoprecipitation, initially focusing on MMR 
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components, and will study these functions in more physiological cell models including differentiated medium spiny 
neurons derived from FAN1 variant-carrying HD patients. 
6.8 Publications relating to this chapter 
The work presented in this chapter was published in: 
FAN1 modifies Huntington's disease progression by stabilising the expanded HTT CAG repeat. Goold, R.*, Flower, M.*, 
Moss, D. H., Medway, C., Wood-Kaczmar, A., Andre, R., Farshim, P., Bates, G. P., Holmans, P., Jones, L. and Tabrizi, S. J. 
Hum Mol Genet, 2018 Oct 24. doi: 10.1093/hmg/ddy375. 
* These authors should be regarded as joint first authors. 
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Chapter 7 Fan1 knockdown in R6/2 mice 
7.1 Background 
7.1.1 Genetic modifiers 
Motor onset in Huntington’s disease (HD) is inversely correlated with CAG repeat length, but still varies by several 
decades in patients with the same CAG repeat length, as measured in blood (Gusella et al., 2014, Keum et al., 2016). In 
human HD, the length of the HTT CAG repeat explains around 56% of variation in onset (Gusella et al., 2014, Langbehn 
et al., 2004), but about 40% of the remaining variability is heritable and due to genetic differences elsewhere in the 
genome (Wexler et al., 2004a). Investigating these genetic modifiers, the GeM genome-wide association study (GWAS) 
of HD age at onset (AAO) identified a locus likely underlain by the DNA interstrand cross link repair nuclease FAN1, a 
protein known to interact with MMR components such as MLH1 (GeM-HD, 2015). Two independent signals underlie this 
locus; the minor allele at rs146353869 was associated with 6.1 year earlier onset (p = 4.3E-20) and at rs2140734 with 1.4 
year later onset (p = 7.1E-14). This suggests polymorphisms at this locus can be damaging or protective in HD. The third 
most significant SNP at the chromosome 15 locus encodes an amino acid change within FAN1 (p.R507H, p = 9.34E-18) 
that is predicted in silico to be functionally deleterious. Pathway analysis showed DNA repair gene sets were associated 
with disease onset. Therefore, FAN1 may be part of a of DNA damage response (DDR) network that modulates HD 
pathogenesis (GeM-HD, 2015). 
Bettencourt et al. (2016) found that some of the most significant DNA repair variants from this GeM GWAS, including 
those in FAN1, RRM2B and MMR component PMS2, also influence onset in other CAG repeat expansion diseases, 
suggesting DNA repair is a common mechanism driving severity of numerous diseases (Chapter 3). A recent GWAS found 
that genetic variation in MSH3 was associated with slow HD progression (Chapter 8) (Hensman Moss et al., 2017b). The 
second most significant association region once again tags the chromosome 15 locus likely underlain by FAN1 (p=2·35E-
06). 
7.1.2 Repeat instability 
In HD, the pathogenic CAG repeat is unstable, tending to expand over time, particularly in the striatum, the tissue most 
prominently affected neuropathologically, correlates with onset (Kennedy et al., 2003, Shelbourne et al., 2007b, Swami 
et al., 2009) and likely contributes to disease progression. In HD transgenic mice, the CAG repeat expands most markedly 
in striatal neurons, correlating with phenotypic severity. It also expands in the cortex and liver, but is stable in the 
cerebellum, blood and tail (Gonitel et al., 2008, Lee et al., 2011a, Mangiarini et al., 1997). As this expansion occurs in 
postmitotic neurons, continues when the cell cycle is arrested (Gomes-Pereira et al., 2014b), and does not occur in mice 
when the HD transgene is not expressed (Mangiarini et al., 1997), expansion likely occurs independent of DNA replication. 
When expansion occurs in germ cells, particularly prominent through the paternal line in HD, it results in 
intergenerational expansion and earlier onset in successive generations, a phenomenon known as anticipation. There is 
significant CAG length mosaicism in HD patients’ sperm, which correlates with expansion on transmission (Telenius et al., 
1995). In transgenic mice, expansion occurs after meiosis, again implicating DNA repair or transcription rather than 
replication (Kovtun and McMurray, 2001). 
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Recent evidence demonstrates that Fan1 protects against expansion of the CGG repeat tract in a mouse model of Fragile 
X (Zhao and Usdin, 2018). A similar stabilisation of the HTT CAG repeat tract would reduce somatic instability and could 
underlie FAN1’s effect on HD course. 
7.1.3 FAN1 
FAN1 is a DNA endo- and exonuclease originally described by four groups in 2010 (Kratz et al., 2010a, Liu et al., 2010b, 
MacKay et al., 2010b, Smogorzewska et al., 2010a). It is required for interstrand crosslink repair (ICL), though its precise 
role in this process remains unclear (Thongthip et al., 2016, Lachaud et al., 2016a, Lachaud et al., 2016b). Repair occurs 
in complex with at least some mismatch repair (MMR) proteins (MacKay et al., 2010b, Kratz et al., 2010a, Liu et al., 2010b, 
Smogorzewska et al., 2010a). FAN1 is structure rather than sequence specific, binding branched DNA structures that 
mimic DNA repair intermediates (Kratz et al., 2010a, Liu et al., 2010b, MacKay et al., 2010b) and cleaving at the 5’ flap 
(Pennell et al., 2014). It also has an independent role maintaining genomic stability and preventing chromosomal 
abnormalities, possibly through the regulation of replication fork dynamics (Lachaud et al., 2016a, Chaudhury et al., 
2014). 
It has four characterised domains. Through its ubiquitin binding domain (UBZ) it interacts with monoubiquitinated 
FANCD2 and FANCI of the FA pathway of ICL repair, which are involved in localisation to nuclear ICL damage foci (Liu et 
al., 2010c, Smogorzewska et al., 2010a). Its DNA binding (SAP) domain is structure rather than sequence specific, binding 
branched DNA structures that mimic DNA repair intermediates (Kratz et al., 2010a, Liu et al., 2010c, MacKay et al., 2010a), 
and may also be involved in recruiting FAN1 to ICL damage foci (Thongthip et al., 2016). The tetratricopeptide repeat 
(TPR) mediates protein-protein interactions and the assembly of multiprotein complexes. Finally, its nuclease domain, a 
viral replication and repair nuclease (VRR Nuc), has endonuclease activity at 5’ flap structures and is a 5’-3’ exonuclease 
(MacKay et al., 2010b). FAN1’s crystal structure has been determined bound to DNA substrates and suggests it may form 
a dimer to orient and nick DNA (Wang et al., 2014b, Zhao et al., 2014, Gwon et al., 2014, Yan et al., 2015). 
FAN1 cleaves DNA at interstrand crosslinks (ICL) and repair occurs in complex with at least some DNA repair proteins, 
including the ID complex (FANCD2 and FANCI) of ICL repair and mismatch repair complexes MutLα (MLH1 and PMS2) and 
MutLγ (MLH1 and MLH3) (MacKay et al., 2010a, Kratz et al., 2010a, Liu et al., 2010c, Smogorzewska et al., 2010b). Its 
interaction with components of MMR system provides a plausible functional link between our genetic data (GeM-HD, 
2015, Bettencourt et al., 2016) and a role in somatic instability. 
Unlike other FA genes, FAN1 mutations do not cause Fanconi anaemia. However, loss of function mutations cause 
karyomegalic interstitial nephritis, a recessive renal syndrome (Zhou et al., 2012, Lachaud et al., 2016b, Thongthip et al., 
2016), and heterozygous truncating mutations, like mutations in MMR proteins, cause pancreatic (Smith et al., 2016) and 
hereditary colorectal cancers (Segui et al., 2015b). FAN1 variants may also be associated with susceptibility to 
schizophrenia and autism (Ionita-Laza et al., 2014). 
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7.2 Aims 
Mismatch repair proteins may act on abnormal structures formed by CAG repeat DNA, such as hairpin loops, attempting 
repair and resulting in expansion. FAN1 may bind at or near the CAG repeat and, through its interaction with DNA damage 
response components, protect against CAG expansion. This chapter aims to assess the impact of reducing Fan1 
expression by AAV-delivered miRNA on somatic instability in the striatum and liver of R6/2 mice. 
7.3 Methods 
7.3.1 Viral vector 
7.3.1.1 Virus 
Adeno-associated virus (AAV) is a single-stranded DNA virus that can produce long term transduction of both dividing 
and non-dividing cells. They are preferred over lentiviruses as they remain primarily episomal, rather than integrating 
into the genome, so do not disrupt chromatin at the site of integration which can affect transgene and neighbouring gene 
expression. AAV infections produce only mild immune responses and are considered non-pathogenic (Aschauer et al., 
2013). Serotypes 1-9 have been extensively used for gene therapy. Capsid protein is a major determinant of cellular 
tropism and transduction efficiency (Van Vliet et al., 2008), so hybrid vectors have been engineered using the genome of 
serotype 2 and capsid proteins of serotypes 1-9. AAV2/9 was selected for its efficient transduction of mouse striatum, 
hippocampus and cortex (Aschauer et al., 2013, Limberis and Wilson, 2006). Our group has previousl found widespread 
expression of a GFP reporter across the brain when delivered by stereotactic striatal injection. 
7.3.1.2 Target sequence 
Two Fan1 target sequences were selected, based on commercially available siRNA oligonucleotides (Dharmacon) 
previously used in our lab to successfully reduce Fan1 expression in vitro in mouse embryonic fibroblast (MEF) cells. 
Artificial miRNA design incorporating these target sequences was based on the Block-IT polII system (Invitrogen). Target 
sequences are 19mers, so a base was added at each end of the Fan1 sequence to make 21mers. Bases 9 and 10 were 
removed from the sense sequence to produce a bulge in the hairpin structure that mimics that of endogenous miR155 
and is important for its function as an artificial miRNA. The link between the hairpins has an A>T substitution to remove 
the HindIII site (underlined in the sequences below). 
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Oligo 09: 
CTAGACTCGAGGACGGGGTGACTGGAGGCTTGCTGAAGGCTGTATGCTGTTAAGTCGGAGGCAATCTCTTGTTTTGGCCAC
TGACTGACAAGAGATTCTCCGACTTAACAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCtagcttcc
cgggataggtacCTGGAGGCTTGCTGAAGGCTGTATGCTGTTAAGTCGGAGGCAATCTCTTGTTTTGGCCACTTGACTGAC
AAGAGATTCTCCGACTTAACAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCACTACGCCTGAATCAA
GCTTATC  
Oligo 10: 
CTAGACTCGAGGACGGGGTGACTGGAGGCTTGCTGAAGGCTGTATGCTGGTAATCGAATGACACTGGCTTGTTTTGGCCAC
TGACTGACAAGCCAGTCATTCGATTACCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCtagcttcc
cgggataggtacCTGGAGGCTTGCTGAAGGCTGTATGCTGGTAATCGAATGACACTGGCTTGTTTTGGCCACTTGACTGAC
AAGCCAGTCATTCGATTACCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCACTACGCCTGAATCAA
GCTTATC 
Figure 7.1. miRNA design. 
Top  schematic representation of miRNA construct. Bottom – sequences of the two miRNA oligonucleotides used in the present study. 
Colours on the sequences and schematic are matched. 
7.3.1.3 Cloning 
The sequences were synthesised by GeneArt and cloned into the AAV9 cB7 GFP vector, 3’ of the  
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open reading frame (ORF) as tandem amiRNAs by Penn Vector Core, University of Pennsylvania. These paradigms were 
developed by Dr Sena-Esteves (University of Massachusetts), who advised on this phase of the project. Insertion in the 
3’ untranslated region, between the GFP stop codon and the WPRE, allows the production of one transcript encoding 
both GFP and our amiRNA molecules. This strategy was adopted to avoid potential in vivo toxicity associated with 
constitutive U6 RNA polymerase III driven shRNA transcription, previously shown to overload miRNA processing factors. 
It is expressed under the control of the CAGG promoter. Two sequences (oligo 09 and 10) and a scrambled control were 
cloned into the AAV9 cB7 GFP vector backbone. Knockdown of Fan1 was tested by transient transfection of mouse 
fibroblast (3T3) cells. 
 
Figure 7.2. Fan1 silencing in 3T3 mouse embryonic fibroblasts (MEF) using AAV9 cB7 eGFP miRNA constructs. 
Top left – live cell GFP imaging of transfected cells with oligonucleotide 09, 10 or scrambled control. Top right – Immunoblot of 
samples probed with S101D anti-Fan1 (1:100 overnight, 5% DMP), anti-GFP and anti-GAPDH. P1 is a sample prepared from mouse 
brain. Bottom left – Densitometric quantification of the immunoblot demonstrating 60% and 20% Fan1 knockdown with 
oligonucleotides 09 and 10 respectively. Bottom right – mean Fan1 knockdown from five transfections. Error bars represent SEM. 
Note approximately 35% knockdown with oligonucleotide 09 relative to scrambled control. 
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Oligonucleotide 09 and a scrambled control sequence were selected for viral packaging. 
• AAV2/9.CB7.CI.eGFP-miR.mFan1.WPRE.rBG (3.53 x 1013 genome copies/ml ddPCR) 
• AAV2/9.CB7.CI.eGFP-miR.Control.WPRE.rBG (3.78 x 1013 genome copies/ml ddPCR) 
7.3.2 Experimental groups 
7.3.2.1 Toxicity study 
To investigate whether there are any adverse effects associated with Fan1 knockdown (KD) at 4 weeks age, the AAV2/9 
vector was administered by four regimens. 
1. Direct unilateral intrastriatal (IS) injection into the left striatum 
2. IS injection and intravenous (IV) tail vein administration 
3. IV tail vein route only 
4. Intraperitoneal (IP) route only 
For these experiments, the R6/2 colony was maintained by backcrossing to (CBA/Ca x C57BL/6J)F1 mice. Animals were 
monitored for 4-5 weeks post-injection for signs of pain, weight loss (at least twice weekly) and routine health checks for 
subdued behaviour, hunched appearance, piloerection, seizures, difficulty handling or jumpy behaviour, nose bulge or 
swollen cheeks, wound scratching or weight loss of greater than 15%. A total of 24 animals were used, aiming to keep 
numbers to a minimum. Treated mice were compared to a control, uninjected group. The IP injection protocol was 
performed on HdhQ150 knock-in colony mice on a C57BL/6J background. 
Treatment group Genotype Age (wk) 
Gender 
(M/F) 
CAG repeat 
length (sd) 
Treatment 
date 
Dissection 
date 
Intrastriatal injection only WT 4 2/2 - 09/05/2017 13/06/2017 R6/2 4 3/1 181 ± 2.13 09/05/2017 13/06/2017 
Intrastriatal and tail vein 
injections 
WT 4 2/2 - 10/05/2017 13/06/2017 
R6/2 4 1/3 182 ± 0.32 10/05/2017 13/06/2017 
Tail vein only WT 4 2/2 - 11/05/2017 13/06/2017 R6/2 4 2/2 181  ± 1 11/05/2017 13/06/2017 
Intraperitoneal injection only WT 4 1/3 - 06/06/2017 04/07/2017 Het HdhQ150 1 0/1 - 06/06/2017 04/07/2017 
Control (uninjected) WT 4 - - - 13/06/2017 R6/2 4 - 180 ± 1.55 - 13/06/2017 
Table 7.1. Animals used in the toxicity study. 
7.3.2.2 Experimental study 
Fan1 miRNA or scrambled miRNA (control) virus was delivered to R6/2 mice by combined left striatal and intraperitoneal 
(IP) injection, the optimal protocols selected following toxicity experiments. Mice from a (CBA/Ca x C57BL/6J)F1 colony 
were backcrossed to C57BL/6J for one generation. A total of 80 mice were used. Weights and temperature were 
measured at least twice weekly. They were co-housed with WT. Due to surgical time-constraints, mice in each group were 
injected over two days.  
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Study Treatment Treatment date 
Age at 
treatment 
(wk) 
Genotype 
Gender 
[M/F] 
(# died in 
brackets) 
Total 
Age at 
dissection 
(wk) 
8wk 
Fan1 miRNA 20/06/2017 4 R6/2 3/3 6 8 22/06/2017 4 R6/2 3/3 6 8 
Scr miRNA 20/06/2017 4 R6/2 3/2 5 8 22/06/2017 4 R6/2 3/2 5 8 
11wk 
Fan1 miRNA 28/06/2017 4 R6/2 2(1)/3 6(4) 11 29/06/2017 4 R6/2 3/3(1) 6(5) 11 
Scr miRNA 28/06/2017 4 R6/2 3(1)/3(1) 6(4) 11 29/06/2017 4 R6/2 3(1)/3(1) 6(4) 11 
Untreated 
control 
- 4 R6/2 3/8 11 11 
- 4 WT 9/5 14 11 
Immunohistochemistry study 
Fan1 
(perfuse) 
11/07/2017 4 R6/2 2/2 4 8 
11/07/2017 4 WT 2/2 4 8 
Control 
(perfuse) 
12/07/2017 4 R6/2 2/2 4 8 
12/07/2017 4 WT 2/2 4 8 
Table 7.2. Animals used in experimental study. 
7.3.3 Pilot studies 
Pilot studies were conducted to determine the baseline level of Fan1 expression across different tissues in R6/2 mice and 
to optimise methods for extraction of DNA, RNA and protein. 
7.3.4 Surgical procedures 
7.3.4.1 Stereotactic microinjection 
The AAV2/9.mFan1 vector was used for toxicity studies. Viral preparations were delivered by unilateral intrastriatal 
stereotactic injection at a volume of 3 μL and at a rate of 0.1 μL/min for 5 min. The needle was left in place for 5 minutes 
before removing the injector. The stereotactic coordinates used to target the striatum were anteroposterior (Y): +0.5; 
mediolateral (X): +2.5 and dorsoventral (Z): -4.0 expressed in mm relative to the Bregma, according to the Allen mouse 
brain atlas. Animals were monitored after surgery.  
7.3.4.2 Intravenous (IV) tail vein injection 
5 μL of 3.53 x 1013 GC/mL (AAV2/9.Fan1miRNA) diluted in 100 μL of sterile PBS was administered to each animal using a 
1 mL syringe with 30 G needle. 
7.3.4.3 Intraperitoneal (IP) injection 
5 μL of 3.53 x 1013 GC/mL (AAV9.Fan1miRNA) was diluted in 100μL of sterile PBS in a 1mL syringe with a 30 G needle and 
was administered to each animal 
7.3.5 Experimental protocol 
At either 4 weeks (8 week cohort) or 7 weeks (11 week cohort) after injection, the left striatum (injected), right striatum, 
rest of brain, liver and tail were snap frozen in liquid nitrogen and stored at -80°C. The protocol is outlined below. 
Toxicity samples were collected at 8-9 weeks age to assess Fan1 protein levels and optimise qPCR assays. 
Experimental samples were collected at 8 or 11 weeks, and assessed for Fan1 knockdown by qPCR and Western blot, 
and studied for CAG repeat expansion. 
Immunohistochemistry samples (fixed brain and liver) were collected at 8 weeks to assess for GFP expression. 
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Figure 7.3. Experimental protocol. 
7.3.6 Immunohistochemistry (IHC) 
Mice were transcardially perfused 3 weeks after injection, first with heparinised PBS, and, then with 4% PFA solution. 
Whole brains and livers were harvested and post fixed in 4% PFA solution for an additional 24 hours. Fixed tissues were 
subjected to sucrose gradient (20% then 30% in PBS) and embedded in Tissue-Tek O.C.T and stored at -80°C. Coronal or 
sagittal brain sections (25 µm) were cut on a cryostat at 50 µm intervals and collected into 12-well plates containing 
tissue cryopreservative solution and stored in -20°C until immunostaining with an antibody to GFP (Invitrogen A11122 at 
1:1000).  
Coronal brain sections were assessed for GFP expression using a Nikon Eclipse A1R point scanning confocal microscope 
using 10x objective lens set to 8 x 8 fields stitching procedure with 15% overlap. Images were acquired in NIS-Elements 
AR Software. Representative images were then processed using Fiji (ImageJ Image Analysis) and prepared in Adobe 
Photoshop and InDesign CS6. 
7.3.7 DNA extraction 
DNA was extracted using a modified high salt method (Aljanabi and Martinez, 1997). Briefly, samples were lysed in 475 
µL lysis buffer and 1 mg/ml proteinase K overnight at 50°C. 300 µL of saturated NaCl solution was added, then shaken 
vigorously and incubated for 2 min before centrifuging at full speed for 35 min. The supernatant, containing the DNA, 
was precipitated by adding to 650 µL of 100% ethanol, shaken and centrifuged at full speed for 20 min. The supernatant 
was discarded and the pellet resuspended in 300 µL of 70% ethanol before centrifugation at full speed for 5-15 min. The 
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supernatant was again discarded and the pellet dried at room temperature for an hour. The pellet was then resuspended 
in 50-150 µL of 5mM TRIS (adjusting buffer volume depending on pellet size, using 10 µL if no pellet was visible). 
7.3.8 RNA extraction 
Samples were stored at -80°C prior to lysis. Brain samples were lysed by homogeniser probe for 30 secs in 500 µL of 
Qiazol (Qiagen). Muscle and peripheral tissues were placed in ribolyser tubes, to which 700 µL of Qiazol was added. They 
were lysed using the Fast-Prep 24 (MP Biomedicals) at 6.5 m/s for 1 min three times. Chloroform (VWR) was added to 
lysed samples (200 µL for brain and 250 µL for peripheral tissues), which were then vortexed for 30 secs and centrifuged 
at 13,000 rpm for 15 min at room temperature. The aqueous phase was transferred to a new tube and an equal volume 
of 70% ethanol added. RNA was purified as per the RNeasy Mini Kit protocol (QIAGEN, 74106). A 15 min genomic DNA 
digestion step (DNAse I, QIAGEN, 79254) was performed between the RW1 buffer washes. RNA was eluted with water 
and concentration was measured on a NanoDrop 1000. 
7.3.9 Protein extraction 
Tissue was homogenised in RIPA buffer with protease inhibitors and benzonase using a small Eppendorf pestle until 
smooth. Protein concentration was determined by Bio-Rad assay. The tissue suspension was methanol precipitated, then 
resuspended in 1x SDS sample buffer to 4 mg/ml. 
7.3.10 3-in-1 DNA, RNA and protein extraction 
Extraction was performed according to the manufacturer’s protocol (GE Healthcare, cat #28-9425-44). Briefly, samples 
were lysed in lysis buffer then added to a DNA column and centrifuged, saving the flow through which contains RNA and 
protein. The bound DNA was washed twice in wash buffer, then eluted in elution buffer. Acetone was added to the flow 
through, which was then added to the RNA column and centrifugation. RNA was treated with DNase I, washed with wash 
buffer and eluted in elution buffer. To the protein-containing flow through a protein precipitation buffer was added. The 
sample was vortexed, incubated at room temperature for 5 min, then centrifuged to remove supernatant. The protein 
pellet was suspended in water, before pelleting and removal of supernatant. The protein was then resuspended in a urea 
and detergent-containing 2-D DIGE buffer. 
7.3.11 Quantitative real time PCR (qPCR) 
The following Taqman probe sets were used. 
Gene Gene name TaqMan probe (ThermoFisher) 
Atp5b ATP synthase subunit 5b Mm01160389_g1 
Eif4a2 Eukaryotic translation initiation factor 4A2 Mm01730183_gH 
Fan1 FANCD2 And FANCI Associated Nuclease 1 Mm00625959_m1 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase  Mm99999915_g1 
Rpl13a Ribosomal protein L13a Mm05910660_g1 
Sdha Succinate dehydrogenase complex flavoprotein subunit a  Mm01352366_m1 
Ubc Ubiquitin C Mm02525934_g1 
Table 7.3. TaqMan qPCR probes. 
7.3.12 Western blot 
60 µg of each protein sample was loaded on a 9% gel, then transferred for 2 hours at 100 V. For immunoblotting, the gel 
blot was blocked in 10% dimethyl pimelimidate (DMP) for 1 hour, before the addition of the indicated primary antibody 
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(see below) overnight at 4°C. Secondary antibodies were added in Li-Cor buffer and incubated at room temperature for 
90 min. The blot was scanned using a Li-Cor Odyssey. 
Fan1: 
• Primary antibody – Mouse Fan1 S101D, 1:250 
• Secondary antibody – Goat anti-mouse, 1:4000 
7.4 Contributions 
This study was conceived and designed by Professors Bates and Tabrizi. Mice were bred and maintained in Professor 
Bates’ lab. Viral injection and immunohistochemistry were performed by Pamela Farshim (UCL). The viral vector was 
designed by Rob Goold (UCL), with the advice of Dr Sena-Esteves (University of Massachusetts), and cloned by Penn 
Vector Core. Optimisation of extraction assays was performed by Michael Flower, with assistance from Rachel Flomen, 
Nadira Ali and Rob Goold (UCL). Tissue preparation was performed by Michael Flower. Quantative PCR was performed 
by Michael Flower and Nadira Ali. CAG repeat sizing was performed by Michael Flower and Rachel Flomen. Western blots 
were performed by Rob Goold. Data analysis was conducted by Michael Flower. 
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7.5 Results 
7.5.1 Pilot studies 
7.5.1.1 Fan1 expression in R6/2 tissues 
In a pilot study, Fan1 expression was measured in different tissues from two 4 week old and two 14 week old R6/2 mice 
by real time qPCR. Housekeeping gene expression was consistent across tissues. Note only one animal was available for 
4 wk cord and no data is available for 14 wk hippocampus or 4 wk striatum. Amplification failed for Sdha in one animal 
for 14 wk adrenal and kidney tissue, so these animals were excluded from further analysis. Fan1 is expressed at a 
relatively low level compared with housekeeping genes, as suggested by the relatively high cycle threshold values across 
all tissues. 
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Figure 7.4. qPCR cycle threshold in pilot study of Fan1 expression in R6/2 tissues at 4 and 14 weeks. 
Ct – mean cycle threshold (± sem). Note no tissue was analysed for 4 wk striatum and failure of amplification in one animal from the 
14 wk adrenal and 14 wk kidney groups. ADR – adrenal, BS – brainstem, HIPP – hippocampus, KID – kidney, LIV – liver, rob – rest of 
brain, STR – striatum. 
Fan1 was expressed at relatively high level in lung and in 4 week cerebellum, spinal cord and hippocampus, and at 
relatively low level in adrenal, kidney and liver tissue. Fan1 expression appeared to decrease with age in cerebellum and 
spinal cord. However, this pilot study was limited by the small number of animals included. 
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Figure 7.5. Relative Fan1 expression level in pilot study of R6/2 tissues at 4 and 14 wk age. 
Blue – 4 week, red – 14 week. Note no tissue was analysed for 4 wk striatum and failure of amplification in one animal from the 14 
wk adrenal and 14 wk kidney groups. ADR – adrenal, BS – brainstem, HIPP – hippocampus, KID – kidney, LIV – liver, ROB – rest of 
brain, STR – striatum. 
7.5.1.2 Optimisation of assays 
7.5.1.2.1 3-in-1 extraction of DNA, RNA and protein 
The striatum is a small tissue from which samples were needed for fragment analysis (CAG repeat sizing), qPCR (Fan1 
transcript levels) and western blot (Fan1 protein expression). Before analysing the experimental samples, we determined 
which of the following methods provided optimal sensitivity and reliability. 
1. 3-in-1 kit to extract DNA, RNA and protein from the same sample (GE Healthcare, #28-9425-44). 
2. One third of each striatum delivered to each analysis method separately. 
7.5.1.2.1.1 Protocol 
Four 9 mg samples of cortex were taken from four R6/2 mice. This volume was selected to be equivalent to the mean 
weight of a left striatum. Each sample was delivered to either the 3-in-1 kit or traditional DNA, RNA or protein extraction, 
as detailed in Methods. 
7.5.1.2.1.2 Results 
DNA was analysed by nanodrop. The 3-in-1 and traditional DNA extractions gave equivalent purity, as demonstrated by 
the 260/280 and 260/230 nm ratios; nucleic acids have maximal absorbance at 260 nm, and absorbance at either 230 or 
280 nm may suggest the presence of contaminants (Thermo). However, the DNA yield from the 3-in-1 kit was only 4% 
that of the traditional extraction method. For RNA extraction, the 3-in-1 kit gave a slightly lower purity than the traditional 
method and the total RNA yield was significantly reduced to 28%. 
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Figure 7.6. Comparing DNA and RNA yield and purity from 3-in-1 and traditional extractions. 
Top– DNA, bottom – RNA. The left panel in each gives total DNA or RNA yield (concentration * elution volume). The right panels give 
absorbance ratios for 260/280 nm and 260/230 nm as indicated. 
qPCR showed the average cycle threshold was significantly higher for housekeeping genes Atp5b and Sdha, suggesting 
lower transcript levels in these eluted samples. As this affects only some housekeeping genes, certain transcripts appear 
to be lost disproportionately in the 3-in-1 extraction. 
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Figure 7.7. Comparing Fan1 expression level in 3-in-1 or traditional RNA-extracted cortex samples. 
Ct – mean cycle threshold (± sem). Top left – Ct for traditional RNA extraction. Top right – Ct for 3-in-1 RNA extraction. Middle – 
mean Ct for each housekeeping gene and geomean. Bottom left – mean Fan1 cycle threshold (± sem). Bottom right – mean relative 
expression, calculated by comparative Ct method (± sem). 
The cycle threshold for Fan1 transcripts was also lower in 3-in-1 than traditional RNA extractions. However, relative 
expression, which controls for housekeeping gene expression level, suggested Fan1 expression levels were higher in the 
3-in-1 extracted samples. Once again, this suggests selective loss of some transcripts during the 3-in-1 extraction process. 
Ponceau staining and western blot demonstrates significantly lower protein yield from the 3-in-1 extraction. 
Concerningly, there appeared to be specific loss of nuclear proteins such as Fan1 and histone H3, relative to Gapdh. This 
may because nuclear fractions are removed with DNA and RNA during 3-in-1. 
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Figure 7.8. Western blot comparing Fan1 protein levels from 3-in-1 or traditional protein extractions from cortex. 
Above – western blot probed with antibodies to Fan1, Gapdh or histone H3. Below – Ponceau stained filter demonstrating protein 
bands. 
7.5.1.2.1.3 Conclusions 
DNA, RNA and protein yields are significantly lower with the 3-in-1 kit compared to traditional extraction methods. Whilst 
DNA yield is adequate for fragment analysis, it appears there is selective loss of transcripts and nuclear proteins, which 
could lead to spurious results. 
7.5.1.3 Traditional DNA, RNA and protein extraction from 1/3 striatum 
Given the poor performance of the 3-in-1 extraction method, we next determined whether DNA, RNA and protein could 
reliably be extracted from 1/3 of a striatum. 
7.5.1.3.1 Protocol 
One striatum from each of 6 mice was divided into thirds, from which DNA, RNA or protein was extracted by traditional 
methods. 
 
Figure 7.9. A striatal sample (left) divided into thirds (right). 
Tissue was frozen on dry ice throughout the procedure. 
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7.5.1.3.2 Results 
Fragment analysis was successfully performed on all samples. A representative trace is shown below, displayed in 
GeneMapper. 
 
Figure 7.10. Fragment analysis from 1/3 of a striatum. Representative trace. 
Protein was reliably extracted from 1/3 striatum, with a mean yield of 191 µg (95% CI 155-227 µg). 
 
Figure 7.11. Protein extraction from 1/3 striatum of R6/2 mice. 
Left – western blot with the antibodies indicated, in the middle is the Ponceau stained filter showing protein bands. Right – total 
protein yield (concentration * volume). 
RNA was reliably extracted from 1/3 striatum, giving a mean yield of 1340 ng (95% CI 894-1784 ng), consistent 
housekeeping gene levels and quantifiable Fan1 expression. 
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Figure 7.12. RNA extraction from 1/3 striatum and Fan1 expression. 
Top left – housekeeping gene cycle threshold. Top middle – RNA yield from 1/3 striatum. Top right – Geomean of housekeeping 
genes. Bottom – Fan1 relative expression in 1/3 striatum from six R6/2 mice. 
7.5.1.3.3 Conclusions 
DNA, RNA and protein can all be reliably extracted from 1/3 of a striatum, permitting the analysis of CAG repeat length 
and Fan1 expression.  
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7.5.2 Toxicity study 
There was no evidence of toxicity with any administration regimen. 
7.5.2.1 Fan1 knockdown 
WT and R6/2 animals treated by tail or striatal injection were compared. Lysates from striatum or liver were prepared 
and 40 µg probed with antibodies to Fan1, b3-tubulin or GFP. GFP expression was generally high in both genotypes, 
particularly on the left, which was directly injected. Fan1 levels appeared reduced compared to tail vein injected animals. 
 
Figure 7.13. Fan1 knockdown in R6/2 following AAV9 cB7 eGFP.oligo 09 transduction. 
Lysates were prepared from striatum of mice treated by tail vein (IV) or striatal injection. 40 µg was probed with the antibodies 
indicated. Left striatal injection produced significant Fan1 knockdown to around 8% of levels in intravenous treated animals (p = 
4.96E-5). 
In liver, GFP expression was lower than striatum, suggesting poorer transduction from both tail and striatal injections. 
Fan1 expression in liver was very low or absent in liver in both treatment groups, independent of GFP expression level. 
This is consistent with published transcriptomic data which show Fan1 is expressed at low levels endogenously 
(Papatheodorou et al., 2018). 
Injection -
Tissue lysate -
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Figure 7.14. Fan1 knockdown in R6/2 liver. 
Lysates were prepared from liver of mice treated by tail vein (IV, left) or striatal (middle) injection. 40 µg was probed with the 
antibodies indicated. Untreated striatal samples are loaded on the right for comparison. Note endogenous Fan1 levels are lower in 
liver than striatum. 
7.5.3 Immunohistochemistry study 
7.5.3.1 Striatum 
Representative images showing CNS transduction following intrastriatal administration of either AAV2/9.CB7.CI.eGFP-
miR.mFan1 (AAV9.mFan1) or AAV2/9.CB7.CI.eGFP-miR.Control vector (AAV9.Scramble). 
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Figure 7.15. GFP expression following intrastriatal delivery of AAV9.mFan1 or AAV9.Scrambled control miRNA. 
Confocal images of coronal sections taken at the level of the OB (olfactory bulb), STR (striatum), HIP (hippocampus) and CBL 
(cerebellum) in WT and R6/2 mice injected with AAV9.mFan1 (a and c) and WT and R6/2 mice injected with AAV9.Scramble miRNA 
vectors (b and d). 
 
Figure 7.16. Representative sagittal sections showing GFP expression in the striatum. 
Top diagrams taken from the Allen brain atlas, with caudate and putamen (CP) shown in purple. 
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The right side was also transduced by anterograde transport in R6/2 mice injected with AAV9.mFan1.miRNA (see below), 
though this was not observed in WT animals or with AAV9.scrambled.miRNA. 
 
Figure 7.17. GFP distribution pattern in R6/2 mice receiving intrastriatal injection of AAV9.mFan1.miRNA. 
7.5.3.2 Liver 
GFP expression was assessed in liver sections from R6/2 and WT mice injected IP with AAV9.mFan1 and AAV9.Scramble 
miRNA vectors. The intensity of GFP signal was found to be lower in AAV9.Scrambled miRNA treated mice compared to 
AAV9.mFan1 treated WT and R6/2 mice. 
 
Figure 7.18. GFP expression in the liver. 
Representative sections from R6/2 mice treated with a) AAV9.mFan1, b) AAV9 scrambled miRNA vector and in WT mice treated with 
c) AAV9.mFan1 and d) AAV9.scramble miRNA vector. 
GFP intensity was lower is all animals receiving the AAV9.scrambled miRNA virus, compared with AAV9.mFan1, regardless 
of genotype. 
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Figure 7.19. GFP expression pattern across all study groups receiving IP injections 
Injection of either A) AAV9.mFan1.miRNA or B) the AAV9.Scrambled control virus. Both R6/2 and WT mice that received the 
scrambled miRNA showed lower GFP intensity profiles as demonstrated in confocal images at x10 magnification. Numbers below 
each micrograph represent animal ID. 
GFP intensity was compared with the striatum. The lower intensity seen in scrambled liver was not seen in scrambled 
striatal sections. 
 
Figure 7.20. GFP intensity profile in transduced striatum and liver of R6/2 mice. 
Striatum (left) and liver (right) of R6/2 mice receiving the AAV9.mFan1 miRNA (top) or AAV9.scrambled miRNA vector (bottom). No 
differences in GFP intensity were found in the striatum between the two treatment groups. Confocal images x10 magnification. 
7.5.3.3 Mutant huntingtin aggregates 
Analysis of striatal S830 antibody stained sections showed no difference in the number of mutant huntingtin aggregates 
between the Fan1 and scrambled miRNA-treated animals. 
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Figure 7.21. Mutant huntingtin aggregates in transduced R6/2 striatum. 
Representative confocal images from the striatum of R6/2 mice transduced with AAV9.scrambled miRNA vector (top) or AAV9.mFan1 
miRNA (bottom). S830 (white), GFP (virus), blue (Hoechst) at x100 magnification. 
7.5.3.4 Conclusions 
The left striatum of both R6/2 and WT mice was successfully transduced with both Fan1 and scrambled viruses. Successful 
transduction in the liver was achieved following IP delivery of AAV9.mFan1.miRNA, but GFP expression in the liver was 
lower for the scrambled control, regardless of genotype. AAV-mediated Fan1 miRNA did not affect mutant huntingtin 
aggregation as demonstrated by S830 staining in striatal sections. 
Though the combination of intrastriatal and IP was not formally assessed, these data suggested that this combination 
would have no adverse effects. Therefore, the combination of intrastriatal and IP delivery was used for the experimental 
study to optimise knockdown, decrease total procedure time, and reduce stress associated with restraint for tail vein 
injection. 
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7.5.4 Experimental study 
7.5.4.1 Weight and body temperature 
Animals were measured at least twice weekly throughout the duration of vector expression. 
 
Figure 7.22. Weight and temperature in 11-week mice. 
(a) Weight and (b) temperature measures of R6/2 mice injected at 4 weeks of age with 3μL of 3.53 x 1013 GC/mL AAV2/9.CB7.eGFP-
miR.mFan1 into the left striatum and 5 μL IP (n=9) or 3 μL of 3.78 x 1013 GC/mL AAV2/9.CB7.CI.eGFP-miR.Control into the left 
striatum and 5 μL IP (n=8). Mice were culled at 7 weeks post transfection. Error bars represent SEM. 
7.5.4.2 Fan1 qPCR 
7.5.4.2.1 Liver 
The following comparisons were made by loading the indicated samples in random order in triplicate on the same 96 well 
plate. 
1. 8 week samples. Liver from 8 week R6/2 scrambled or Fan1 knockdown (n = 11 and 13, respectively) 
2. 11 week samples. Liver from 11 week R6/2 scrambled (n = 10), Fan1 knockdown (n = 10), or untreated R6/2 (n 
= 13), or 11 week wild type (WT, n = 12). 
Atp5b, Sdha and Ubc were selected as housekeeping genes and the comparative Ct method was used to calculate relative 
Fan1 knockdown. Fan1 knockdown at 8 weeks was 21% (se = 8.9%, p = 0.0353) and at 11 weeks was 23% (se = 11.8%, p 
= 0.0671). 
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Figure 7.23. Liver Fan1 expression. 
Top left – 8 week liver housekeeping gene cycle threshold, top right – 11 week liver housekeeping gene cycle threshold. Middle left – 
8 week liver Fan1 cycle threshold, middle right – 11 week liver Fan1 cycle threshold. Bottom left – 8 week liver Fan1 expression, 
relative to the mean of 8 week scrambled. Bottom right – 11 week liver Fan1 expression, relative to the mean of 11 week R6/2 
untreated. LIV – liver, Scr – scrambled, KD – knockdown. 
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7.5.4.2.2 Striatum 
The following comparisons were made. 
1. Left vs. right striatum. A subset of left striatum scrambled (n = 6) or Fan1 knockdown (n = 8), and right striatum 
scrambled (n = 7) or Fan1 knockdown (n = 8) samples. This permits the accurate comparison of left and right 
striatum, as samples are analysed on the same plates. Fan1 expression in 8 week samples was calculated relative 
to 8 week scrambled left striatum, and expression in 11 week samples was calculated relative to 11 week 
untreated left striatum. 
2. Fan1 knockdown in left striatum. All left striatal samples. 8 week R6/2 scrambled (n = 8) or Fan1 knockdown (n 
= 9), 11 week R6/2 scrambled (n = 9), Fan1 knockdown (n = 9), and untreated (n = 9), and 11 week untreated WT 
(n = 9). Fan1 expression calculated relative to 11 week untreated R6/2. 
3. Fan1 knockdown in right striatum. All right striatal samples. 8 week R6/2 scrambled (n = 9) or Fan1 knockdown 
(n = 9), 11 week R6/2 scrambled (n = 9), Fan1 knockdown (n = 9), or untreated (n = 9), and 11 week untreated 
WT (n = 9). Fan1 expression calculated relative to 11 week untreated R6/2. 
7.5.4.2.2.1 Fan1 expression in left vs right striatum 
To accurately compare Fan1 expression in the injected left striatum with the uninjected right striatum, a subset of left 
and right striatum samples, injected with either the scrambled or Fan1 knockdown virus, were loaded on the same plate. 
There was no significant difference between Fan1 expression level in 11 week untreated left and right striatum (mean 
relative expression 1.024 and 1.063, p = 0.7310), or between left and right striatum treated with the scrambled virus at 
8 weeks (1.06 and 0.703, p = 0.0791) or 11 weeks (0.919 and 0.845, p = 0.324). 
The active virus reduced Fan1 expression in the left striatum at 8 weeks by 29% (p = 0.0513) and at 11 weeks by 25% (p 
= 0.0506). Later analyses, which focus on left or right striatum and include more animals, improve the power for 
evaluation of Fan1 knockdown. 
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Figure 7.24. Striatum Fan1 relative expression. 
Top left – 8 week striatum housekeeping gene cycle threshold, top right – 11 week striatum housekeeping gene cycle threshold. 
Middle left  8 week striatum Fan1 cycle threshold, middle right – 11 week striatum Fan1 cycle threshold. Bottom left – 8 week 
striatum Fan1 expression, relative to the mean of 8 week scrambled, Bottom right – 11 week striatum Fan1 expression, relative to the 
mean of 11 week R6/2 untreated. SL – left striatum, SR – right striatum, Scr – scrambled, KD – knockdown. 
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7.5.4.2.2.2 Fan1 knockdown in left and right striatum 
To accurately quantify Fan1 knockdown, all samples from left and right striatum were analysed together. The active virus 
reduced Fan1 expression in 8 week left striatum by 19% (se = 9.0%, p = 0.0209) and in 11 week left striatum by 28% (se 
= 7.8%, p = 0.0024). There was no significant knockdown in 8 or 11 week right striatum (p = 0.3658 and 0.8405), and once 
again Fan1 expression in the 8 and 11 week scrambled treated right striatum did not significantly differ from 11 week 
untreated R6/2.  
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Figure 7.25. Striatum Fan1 expression. 
Top left – left striatum housekeeping gene cycle threshold, top right – right striatum housekeeping gene cycle threshold. Middle left 
– left striatum Fan1 cycle threshold, middle right – right striatum Fan1 cycle threshold. Bottom left – left striatum Fan1 expression, 
relative to 11 week untreated R6/2 left striatum. Bottom right – right striatum Fan1 expression, relative to 11 week untreated R6/2 
right striatum. SL – left striatum, SR – right striatum, Scr – scrambled, KD – knockdown.  
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7.5.4.2.3 Conclusions 
The active virus reduced Fan1 expression on average in left striatum and liver throughout the experiment by 22.7% (sem 
= 1.9%). Expression in right striatum was unaffected. 
 
Figure 7.26. Fan1 knockdown in R6/2 tissues. 
Fan1 KD expressed as a proportion of scrambled ± SE. SL – striatum left, SR – striatum right. 
7.5.4.3 CAG repeat sizing 
7.5.4.3.1 Modal CAG repeat length 
CAG repeat size was determined by fragment analysis using the Bates lab protocol (see Methods). Each sample was sized 
three times independently, then averaged. In 12 day tail at baseline, there was no significant difference between the CAG 
repeat size in Fan1 knockdown and scrambled (p = 0.721) or untreated animals (p = 0.637). Mean repeat sizes were 188.0 
(95% CI 185.7-190.3), 188.4 (95% CI 187.5-189.4) and 187.8 (95% CI 183.9-191.7) respectively. 
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Figure 7.27. Modal CAG repeat size at baseline (12 day tail). 
Error bars represent SEM. Scr – scrambled, KD – knockdown. 
Each tissue is considered in turn below. 
7.5.4.3.1.1 Tail 
Modal CAG repeat length was not significantly different between 11 week scrambled and untreated tail, suggesting viral 
transduction itself did not influence CAG repeat length (p = 0.236). CAG length increased in scrambled 8 week tail on 
average by 0.83 repeats (sem = 0.40, p = 7.13E-3), in 11 week scrambled tail by 0.97 (sem = 0.39, p = 5.01E-4) and in 11 
week untreated tail by 0.36 (sem = 0.26, p = 5.74E-2). Modal change was not significantly different between scrambled 
and Fan1 knockdown 8 week tail (p = 0.636) or 11 week tail (p = 0.637), suggesting Fan1 knockdown did not affect 
expansion in the tail. 
7.5.4.3.1.2 Left striatum 
For left striatum, there was no significant difference between 11 week scrambled and untreated animals (p = 0.236), 
again showing the virus itself had no effect on expansion. The CAG increased in scrambled 8 week left striatum on average 
by 1.79 repeats (sem = 0.22, p = 3.97E-12), in 11 week scrambled left striatum by 1.81 repeats (sem = 0.33, p = 9.43E-9) 
and in 11 week untreated left striatum by 0.91 (sem = 0.50, p = 1.64E-2). There was no significant difference in modal 
change between scrambled and Fan1 knockdown 8 week left striatum (p = 0.636), or 11 week left striatum (p = 0.706), 
suggesting Fan1 knockdown did not affect expansion in the left striatum. 
7.5.4.3.1.3 Right striatum 
For right striatum, there was no significant difference between 11 week scrambled and untreated animals (p = 0.757). 
The CAG increased in scrambled 8 week right striatum on average by 1.88 repeats (sem = 0.35, p = 2.43E-8), in 11 week 
scrambled right striatum by 2.10 repeats (sem = 0.47, p = 2.91E-7) and in 11 week untreated right striatum by 1.87 (sem 
= 0.50, p = 1.21E-5). There was no significant difference in modal change between scrambled and Fan1 knockdown 8 
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week right striatum (p = 0.6073), or 11 week right striatum (p = 0.424), suggesting Fan1 knockdown did not affect 
expansion in the right striatum. 
7.5.4.3.1.4 Liver 
In liver, there was no significant difference between 11 week scrambled and untreated animals (p = 0.532). The CAG 
increased in scrambled 8 week liver on average by 2.66 repeats (sem = 0.5, p = 3.35E-8), in 11 week scrambled liver by 
3.29 repeats (sem = 1.24, p = 1.05E-3) and in 11 week untreated liver by 1.97 (sem = 1.38, p = 0.053). There was no 
significant difference in modal change between scrambled and Fan1 knockdown 8 week liver (p = 0.708), or 11 week liver 
(p = 0.314), suggesting Fan1 knockdown did not affect expansion in the liver. 
 
Figure 7.28. Change in modal CAG repeat length relative to 12 day tail.  
Change in modal CAG repeat length is calculated relative to each animal’s own 12d tail. Error bars represent SEM. Brown – 12 day 
tail, orange – 8-11 week tail, blue – left striatum (SL), red – right striatum (SR), purple – liver (LIV). Scr – scrambled. KD – knockdown. 
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Treatment n Modal (CAG)n SEM (mode) 
Change in 
modal 
(CAG)n 
SEM 
(∆mode) 
12d R6/2 tail Scr 21 188.02 1.10 0.00 0.00 
12d R6/2 tail KD 23 188.43 0.45 0.00 0.00 
12d R6/2 tail untreated 11 187.79 1.74 0.00 0.00 
8wk R6/2 tail Scr 11 190.12 0.68 0.83 0.40 
8wk R6/2 tail KD 13 188.64 0.74 -0.07 0.45 
11wk R6/2 tail Scr 9 188.90 1.85 0.97 0.39 
11wk R6/2 tail KD 9 189.36 0.47 1.13 0.43 
11wk R6/2 tail untreated 11 187.71 1.95 0.36 0.26 
8wk R6/2 SL Scr 11 191.01 0.74 1.79 0.22 
8wk R6/2 SL KD 13 190.18 0.79 1.60 0.28 
11wk R6/2 SL Scr 10 188.04 2.29 1.81 0.33 
11wk R6/2 SL KD 10 190.23 0.45 1.99 0.31 
11wk R6/2 SL untreated 11 188.70 1.88 0.91 0.50 
8wk R6/2 SR Scr 11 191.43 0.76 1.88 0.35 
8wk R6/2 SR KD 13 190.27 0.80 1.68 0.16 
11wk R6/2 SR Scr 10 188.33 2.27 2.10 0.47 
11wk R6/2 SR KD 10 189.83 0.46 1.59 0.38 
11wk R6/2 SR untreated 11 189.46 1.97 1.87 0.50 
8wk R6/2 LIV Scr 11 192.21 0.71 2.66 0.50 
8wk R6/2 LIV KD 13 191.50 0.93 2.92 0.46 
11wk R6/2 LIV Scr 10 189.52 1.40 3.29 1.34 
11wk R6/2 LIV KD 10 189.91 0.84 1.67 0.76 
11wk R6/2 LIV untreated 11 191.38 1.40 1.97 1.38 
Table 7.4. Change in modal CAG relative to 12 day tail. 
SL – left striatum, SR – right striatum, LIV – liver, Scr – scrambled, KD – knockdown, dmode – change in modal CAG repeat length. 
7.5.4.3.2 Somatic instability index 
The somatic instability index (SII), which is measured in CAG repeat units, is considered a more sensitive measure of 
change in repeat length (Lee et al., 2010, Zhao and Usdin, 2018). 
7.5.4.3.2.1 Scrambled and untreated tissues 
SII increased in scrambled 8 week tail by 1.30 (sem = 0.45, p = 3.34E-4), in 11 week scrambled tail by 1.82 (sem = 0.48, p 
= 9.44E-7), in 11 week untreated tail by 1.17 (sem = 0.20, p = 2.39E-6), in 8 week scrambled left striatum by 3.50 (sem = 
0.47, p = 2.45E-12), in 11 week scrambled left striatum by 7.46 (sem = 0.93, p = 4.68E-13), in 11 week untreated left 
striatum by 6.16 (sem = 0.91, p = 1.58E-10), in 8 week scrambled right striatum by 6.27 (sem 0.38, p = <1.00E-15), in 11 
week scrambled week right striatum by 9.03 (sem = 1.10, p = 3.15E-13), in 11 week untreated right striatum by 5.867 
(sem = 1.02, p = 2.37E-9), in 8 week scrambled liver by 4.40 (sem = 0.31, p = <1.00E-15), in 11 week scrambled liver by 
6.56 (sem  = 0.44, p = <1.00E-15) and in 11 week untreated liver by 6.84 (sem = 0.79, p = 8.40E-14). 
There was significantly more expansion in scrambled left striatum compared to tail at 8 weeks (p = 3.47E-3) and 11 weeks 
(p = 1.08E-4). Untreated left striatum expanded significantly more than tail at 11 weeks (p = 1.60E-4). There was 
significantly more expansion in right compared to left scrambled striatum at 8 weeks (p = 2.52E-4), but not at 11 weeks 
(p = 0.29). Expansion was not significantly different between scrambled left striatum and liver at 8 weeks (p = 0.12) or 11 
weeks (p = 0.39), or between untreated left striatum and liver at 11 weeks (p = 0.59). 
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7.5.4.3.2.2 Fan1 knockdown 
Comparing scrambled and Fan1 knockdown, there was no significant difference in tail at 8 weeks (p = 0.49) or 11 weeks 
(p = 0.50), in left striatum at 8 weeks (p = 0.10) or 11 weeks (p = 0.28), in right striatum at 8 weeks (p = 0.26) or 11 weeks 
(p = 0.34), or in liver at 8 weeks (p = 0.86) or 11 weeks (p = 0.32). 
 
Figure 7.29. Somatic instability index relative to 12 day tail. 
Instability index is calculated relative to each animal’s own 12d tail. Error bars represent SEM. Brown – 12 day tail, orange – 8-11 
week tail, blue – left striatum (SL), red – right striatum (SR), purple – liver (LIV). Scr – scrambled. KD – knockdown. 
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Treatment n Somatic Instability index (SII) SEM (sii) 
12d R6/2 tail Scr 21 0.00 0.00 
12d R6/2 tail KD 23 0.00 0.00 
12d R6/2 tail untreated 11 0.00 0.00 
8wk R6/2 tail Scr 11 1.30 0.45 
8wk R6/2 tail KD 13 0.87 0.42 
11wk R6/2 tail Scr 9 1.82 0.45 
11wk R6/2 tail KD 9 2.34 0.57 
11wk R6/2 tail untreated 11 1.17 0.28 
8wk R6/2 SL Scr 11 3.50 0.42 
8wk R6/2 SL KD 13 4.83 0.55 
11wk R6/2 SL Scr 10 7.45 0.88 
11wk R6/2 SL KD 10 6.05 0.84 
11wk R6/2 SL untreated 11 6.16 0.91 
8wk R6/2 SR Scr 11 6.27 0.37 
8wk R6/2 SR KD 13 6.85 0.32 
11wk R6/2 SR Scr 10 9.03 1.05 
11wk R6/2 SR KD 10 7.72 0.78 
11wk R6/2 SR untreated 11 5.87 0.97 
8wk R6/2 LIV Scr 11 4.40 0.29 
8wk R6/2 LIV KD 13 4.32 0.26 
11wk R6/2 LIV Scr 10 6.56 0.41 
11wk R6/2 LIV KD 10 7.21 0.47 
11wk R6/2 LIV untreated 11 6.84 0.72 
Table 7.5. Somatic instability index relative to 12d tail. 
SL – left striatum, SR – right striatum, LIV – liver, Scr – scrambled, KD – knockdown, sii – somatic instability index. 
7.5.4.3.3 Proportional expansion analysis 
7.5.4.3.3.1 Scrambled and untreated tissues 
The proportion of the distribution width greater than the baseline mode (12d tail) increased significantly in 8 week 
scrambled tail (p = 1.02E-4), 11 week scrambled tail (p = 1.68E-6), 11 week untreated tail (p = 1.74E-3), 8 week scrambled 
left striatum (p = 9.37E-8), 11 week scrambled left striatum (p = 1.49E-11), 11 week untreated left striatum (p = 4.85E-8), 
8 week scrambled right striatum (p = 1.10E-14), 11 week scrambled right striatum (p = 3.40E-13), 11 week untreated right 
striatum (p = 1.01E-5), 8 week scrambled liver (p = 1.14E-11), 11 week scrambled liver (p = 4.50E-14) and 11 week 
untreated liver (p = 3.27E-6). 
Scrambled left striatum expanded significantly more than tail at 8 weeks (p = 0.049) and 11 weeks (p = 0.012). Untreated 
left striatum expanded significantly more than tail at 11 weeks (p = 8.22E-5). There was no significant difference between 
scrambled left and right striatum at 8 weeks (p = 0.21) or 11 weeks (p = 0.21), or between untreated left and right striatum 
at 11 weeks (p = 0.46). There was no significant difference between scrambled left striatum and liver at 8 weeks (p = 0.97) 
or 11 weeks (p = 0.86), or between untreated left striatum and liver at 11 weeks (p = 0.29). 
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7.5.4.3.3.2 Fan1 knockdown 
Comparing scrambled and Fan1 knockdown animals, there was no significant difference in tail at 8 weeks (p = 0.46) or 11 
weeks (p = 0.85), in left striatum at 8 weeks (p = 0.77) or 11 weeks (p = 0.67), in right striatum at 8 weeks (p = 0.28) or 11 
weeks (p = 0.51), or in liver at 8 weeks (p = 0.50) or 11 weeks (p = 0.77). 
 
Figure 7.30. Proportional expansion analysis. 
The proportion of the distribution width greater than the baseline (12d tail) modal CAG length. 0.5 represents a normal distribution 
with a mode equal to the control mode. The maximum is 1.0 (the entire distribution is greater than the control mode) and minimum is 
0.0 (the entire distribution is less than the control mode). Error bars represent SEM. Brown – 12 day tail, orange – 8-11 week tail, blue 
– left striatum (SL), red – right striatum (SR), purple – liver (LIV). Scr – scrambled. KD – knockdown.  
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Treatment n Proportion of distribution > control mode SEM (proportion) 
12d R6/2 tail Scr 21 0.45 0.01 
12d R6/2 tail KD 23 0.44 0.01 
12d R6/2 tail untreated 11 0.45 0.02 
8wk R6/2 tail Scr 11 0.58 0.03 
8wk R6/2 tail KD 13 0.54 0.04 
11wk R6/2 tail Scr 9 0.61 0.03 
11wk R6/2 tail KD 9 0.62 0.03 
11wk R6/2 tail untreated 11 0.57 0.02 
8wk R6/2 SL Scr 11 0.69 0.04 
8wk R6/2 SL KD 13 0.71 0.03 
11wk R6/2 SL Scr 10 0.73 0.03 
11wk R6/2 SL KD 10 0.75 0.02 
11wk R6/2 SL untreated 11 0.74 0.02 
8wk R6/2 SR Scr 11 0.75 0.02 
8wk R6/2 SR KD 13 0.78 0.02 
11wk R6/2 SR Scr 10 0.78 0.03 
11wk R6/2 SR KD 10 0.76 0.03 
11wk R6/2 SR untreated 11 0.71 0.04 
8wk R6/2 LIV Scr 11 0.69 0.02 
8wk R6/2 LIV KD 13 0.71 0.02 
11wk R6/2 LIV Scr 10 0.74 0.01 
11wk R6/2 LIV KD 10 0.73 0.02 
11wk R6/2 LIV untreated 11 0.70 0.03 
Table 7.6. Proportional expansion analysis. 
The proportion of the distribution width greater than the baseline (12d tail) modal CAG length. 0.5 represents a normal distribution 
with a mode equal to the control mode. The maximum is 1.0 (the entire distribution is greater than the control mode) and minimum is 
0.0 (the entire distribution is less than the control mode). SL – left striatum, SR – right striatum, LIV – liver, Scr – scrambled. KD – 
knockdown. 
7.5.4.4 Comparing CAG repeat expansion and Fan1 expression 
7.5.4.4.1 Change in modal CAG repeat length 
Change in modal CAG repeat length was regressed against Fan1 expression level. No significant effect was observed in 
left striatum, right striatum or liver. Grouping liver tissue at all ages, there was a trend towards reduced expansion with 
higher Fan1 expression (slope = -2.54 ± 1.48, p = 0.093). 
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Figure 7.31. Change in modal CAG repeat length against Fan1 expression. 
Top left – left striatum (SL), top right – right striatum (SR), bottom – liver (LIV). Lines represent linear regression. Blue – 8 week R6/2, 
orange – 11 week R6/2. 
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7.5.4.4.2 Somatic instability index 
There was no significant correlation between somatic instability index (SII) and Fan1 expression level. 
 
Figure 7.32. Somatic instability index against Fan1 expression. 
Top left – left striatum (SL), top right – right striatum (SR), bottom – liver (LIV). Lines represent linear regression. Blue – 8 week R6/2, 
orange – 11 week R6/2. 
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7.5.4.4.3 Proportional expansion analysis 
The proportional expansion metric was not significantly associated with Fan1 expression. 
 
Figure 7.33. Proportional expansion analysis against Fan1 expression. 
The proportion of the distribution width greater than the baseline (12d tail) modal CAG length. 0.5 represents a normal distribution 
with a mode equal to the control mode. The maximum is 1.0 (the entire distribution is greater than the control mode) and minimum is 
0.0 (the entire distribution is less than the control mode). Top left – left striatum (SL), top right – right striatum (SR), bottom – liver 
(LIV). Lines represent linear regression. Blue – 8 week R6/2, orange – 11 week R6/2. 
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7.6 Discussion 
7.6.1 Fan1 expression level in R6/2 tissues 
Our pilot study of Fan1 expression in ten R6/2 tissues at 4 and 14 weeks showed relatively high transcript levels in 
cerebellum, cord, hippocampus and lung, and relatively low levels in adrenal, kidney and liver, all of which are consistent 
with published microarray and RNA-Seq data (EMBL-EBI Expression Atlas) (Papatheodorou et al., 2018). CAG expansion 
is known to be marked in the liver and limited in the cerebellum, suggesting Fan1 expression may be a protective 
modifier. 
7.6.2 Optimisation of assays 
This project required DNA, RNA and protein extraction from a small 9 mg striatum sample. A 3-in-1 extraction kit was 
trialled, which uses filter column technology to sequentially extract DNA, RNA and protein from the same sample. Though 
DNA and RNA purity were equivalent to traditional extraction techniques, the yield was significantly reduced to 4% and 
28% respectively. Fan1 relative expression, as calculated by the comparative Ct method, was significantly different 
between 3-in-1 and traditionally extracted cDNA. The protein yield was also significantly reduced, and nuclear proteins 
were selectively lost, possibly because nuclear fractions were removed with DNA and RNA during the 3-in-1 protocol. 
Traditional DNA, RNA and protein extraction, followed by CAG repeat sizing, RT-qPCR and western blot demonstrated 
that robust data can be generated from 1/3 of a striatum. Therefore, experimental striatal samples were divided into 
thirds and extracted using traditional methods. 
7.6.3 Toxicity study 
The left striatum was successfully transduced by direct injection, as demonstrated on western blot and 
immunohistochemistry by high GFP expression and Fan1 knockdown by around 90%. Though not directly injected, the 
right striatum was transduced at a lower level and showed around 50% Fan1 knockdown. Fan1 expression levels in the 
liver are endogenously low, making interpretation of knockdown difficult (Papatheodorou et al., 2018). Following 
intravenous administration there was modest GFP expression in liver, and lower level expression following striatal 
injection. Intraperitoneal injection effectively transduced the liver, as demonstrated by immunohistochemistry, though 
GFP level was lower in the scrambled virus. Neither striatal or intravenous method produced toxicity. There was no 
difference in HTT aggregate levels between scrambled or Fan1 knockdown animals. 
Given the limited transduction efficiency of intravenous injection, a combined striatal and intraperitoneal injection 
protocol was selected for the experimental study, aiming to maximise knockdown Fan1 in the striatum and liver; the 
tissues most prone to CAG repeat expansion in R6/2. 
7.6.4 Fan1 knockdown 
Mice were treated by left striatal and intraperitoneal injection at 4 weeks age which produced stable 23% transcript 
knockdown, relative to scrambled control, in left striatum and liver throughout the experiment. Fan1 expression in right 
striatum was unaffected. This is a significantly smaller effect than observed in the toxicity experiment. 
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7.6.5 CAG repeat instability 
R6/2 mice at the 12 day baseline in each of the scrambled, knockdown and untreated groups had a mean tail CAG repeat 
length of 188, with no significant difference between groups. Three measures of somatic instability were used, as detailed 
in the Methods chapter. 
1. Change in modal repeat size. 
2. Somatic instability index (SII). 
3. Proportional expansion analysis. 
The modal CAG repeat size increased by around 2 repeat units in left striatum (1.81 ± 0.33), right striatum (2.10 ± 0.47) 
and liver (3.29 ± 1.34), and by 0.97 ± 0.39 units in tail over the course of the experiment. Using this measure, there was 
significantly more expansion in striatum and liver than in tail (p = 0.026), but there was no significant difference between 
striatum and liver. Critically, there was no significant difference between Fan1 knockdown, scrambled or untreated 
animals at either 8 or 11 weeks age in any of the tissues sampled. 
SII is expressed in CAG repeat units and is a more sensitive measure of instability (Lee et al., 2010, Zhao and Usdin, 2018). 
Once again this showed significantly more expansion in left striatum (7.45 ± 0.88Q), right striatum (9.03 ± 1.05Q) and 
liver (6.56 ± 0.41Q) than in tail (1.82 ± 0.45Q) at 11 weeks age (p = 4.68E-13). There was no significant difference between 
expansion rate in liver and striatum. Once again, Fan1 knockdown did not significantly alter the SII in any of the tissues. 
The proportional expansion method measures the width of the CAG repeat distribution above the modal CAG length of 
the baseline 12d tail sample. It is expressed as a proportion, with 0.5 indicating a normal distribution centred on the 
baseline modal CAG length. There was significantly more expansion in left striatum (0.73 ± 0.03), right striatum (0.78 ± 
0.02) and liver (0.74 ± 0.01) than in tail (0.61 ± 0.03) at 11 weeks (p = 0.012). Again, there was no significant difference 
between expansion rate in striatum and liver. Concurring with the previous analyses, Fan1 knockdown did not 
significantly alter proportional expansion relative to scrambled or untreated animals. 
Several lines of evidence, including in patient-derived stem cell and differentiated medium spiny neurons (Chapters 5 
and 6), suggest Fan1 knockdown accelerates CAG repeat expansion in vitro. The lack of effect in this mouse model is likely 
due to the low level of knockdown. By comparison, stable shRNA-mediated 50% Fan1 knockdown in a stem cell model 
with ~120 CAG repeats accelerated expansion rate from 13.95 ± 0.31 days/Q to 9.81 ± 0.27 days/Q (p = 3.15E-15). 
Regressing CAG expansion against Fan1 expression in left and right striatum and liver, there was no significant correlation. 
However, there did appear to be a trend towards slower expansion in animals with higher Fan1 expression at 11 weeks 
in all tissues. 
7.7 Summary 
Fan1 is expressed at relatively low level in some tissues that show marked CAG repeat expansion, such as liver, and at 
relatively high levels in some tissues in which expansion is limited, such as cerebellum. This warrants a more detailed 
exploration of Fan1 expression and CAG expansion across mouse tissue. 
Traditional extraction methods for DNA, RNA and give higher and purer yields than a combined extraction kit, with which 
we found selective loss of transcripts and nuclear proteins. 
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The toxicity study suggested left striatal injection gave up to 90% Fan1 knockdown in the left striatum and 50% 
knockdown in the right striatum. Liver was well transduced following intraperitoneal injection of active Fan1 knockdown 
virus, as evidenced by GFP expression, but low endogenous Fan1 levels made relative knockdown difficult to ascertain. 
A combined left striatal and intraperitoneal injection technique was selected for the experimental study. 
Fan1 was knocked down by 23% in experimental left striatum and liver throughout the experiment, and there was no 
effect on right striatum. This level of knockdown is significantly lower than observed in vitro an in the toxicity study using 
the same target sequence. 
There was significant CAG repeat expansion in striatum and liver, more so than tail. However, Fan1 knockdown did not 
modify expansion rate. There was a suggestion of correlation between Fan1 expression level and slower expansion in 11 
week old striatum and liver, though this was not significant. 
It is likely that a greater level of knockdown, or indeed Fan1 knockout, may be required in order to observe an effect on 
CAG repeat expansion rate over this experimental timeframe. 
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Chapter 8 MSH3 modifies somatic instability and disease severity in 
Huntington’s disease and myotonic dystrophy type 1 
8.1 Background 
8.1.1 Trinucleotide repeat instability in Huntington’s and myotonic dystrophy 
Huntington’s disease (HD) and myotonic dystrophy type 1 (DM1) are autosomal dominant disorders caused by CAG·CTG 
trinucleotide repeat expansions. HD is characterised by a progressive movement disorder, cognitive impairment and 
psychiatric symptoms (Bates et al., 2014), and DM1 by myotonia, muscular dystrophy, cognitive impairment, cardiac 
conduction defects and endocrine dysfunction (Harper, 2001). No disease-modifying treatments are available for either 
(Meola and Cardani, 2015, Bates et al., 2015b). 
HD is caused by a (CAG)n repeat expansion in HTT exon 1 and DM1 by a (CTG)n expansion in the 3’ untranslated region 
(UTR) of DMPK (Bates et al., 2014, Brook et al., 1992). In both, inherited repeat length is the major determinant of disease 
course, correlating inversely with the age at onset (AAO) and positively with disease severity. The repeat is unstable and 
expansion during germline transmission results in genetic anticipation (Bates et al., 2014, Hunter et al., 1992). Consistent 
with this, there is significant CAG length mosaicism HD patient sperm, which correlates with expansion on transmission 
(Telenius et al., 1995). In transgenic mice, expansion occurs after meiosis, suggesting DNA replication is not involved 
(Kovtun and McMurray, 2001). Repeat tracts are also unstable in somatic cells, tending to expand over time, particularly 
in HD striatum (Kennedy et al., 2003) and DM1 muscle (Ashizawa et al., 1993), the most prominently affected tissues in 
each disease. Such expansion-biased, age-dependent and tissue-specific somatic instability is thought to contribute to 
disease onset and progression (Kennedy et al., 2003, Shelbourne et al., 2007b, Swami et al., 2009, Morales et al., 2012). 
As this expansion occurs in postmitotic neurons, continues in transgenic mouse cells when the cell cycle is arrested 
(Gomes-Pereira et al., 2014b), and does not occur in mice when the HD transgene is not expressed (Mangiarini et al., 
1997), expansion likely occurs during DNA repair, rather than during replication or transcription. 
8.1.2 Modifiers of repeat instability 
In CAG·CTG expansion mouse models, the DNA mismatch repair complex MutSβ is essential for repeat expansion, and 
inactivating or reducing expression of the MutSβ components Msh2 and Msh3 limits expansion events and improves 
disease phenotype (Dragileva et al., 2009, Tome et al., 2013a, van den Broek et al., 2002, Foiry et al., 2006, Pinto et al., 
2013a). Mismatch repair components have also been implicated as genetic modifiers in patients with HD and DM1. A 
candidate gene association study in DM1 reported a single nucleotide polymorphism (SNP) in MSH3 that was associated 
with the rate of somatic expansion (Morales et al., 2016). Genome-wide association studies (GWAS) in HD identified 
genetic variation in DNA repair genes including FAN1, RRM2B, MSH3 and MLH1, that modifies disease course, and 
pathway analyses in each study highlighted sets of DNA repair genes (GeM-HD, 2015, Lee et al., 2017, Hensman Moss et 
al., 2017b). Such variants have also been shown to influence onset in other CAG expansion polyglutamine diseases 
(Chapter 3), suggesting a common mechanism operates in conditions caused by repeat expansion (Bettencourt et al., 
2016).  
The lead variant in a recent GWAS linking MSH3 with HD progression was the imputed single nucleotide polymorphism 
(SNP) rs557874766, which nominally results in the Pro67Ala amino acid change at the N-terminus (Hensman Moss et al., 
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2017b). However, rs557874766 is located within a 9 bp tandem repeat in exon 1 of MSH3 and the promoter of the 
dihydrofolate reductase gene (DHFR) on the opposite strand. The 9 bp tandem repeat is polymorphic in copy number 
(Nakajima et al., 1995, Morales et al., 2016) and sequence (Morales, 2006). The region was first identified by Nakajima 
et al. (1995), who observed a 3-repeat variant in HeLa cells. In the Japanese population they estimated allele frequencies 
of 0.603 for 6 repeats, 0.190 for 7 repeats, 0.155 for 3 repeats, 0.043 for 4 repeats and 0.009 for 5 repeats. Additionally, 
the 500 bp region flanking the MSH3 repeat is highly polymorphic, containing six SNPs and a 1 bp indel. 
8.1.3 MSH3 function 
MSH3 complexes with MSH2 to form MutSβ, which binds DNA mismatches incorporated during replication and initiates 
repair by recruiting the MutLa complex (MLH1/PMS). However, MSH3 has also been shown to bind and stabilise CAG 
hairpin loops (Owen et al., 2005) and actively repair lesions in non-replicating cells (Rodriguez et al., 2012, Tome et al., 
2013a). Its published crystal structure (Acharya et al., 1996) excludes the N-terminal repeat region, in which rs557874766, 
the variant implicated in HD, is located (Hensman Moss et al., 2017b). MSH3 is expressed ubiquitously, but it is 
upregulated in the brains of HD mouse models (Gonitel et al., 2008). Frameshift and compound heterozygous mutations 
can cause endometrial cancer (Risinger et al., 1996) and recessively inherited colorectal cancer (Adam et al., 2016) 
respectively, but Msh3 inactivation is not associated with cancer predisposition (de Wind et al., 1999). 
8.2 Aims 
Given the complex nature of the 9 bp tandem repeat in exon 1 of MSH3, rs557874766 may be an alignment artefact 
resulting from differences in number and sequence of MSH3 repeat alleles. The Hensman Moss et al. (2017b) GWAS 
identified a genomic region associated with disease progression, but the variant with the smallest p-value (the ‘lead’ SNP) 
is not necessarily causal (Bush and Moore, 2012, Spain and Barrett, 2015). In order to finely map this association region, 
this chapter describes targeted Illumina sequencing of the MSH3 exon 1 region in 218 HD and 247 DM1 subjects. By 
directly genotyping all the variants within the region, including repeat alleles and flanking variants, with high confidence 
in multiple patient cohorts, accurate haplotype information was generated (Spain and Barrett, 2015). Though long read 
sequencing gives significant advantages for complex and repetitive regions, Ilumina MiSeq amplicon sequencing, with a 
read length of 2 x 300 bp and primers targeting the MSH3 association region, was sufficient to accurately sequence the 
9 bp tandem repeat, and its flanking variants (Pollard et al., 2018). Using lymphoblastoid cells and whole blood RNA-Seq 
in HD, this chapter studies whether sequence variation at the MSH3/DHFR locus influences their expression. A 
transcriptome-wide association study (TWAS) investigates whether genetic variation in MSH3 and FAN1 that is associated 
with HD disease course also influences expression in brain. 
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8.3 Methods 
8.3.1 Cohorts 
The HD cohort was from TRACK-HD, a prospective, observational study with detailed phenotypic data from 218 adults 
with early HD or premanifest carriers of disease-associated alleles (Tabrizi et al., 2009a). 
The DM1 cohort was from OPTIMISTIC, a multicentre randomised clinical trial (van Engelen and Consortium, 2015) that 
recruited 255 ambulant adult patients affected by severe fatigue and with a genetic diagnosis of DM1. 
8.3.2 Progenitor allele length 
Molecular diagnosis and genotyping of the HD CAG repeat has traditionally used estimation of PCR fragment size. 
However, this approach is complicated by the presence of an adjacent polymorphic CCG repeat and provides no 
information on the presence of variant repeats, flanking sequence variants or on the degree of somatic mosaicism. To 
overcome these limitations, Ciosi et al. (2018) developed an amplicon-sequencing protocol on the MiSeq (Illumina) 
platform. Progenitor pure CAG length for HD in this chapter was determined in Ciosi et al., (under review) by MiSeq 
sequencing (Ciosi et al., 2018). The HTT sequence encoding the polyglutamine and polyproline tracts was amplified using 
MiSeq-compatible PCR primers. The HTT locus-specific primers used were HS319F (5’-GCGACCCTGGAAAAGCTGATGA-3’) 
and 33935.5 (5’-AGCAGCGGCTGTGCCTGC-3’) which respectively bind 26 bp 5’ upstream of the CAG repeat and 26 bp 3’ 
downstream of the CCG repeat. PCR was conducted with the Nextera XT Kit v2 set, and a fraction of each product was 
pooled and cleaned using AMPure XP beads (Beckman Coulter). Library concentration was measured using a Qubit 
fluorometer and the dsDNA High Sensitivity (HS) Assay Kit (Qubit), then library size and purity were checked on a 
Bioanalyzer before accurate quantification by qPCR using the KAPA Library Quantification Kit (KAPABIOSYSTEMS). The 
library was sequenced on the MiSeq platform. 
Five HD subjects were excluded because they were part of a twin pair (n=1) or the progenitor CAG length could not be 
unambiguously identified (n=4) (Ciosi et al., under review). For the remaining 213 HD subjects, mean CAG repeat length 
was 43.10 (sd = 2.24), mean AAO was 44.83 (sd = 8.82) and mean progression score was 0.0 (sd = 1.0). CAG length 
negatively correlated with AAO, with each repeat advancing onset by 3.16 ± 0.22 years (r2 = 0.621, p = 2.2E-16). 
DM1 progenitor allele length was determined by small pool PCR (van Engelen and Consortium, 2015) (Cumming et al., 
under review). DM1 patients were tested for CCG repeat interruptions, known cis-modifiers of CTG repeat stability and 
disease phenotype (Cumming et al., 2018) (Cumming et al., under review). 
8.3.3 Phenotypes 
Two phenotypes were common to both cohorts: AAO and rate of somatic expansion of the pathogenic CAG·CTG repeat. 
HD AAO represents onset of motor symptoms (Tabrizi et al., 2009a). DM1 AAO was subject self-assessment of the first 
occurrence of symptoms likely related to DM1 (Cumming et al., under review). Somatic CAG·CTG expansion in blood was 
previously quantified in both cohorts (Ciosi et al. under review; Cumming et al., under review). With sufficient sequencing 
depth, HTT MiSeq data can also be used to quantify the degree of somatic mosaicism of the HTT CAG. For HD MiSeq data, 
the measure of somatic expansion was the proportion of reads in the sample that correspond to somatic expansions 
(reads with more CAG repeats than the progenitor allele) relative to the proportion of reads obtained for the progenitor 
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allele (Ciosi et al. under review). This measure correlated with disease course in the Track-HD and Enroll-HD cohorts, 
suggesting subjects with a greater level of somatic expansion had earlier onset and progressed more rapidly. 
ln(SM) = β0 + β1 Q1+ β2 Age + β3 Q1 * Age 
Equation 8.1. Regression model of the relationship between disease severity, allele structures and somatic mosaicism in HD, from 
Ciosi et al. (2018). 
β0 (intercept) = -9.5, β1 = 0.18, Q1 = pure CAG repeat length, β2 = -0.02, β3 = 8.8E-04. 
For DM1, the measure of somatic expansion was the difference in number of repeats between the modal allele and the 
estimated progenitor allele length (Cumming et al., 2018). In both cohorts, relative rate of somatic expansion corresponds 
to the variation in the measures of somatic expansion that is not explained by age and CAG·CTG repeat length. Positive 
values reflect a faster rate of somatic expansion. 
Two phenotypes were only available for HD; progression score (Hensman Moss et al., 2017b) and gene expression. 
Progression score was derived for 213 TRACK-HD subjects in Ciosi et al., (under review), as described in Hensman Moss 
et al. (2017b). It measures typical HD progression that is not explained by age and pure CAG repeat length, with positive 
scores reflecting faster progression. One unit increase in the unified HD progression measure corresponds to an increase 
of 0·71 units per year (95% CI 0·34-1·08) in the rate of change of UHDRS total motor score (TMS), and an increase of 
approximately 0·2 units per year (0·12-0·30) in the rate of change of total functional capacity (TFC). Whole blood RNA-
Seq was available for a representative sample of 54 premanifest gene carriers and 63 manifest HD subjects from the 
Track-HD cohort, selected to ensure a range of disease risk and severity. RNA extraction and sequencing were performed 
as detailed in chapter 4 (Hensman Moss et al., 2017a). Four samples failed quality control for duplication rate over 75%, 
GC bias or 5’ bias, and were removed, leaving 48 premanifest and 61 manifest subjects. 
MSH3 expression was measured by Western blot, normalised to actin, and by Taqman qPCR using the Hs00989003_m1 
probe set (ThermoFisher), and housekeeping genes ACTB (Hs01060665_g1), ATP5B (Hs00969569_m1) and EIF4A2 
(Hs00756996_g1) (see Materials and Methods). 
8.3.4 Illumina sequencing 
MiSeq amplicon sequencing, adapted from Ciosi et al. (2018), was used to genotype the MSH3 exon 1 repeat and flanking 
variants (Figure 1). The MSH3 repeat region was amplified from 10 ng blood genomic DNA using gene-specific primers 
(forward 5’- AGTTTGGCGCGAAATTGTGG-3’, reverse 5’-CTTCCTCCTCCAGCCCTATC-3’) with attached Nextera XT Index Kit 
v2 barcode adaptors (see Appendix). This includes 40 indexes (16 i5 and 24 i7) and can be used to process up to 384 
samples per run. The 524 bp amplicon was designed to balance limits of efficient PCR amplification with inclusion of 
variants in linkage disequilibrium (LD) with rs557874766. A 10 µL PCR reaction included 1 µL DNA, 10% DMSO, 1 µM of 
each primer, 1 µL of 10X Custom PCR master mix (Thermo Scientific; 45 mM Tris-HCl (pH 8.8), 11 mM (NH4)2SO4, 4.5 mM 
MgCl2, 0.113 mg/ml BSA, 4.4 µM EDTA, 1 mM each of dATP, dCTP, dGTP and dTTP), 0.048 % (v/v) 2-mercaptoethanol and 
1 U of Taq polymerase (Sigma). Thermal cycling conditions were an initial denaturation of 96°C for 5 min, followed by 30 
cycles of 96°C for 45 s, 60°C for 45 s and 70°C for 2 min with a final extension of 65°C for 1 min and 70°C for 10 min. After 
amplification, 5 µL of each PCR reaction was pooled, purified and concentrated with two cycles of AMPure XP bead clean-
up (Beckman Coulter) on a magnetic stand, as described in Ciosi et al. (2018). DNA concentration of the purified library 
was measured using a Qubit fluorimeter and the dsDNA High Sensitivity (HS) assay kit (Life Technologies). This was used 
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to prepare a 0.5 ng/µL dilution that could be run on a Bioanalyzer (Agilent) to check library size, ensure primer dimer 
exclusion and check concentration, aiming for a library of at least 30 µL at 10 nM. The quantity of sequencable molecules 
was measured by qPCR using the KAPA Library Quantification Kit (KAPABIOSYSTEMS). The concentration of the 
sequencing library was then calculated and corrected for size using the average fragment size estimated by the 
Bioanalyzer. The library was diluted to 4 nM, based on the qPCR molarity estimate, and sequenced following Illumina 
guidelines for an amplicon MiSeq run, using MiSeq Reagent Kit v3 (Illumina) with a cluster density of 1000k cluster/mm2 
but with 5% PhiX spike-in (the PhiX library allows increasing nucleotide diversity during the run and also serves as a 
sequencing control). The 600 sequencing cycles were run 400 forward, 200 reverse to maximise coverage of the MSH3 
repeat region. Quality control of the sequencing run confirmed >80% of bases had a quality >30. The MiSeq Reporter 
software (version 2.5.1) was used to demultiplex reads corresponding to the index primer pair used. This outputs the 
sequencing reads in .fastq format, two (Read 1 and Read 2) for each of the 96 or 384 indexes, as well as two (Read 1 and 
Read 2) undetermined reads (reads corresponding to the PhiX control library, which is not indexed, and reads for which 
the indexes could not be identified). 
 
Figure 8.1. Schematic of sequencing design for the MSH3 exon 1 region. 
Gene-specific primers with attached MiSeq Illumina barcodes were designed to amplify 534 bp covering MSH3 9 bp tandem repeat 
region and seven flanking variants. SNP IDs are indicated for each variant, repeat units are coded by coloured boxes, the imputed SNP 
from GWAS on HD progression is shown in red. Arrows show direction of forward (Read 1) and reverse (Read 2) reads during MiSeq 
Illumina sequencing, 400 nucleotides were sequenced in a forward read and 200 nucleotides in a reverse read. 
MiSeq runs were quality controlled by running the ‘PhiX.R1andR2.QC.400x200bp.run’ workflow on undetermined.fastq 
files, which correspond to PhiX reads and lack barcodes, with the PhiX reference sequence (see Appendix). This confirmed 
>80% of bases had a Phred quality >30. 
8.3.5 Bioinformatic analyses 
Genotyping was conducted on the University of Glasgow Galaxy platform (heighliner.cvr.gla.ac.uk). Paired-end reads 
were merged with Pear and aligned with BWA-MEM to 84 references corresponding to potential 9 bp repeat alleles (see 
GCTGCAGCG GCCGCAGCG CCCCCAGCG CCCCCAGCT
MiSeq amplicon
rs1511273
rs10168
rs2250063
rs1105524 rs1677658
rs1650697rs1105525
rs557874766
Read 1Read 2
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Appendix), followed by variant calling using the Naive Variant Caller (NVC). For repeat homozygotes, haplotypes were 
confirmed from .sam files using Tablet (Milne et al., 2013). The Galaxy workflow is available in the Appendix and at 
https://www.myexperiment.org/workflows/5087.html. Conservation analysis used PhastCons and PhyloP (UCSC), with 
species sequence alignment in Clustal Omega. 
8.3.6 Transcriptome-wide association study (TWAS) 
The method of Gusev et al. (2016) was used to test for association between phenotype and gene expression in control 
dorsolateral prefrontal cortex from the CommonMind Consortium (n=452) (CMC, 2017) using GWAS summary statistics 
from the Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium GWAS of AAO (n = 4082) (GeM-HD, 2015) and 
the combined TRACK-HD and REGISTRY GWAS of HD progression (n = 2078) (Hensman Moss et al., 2017b). 
8.3.7 Statistical analyses 
Linear regression modelling of genotype-phenotype correlation was conducted in R (R Core Team, 2013). An additive 
genetic model was used to score genotypes. For AAO, analyses controlled for CAG·CTG repeat length in HD and DM1, and 
for repeat interruptions in DM1 (Table 1). Meta-analysis of somatic expansion and AAO in HD and DM1 was conducted 
with METAL (Willer et al., 2010). PLINK 1.07 (Purcell et al., 2007) was used to derive allele frequencies, Hardy-Weinberg 
equilibrium (HWE) and linkage disequilibrium (LD). Haplotype relationships were visualised as a network using median 
joining on NETWORK (Bandelt et al., 1999). 
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  Model Adjusted r2 Model p Parameter   Coefficient Standard error t-statistic Parameter p 
1a AAO = β0 + β1 log10(CAG.CTG) + β2 Variant Repeats 0.24 3.35 x 10-14 Intercept β0 86.63 7.73 11.21 < 2 x 10-16 
 OPTIMISTIC, n = 222   log10(CAG.CTG) β1 -26.5 3.3 -8.04 5.50 x 10-14 
    Variant Repeats β2 13.85 3.2 4.33 2.23 x 10-05 
1b log10(SE) = β0 + β1 log10(CAG.CTG) + β2 Variant Repeats 0.581 
< 2.2 x 10-
16 Intercept β0 -0.96 0.18 -5.47 1.14 x 10
-07 
 OPTIMISTIC, n = 247   log10(CAG.CTG) β1 1.38 0.07 18.46 < 2 x 10-16 
        Variant Repeats β2 -0.38 0.07 -5.31 2.47 x 10-07 
2a ln(AAO) = β0 + β1 CAG.CTG 0.661 < 2.2 x 10
-
16 Intercept β0 6.59 0.18 37.03 < 2 x 10
-16 
  TRACK-HD, n = 130     CAG.CTG β1 -0.06 0 -15.88  < 2 x 10-16 
Table 8.1. Regression models of the relationships between allele structures, relative rate of somatic expansion and disease 
phenotypes in Huntington’s disease and myotonic dystrophy type 1. 
The table shows the adjusted squared coefficient of correlation (adjusted r2), and statistical significance (p) for each model, and the 
coefficient, standard error, t statistic and statistical significance (p), associated with each parameter in the model. The coefficient 
provides an indication of the relative weight of the contribution of each parameter to the model and its associated standard error. 
The t statistic and corresponding p value provide an indication of the statistical significance that the parameter is adding to the 
explanatory power to the model. AAO: age at onset of HD and DM1. CAG·CTG: inherited repeat allele length in HD and DM1. Variant 
repeats – presence/absence of repeat interruptions in DM1 expanded repeat allele. SE: relative rate of somatic expansions. Note that 
model for relative rate of somatic expansion, not shown here, was obtained from (Ciosi et al. under review). 
8.4 Contributions 
This study was conceived by Professors Sarah Tabrizi (UCL) and Darren Monckton (University of Glasgow). The Illumina 
sequencing protocol was developed by Marc Ciosi and Vilija Lomeikaite (University of Glasgow). Sequencing and analysis 
in the HD cohort was conducted by Michael Flower and in the myotonic dystrophy type 1 cohort by Vilija Lomeikaite. 
Somatic instability in the DM1 cohort was determined by Fernando Morales (University of Glasgow), and for the HD 
cohort DNA was prepared by Michael Flower and instability was measured by Marc Ciosi. HD patient blood RNA was 
prepared by Davina Hensman Moss, sequenced at Biorep, aligned by Kitty Lo (University of Sydney) and Vincent Plagnol 
(UCL), and analysed by Michael Flower. Statistical analyses were conducted by Michael Flower. The transcriptome-wide 
association study (TWAS) was conducted by Prof Peter Holmans (Cardiff University). These results were included in a 
manuscript written by Michael Flower, which has been accepted for publication in Brain. 
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8.5 Results 
8.5.1 Rs557874766 is an alignment artefact 
In order to better understand the association between the variation in MSH3 and trinucleotide repeat disease phenotype, 
the exon 1 region was sequenced in cohorts of HD and DM1 patients. Sanger sequencing shows the 9 bp tandem repeat 
is polymorphic and varies in the repeat number and sequence, with heterozygosity of 0.57 (Nakajima et al., 1995). 
Here, sixteen MSH3 repeat alleles were observed, differing in sequence and length from three to nine repeats (Figure 2A 
and Table 2). Alleles contained combinations of five types of repeat units, with coding potential for proline or alanine 
(Figure 2A). They were numbered by repeat length, and suffixed alphabetically by frequency i.e. ‘3a’ represents the most 
common three-repeat allele. 
The commonest allele in both cohorts, 6a (Figure 2B), corresponds to the human reference sequence (NC_000005.10, 
GRCh38.p12). Illumina sequencing revealed that rs557874766 (Hensman Moss et al., 2017b) was not a SNP, but an 
alignment artefact resulting from the complex 9 bp repeat sequence (Figure 2C). Individuals with the rs557874766 minor 
allele instead carry a three-repeat allele, 3a, the second most common allele observed in both cohorts. Two HD subjects 
imputed as homozygous for the rs557874766 major allele were determined to be heterozygous for the 3a repeat allele 
by both Illumina and Sanger sequencing (Figure 3), highlighting the importance of directly genotyping such complex loci. 
In conclusion, the rs557874766 does not exist in the form of a SNP and results from incorrect alignment of the 3a allele 
to the reference 6a allele (Figure 2C). 
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Figure 8.2. MSH3/DHFR 9bp tandem repeat allele structure and frequency observed in HD and DM1 cohorts. 
(A) Schematic representation of the 9 bp tandem repeat alleles observed in this study and their coding potential. Repeat units are 
colour-coded by DNA and amino acid sequence. Location of the repeat and flanking variants in relation to MSH3/DHFR locus are 
shown in the top panel. This locus contains overlapping MSH3 exon 1 and DHFR promoter regions. For both MSH3 and DHFR, the 5’-
untranslated region is shown in white and coding sequence in light grey. The direction of transcription is indicated by arrows for each 
gene. (B) Repeat allele frequencies observed in HD and DM1. Four common alleles, 3a, 6a, 7a and 8a, are observed in HD and DM1 
cohorts at similar frequencies. (C) Schematic showing potential misalignments of 3a and 6a alleles, resulting in the apparent SNP 
rs557874766, shown in red on the lower alignment. Black marks in the top alignment represent mismatches that could be created in 
a similar manner as rs557874766, by misalignment of the 3a and 6a repeat alleles. 
MSH3 
repeat 
allele 
Number 
of 
repeats 
Repeat Sequence Allele 
Frequency 
HD DM1 
3a 3 (GCTGCAGCG)1(GCCGCAGCG)1(CCCGCAGCG)0(CCCCCAGCG)1(CCCCCAGCT)0 0.251 0.266 
3b 3 (GCTGCAGCG)2(GCCGCAGCG)0(CCCGCAGCG)0(CCCCCAGCG)1(CCCCCAGCT)0 0.002 0.000 
5a 5 (GCTGCAGCG)2(GCCGCAGCG)1(CCCGCAGCG)0(CCCCCAGCG)1(CCCCCAGCT)1 0.007 0.004 
5b 5 (GCTGCAGCG)2(GCCGCAGCG)2(CCCGCAGCG)0(CCCCCAGCG)0(CCCCCAGCT)1 0.002 0.000 
6a 6 (GCTGCAGCG)2(GCCGCAGCG)2(CCCGCAGCG)0(CCCCCAGCG)1(CCCCCAGCT)1 0.585 0.592 
6b 6 (GCTGCAGCG)2(GCCGCAGCG)1(CCCGCAGCG)1(CCCCCAGCG)1(CCCCCAGCT)1 0.007 0.002 
6c 6 (GCTGCAGCG)1(GCCGCAGCG)3(CCCGCAGCG)0(CCCCCAGCG)1(CCCCCAGCT)1 0.002 0.000 
7a 7 (GCTGCAGCG)2(GCCGCAGCG)2(CCCGCAGCG)1(CCCCCAGCG)1(CCCCCAGCT)1 0.092 0.069 
7b 7 (GCTGCAGCG)2(GCCGCAGCG)2(CCCGCAGCG)0(CCCCCAGCG)2(CCCCCAGCT)1 0.005 0.006 
7c 7 (GCTGCAGCG)1(GCCGCAGCG)3(CCCGCAGCG)0(CCCCCAGCG)2(CCCCCAGCT)1 0.002 0.002 
7d 7 (GCTGCAGCG)1(GCCGCAGCG)3(CCCGCAGCG)1(CCCCCAGCG)1(CCCCCAGCT)1 0.002 0.000 
7e 7 (GCTGCAGCG)2(GCCGCAGCG)3(CCCGCAGCG)0(CCCCCAGCG)1(CCCCCAGCT)1 0.002 0.000 
8a 8 (GCTGCAGCG)2(GCCGCAGCG)3(CCCGCAGCG)1(CCCCCAGCG)1(CCCCCAGCT)1 0.036 0.055 
8b 8 (GCTGCAGCG)1(GCCGCAGCG)4(CCCGCAGCG)1(CCCCCAGCG)1(CCCCCAGCT)1 0.002 0.000 
9a 9 (GCTGCAGCG)2(GCCGCAGCG)1(CCCGCAGCG)0(CCCCCAGCG)5(CCCCCAGCT)1 0.000 0.002 
9b 9 (GCTGCAGCG)2(GCCGCAGCG)3(CCCGCAGCG)1(CCCCCAGCG)2(CCCCCAGCT)1 0.000 0.002 
Table 8.2. MSH3 9 bp tandem repeat alleles observed in HD and DM1 cohorts. 
Allele frequency in each cohort is given. 
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Figure 8.3. Representative Sanger sequencing of a 3a heterozygote. 
Two HD samples genotyped as homozygous for the reference allele rs557874766 were subsequently found to have one 3a allele each 
by MiSeq Illumina sequencing. Sanger sequencing confirmed heterozygosity at the 9 bp tandem repeat, consistent with the MiSeq 
sequencing result (representative trace shown). On top is the human reference sequence (GRCh38), then the 3a allele sequence (note 
this is aligns to the reference as separate 18 and 9 bp deletions, light red). The 9 bp tandem repeat is marked in relation to the 
reference sequence in red. 
The MSH3 exon 1 repeat region is poorly conserved between species, with mean scores of 0.29 (SD 0.41) and 
0.25 (SD 0.91) in PhastCons and PhyloP respectively (see Appendix). Sequence alignment of 20 mammalian reference 
genomes showed most have two repeats (Figure 8.4). Together with a four- and a five-repeat allele, the 3a allele has 
been observed in gorillas and chimpanzees, suggesting 3a is an ancestral allele in humans (Morales, 2006). 
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GRCh38/hg38 chr5:80654861-80654969 
Human                     accaggtggaccctggcgctgcagcggctgcagcggccgcagcggccgcagcgcccccagcgcccccagctcccgccttcccgccccagctgccgccgcacatagtagg 
Chimp                     accaggtggaccctggcgctgcagcggc------------------cgcagcgcccccagcgcccccagcgcccgccttcccgccccagctgccgccgcacgtagtagg 
Bonobo                    accaggtggaccctggcgctgcagcggc------------------cgcagcgcccccagcgcccccagcgcccgccttcccgccccagctgccgccgcacgtagtagg 
Gorilla                   accaggttgaccctggcgctgcagcggc------------------cgcagcgcccccagcg---------cccgccttcccgccccagctgccgccacacgcagtagg 
Orangutan                 accaggtggaccctgacgc---------------------------tgcagcgcccccagcg---------cccactttcccgccccagctgccgccgcacgtagtagg 
Gibbon                    accaggtggatcctaacgc---------------------------tgcagcacccccagcg---------cccactgtcccgccccagctgccgctccacgtagtagg 
Crab-eating macaque       atcaggtggaccgtgacgc---------------------------cgcagcgcccccagcg---------tccactttcccgccccagctgccgccgctcgtggtagg 
Baboon                    atcaggtggaccgtgacgc---------------------------cgcagcgcccccagcg---------tccactttcccgccccagctgccgccgctagtggtagg 
Green monkey              atcaggtggaccgtgacgc---------------------------cgcagcgcccccagcg---------tccactttcccgccccagctgccgccgctcgtggtagg 
Proboscis monkey          atcaggtggaccatgacgc---------------------------cgcagcgcccccagcg---------tcctctttcccgccccagttgccgccgctcgtggtagg 
Golden snub-nosed monkey  atcaggtggaccatgacgc---------------------------cgcagcgcccccagcg---------tccactttcccgccccagttgccgccgctcgtggtagg 
Marmoset                  accaggtggaccccgacgc---------------------------cgcagcgcccccagcg---------tccactttcccgccccagctgccgccgcacgtggtggg 
Squirrel monkey           accaggtggaccctgacgc---------------------------cgcagcgcccccagcg---------tccactttcccgccccagctgccgccgcacgtggtggg 
Tarsier                   gccagacggaccccgactc---------------------------cgcagcgtcccgagcg---------tccgccttcccgct---ggtgcagccacacctggtagg 
Bushbaby                  accaggcggactctggctc---------------------------tgcagcgcccccagcg---------tccactttcccgccccaattgccggtacacgtggtggg 
Mouse                     agaaggtaaagtacggctc---------------------------cgcggcgcccctagcg---------tccacct--------aggcgaaggccgtcccgggcggg 
Dog                       ------------------------------------------------------------------------------------------------------------- 
Rhesus                    ------------------------------------------------------------------------------------------------------------- 
Tree shrew                ------------------------------------------------------------------------------------------------------------- 
Mouse lemur               ------------------------------------------------------------------------------------------------------------- 
 
Figure 8.4. The MSH3 N-terminal region is poorly conserved between species. 
Alignment of MSH3 orthologues of 20 mammals (17 primates). Sequences from Ensembl, aligned in Clustal. Most mammals have two 
repeats (blue and green). Gorillas have the three-repeat allele observed in slow progressing HD subjects, and chimpanzees have four 
repeats. Rodents and canines lack the 9 bp tandem repeat region 
8.5.2 Variants at the MSH3/DHFR locus are associated with the rate of somatic expansion and disease phenotypes in 
HD and DM1 
The 3a allele correlated negatively with relative rate of somatic expansion in HD subjects (p=0.032) and showed similar 
effect direction, though above nominal significance, in DM1 (p=0.053) (Fig. 8.5, Table 8.3). Additionally, 3a was associated 
with delayed AAO by 1.05 years (p=0.0029) and slower progression in HD by 0.52 units (p=3.86×10-7), which corresponds 
to 0.37 and 0.10 units per year on the UHDRS total motor score and total functional capacity respectively. In DM1, the 
association between 3a and AAO showed a consistent effect direction, approaching significance (p=0.061). In meta-
analysis, 3a was significantly associated with relative rate of somatic expansion (p=0.004) and AAO (p=0.003) in HD and 
DM1. Detailed analysis of the relationship between repeat alleles and phenotypes (Table 8.4) showed that the 3a allele 
accounts for the reduced somatic expansion rate, delayed onset and slower progression observed in HD. In DM1, the 
number of seven-repeat alleles was associated with reduced expansion rate (Table 8.4). 
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Figure 8.5. The number of MSH3 3a repeat alleles is associated with HD and DM1 phenotypes. 
Boxplots for three measures of disease phenotype are shown: rate of somatic expansion corrected for the inherited CAG·CTG length in 
HD (A) and for the inherited CAG·CTG length and variant repeats in DM1 (B); age at onset corrected for the inherited CAG·CTG length 
in HD (C) and DM1 (D); progression score in HD (E). For each dataset, the diamond and horizontal line spanning the diamond indicate 
the mean, the box the standard deviation and the whiskers the 95% confidence intervals of the mean. 
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HDTRACK) 
Meta-analysis 
(DM1OPTIMISTIC + 
DM1CostaRica) 
Meta-analysis 
(DM1OPTIMISTIC + 
DM1CostaRica + 
HDTRACK) 
HD HD HD HD HD 
β p  r2 β p  r2 Z-score p  Z-score p  Z-score p  β p  r2 β p r2 Z-score p  Z-score p  Z-score p  β p  r2 β p  r2 β p  r2 β p  r2 β p  r2 
3a -0.217 0.032 0.017 -0.193 0.053 0.011 -2.876 4.02E-03 -2.87 4.16E-03 -3.58 3.46E-04 0.052 2.96E-03 0.061 2.277 0.061 0.011 2.997 2.72E-03 2.06 3.99E-02 3.02 2.57E-03 -0.516 3.86E-07 0.112 -0.167 0.139 0.012 -0.400 2.48E-04 0.116 -1.363 4.55E-75 0.801 -0.319 2.49E-03 0.039 
3b                                        
5a                                        
5b                                        
6a 0.077 0.393 -0.001 0.238 8.86E-03 0.024 2.498 0.012     -0.028 0.078 0.017 -2.981 7.04E-03 0.028 -1.252 0.211     0.329 3.18E-04 0.056 -0.126 0.189 0.007 0.362 8.59E-05 0.134 0.609 6.20E-12 0.200 0.403 1.25E-05 0.084 
6b                                        
6c                                        
7a 0.112 0.485 -0.002 -0.468 0.011 0.022 -1.393 0.164     -0.019 0.519 -0.005 3.983 0.076 0.010 1.779 0.075     -0.046 0.781 -0.004 0.555 8.55E-04 0.096 -0.137 0.421 -0.003 0.893 3.60E-08 0.132 -0.576 5.66E-04 0.051 
7b                                        
7c                                        
7d                                        
7e                                        
8a 0.302 0.242 0.002 0.175 0.393 -0.001 1.421 0.155     -2.13E-02 0.615 -0.006 0.426 0.861 -0.004 0.146 0.884     0.705 7.87E-03 0.029 0.696 8.26E-03 0.096 -0.116 0.663 -0.008 1.119 2.19E-05 0.079 0.443 0.102 0.008 
8b                                        
9a                                        
9b                                        
Table 8.3. MSH3 9 bp tandem repeat alleles and their association with phenotypes in DM1 and HD. 
An additive genetic model was used to score repeat genotypes and run linear regression analysis. Relative rate of somatic expansion and age at onset were corrected for CAG·CTG length (DM1 and HD) and variant 
repeats (DM1).  
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Repeat covariate Regression with relative rate of somatic expansion Residual variation in age at onset Progression score MSH3 expression DHFR expression 
HD DM1 Meta-analysis HD DM1 Meta-analysis HD HD HD 
β p  β p  β p  β p  β p β p  β p  β p  β p  
number of 3-repeat alleles -0.215 0.031 -0.192 0.053 -0.207 3.71E-03 0.415 3.28E-03 0.197 0.060 0.272 1.15E-03 -0.504 5.63E-07 -0.160 0.146 -0.393 2.33E-04 
homozygous 3-repeat genotype -0.729 1.12E-03 -0.158 0.497 -0.456 5.66E-03 0.919 7.32E-03 0.343 0.164 0.536 7.20E-03 -0.702 2.49E-03 -0.530 0.035 -0.766 1.93E-03 
number of 7-repeat alleles 0.146 0.333 -0.559 1.42E-03 -0.160 0.170 -0.171 0.436 0.327 0.076 0.121 0.393 0.009 0.954 0.535 1.09E-03 -0.088 0.599 
number of 8-repeat alleles 0.223 0.344 0.174 0.394 0.197 0.207 -0.175 0.615 0.038 0.859 -0.019 0.914 0.596 0.014 0.698 8.26E-03 -0.116 0.663 
number of 7 or 8-repeat alleles 0.138 0.166 -0.266 0.058 -0.035 0.720 -0.180 0.343 0.218 0.131 0.072 0.532 0.196 0.153 0.664 4.53E-06 -0.110 0.469 
sum of repeat lengths across both 
alleles 0.069 0.019 0.045 0.119 0.058 5.93E-03 -0.118 4.48E-03 -0.039 0.200 -0.066 6.97E-03 0.152 3.34E-07 0.089 0.007 0.102 1.76E-03 
Table 8.4. Detailed investigation of the role of repeat alleles in phenotypic modification. 
Note that age at onset and somatic expansion residuals are standardised, to facilitate meta-analysis. Beta and p-value are given for each covariate separately. Covariates in bold are present in the best-fitting 
model (forward stepwise regression). Where two or more covariates are highlighted, it is impossible to tell which is driving the association, except for DM1 where both the number of 7-repeat and the number of 3-
repeat alleles reduce expansion and increase age at onset. Association between DHFR and number of 3-repeat alleles remains significant after correcting for MSH3 expression (p=0.000751). Association between 
MSH3 and number of 7 or 8-repeat alleles remains significant after correcting for DHFR expression (p=1.30E-07). The 6-repeat allele was the baseline to which the other alleles were compared. 
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In addition to testing repeat allele effects, we also assessed correlation between flanking SNP genotypes and disease 
phenotypes. All the flanking variants were in HWE (Table 8.5) and in strong LD with each other (Fig. 6B). Three variants 
(rs151182735, rs10168 and rs2250063) were in nearly complete LD with the 3a allele, and as such were as significantly 
associated with phenotypes (Fig. 8.6A, Table 8.6). All three are non-coding variants 5’ to the repeat and their alternative 
alleles are associated with reduced MSH3 and DHFR expression in the prefrontal cortex (CMC, 2017) and in multiple 
tissues in GTEx (GTEx, 2015) (Appendix). Three SNPs, rs1105524, rs1650697 and rs1677658, also correlated with some 
phenotypes, though not uniformly (Fig. 6A and Table 6). Rs1105524 and rs1677658 are non-coding variants, whereas 
rs1650697 corresponds to Ile79Val. All three are expression quantitative trait loci (eQTL) for MSH3 and DHFR in the 
prefrontal cortex (CMC, 2017) and in multiple tissues in GTEx (Appendix). 
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Figure 8.6. Variants at the MSH3/DHFR locus are associated with phenotypes in HD and DM1. 
(A) Bar charts showing associations between variant genotypes and disease phenotypes: relative rate of somatic expansion and age 
at onset corrected for the CAG·CTG length and progression score for HD (TRACK-HD), rate of somatic expansion and age at onset 
corrected for the CAG·CTG length and repeat interruptions for DM1 (OPTIMISTIC), and rate of somatic expansion and age at onset in 
the meta-analysis of HD and DM1. Each bar represents association for a single variant. Red dotted line in plot panels represents the 
p=0.05 significance threshold. Variant location in relation to the MSH3 exon 1 region is shown in the bottom panel; white box – 5’ 
untranslated region, grey – coding sequence, red – MSH3 repeat region, intron is shown by a black line. (B) Linkage disequilibrium 
heatmap for the seven variants flanking the MSH3 repeat. Colour intensity represents the D’ value for each SNP pair. R2 values are 
indicated in text for each variant pair. (C) Haplotype network for eight haplotypes with frequency > 0.035 observed at the MSH3 exon 
1 region. Circles represent different haplotypes. The size of the circle is proportional to the number of individuals with a particular 
haplotype. Each haplotype is connected with the most similar haplotype by a line. Length of the line represents the number of 
genotypes that are different between each two haplotypes. Circles are colour coded according to the repeat allele found on the 
haplotype. 
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SNP ID Chromosomal 
position 
Reference 
allele 
Alternative 
allele 
Minor 
allele 
Minor allele 
frequency 
HWE 
(HD+DM1) 
LD with 3a 
repeat allele 
(HD+DM1) HD DM1 
p r2 
rs151182735 5:80654571 GC G G 0.255 0.266 0.0511 0.995 
rs10168 5:80654584 C T T 0.255 0.266 0.0511 0.995 
rs2250063 5:80654678 C T T 0.255 0.266 0.0511 0.995 
rs1105525 5:80654689 C T T 0.164 0.171 0.2478 0.081 
rs1105524 5:80654693 A G A 0.343 0.313 0.0054 0.192 
rs746491510 5:80654720 G T T 0.002 0.002   0.003 
rs6151597 5:80654748 G A A 0.002 0.000   0.001 
rs1650697 5:80654962 A G A 0.264 0.268 0.654 0.143 
rs943394665 5:80655025 A T T 0.002 0.002   0.010 
rs1677658 5:80655040 G T T 0.174 0.159 0.0533 0.610 
Table 8.5. MSH3 exon 1 region variants. 
Linkage disequilibrium (LD) with the 3a allele is given in r2. Note that correct alignment of the repeat region shows rs1105524 and 
rs1650697 alternative allele frequencies are >0.5. HWE – Hardy-Weinberg equilibrium. 
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SNP ID Regression with relative rate of somatic expansion Regression with residual variation in age at onset Regression with progression 
score 
MSH3 expression (blood) DHFR expression (blood) MSH3 expression (cortex, imputed) DHFR expression (cortex, imputed) 
HD DM1 Meta-analysis 
(DM1OPTIMISTIC + 
HDTRACK) 
Meta-analysis 
(DM1OPTIMISTIC + 
DM1CostaRica) 
Meta-analysis 
(DM1OPTIMISTIC + 
DM1CostaRica + HDTRACK) 
HD DM1 Meta-analysis 
(DM1OPTIMISTIC + HDTRACK) 
Meta-analysis 
(DM1OPTIMISTIC + 
DM1CostaRica) 
Meta-analysis 
(DM1OPTIMISTIC + DM1CostaRica 
+ HDTRACK) 
HD HD HD HD HD 
β p  r2 β p  r2 Z-score p  Z-score p  Z-score p  β p  r2 β p r2 Z-score p  Z-score p  Z-score p  β p  r2 β p  r2 β p  r2 β p  r2 β p  r2 
rs151182735 -0.215 0.031 0.018 -0.193 0.053 0.011 -2.885 0.004     0.051 3.28E-03 0.060 2.277 0.061 0.011 2.981 2.87E-03     -0.504 5.63E-07 0.109 -0.160 0.146 0.011 -0.393 2.33E-04 0.118 -1.356 2.22E-77 0.811 -0.320 2.15E-03 0.040 
rs10168 -0.215 0.031 0.018 -0.193 0.053 0.011 -2.885 0.004 -2.866 0.004 -3.585 3.37E-04 0.051 3.28E-03 0.060 2.277 0.061 0.011 2.981 2.87E-03 2.055 0.03988 3.00 2.68E-03 -0.504 5.63E-07 0.109 -0.160 0.146 0.011 -0.393 2.33E-04 0.118 -1.356 2.22E-77 0.811 -0.320 2.15E-03 0.040 
rs2250063 -0.215 0.031 0.018 -0.193 0.053 0.011 -2.885 0.004     0.051 3.28E-03 0.060 2.277 0.061 0.011 2.981 2.87E-03     -0.504 5.63E-07 0.109 -0.160 0.146 0.011 -0.393 2.33E-04 0.118 -1.356 2.22E-77 0.811 -0.320 2.15E-03 0.040 
rs1105525 0.212 0.101 0.008 -0.071 0.566 -0.003 0.692 0.489     -0.007 0.739 -0.007 1.456 0.332 -2.53E-04 1.064 0.287     0.175 0.192 0.003 0.124 0.394 -0.003 0.010 0.945 -0.010 0.671 3.22E-07 0.114 0.572 1.86E-05 0.080 
rs1105524 0.006 0.950 -0.005 -0.261 4.63E-03 0.028 -2.019 0.044     0.028 0.074 0.017 2.928 8.57E-03 0.027 2.914 3.57E-03     -0.290 2.15E-03 0.040 0.160 0.122 0.014 -0.442 7.78E-06 0.172 -0.278 3.58E-03 0.035 -0.047 0.628 -0.004 
rs746491510                                        
rs6151597                                        
rs1650697 -0.232 0.026 0.019 0.03183 0.753 -0.004 -1.280 0.201     0.019 0.284 0.001 -2.021 0.100 0.008 -0.803 0.422     -0.225 0.038 0.016 -0.494 7.01E-06 0.174 0.208 0.069 0.023 -1.078 2.69E-30 0.465 -0.083 0.452 -0.002 
rs943394665                                        
rs1677658 -0.315 0.007 0.030 -0.076 0.525 -0.002 -2.297 0.022 -2.164 0.030 -3.325 8.85E-04 0.058 0.005 0.055 4.250 3.43E-03 0.271 3.684 2.30E-04 2.614 0.008957 3.352 0.0008023 -0.501 2.50E-05 0.077 -0.268 0.028 0.038 -0.390 1.12E-03 0.091 -1.333 2.64E-40 0.571 -0.043 0.728 -0.004 
Table 8.6. MSH3 exon 1 region variants and the association of their alternative alleles with phenotypes in DM1 and HD. 
Linkage disequilibrium (LD) with the 3a allele is given in R2. An additive genetic model was used to score variant genotypes and run linear regression analysis. Relative rate of somatic expansion and age at onset 
were corrected for CAG·CTG length (DM1 and HD) and variant repeats (DM1). MSH3 and DHFR expression are derived from RNA-Seq in HD whole blood. Note that correct alignment of the repeat region shows 
rs1105524 and rs1650697 alternative allele frequencies are >0.5. HWE – Hardy-Weinberg equilibrium.  
256 
Phenotype Dataset rs151182735 rs10168 rs2250063 rs1105525 rs1105524 rs1650697 rs1677658 β p β p β p β p β p β p β p 
Relative rate of somatic 
expansion 
HD+DM1   NA   NA   NA -0.014 0.883 -0.059 0.42 -0.015 0.849 -0.015 0.914 
HD 0.043 0.773 0.043 0.773 0.043 0.773 0.135 0.319 0.113 0.251 -0.159 0.151 -0.134 0.382 
DM1   NA   NA   NA -0.185 0.142 -0.128 0.222 -0.04 0.738 0.257 0.147 
Residual variation in age at 
onset  
HD+DM1   NA   NA   NA 0.162 0.121 0.165 0.049 -0.2 0.029 0.375 0.015 
HD   NA   NA   NA 0.071 0.673 0.09 0.505 0.005 0.976 0.23 0.382 
DM1   NA   NA   NA 0.244 0.068 0.163 0.145 -0.256 0.043 0.42 0.028 
Progression score HD   NA   NA   NA -0.008 0.95 -0.107 0.285 -0.05 0.646 -0.054 0.789 
MSH3 expression HD -0.091 0.367 -0.091 0.367 -0.091 0.367 0.174 0.186 -0.01 0.92 -0.271 0.076 -0.199 0.075 
DHFR expression HD   NA   NA   NA -0.206 0.156 -0.345 1.38E-03 0.362 1.02E-03 -0.114 0.552 
Table 8.7. Associations of SNP alternative alleles with phenotypes conditional on the repeat structure (Table 4). 
Note rs151182735, rs10168, rs2250063 perfectly correlated with the 3-repeat allele, so these cannot be tested when the repeat structure effect being conditioned on contains that allele. Best-fitting model for 
DHFR expression contains effects of either rs1105524 or rs1650697 and number of 3-repeat alleles (bold). rs1677658 explains the association between repeat structure and AAO in the combined HD+DM1 sample 
(bold). Otherwise, the association between SNPs and phenotypes can be explained by the repeat alleles.
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The associations of SNPs with phenotypes were conditioned on the effects of MSH3 repeat alleles (Table 8.7). As 
rs151182735, rs10168, rs2250063 perfectly correlated with 3a, their independent effects could not be determined (Table 
5). With the exception of rs1677658 (LD with 3a: r2=0.610) and rs1650697 (LD with 3a: r2=0.143), whose alternative alleles 
were associated with delayed and early AAO respectively in the combined HD and DM1 meta-analysis (p=0.015 and 
p=0.029, Table 7), there was no significant evidence for association between SNPs and expansion rate, onset or 
progression independent of repeat alleles. 
Considering variants with minor allele frequency >0.1 and all of the repeat alleles, we observed 25 haplotypes in the 
region, named Hap1 to Hap25 (Table 8). The 3a repeat allele occurs on both Hap1 and Hap2, which differ only in the 
presence of the rs1677658 alternative allele on the commoner Hap2. Hap1 was associated with reduced somatic 
expansion in DM1 (p=0.032) and slower progression in HD (p=0.020), whereas Hap2 was associated with reduced somatic 
expansion (p=0.021) and delayed onset (p=4.03×10-5) in both HD and DM1, and with slower progression (p=1.64×10-5) 
and reduced expression of MSH3 (p=0.024) and DHFR (p=1.12×10-3) in HD (Table 9). 
Overall, this analysis clarifies the sequence and variants present in MSH3 exon 1 and demonstrates that MSH3 repeat 
variants are associated with disease phenotypes in both HD and DM1. 
Haplotype ID Repeat id 
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DM1 HD 
Hap1 3a 1 1 1 0 1 1 0 0.108 0.081 
Hap2 3a 1 1 1 0 1 1 1 0.159 0.171 
Hap3 3b 1 1 1 0 1 1 1 0.000 0.002 
Hap4 5a 0 0 0 0 0 1 0 0.004 0.007 
Hap5 5b 0 0 0 0 1 1 0 0.000 0.002 
Hap6 6a 0 0 0 0 0 0 0 0.004 0.000 
Hap7 6a 0 0 0 0 0 1 0 0.297 0.331 
Hap8 6a 0 0 0 0 1 0 0 0.002 0.000 
Hap9 6a 0 0 0 0 1 1 0 0.120 0.083 
Hap10 6a 0 0 0 1 1 0 0 0.132 0.120 
Hap11 6a 0 0 0 1 1 1 0 0.037 0.044 
Hap12 6b 0 0 0 0 1 0 0 0.002 0.007 
Hap13 6c 0 0 0 0 1 1 0 0.000 0.002 
Hap14 7a 0 0 0 0 1 0 0 0.069 0.093 
Hap15 7b 0 0 0 0 0 1 0 0.002 0.002 
Hap16 7b 0 0 0 0 1 1 0 0.002 0.005 
Hap17 7b 0 0 0 1 1 0 0 0.002 0.000 
Hap18 7c 0 0 0 0 1 1 0 0.002 0.002 
Hap19 7d 0 0 0 0 1 0 0 0.000 0.002 
Hap20 7e 0 0 0 0 0 1 0 0.000 0.002 
Hap21 8a 0 0 0 0 0 0 0 0.004 0.000 
Hap22 8a 0 0 0 0 1 0 0 0.051 0.039 
Hap23 8b 0 0 0 0 1 0 0 0.000 0.002 
Hap24 9a 0 0 0 0 0 1 0 0.002 0.000 
Hap25 9b 0 0 0 0 1 0 0 0.002 0.000 
Table 8.8. MSH3 exon 1 region haplotypes. 
For variants, 0 represents a reference allele and 1 represents an alternative allele. 
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Haplotype ID 
Regression with relative rate of somatic expansion Regression with residual variation in age at onset Regression with progression score MSH3 expression (blood) DHFR expression (blood) MSH3 expression (cortex, imputed) 
DHFR expression (cortex, 
imputed) 
HD DM1 Meta-analysis HD DM1 Meta-analysis HD HD HD HD HD 
β p r2 β p r2 Z-score p β p r2 β p r2 Z-score p β p r2 β p r2 β p r2 β p r2 β p r2 
Hap1 0.045 0.796 -0.004 -0.091 0.032 0.015 -1.399 0.162 0.024 0.385 -0.002 -1.596 0.391 -0.001 -0.153 0.878 -0.419 0.020 0.021 0.149 0.408 -0.003 -0.208 0.246 0.004 -1.158 1.92E-11 0.191 -0.875 9.32E-07 0.105 
Hap2 -0.321 6.53E-03 0.030 -0.021 0.523 -0.002 -2.300 0.021 0.061 3.83E-03 0.057 4.250 3.28E-03 0.034 4.106 4.03E-05 -0.521 1.64E-05 0.081 -0.285 0.024 0.040 -0.403 1.12E-03 0.091 -1.347 1.51E-39 0.564 -0.033 0.792 -0.004 
Hap3                                
Hap4                                
Hap5                                
Hap6                                
Hap7 -0.013 0.885 -0.005 0.069 0.010 0.023 1.793 0.073 -0.025 0.106 0.013 -2.357 0.043 0.014 -2.589 0.010 0.274 3.83E-03 0.035 -0.141 0.173 0.009 0.431 1.20E-05 0.165 0.251 8.61E-03 0.028 0.064 0.512 -0.003 
Hap8                                
Hap9 -0.037 0.814 -0.005 0.021 0.598 -0.003 0.228 0.820 0.007 0.795 -0.007 -3.719 0.039 0.015 -1.481 0.139 -0.037 0.822 -0.005 -0.279 0.181 0.008 -0.064 0.759 -0.009 0.162 0.330 0.000 0.221 0.187 0.004 
Hap10 0.266 0.083 0.010 0.005 0.904 -0.004 1.265 0.206 -0.015 0.527 -0.005 1.142 0.495 -0.002 0.157 0.875 0.283 0.076 0.010 0.251 0.138 0.012 -0.227 0.177 0.008 1.003 4.91E-11 0.184 0.503 1.70E-03 0.042 
Hap11 0.074 0.749 -0.004 -0.094 0.173 0.004 -0.784 0.433 0.013 0.718 -0.007 1.328 0.642 -0.004 0.589 0.556 -0.081 0.735 -0.004 -0.154 0.508 -0.006 0.451 0.049 0.028 -0.136 0.575 -0.003 0.684 4.62E-03 0.033 
Hap12                                
Hap13                                
Hap14 0.112 0.485 -0.002 -0.132 0.011 0.022 -1.393 0.164 -0.019 0.519 -0.005 3.983 0.076 0.010 1.017 0.309 -0.046 0.781 -0.004 0.555 8.55E-04 0.096 -0.137 0.421 -0.003 0.893 3.60E-08 0.132 -0.576 5.66E-04 0.051 
Hap15                                
Hap16                                
Hap17                                
Hap18                                
Hap19                                
Hap20                                
Hap21                                
Hap22 0.302 0.242 0.002 0.037 0.531 -0.002 1.254 0.210 -0.021 0.615 -0.006 1.596 0.525 -0.003 0.199 0.842 0.705 7.87E-03 0.029 0.696 8.26E-03 0.058 -0.116 0.663 -0.008 1.119 2.19E-05 0.079 0.443 0.102 0.008 
Hap23                                
Hap24                                
Hap25                                
Table 8.9. MSH3 exon 1 region haplotypes and their association with phenotypes in DM1 and HD. 
An additive genetic model was used to score haplotypes for linear regression analysis. Relative rate of somatic expansion and age at onset were corrected for CAG·CTG length (DM1 and HD) and variant repeats 
(DM1).
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8.5.3 MSH3 expression in lymphoblasts 
The mean expression level of MSH3 was 36.4% (sem = 10.2%, p = 0.021) lower in lymphoblasts derived from six TRACK-
HD 3a repeat homozygotes, relative to six 6a homozygotes, on western blot (Figure 7). The difference was not significant 
on qPCR, and investigation in a larger sample is warranted (Figure 7). 
 
Figure 8.7. MSH3 expression in 6a and 3a repeat homozygotes. 
Top left – western blot for MSH3 and actin. Top right – quantification of western blot. Mean expression level of MSH3 was 36.4% 
lower in lymphoblasts derived from six TRACK-HD 3a repeat homozygotes, relative to six 6a homozygotes, on western blot (p = 0.021). 
Bottom left – qPCR of housekeeping genes (ACTB, ATP5B and EIF4A2), Geomean of housekeeping genes, and MSH3 cycle thresholds. 
Samples are named by repeat genotype, suffixed with subject ID number. Bottom right – MSH3 expression relative to the mean of 6a 
repeat homozygotes, calculated using the 2^-ddCt method. 
8.5.4 MSH3 and DHFR expression in blood is associated with repeat alleles 
Each 3a allele was associated with reduced DHFR expression in blood (p=2.48×10-4) and homozygosity for 3a was 
associated with reduced MSH3 expression (p=0.0273, Figure 8A), whereas each 7a or 8a allele was associated with 
increased MSH3 expression (p=8.55×10-4 and p=8.26×10-3 respectively). The sum of MSH3 repeat lengths on both alleles 
appeared to correlate with MSH3 (p=7.00×10-3) and DHFR expression (p=1.76×10-3), which would suggest increasing 
repeat length increases expression of both (Figure 9). However, a more detailed analysis of MSH3 repeat alleles (Table 4) 
shows the number of seven- or eight-repeat alleles is associated with increased expression of MSH3 (p=4.53×10-6), and 
that this explains the apparent association with the sum of repeat lengths. 
In the detailed analysis, the number of three-repeat alleles was associated with reduced DHFR expression (Figure 8B, 
p=2.33×10-4), and this was sufficient to explain the apparent association of DHFR expression with other repeat alleles 
(Table 4), including that observed with increasing total repeat length. DHFR and MSH3 expression are correlated (Fig. 8C, 
r2=0.120, p=2.06×10-4). However, association between DHFR and three-repeat alleles remains significant after correcting 
for MSH3 expression (p=7.51×10-4), and association between MSH3 and seven- or eight-repeat alleles remains significant 
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after correcting for DHFR expression (p=1.30×10-7). In the best-fitting model for DHFR expression, the alternative allele 
at rs1105524 (LD with 3a: r2=0.192) increases and rs1650697 decreases DHFR expression independently of the three-
repeat alleles (Table 7). Otherwise, the repeat allele is the major determinant of MSH3 and DHFR expression, and there 
is no evidence of independent SNP effects. 
 
Figure 8.8. Association of the MSH3 3a allele with MSH3 and DHFR expression in HD whole blood. 
Whole blood RNA-Seq in a subset of 108 HD subjects. (A) Significant correlation between MSH3 and DHFR expression levels (r=0.358, 
p=2.06×10-4). Grey area around the blue regression line represents 95% confidence interval of the model. (B) Homozygosity for MSH3 
3a repeat allele is associated with lower MSH3 expression in blood (p=0.028). (C) MSH3 3a repeat allele is associated with lower DHFR 
expression (p=2.33×10-4). Rpkm - Reads Per Kilobase of transcript per Million mapped reads. In boxplots, the diamond and horizontal 
line spanning the diamond indicate the mean, the box indicates the standard deviation and the whiskers indicate the 95% confidence 
intervals of the mean. 
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Figure 8.9. MSH3 repeat length correlation with somatic expansion, age at onset, progression score and blood expression of MSH3 
and DHFR in HD. 
Left column – sum of the number of MSH3 repeats on both alleles, right column – MSH3 repeat length in repeat homozygotes. Rows 
in order – residual rate of somatic expansion, age at onset (AAO), progression score, MSH3 and DHFR expression. 79/81 subjects with 
a sum of 12 repeats are 6 repeat homozygotes. 
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8.5.5 MSH3 expression in cortex is associated with somatic expansion, disease onset and progression in HD 
In a TWAS, increased expression of both MSH3 and DHFR in prefrontal cortex (CMC, 2017) was associated with faster 
progression in TRACK-HD (Hensman Moss et al., 2017b) at similar levels of significance (p=2.52×10-6 and p=4.08×10-6 
respectively, see Appendix), making it difficult to distinguish which is more functionally relevant. This ties in with the 
observation that SNPs significantly associated with somatic expansion, AAO and progression (Table 8.6) were eQTLs for 
both MSH3 and DHFR in CMC data. Notably, however, increased MSH3 expression was significantly associated with early 
onset (p=1.71×10-3) in a TWAS of the GeM dataset (GeM-HD, 2015), while DHFR expression was not significantly 
associated with onset (Appendix). This favours MSH3 over DHFR expression as a modifier of HD disease course. 
In the TRACK-HD cohort, 3a genotype correlates with MSH3 expression in cortex (p=4.55E-75, Table 8.3). It’s correlation 
with DHFR expression is not as strong (p=2.49E-03, Table 8.3) 
 
Figure 8.10. Association of the MSH3 3a allele with MSH3 and DHFR expression in the TRACK-HD prefrontal cortex TWAS. 
The MSH3 3a repeat allele is associated with lower MSH3 expression in prefrontal cortex (p=4.55E-75). It is less significantly 
correlated with reduced DHFR expression in cortex (p=2.49E-03). 
The sum of each subject’s MSH3 repeat lengths correlated with MSH3 expression in cortex (p≤2.2e-16) more strongly 
than in blood (p=0.007002). It also correlated more strongly than with DHFR expression in cortex (p=0.009946). This 
suggests that increasing MSH3 repeat length increases MSH3 expression in the central nervous system. 
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Figure 8.11. MSH3 repeat length correlation with prefrontal cortex expression of MSH3 and DHFR in TRACK-HD. 
Left– Sum of MSH3 repeat length is more strongly correlated with MSH3 expression in cortex (p=< 2.2e-16) than blood (p=0.007002). 
Right MSH3 repeat length correlation with DHFR expression in cortex is not as strong as for MSH3 (p=0.009946). 
In the TRACK-HD TWAS, prefrontal cortex MSH3 expression was associated with CAG expansion rate in blood (p=0.0143). 
This suggests that variants which predict MSH3 expression in cortex are also associated with CAG expansion rate. 
Prefrontal cortex DHFR expression was not associated with CAG expansion rate, favouring MSH3 as the driver of somatic 
expansion. 
 
Figure 8.12. CAG repeat expansion correlation with MSH3 or DHFR expression in TRACK-HD prefrontal cortex. 
Left – Blood CAG expansion rate correlates better with MSH3 expression level in cortex (p=0.0143) than expression level blood 
(p=0.6248). Right – Blood CAG expansion rate was not significantly associated with DHFR expression in prefrontal cortex (p=0.6054). 
 
264 
8.6 Discussion 
8.6.1 MSH3 repeat alleles 
MSH3 has recently been identified as a genetic modifier of somatic instability in DM1 (Morales et al., 2016), and 
progression in HD (Hensman Moss et al., 2017b). The MSH3 signal in the GWAS of HD progression was driven by an 
imputed SNP, rs557874766, located within a 9 bp tandem repeat sequence in exon 1 of MSH3, which is also in the 5’ UTR 
of DHFR on the opposite strand. MSH3 and DHFR are organised head-to-head, transcribed in opposite directions and are 
regulated by the same promoter (Drummond, 1999). This chapter demonstrates that rs557874766 is an alignment 
artefact and corresponds to a three-repeat allele, 3a. 3a was the shortest repeat allele observed and is likely ancestral. 
At the protein level, in silico modelling predicts that 3a results in the loss of a surface α-helix (Kallberg et al., 2012) at the 
N-terminus of MSH3. 
A total of 16 MSH3 repeat alleles were observed, varying in sequence and length from three to nine repeats. 6a and 3a 
are the first and second commonest in this European cohort, though previous studies suggest a seven-repeat allele may 
be second commonest in East Asian populations (Nakajima et al., 1995). In HD, 3a was associated with reduced somatic 
expansion, delayed onset and slower progression. In DM1, each 3a allele showed a trend towards reduced somatic 
expansion and delayed onset but was significant with both measures in meta-analysis of HD and DM1. Longer seven-
repeat alleles were associated with reduced somatic expansion only in DM1. Whether this reflects a subtle difference in 
MSH3 biology between the two disorders, or simply a sampling error, remains to be determined. 
The MSH3 repeat lies within a region of basic amino acids 23 residues downstream of the PCNA interaction domain (PIP 
box) (Kleczkowska et al., 2001, Clark et al., 2000, Flores-Rozas et al., 2000, Finn et al., 2016), 7 residues upstream of the 
EXO1 binding region (Schmutte et al., 2001) and 58 upstream of the MSH2 binding region (Dragileva et al., 2009, Tome 
et al., 2013a, Campregher et al., 2012), all of which are involved in mismatch repair. PCNA is a sliding clamp that 
participates in DNA replication, but in MMR it delivers MSH proteins to mismatches and increases mismatch binding 
specificity (Flores-Rozas et al., 2000). Exonuclease 1 (EXO1) excises the daughter strand after mismatch recognition, as 
well as being involved in end resection during homologous recombination. Whilst it is involved in MMR, it is not absolutely 
required, with MutL or other nucleases able to compensate (Goellner et al., 2015). Sequence conservation suggests this 
region may form a short, flexible connector domain involved in protein interaction (Kleczkowska et al., 2001). The MSH3 
repeat region is poorly conserved between species, with other mammals having between zero and five repeats. This lack 
of evolutionary constraint suggests functional redundancy in the MMR pathway and a lack of a major effect of N-terminal 
MSH3 variation outside the context of repeat expansion disease. Unlike other MMR components, germline heterozygous 
MSH3 mutations are not associated with increased risk of cancer, most likely because MSH2/MSH6 can also initiate repair 
at replication errors (Haugen et al., 2008, Edelmann et al., 2000, Jiricny, 2006). 
8.6.2 Repeat-flanking variants 
Three non-coding variants 5’ of the repeat were in near complete LD with 3a, so it is not possible to determine their 
independent effects on disease phenotypes. All three are associated with reduced MSH3 expression in multiple tissues, 
including cortex (CMC and GTEx). Controlling for repeat alleles, no SNPs were significantly associated with phenotypes, 
except the intronic rs1677658 and the exon 1 rs1650697 variants, which contributed to delayed or early onset 
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respectively in the combined HD and DM1 dataset. rs1677658 was associated with reduced MSH3 and DHFR expression 
(CMC and GTEx), whereas rs1650697 was associated with increased DHFR in HD blood, as well as multiple tissues in GTEx. 
Hap2, the MSH3 haplotype most significantly linked with reduced somatic expansion and delayed onset in HD and DM1, 
and with slower progression in HD, contains the 3a allele, along with alternative alleles of non-coding variants 
rs151182735, rs10168, rs2250063, which are in complete LD with it, and rs1677658. It is thus difficult to assess which (if 
any) MSH3 variants (repeats or SNPs) are driving associations with disease phenotypes, and further investigation in a 
larger sample is warranted. 
8.6.3 Transcriptomic analysis 
Whole blood transcriptomic analysis in a subset of the HD patients found the 3a allele was associated with reduced 
expression of MSH3 and DHFR, and seven- or eight-repeat alleles with increased MSH3 expression. DHFR, which shares 
a promoter with MSH3 (Drummond, 1999), is a ubiquitously expressed enzyme involved in purine, thymidylic acid and 
amino acid synthesis, but has not previously been implicated in HD pathogenesis. 
The TWAS found that increased expression of MSH3 and DHFR in cortex are associated with faster HD progression 
(Hensman Moss et al., 2017b). While MSH3 expression was significantly associated with early onset in the GeM TWAS 
(p=1.71×10-3) (GeM-HD, 2015), DHFR expression was not associated with disease course. This is consistent with HD mouse 
brain, in which expression of MSH3, but not DHFR, correlates with somatic expansion (Tome et al., 2013a). The 3a repeat 
was associated with reduced MSH3 expression in cortex (p=4.55E-75), more so than DHFR (p=2.49E-03, Fig. 8.10), and 
MSH3 expression level in cortex was associated with CAG repeat expansion rate (p=0.0143, Fig. 8.12). This suggests 
variants that predict MSH3 expression in cortex are also associated with CAG expansion. HD TWA studies also found that 
increased FAN1 expression in cortex was associated with delayed onset in GeM-HD (p=2.80×10-12) (GeM-HD, 2015) and 
slower progression in TRACK-HD and REGISTRY (p=1.58×10-4) (Hensman Moss et al., 2017b). This suggests that MSH3 
expression is deleterious and FAN1 is protective in HD brain. 
8.6.4 MSH3 variants modify somatic instability and disease severity in HD and DM1 
Collectively, these results suggest the MSH3 3a repeat allele reduces somatic expansion and improves phenotype in both 
HD and DM1, potentially through altering MSH3 expression levels. However, given the proximity of the repeat region to 
MMR protein binding domains, the 3a allele could also alter MSH3 function in the recognition and repair of insertion-
deletion loops, double-strand breaks or single-strand annealing (Lyndaker and Alani, 2009, Schmidt and Pearson, 2016). 
Repetitive DNA sequences form unusual secondary structures such as slipped strands, hairpin loops, G-quadruplexes and 
R-loops (Mirkin, 2007, Neil et al., 2017), the stability of which correlates with expansion (Gacy et al., 1995). MSH3 may 
recognise these structures (Owen et al., 2005) and initiate repair, during which out of register synthesis could result in 
repeat expansion (Neil et al., 2017, Khan et al., 2015). Together, these results suggest a common mechanism, involving 
somatic expansion, operates in vivo in distinct trinucleotide repeat diseases to influence disease course. Therefore, 
modulation of MSH3 has significant therapeutic potential in a range of diseases caused by repeat expansions. 
8.7 Summary 
The mismatch repair gene MSH3 has been implicated as a genetic modifier of the CAG·CTG repeat expansion disorders 
Huntington’s disease (HD) and myotonic dystrophy type 1 (DM1). A recent HD genome-wide association study found 
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rs557874766, an imputed single nucleotide polymorphism (SNP) located within a polymorphic 9 bp tandem repeat in 
MSH3/DHFR, as the variant most significantly associated with progression in HD. Using Illumina sequencing in HD and 
DM1 subjects, this chapter shows that rs557874766 is an alignment artefact, the minor allele for which corresponds to a 
three-repeat allele in MSH3 exon 1 that is associated with a reduced rate of somatic CAG·CTG expansion (p=0.004) and 
delayed disease onset (p=0.003) in both HD and DM1, and slower progression (p=3.86×10-7) in HD. RNA-Seq of whole 
blood in the HD subjects found that repeat variants are associated with MSH3 and DHFR expression. A transcriptome-
wide association study in the HD cohort found increased MSH3 and DHFR expression are associated with disease 
progression, and increased MSH3 expression in cortex was associated with increased somatic expansion. These results 
suggest that variation in the MSH3 exon 1 repeat region influences somatic expansion and disease phenotype in HD and 
DM1, and suggests a common DNA repair mechanism operates in both repeat expansion diseases. 
8.8 Publications related to this chapter 
The work presented in this chapter was published in: 
MSH3 modifies somatic instability and disease severity in Huntington’s and myotonic dystrophy type 1. Flower M.*, 
Lomeikaite V.*, Ciosi M., Cumming S., Morales F., Lo K., Hensman Moss D., Jones L., Holmans P., the TRACK-HD 
Investigators, the OPTIMISTIC Consortium, Monckton D.G#. and Tabrizi S.J.# Brain (accepted March 2019). 
* These authors should be regarded as joint first authors. 
# These authors jointly supervised the work. 
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Chapter 9 Conclusions and future work 
9.1 Conclusions 
9.1.1 DNA repeat instability in disease 
Expansion of repeated DNA sequences cause dozens of human diseases, and though the repeats occur in different 
proteins and genomic contexts, and have varied pathogenic mechanisms ranging from silencing expression (Colak et al., 
2014) and RNA foci (Thornton, 2014) to RAN translation (Zu et al., 2011, Banez-Coronel et al., 2015, Cleary and Ranum, 
2014) and aggregate formation (Ross and Tabrizi, 2011), they usually have a neurological phenotype, suggesting the 
nervous system is particularly susceptible to this type of mutation (Neil et al., 2017). The repeats are inherently unstable 
and tend to expand over time in the tissues most vulnerable in each disease (Thornton et al., 1994, Zatz et al., 1995, 
Kennedy et al., 2003, Shelbourne et al., 2007b, Swami et al., 2009, Jedele et al., 1998, Tanaka et al., 1999). Expansion 
correlates with disease onset, progression and severity in animal models and patients (Kennedy et al., 2003, Shelbourne 
et al., 2007b, Swami et al., 2009, Gonitel et al., 2008, Lee et al., 2011a, Mangiarini et al., 1997, Ashizawa et al., 1993, Lia 
et al., 1998, Fortune et al., 2000, Kennedy and Shelbourne, 2000). Instability likely happens during DNA repair or 
transcription, rather than during replication, as it continues when the cell cycle is arrested (Gomes-Pereira et al., 2014b), 
is negatively correlated with cell cycle pathways (Lee et al., 2010), and occurs in the post-mitotic neurons of animal 
models and patients (Kennedy et al., 2003, Shelbourne et al., 2007b, Swami et al., 2009, Gomes-Pereira et al., 2014b). 
Interruptions in the repeat sequence, which reduce formation of abnormal structures such as hairpin loops, protect 
against instability (Massey and Jones, 2018, Menon et al., 2013, Pearson et al., 1998, Sobczak and Krzyzosiak, 2004, Kraus-
Perrotta and Lagalwar, 2016). This suggests the DNA secondary structure is important in modulating susceptibility to 
instability. 
9.1.2 CAG repeat expansion in vitro 
Whilst CTG (Ashizawa et al., 1996, Bidichandani et al., 1999, Ashizawa et al., 1993, De Temmerman et al., 2008, Seriola 
et al., 2011a, Du et al., 2013a), GAA (Lai et al., 2014, Ku et al., 2010, Du et al., 2012a) and ATTCT (Lin and Ashizawa, 2003, 
Liu et al., 2007) repeats appear readily unstable in cultured cells, no cell models of robust and significant CAG repeat 
expansion exist (Kovtun et al., 2007, Jonson et al., 2013a, Jacquet et al., 2015, Mollica et al., 2016). In chapters 5 and 6, 
several were developed, including human osteosarcoma and neural stem cells transduced with HTT exon 1 containing 97 
or 129 CAG repeats, and patient-derived lymphoblastoid (LB), stem cell and differentiated medium spiny neurons (MSN) 
from HD subjects with 109 and 125 CAG repeats. This is the first demonstration of CAG repeat instability in cultured 
patient MSNs, the cell type most vulnerable in HD and the most physiologically relevant cell model in which to study HD 
pathogenesis. Expansion was repeat length-dependent, with rate increasing exponentially after a trigger point between 
73 and 97 CAG repeats. 
Human cell lines and patient-derived LBs, stem cells and differentiated MSNs with up to 73 CAG repeats were stable in 
long term culture up to 29 weeks, even on exposure to chronic oxidative stress. This is consistent with previous studies 
which have shown that to trigger expansion, cultured cells must harbour over 64 repeats (Cannella et al., 2009). Human 
disease is most commonly caused by repeat lengths around 40 CAG, and expansion likely occurs slowly over decades until 
a toxic threshold is reached, after which time the polyglutamine tract confers toxicity in vulnerable striatal neurons, 
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causing clinical onset (Kaplan et al., 2007, Kennedy et al., 2003, Swami et al., 2009). The lack of observable instability may 
reflect the rarity of expansion events at these repeat lengths, and extremely long-term culture may be required to 
observe a change. 
9.1.3 DNA repair modifies the course of repeat expansion diseases 
In HD, repeat length is the main influence on disease course, though a significant proportion of the variation in disease 
onset is due to variation elsewhere in the genome (Gusella et al., 2014, Wexler et al., 2004a). GWAS studies probing this 
variation have identified loci on chromosomes 15, 8, 5 and 3 that modify onset or progression (GeM-HD, 2015, Lee et al., 
2017, Hensman Moss et al., 2017b). These are likely underlain by FAN1, RRM2B, MSH3 and MLH1 respectively, suggesting 
that, after repeat length, DNA repair is the strongest determinant of disease course. Supporting this, pathway analyses 
in each GWAS highlighted sets of DNA repair genes, particularly mismatch repair, and MSH3 variants have been shown 
to modify expansion of CTG repeats in myotonic dystrophy type 1 (DM1) patients (Morales et al., 2016). Chapter 3 showed 
that DNA repair variants from HD GWA studies also influence onset in the other polyglutamine diseases (Bettencourt et 
al., 2016), suggesting a common mechanism operates in conditions caused by repeat expansion. The lead SNP, rs3512 in 
FAN1, was associated with 1.3 year delayed onset in the GeM-HD GWAS (p = 5.28E-13), but variants in PMS2, a 
component of the MutLa MMR complex, and RRM2B, involved in nucleotide synthesis, were also significant. 
9.1.4 DNA repair drives repeat instability 
The DNA damage response (DDR) is a series of overlapping pathways that sense and repair lesions that occur continually 
throughout the body (Ciccia and Elledge, 2010). The nervous system appears particularly susceptible to DNA damage, 
with DDR defects implicated in many neurological diseases, including oxidative lesions in Alzheimer’s, Parkinson’s and 
amyotrophic lateral sclerosis (ALS) (McKinnon, 2009, Canugovi et al., 2013) and strand breaks in several hereditary ataxias 
(Jackson, 2002, Madabhushi et al., 2014, Suberbielle et al., 2013, El-Khamisy et al., 2005, Clements et al., 2004). 
In repeat expansion diseases, however, it appears the DDR actively promotes instability. Several pathways have been 
implicated, but mismatch repair (MMR) is the strongest driver (Castel et al., 2010, Slean et al., 2008), with depletion of 
complexes MutSβ (MSH2/MSH3), MutLα (MLH1/PMS2) and MutLγ (MLH1/MLH3) protecting against repeat expansion in 
cell and animal models of HD (Lopez Castel et al., 2010, Manley et al., 1999, Dragileva et al., 2009, Tome et al., 2013a, 
Gomes-Pereira, 2004, Gomes-Pereira et al., 2014b, Pinto et al., 2013b, Pinto et al., 2013a), DM1 (Nakatani et al., 2015b, 
Stevens et al., 2013, Du et al., 2013b, Seriola et al., 2011b, Nakatani et al., 2015c, Williams and Surtees, 2015, Kantartzis 
et al., 2012, Dragileva et al., 2009, Tome et al., 2013a, van den Broek et al., 2002, Foiry et al., 2006, Morales et al., 2016), 
fragile X (Lokanga et al., 2014) and Friedreich’s ataxia (Bourn et al., 2012, Zhao et al., 2015b, Ezzatizadeh et al., 2012), as 
well as in HD (Hensman Moss et al., 2017b) and DM1 patients (Morales et al., 2016). Fan1 knockout in a fragile X mouse 
model has also been shown to accelerate CGG repeat expansion (Zhao and Usdin, 2018). A great challenge currently 
facing the field is understanding how a system that normally guards genomic stability is instead contributing to cell 
dysfunction and death (Jiricny, 2006). MutSβ, which normally recognises short insertion-deletion loops (IDL), may bind 
abnormal DNA secondary structures formed on lagging strand templates (Freudenreich et al., 1997, Kang et al., 1995, Liu 
et al., 2010a, Panigrahi et al., 2002, Cleary et al., 2010, Nenguke et al., 2003) by repeat sequences (Mirkin, 2007, Neil et 
al., 2017, McMurray, 2010, Gacy et al., 1995), initiating inaccurate repair that leads to expansion (Schmidt and Pearson, 
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2016, Williams and Surtees, 2015). The prevalence (Axford et al., 2013) and stability (Gacy et al., 1995) of such structures 
has been shown to correlate with expansion. 
9.1.5 FAN1 
9.1.5.1 What is already known about FAN1 
FAN1 is a structure-specific endo/exonuclease involved in DNA interstrand crosslink (ICL) repair (Kratz et al., 2010a, Liu 
et al., 2010b, MacKay et al., 2010b, Smogorzewska et al., 2010a) and the recovery of stalled replication forks (Lachaud et 
al., 2016a, Chaudhury et al., 2014), though its precise role in both processes is unknown (Thongthip et al., 2016, Lachaud 
et al., 2016a, Lachaud et al., 2016b). It stabilises CGG repeats (Zhao and Usdin, 2018) and its knockout prevents the 
resolution of double strand breaks (DSB) induced during ICL repair (Thongthip et al., 2016, Lachaud et al., 2016a, Lachaud 
et al., 2016b). Its PCNA interaction domain is required for recruitment to stalled replication forks (Porro et al., 2017), the 
UBZ domain is needed for an interaction with FANCD2 that regulates its activity at stalled forks (Chaudhury et al., 2014, 
Chen et al., 2015, Schlacher et al., 2012, Lachaud et al., 2016a), and its nuclease domain is required for all its currently 
known functions (Ray Chaudhuri et al., 2012, Ge and Blow, 2010, Lachaud et al., 2016a). Mutations are linked with a 
recessive renal syndrome with polyploidy (Zhou et al., 2012, Lachaud et al., 2016b, Thongthip et al., 2016), as well as 
colorectal (Segui et al., 2015b) and pancreatic (Smith et al., 2016) cancers, but unlike other ICL repair genes, they do not 
cause Fanconi anaemia. FAN1 is known to interact directly with the ID complex (FANCD2 and FANCI), but a substantial 
proportion of cellular FAN1 binds MLH1 of the MMR MutLα complex (MacKay et al., 2010b). A role has not yet been 
shown for the latter, but one can speculate FAN1 and MMR interact in a pathway promoting repeat instability, with FAN1 
potentially sequestering MLH1 away from the expansion-inducing MutSb complex. 
9.1.5.2 FAN1 depletion sensitises cells to interstrand crosslinks 
FAN1 knockout, knockdown or inactivation of its nuclease domain by the p.D960A mutation in human cell lines prevented 
the resolution of DSBs during ICL repair and sensitised them to chemically-induced ICLs, supporting the known 
involvement of FAN1 nuclease in the ICL repair pathway (Kratz et al., 2010a, Liu et al., 2010b, MacKay et al., 2010b, 
Smogorzewska et al., 2010a). There was no effect on mismatch or strand break repair, suggesting FAN1 does not 
participate in these functions. In patient-derived and artificial cell lines expressing FAN1 variants associated with fast HD 
progression, including the p.R507H DNA binding domain variant associated with 6 year early HD onset (p = 9.34E-18) 
(GeM-HD, 2015), ICL sensitivity was unaffected. This suggests FAN1 activity at the HTT CAG repeat is independent of its 
ICL repair function. 
9.1.5.3 FAN1 protects against CAG repeat expansion 
Knockout or knockdown of FAN1 in human cells expressing a 118 CAG tract, patient-derived iPSCs and post-mitotic MSNs, 
nearly doubled the expansion rate from around 15-18 days/Q to just 10 days/Q (Chapters 5 and 6). Expansion was FAN1 
concentration-dependent, with higher levels increasing the stability of the CAG repeat. Supporting this, the 
transcriptome-wide association study (TWAS) in chapter 10 showed increased FAN1 expression was associated with 
delayed onset and slow progression in HD. Collectively these results suggest the genome-wide chromosome 15 signal 
linked with HD disease course (GeM-HD, 2015, Lee et al., 2017, Hensman Moss et al., 2017b) results from FAN1 
protectively stabilising the CAG tract in a mechanism that is independent of DNA replication (Gomes-Pereira et al., 2014b, 
Lee et al., 2010, Kennedy et al., 2003, Shelbourne et al., 2007b, Swami et al., 2009). Consistent with this and DM1 cell 
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models (Gomes-Pereira et al., 2014a, Gomes-Pereira et al., 2001), there was no correlation between mitotic rate and 
CAG expansion (Chapter 5). 
In the R6/2 mouse model of HD, Fan1 was expressed at relatively high levels in somatically stable tissues such as 
cerebellum, and low levels in those showing expansion, such as liver. Unfortunately, intrastriatal and peritoneal shRNA-
mediated Fan1 knockdown failed to demonstrate an effect on CAG repeat expansion rate, though this was likely due to 
relatively poor knockdown by only 23%. In iPSC models, where FAN1 depletion accelerated expansion rate, 60% 
knockdown was achieved. 
Surprisingly, the nuclease inactivating p.D960A mutation did not affect expansion rate. As FAN1 activity in ICL repair and 
replication fork recovery require nuclease activity, this suggests a novel function underlies CAG repeat stabilisation. The 
HD onset-associated p.R507H DNA binding domain variant (GeM-HD, 2015) did not significantly alter expansion rate in 
the U20S system, though high expression, which as shown above stabilises the repeat, may have obscured a subtle effect 
on FAN1 function. 
9.1.5.4 FAN1 DNA binding 
FAN1 has been shown to bind artificial branched DNA substrates (Kratz et al., 2010a, Liu et al., 2010b, MacKay et al., 
2010b, Pennell et al., 2014), but its DNA binding preferences in cells have not yet been demonstrated. Through ChIP-
qPCR in human cells expressing a 129 CAG repeat and patient-derived LB and iPSCs, a novel interaction was found 
between FAN1 and CAG repeat DNA in HTT, as well as other polyglutamine disease genes. FAN1 also bound other DNA 
regions, suggesting it does not preferentially interact with CAG repeats. Once again, the p.R507H variant did not alter 
DNA binding, suggesting it does not affect FAN1 substrate preference. 
9.1.6 MSH3 
9.1.6.1 What is already known about MSH3 
MSH3 heterodimerises with MSH2 to form the MutSb complex that recognises IDLs and initiates MMR (Tome et al., 
2013a, Gonitel et al., 2008). As above, it has been shown to be required for repeat expansion in numerous diseases, 
including HD. Unlike other MMR proteins, its depletion does not cause cancer, likely because MutSα is able to partially 
compensate (Edelmann et al., 2000, Jiricny, 2006). 
9.1.6.2 MSH3 modifies somatic instability and disease severity in Huntington’s disease and myotonic dystrophy type 1 
The lead variant in a recent GWAS linking MSH3 with HD progression was the imputed SNP rs557874766 (Hensman Moss 
et al., 2017b). In chapter 8, Illumina sequencing of this 9 bp tandem repeat region showed this variant to be an alignment 
artefact, and that subjects instead had a 3-repeat variant, named 3a, which was associated with reduced blood MSH3 
and DHFR expression, reduced somatic expansion in blood, delayed onset and slower progression in HD and myotonic 
dystrophy type 1 (DM1). Decreased MSH3 expression has already been shown to reduce repeat expansion and improve 
disease phenotype in cell and animal models (Dragileva et al., 2009, Tome et al., 2013a, Nakatani et al., 2015b, Stevens 
et al., 2013, Du et al., 2013b, Seriola et al., 2011b, Nakatani et al., 2015c, Williams and Surtees, 2015, Kantartzis et al., 
2012, van den Broek et al., 2002, Foiry et al., 2006, Morales et al., 2016). 16 repeat alleles were observed, with between 
three and nine repeats, and the relatively common, longer 7 or 8 repeat alleles were associated with increased MSH3 
expression. The repeat region lies between binding sites for MMR proteins PCNA, EXO1 and MSH2 (Kleczkowska et al., 
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2001, Clark et al., 2000, Flores-Rozas et al., 2000, Finn et al., 2016, Schmutte et al., 2001, Tome et al., 2013a), and is 
poorly conserved between species. 
Three non-coding variants were in complete linkage disequilibrium (LD) with 3a. The intronic rs1677658 and the exon 1 
rs1650697 variants contributed to delayed or early onset respectively. The haplotype most significantly associated with 
reduced somatic expansion, delayed onset and slower progression in HD and DM1, named Hap2, contained the 3a repeat 
allele, the non-coding variants rs151182735, rs10168, rs2250063 which are in complete LD with it, and the exon 1 variant 
rs1677658 (LD with 3a; r2 = 0.610). Further investigation in a larger sample is warranted to clarify which variants are 
driving association with disease phenotypes. 
A transcriptome-wide association study (TWAS) showed increased MSH3 expression and reduced FAN1 expression in 
prefrontal cortex were associated with early onset and faster progression in HD, suggesting MSH3 is deleterious and 
FAN1 is protective in the context of a HTT CAG expansion. Increased MSH3 expression in prefrontal cortex was associated 
with increased somatic expansion. 
Genetic variation in MSH3 may influence disease course through altering MSH3 expression levels or the protein’s 
interaction with other MMR components. These results suggest a common mechanism involving somatic expansion 
operates in vivo in several repeat expansion disorders, and that modulation of MSH3 has significant therapeutic potential 
in a range of diseases. 
9.1.7 Transcriptional dysregulation in Huntington’s disease blood 
HD is a systemic condition and the expanded CAG repeat is expressed in mutant HTT (mHTT) throughout the body, causing 
immune dysfunction (Tai et al., 2007a, Bjorkqvist et al., 2008, Kwan et al., 2012c, Träger et al., 2015), metabolic disruption 
with weight loss (Carroll et al., 2015), muscle wasting (Busse et al., 2008) and cardiac dysfunction (Lanska et al., 1988, 
Mihm et al., 2007, Pattison et al., 2008), endocrine disturbance (Saleh et al., 2009) and liver impairment (Carroll et al., 
2015) in animal models (Orth et al., 2003) and patients (Turner et al., 2007). In chapter 4, RNA-Seq of whole blood from 
Track-HD patients identified immune upregulation and dysregulation of DNA repair, RNA processing, energy metabolism. 
The transcriptional changes in blood correlated with disease severity and replicated the signatures of HD patient caudate 
(Neueder and Bates, 2014, Hodges et al., 2006) and prefrontal cortex (Labadorf et al., 2015), as well as those of other 
studies on whole blood (Mina et al., 2016) and hyperactive monocytes (Miller et al., 2016), and significantly overlapped 
with immune upregulation found in Alzheimer’s disease brain (International Genomics of Alzheimer's Disease, 2015, 
Zhang et al., 2013). These results suggest a key role for the immune system in neurodegenerative disease and support 
the study of peripheral tissue which, unlike the nervous system, can be sampled minimally invasively and inexpensively 
from living patients throughout the course of the disease. 
9.1.8 Summary 
A model is emerging, in which a FAN1/MLH1 complex may bind abnormal secondary structures which are formed by CAG 
repeat DNA and occur more readily as repeat length increases. Several mechanisms can be hypothesised; firstly, the 
complex may block access of MutSb (MSH2/MSH3), which would otherwise misidentify these structures as insertion-
deletion loops, initiating mismatch repair that erroneously introduces extra repeats. Secondly, as MutLα (MLH1/PMS2) 
independently binds FAN1 and MutSβ (MSH2/MSH3) (MacKay et al., 2010b), FAN1 could sequester MLH1 that would 
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otherwise act with MSH3 to promote repeat expansion. Finally, FAN1 could act on the CAG repeat, promoting accurate 
repair either directly or as a scaffold for a repair complex. FAN1 has the potential DNA binding and nuclease activity to 
act directly in repair, though the protection offered against expansion by the nuclease dead p.D960A mutant argues 
against this. 
 
Figure 9.1. Potential mechanisms by which FAN1 may protect against CAG repeat expansion. 
A) MutSβ (MSH2/MSH3, orange) and MutLα (MLH1/PMS2, blue) misidentify abnormal secondary structures formed by CAG repeat 
DNA (red), such as hairpins, invoking mismatch repair, during which out of register alignment introduces repeat expansion. B) FAN1 
(green) may bind CAG repeat DNA, prohibiting access of MutSβ. C) FAN1 may sequester MutLα (MLH1/PMS2) away from MutSβ, 
preventing MMR. D) FAN1 may act directly at the CAG repeat, promoting accurate repair. 
Neurons appear particularly susceptible to repeat expansion and the dysfunctional proteins it produces, though the 
reasons for this remain unclear. Therapies increasing FAN1 or reducing MSH3 are expected to restrict CAG repeat 
expansion, delay onset and slow progression in numerous conditions caused by repeat tracts, including the polyglutamine 
diseases and myotonic dystrophy, without increasing cancer risk. However, preclinical trials should observe for toxicity 
associated with FAN1 overexpression and microsatellite instability associated with reduced MSH3 (Haugen et al., 2008). 
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9.2 Future work 
9.2.1 Elucidating the somatic instability network (SIN) 
FAN1 and MSH3 are at the core of a wider DDR network involved in CAG repeat instability (Muro et al., 2015), which may 
include the MMR nuclease EXO1 (McMurray, 2010, Usdin et al., 2015), the DNA clamp PCNA (Usdin et al., 2015, Lopez 
Castel et al., 2009, Ren et al., 2017), the DNA ligase LIG1 (Usdin et al., 2015, Lopez Castel et al., 2009), the MSH3 binding 
partner MSH2 (Lopez Castel et al., 2010, Manley et al., 1999), and MutL proteins MLH1 (Pinto et al., 2013a, Lee et al., 
2017, Hensman Moss et al., 2017b), PMS2 (Gomes-Pereira, 2004, Gomes-Pereira et al., 2014b, Pinto et al., 2013b) and 
MLH3 (Pinto et al., 2013a), all of which have been implicated in repeat instability. Each component of this somatic 
instability network (SIN) will be studied for independent effects on instability and cell phenotype using a panel of shRNA 
oligonucleotides, as shown in Chapter 5. To assess for gain of function activities, expression vectors encoding proteins 
modulating repeat stability will be introduced in parallel. 
9.2.2 How FAN1 stabilises the CAG repeat 
9.2.2.1 Cell models 
Building on the work in chapter 6, U20S cells will be complemented with FAN1 constructs containing the p.C44A/C47A 
ubiquitin domain inactivating mutation (Jin and Cho, 2017, Thongthip et al., 2016) and the p.L477P DNA binding domain 
mutant (Smogorzewska et al., 2010a), as well as truncated forms lacking other protein domains (Smogorzewska et al., 
2010a). Studies suggest N-terminal constructs, which retain epitopes for the FS2 anti-FAN1 goat antibody, correctly 
localise to the nucleus and can be used to investigate the function of FAN1 domains (Smogorzewska et al., 2010a). This 
will allow investigation of which domains, including DNA binding, UBZ and protein interaction, are required for 
stabilisation of the CAG repeat. 
9.2.2.2 Protein interactions 
The U20S system allows regulated expression of tagged FAN1, and through co-immunoprecipitation the effect of 
variation on protein interactions can be probed. The nature of the FAN1-MLH1 interaction will be further studied by 
chemical cross-linking mass spectrometry (CL-MS), in collaboration with Dr Kostas Thalassinos (UCL). 
9.2.2.3 DNA binding 
Building on chapter 6, CAG length-dependent binding will be assessed in ChIP fractions by TapeStation and Bioanalyzer 
(Agilent). ChIP will be also be used to investigate whether FAN1 variants influence its DNA binding, whether other SIN 
components bind HTT CAG repeat DNA and how their occupancy is affected by FAN1 variation. This will answer the 
question of whether FAN1 regulates access of SIN components to DNA. 
9.2.2.4 Mechanism 
To investigate the mechanism by which FAN1 regulates instability, cells will be probed using host cell reactivation assays, 
which involve transfection with reporter plasmids containing a range of DNA structures (Nagel et al., 2014). The role of 
abnormal DNA structures such as R-loops, which are RNA:DNA hybrids that form during transcription and have been 
linked with repeat instability (Reddy et al., 2014, Freudenreich, 2018, Su and Freudenreich, 2017), will be assessed using 
the S9.6 DNA:RNA specific antibody (Merck). The presence of R-loops in the CAG repeat itself can be tested by a modified 
ChIP procedure termed DRIP (DNA-RNA immunoprecipitation) (Yu et al., 2006), where CAG repeat primers amplify DNA 
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immunoprecipitated using S9.6. To study the requirement for DNA replication, the cell cycle will be arrested chemically 
and genetically in unstable cell lines (Gomes-Pereira et al., 2001). 
9.2.2.5 p.R507H 
The p.R507H FAN1 variant, which is associated with fast progression (GeM-HD, 2015), lies in the SAP DNA binding domain 
(Jin and Cho, 2017), but preliminary studies in U20S and patient-derived lymphoblasts have found no functional 
differences in DNA binding or CAG stabilisation. Its impact on protein interactions will be investigated, and iPSCs have 
been generated from a fast progressing Track-HD patient expressing the variant, which will allow study of its effects in 
more physiological, neuronally differentiated cells. Structural analysis reveals p.R507H lies near the surface of the SAP 
domain, a region important for FAN1 dimerisation (Wang et al., 2014b), so its oligomerisation state and protein 
complexing will be investigated by mass spectrometry. 
9.2.3 How N-terminal MSH3 variation slows disease course 
9.2.3.1 Cell models 
MSH3 knockout U20S cells will be generated by CRISPR, as described by Munoz et al. (2014), then cells will be 
complemented with GeneArt synthesised Myc-tagged constructs encoding repeat region variants cloned into the pcDNA5 
FRT/TO tetracycline-inducible expression vector, along with pathogenic HTT exon 1, as demonstrated in chapter 6. These 
will be complemented by CRISPR knockout of MSH3 in 109Q and 125Q iPSCs, currently under way in collaboration with 
UCL Cancer Institute’s Genomics and Genome Engineering department. These iPSCs can differentiate into MSNs and 
cortical neurons and, as described in chapter 5, demonstrate robust repeat expansion. Sanger sequencing in both lines 
has shown them to be wild type for the FAN1 and MSH3 variants implicated in HD. Whole genome sequencing is under 
way to fully characterise their genetic background. These lines can then be used to assess the effect of MSH3 level on 
CAG repeat expansion. Several patient-derived cell lines homozygous for the relatively common 3a repeat allele are also 
available from the Track-HD and MTM studies. 
9.2.3.2 Protein structure 
The primary protein structure of the 3a MSH3 repeat allele will be confirmed by tandem mass spectrometry using protein 
immunoprecipitated from homozygous cell lines using an MSH3-specific antibody (BD Biosciences). 
9.2.3.3 Protein interactions 
As the MSH3 repeat variant lies close to domains interacting with PCNA, EXO1 and MSH2, its effect on protein interactions 
will be investigated by co-immunoprecipitation using an MSH3 antibody in patient-derived LBs and Myc-trap beads from 
U20S cells, followed by mass spectrometry to identify and quantify binding partners. 
9.2.3.4 Mismatch repair 
The effect of repeat variation on MSH3 mismatch repair function will be assessed by sensitivity of patient-derived LB cells 
to genotoxins including cisplatin (MacKay et al., 2010a, Kratz et al., 2010b), 6-thioguanine (Karran and Attard, 2008, 
Swann et al., 1996) and hydrogen peroxide (Driessens et al., 2009), and the induced protein interactions will be probed 
by co-immunoprecipitation, subcellular fractionation and ChIP. 
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9.2.3.5 DNA interaction 
ChIP using highly specific Myc-Trap beads (ChromoTec) will be used to quantify the interaction between MSH3 and HTT 
CAG repeat DNA. 
9.2.4 Sequelae of repeat expansion 
The Opera high content screening platform will be used to assess how HD cell phenotypes including HTT aggregation 
using S830 and EM48 antibodies, cell morphology, differentiation, synaptogenesis and mitochondrial function correlate 
with CAG repeat instability in patient-derived MSNs. To investigate whether genetic variation in SIN components causes 
widespread DNA damage, oxidative lesions and strand breaks will be studied using the 53BP1, γ-H2AX and the Comet 
assays (Brierley and Martin, 2013, Niedernhofer et al., 2004, Kurashige et al., 2016). 
9.2.5 Summary 
This thesis determined that FAN1 and MSH3 form a key part of a DNA repair network that regulates repeat stability, 
thereby modifying the course of repeat expansion disease. Their modulation has significant therapeutic potential in 
several of the commonest genetic neurodegenerative diseases (Paulson, 2018). The planned work presented above can 
be summarised by posing the following questions. 
1. How does FAN1 stabilise trinucleotide repeat tracts independent of its nuclease activity? 
2. How does N-terminal genetic variation in MSH3 limit its potentiation of repeat expansion? 
3. Along with FAN1 and MSH3, which DNA repair components are involved in the network that regulates repeat 
stability? 
4. Does reducing somatic expansion through therapeutic modulation of this network slow disease course? 
The answers to these questions will advance our understanding of repeat expansion disease pathogenesis, and will have 
important implications for future therapeutic approaches. 
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Chapter 10  Appendix 
10.1 p’HRsincpptUCOE+htt exon1 IRES eGFP 129CAG vector sequence 
TCGACCTCGAGGTCGATCCCATGGCGACCCTGGAAAAGCTGATGAAGGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG
CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA
GCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC
AGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG
CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAACAGCCGCCACCGCCGCCGCCGCCGCCGCCGCCTCCTCAGCTTCC
TCAGCCGCCGCCGCAGGCACAGCCGCTGCTGCCTCAGCCGCAGCCGCCCCCGCCGCCGCCCCCGCCGCCACCCGGCCCGGCTGTGGCTGAGGAGCCGCTGC
ACCGACCGTGAGTTTGGGCCCGCTGCAGTCGACGGTACCGCGGGCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTG
GAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAG
CATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGT
CTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAA
CCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCA
TTGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTT
TCCTTTGAAAAACACGATGATAATATGGCCACAACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGA
CGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCG
TGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATG
CCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCG
CATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACA
AGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGC
GACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTT
CGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCCATATGATAGTTTAAACATTACGGAACTTCGATAATCAACCTC
TGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATT
GCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTG
CACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGG
AACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGTCCTTTCCTTGG
CTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCC
GGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGAATCTATGCAGATTCGAGGAATT
AATTCGAGCTCGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTC
CCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTA
AGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGG
AAAATCTCTAGCAGCATCTAGAATTAATTCCGTGTATTCTATAGTGTCACCTAAATCGTATGTGTATGATACATAAGGTTATGTATTAATTGTAGCCGCGT
TCTAACGACAATATGTACAAGCCTAATTGTGTAGCATCTGGCTTACTGAAGCAGACCCTATCATCTCTCTCGTAAACTGCCGTCAGAGTCGGTTTGGTTGG
ACGAACCTTCTGAGTTTCTGGTAACGCCGTCCCGCACCCGGAAATGGTCAGCGAACCAATCAGCAGGGTCATCGCTAGCCAGATCCTCTACGCCGGACGCA
TCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGC
GCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGG
CCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCGAATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTA
AGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTG
CATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTT
CTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAA
CCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGT
TTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCC
TTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAA
CTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAG
TGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATC
ATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGC
AAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCT
TCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCG
TAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGAC
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCC
TTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAA
CAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAAT
ACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGC
CAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCA
GCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTA
AGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCG
TCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACA
TGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAG
TCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGTGGAATGTGTGTCAGTTAGGG
TGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGG
CAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTC
CGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTA
GGCTTTTGCAAAAAGCTTGGACACAAGACAGGCTTGCGAGATATGTTTGAGAATACCACTTTATCCCGCGTCAGGGAGAGGCAGTGCGTAAAAAGACGCGG
ACTCATGTGAAATACTGGTTTTTAGTGCGCCAGATCTCTATAATCTCGCGCAACCTATTTTCCCCTCGAACACTTTTTAAGCCGTAGATAAACAGGCTGGG
ACACTTCACATGAGCGAAAAATACATCGTCACCTGGGACATGTTGCAGATCCATGCACGTAAACTCGCAAGCCGACTGATGCCTTCTGAACAATGGAAAGG
CATTATTGCCGTAAGCCGTGGCGGTCTGTACCGGGTGCGTTACTGGCGCGTGAACTGGGTATTCGTCATGTCGATACCGTTTGTATTTCCAGCTACGATCA
CGACAACCAGCGCGAGCTTAAAGTGCTGAAACGCGCAGAAGGCGATGGCGAAGGCTTCATCGTTATTGATGACCTGGTGGATACCGGTGGTACTGCGGTTG
CGATTCGTGAAATGTATCCAAAAGCGCACTTTGTCACCATCTTCGCAAAACCGGCTGGTCGTCCGCTGGTTGATGACTATGTTGTTGATATCCCGCAAGAT
ACCTGGATTGAACAGCCGTGGGATATGGGCGTCGTATTCGTCCCGCCAATCTCCGGTCGCTAATCTTTTCAACGCCTGGCACTGCCGGGCGTTGTTCTTTT
TAACTTCAGGCGGGTTACAATAGTTTCCAGTAAGTATTCTGGAGGCTGCATCCATGACACAGGCAAACCTGAGCGAAACCCTGTTCAAACCCCGCTTTAAA
CATCCTGAAACCTCGACGCTAGTCCGCCGCTTTAATCACGGCGCACAACCGCCTGTGCAGTCGGCCCTTGATGGTAAAACCATCCCTCACTGGTATCGCAT
GATTAACCGTCTGATGTGGATCTGGCGCGGCATTGACCCACGCGAAATCCTCGACGTCCAGGCACGTATTGTGATGAGCGATGCCGAACGTACCGACGATG
ATTTATACGATACGGTGATTGGCTACCGTGGCGGCAACTGGATTTATGAGTGGGCCCCGGATCTTTGTGAAGGAACCTTACTTCTGTGGTGTGACATAATT
GGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGA
277 
TTCCAACCTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTTAATGAGGAAAACCTGTTTTGCTCAGAAGAAATGCCATCTAGTGATGATGAGGCT
ACTGCTGACTCTCAACATTCTACTCCTCCAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTTTTTTGAGTCATGCTGT
GTTTAGTAATAGAACTCTTGCTTGCTTTGCTATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAATATTCTGTAACCTTTA
TAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTCTTACTCCACACAGGCATAGAGTGTCTGCTATTAATAACTATGCTCAAAAATTGTGTACC
TTTAGCTTTTTAATTTGTAAAGGGGTTAATAAGGAATATTTGATGTATAGTGCCTTGACTAGAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTAC
TTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAA
TAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGAT
CAACTGGATAACTCAAGCTAACCAAAATCATCCCAAACTTCCCACCCCATACCCTATTACCACTGCCAATTACCTAGTGGTTTCATTTACTCTAAACCTGT
GATTCCTCTGAATTATTTTCATTTTAAAGAAATTGTATTTGTTAAATATGTACTACAAACTTAGTAGTTGGAAGGGCTAATTCACTCCCAAAGAAGACAAG
ATATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACCTTTGGATGG
TGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGGATGGATGA
CCCGGAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTGATATC
GAGCTTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAAGCAGCT
GCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGC
CTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGC
GCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGA
CTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATGGGA
AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGT
TAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACC
CTCTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAAGC
GGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCA
CCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGG
CGCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATC
TGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGC
TCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGA
CAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAAT
GGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTT
GCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAAT
AGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGCCAAATGGCAGTATTCATCCACAATTTTAAAA
GAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATT
CAAAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCAGTTTGGATTGATAAGCTTGATATCGAATTCGTTTTTCTCTTAATTTTCCCCTGTAATTTACA
CTGGGAGAGCTGGGAAATATGTGGATGTAAATTTCTCAGCCACAGAGATGCAAAGTTATACTGTGGGGAAAAAAAACTTGAGTTAAATCCTTACATATTTT
AGGTTTTCATTAACTTACCAATGTAGTTTTGTTGGAGGCCATTTTTTATTGCAGACTTGAAGAGCTATTACTAGAAAAATGCATGACAGTTAAGGTAAGTT
TGCATGACACAAAAAAGGTAACTAAATACAAATTCTGTTTGGATTCCAACCCCCAAGTAGAGAGCGCACACTTTCAAACGTGAATACAAATCCAGAGTAGA
TCTGCGCTCCTACCTACATTGCTTATGATGTACTTAAGTACGTGTCCTAACCATGTGAGTCTAGAAAGACTTTACTGGGGATCCTGGTACCTAAAACAGCT
TCACATGGCTTAAAATAGGGGACCAATGTCTTTTCCAATCTAAGTCCCATTTATAATAAAGTCCATGTTCCATTTTTAAAGGACAATCCTTTCGGTTTAAA
ACCAGGCACGATTACCCAAACAACTCACAACGGTAAAGCACTGTGAATCTTCTCTGTTCTGCAATCCCAACTTGGTTTCTGCTCAGAAACCCTCCCTCTTT
CCAATCGGTAATTAAATAACAAAAGGAAAAAACTTAAGATGCTTCAACCCCGTTTCGTGACACTTTGAAAAAAGAATCACCTCTTGCAAACACCCGCTCCC
GACCCCCGCCGCTGAAGCCCGGCGTCCAGAGGCCTAAGCGCGGGTGCCCGCCCCCACCCGGGAGCGCGGGCCTCGTGGTCAGCGCATCCGCGGGGAGAAAC
AAAGGCCGCGGCACGGGGGCTCAAGGGCACTGCGCCACACCGCACGCGCCTACCCCCGCGCGGCCACGTTAACTGGCGGTCGCCGCAGCCTCGGGACAGCC
GGCCGCGCGCCGCCAGGCTCGCGGACGCGGGACCACGCGCCGCCCTCCGGGAGGCCCAAGTCTCGACCCAGCCCCGCGTGGCGCTGGGGGAGGGGGCGCCT
CCGCCGGAACGCGGGTGGGGGAGGGGAGGGGGAAATGCGCTTTGTCTCGAAATGGGGCAACCGTCGCCACAGCTCCCTACCCCCTCGAGGGCAGAGCAGTC
CCCCCACTAACTACCGGGCTGGCCGCGCGCCAGGCCAGCCGCGAGGCCACCGCCCGACCCTCCACTCCTTCCCGCAGCTCCCGGCGCGGGGTCCGGCGAGA
AGGGGAGGGGAGGGGAGCGGAGAACCGGGCCCCCGGGACGCGTGTGGCATCTGAAGCACCACCAGCGAGCGAGAGCTAGAGAGAAGGAAAGCCACCGACTT
CACCGCCTCCGAGCTGCTCCGGGTCGCGGGTCTGCAGCGTCTCCGGCCCTCCGCGCCTACAGCTCAAGCCACATCCGAAGGGGGAGGGAGCCGGGAGCTGC
GCGCGGGGCCGCCGGGGGGAGGGGTGGCACCGCCCACGCCGGGCGGCCACGAAGGGCGGGGCAGCGGGCGCGCGCGCGGCGGGGGGAGGGGCCGGCGCCGC
GCCCGCTGGGAATTGGGGCCCTAGGGGGAGGGCGGAGGCGCCGACGACCGCGGCACTTACCGTTCGCGGCGTGGCGCCCGGTGGTCCCCAAGGGGAGGGAA
GGGGGAGGCGGGGCGAGGACAGTGACCGGAGTCTCCTCAGCGGTGGCTTTTCTGCTTGGCAGCCTCAGCGGCTGGCGCCAAAACCGGACTCCGCCCACTTC
CTCGCCCGCCGGTGCGAGGGTGTGGAATCCTCCAGACGCTGGGGGAGGGGGAGTTGGGAGCTTAAAAACTAGTACCCCTTTGGGACCACTTTCAGCAGCGA
ACTCTCCTGTACACCAGGGGTCAGTTCCACAGACGCGGGCCAGGGGTGGGTCATTGCGGCGTGAACAATAATTTGACTAGAAGTTGATTCGGGTGTTTCCG
GAAGGGGCCGAGTCAATCCGCCGAGTTGGGGCACGGAAAACAAAAAGGGAAGGCTACTAAGATTTTTCTGGCGGGGGTTATCATTGGCGTAACTGCAGGGA
CCACCTCCCGGGTTGAGGGGGCTGGATCTCCAGGCTGCGGATTAAGCCCCTCCCGTCGGCGTTAATTTCAAACTGCGCGACGTTTCTCACCTGCCTTCGCC
AAGGCAGGGGCCGGGACCCTATTCCAAGAGGTAGTAACTAGCAGGACTCTAGCCTTCCGCAATTCATTGAGCGCATTTACGGAAGTAACGTCGGGTACTGT
CTCTGGCCGCAAGGGTGGGAGGAGTACGCATTTGGCGTAAGGTGGGGCGTAGAGCCTTCCCGCCATTGGCGGCGGATAGGGCGTTTACGCGACGGCCTGAC
GTAGCGGAAGACGCGTTAGTGGGGGGGAAGGTTCTAGAAAAGCGGCGGCAGCGGCTCTAGCGGCAGTAGCAGCAGCGCCGGGTCCCGTGCGGAGGTGCTCC
TCGCAGAGTTGTTTCTCGAGCAGCGGCAGTTCTCACTACAGCGCCAGGACGAGTCCGGTTCGTGTTCGTCCGCGGAGATCTCTCTCATCTCGCTCGGCTGC
GGGAAATCGGGCTGAAGCGACTGAGTCCCCGGGTCTAGAATCGATAAGCTTGAGCTCGATATCG  
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10.2 U20S curve modelling in R 
# Get data 
series <- read_excel('data.xlsx') 
# Change the shape of the data to long format 
series.long <- series %>% 
  gather(Q, value, 2:5) %>% 
  mutate(Q = factor(Q, levels=c('30Q', '70Q', '97Q', '118Q'))) 
na.omit() %>% 
  as.data.frame() 
# Fit the model (you can change the model here) 
expmod_118Q <- lm(log(`118Q`) ~ day, data=series) 
expmod_97Q <- lm(log(`97Q`) ~ day, data=series) 
# Make predictions 
prediction.data_118Q <- data.frame(day=1:3000) 
predictions_118Q <- predict(expmod_118Q, prediction.data_118Q, interval = "c", level=0.95) %>% 
as.data.frame() %>% mutate(day=1:3000) 
prediction.data_97Q <- data.frame(day=1:3000) 
predictions_97Q <- predict(expmod_97Q, prediction.data_97Q, interval = "c", level=0.95) %>%  
as.data.frame() %>% mutate(day=1:3000) 
# Change the fit to normal value not log 
predictions_118Q[, 1:3] <- exp(predictions_118Q[, 1:3]) 
predictions_97Q[, 1:3] <- exp(predictions_97Q[, 1:3]) 
# Plot values and predictions 
ggplot(series.long, aes(day, value)) + 
  geom_smooth(aes(y=fit, ymin=lwr, ymax=upr), data=predictions_118Q, stat="identity", color="Purple", 
fill="Purple") + 
  geom_smooth(aes(y=fit, ymin=lwr, ymax=upr), data=predictions_97Q, stat="identity", 
color="Turquoise", fill="Turquoise") + 
  geom_point(aes(col=Q)) + 
  theme_bw() + 
  labs(x="Day", y="CAG") + 
  theme(text = element_text(size=20)) 
# Filter the data 
series.long %>% 
  filter(Q %in% c('97Q', '118Q')) %>% 
  ggplot(aes(day, value)) + 
  geom_smooth(aes(y=fit, ymin=lwr, ymax=upr), data=predictions_118Q, stat="identity", color="Purple", 
fill="Purple") + 
  geom_smooth(aes(y=fit, ymin=lwr, ymax=upr), data=predictions_97Q, stat="identity", 
color="Turquoise", fill="Turquoise") + 
  geom_point(aes(col=Q)) + 
  xlim(1700, 2500) + 
  theme_bw() 
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10.3 pSUPER.retro.puro vector sequence 
TGAAAGACCCCACCTGTAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAATACATAACTGAGAATAGAGAAGTTCAGATCAAGGT
TAGGAACAGAGAGACAGCAGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGT
CCCGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCT
TCTCGCTTCTGTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGCGCGCCAGTCCTCCGATAGACTGCGTCGCCCGGGT
ACCCGTATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAATCGTGGACTCGCTGATCCTTGGGAGGGTCTCCTCAGATTGATTGACTGCCCACCTCGGGG
GTCTTTCATTTGGAGGTTCCACCGAGATTTGGAGACCCCTGCCCAGGGACCACCGACCCCCCCGCCGGGAGGTAAGCTGGCCAGCGGTCGTTTCGTGTCTG
TCTCTGTCTTTGTGCGTGTTTGTGCCGGCATCTAATGTTTGCGCCTGCGTCTGTACTAGTTAGCTAACTAGCTCTGTATCTGGCGGACCCGTGGTGGAACT
GACGAGTTCTGAACACCCGGCCGCAACCCTGGGAGACGTCCCAGGGACTTTGGGGGCCGTTTTTGTGGCCCGACCTGAGGAAGGGAGTCGATGTGGAATCC
GACCCCGTCAGGATATGTGGTTCTGGTAGGAGACGAGAACCTAAAACAGTTCCCGCCTCCGTCTGAATTTTTGCTTTCGGTTTGGAACCGAAGCCGCGCGT
CTTGTCTGCTGCAGCGCTGCAGCATCGTTCTGTGTTGTCTCTGTCTGACTGTGTTTCTGTATTTGTCTGAAAATTAGGGCCAGACTGTTACCACTCCCTTA
AGTTTGACCTTAGGTCACTGGAAAGATGTCGAGCGGATCGCTCACAACCAGTCGGTAGATGTCAAGAAGAGACGTTGGGTTACCTTCTGCTCTGCAGAATG
GCCAACCTTTAACGTCGGATGGCCGCGAGACGGCACCTTTAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTTTCACCTGGCCCGCATGGACACC
CAGACCAGGTCCCCTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCCCCTCCCTGGGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTCTTCCT
CCATCCGCCCCGTCTCTCCCCCTTGAACCTCCTCGTTCGACCCCGCCTCGATCCTCCCTTTATCCAGCCCTCACTCCTTCTCTAGGCGCCGGAATTAGATC
GATCTCTCGAGGTCGACGGTATCGATAAGCTTAGATCTGTGGTCTCATACAGAACTTATAAGATTCCCAAATCCAAAGACATTTCACGTTTATGGTGATTT
CCCAGAACACATAGCGACATGCAAATATTGCAGGGCGCCACTCCCCTGTCCCTCACAGCCATCTTCCTGCCAGGGCGCACGCGCGCTGGGTGTTCCCGCCT
AGTGACACTGGGCCCGCGATTCCTTGGAGCGGGTTGATGACGTCAGCGTTCGAATTCTACCGGGTAGGGGAGGCGCTTTTCCCAAGGCAGTCTGGAGCATG
CGCTTTAGCAGCCCCGCTGGGCACTTGGCGCTACACAAGTGGCCTCTGGCCTCGCACACATTCCACATCCACCGGTAGGCGCCAACCGGCTCCGTTCTTTG
GTGGCCCCTTCGCGCCACCTTCTACTCCTCCCCTAGTCAGGAAGTTCCCCCCCGCCCCGCAGCTCGCGTCGTGCAGGACGTGACAAATGGAAGTAGCACGT
CTCACTAGTCTCGTGCAGATGGACAGCACCGCTGAGCAATGGAAGCGGGTAGGCCTTTGGGGCAGCGGCCAATAGCAGCTTTGCTCCTTCGCTTTCTGGGC
TCAGAGGCTGGGAAGGGGTGGGTCCGGGGGCGGGCTCAGGGGCGGGCTCAGGGGCGGGGCGGGCGCCCGAAGGTCCTCCGGAGGCCCGGCATTCTGCACGC
TTCAAAAGCGCACGTCTGCCGCGCTGTTCTCCTCTTCCTCATCTCCGGGCCTTTCGACCTGCAGCCCAAGCTAGCTTACCATGACCGAGTACAAGCCCACG
GTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCG
CCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGACGACGGCGCCGCGGTGGCGG
TCTGGACCACGCCGGAGAGCGTCGAAGCGGGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCCGCGCAGCAACAG
ATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTCCTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGC
CGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGCGCCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCT
TCACCGTCACCGCCGACGTCGAGGTGCCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACGCCCGCCCCACGACCCGCAGCGCCCG
ACCGAAAGGAGCGCACGACCCCATGCATCGATAAAATAAAAGATTTTATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCACCTGTAGGTTTGGCAA
GCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTCGC
GCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGCGCGCCAGTCCTCCGATAGACTGCGTCGCCCGGGTACCCGTGTATCCAATA
AACCCTCTTGCAGTTGCATCCGACTTGTGGTCTCGCTGTTCCTTGGGAGGGTCTCCTCTGAGTGATTGACTACCCGTCAGCGGGGGTCTTTCATGGGTAAC
AGTTTCTTGAAGTTGGAGAACAACATTCTGAGGGTAGGAGTCGAATATTAAGTAATCCTGACTCAATTAGCCACTGTTTTGAATCCACATACTCCAATACT
CCTGAAATAGTTCATTATGGACAGCGCAGAAGAGCTGGGGAGAATTAATTCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAA
TTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC
CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGA
CTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACA
TGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGA
CGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCT
TACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGC
TGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTG
GCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGT
ATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTG
TTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAA
GGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTG
GTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTA
CGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGA
AGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTT
GCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACAT
GATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCA
CTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAG
TTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAA
GGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAA
ACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGG
TTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAG
AAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATG
CAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCT
TAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCCATT
CGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGT
TGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGG
CCTGCCACCATACCCACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTCCCCATCGGTGATGTCGGCGATATAGGCGCCAGCAACCGC
ACCTGTGGCGCCGGTGATGCCGGCCACGATGCGTCCGGCGTAGAGGCGATTAGTCCAATTTGTTAAAGACAGGATATCAGTGGTCCAGGCTCTAGTTTTGA
CTCAACAATATCACCAGCTGAAGCCTATAGAGTACGAGCCATAGATAAAATAAAAGATTTTATTTAGTCTCCAGAAAAAGGGGGGAA  
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10.4 pcDNA5-GFP-FAN1/FRT/TO vector sequence 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGG
CGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACG
GCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTGCAGGAGCGCACCATCTTCTTC
AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGG
CAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCC
GCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTG
AGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGA
GCTGTACAAGTCCGGACTCGGATCTATGATGTCAGAAGGGAAACCTCCTGACAAAAAAAGGCCTCGTAGAAGCTTATCAATCAGCAAGAATAAGAAAAAAG
CATCTAATTCTATTATTTCGTGTTTTAACAATGCACCACCTGCTAAACTTGCCTGCCCCGTTTGCAGTAAAATGGTGCCTAGATATGACTTAAACCGGCAC
CTTGATGAAATGTGTGCTAACAATGACTTCGTTCAAGTGGATCCAGGGCAGGTTGGCTTAATAAATTCAAATGTGTCTATGGTAGATTTAACCAGTGTTAC
CTTAGAAGATGTAACACCTAAGAAGTCACCACCACCAAAGACAAATTTAACCCCTGGCCAAAGTGATTCAGCAAAAAGGGAAGTAAAGCAGAAGATCAGTC
CCTACTTTAAAAGTAATGATGTGGTGTGCAAAAATCAAGATGAGCTGAGAAATCGTAGTGTGAAAGTCATTTGTTTGGGAAGCCTAGCATCTAAATTGTCC
AGAAAATACGTAAAGGCTAAAAAATCAATAGATAAGGATGAAGAATTTGCCGGTTCTAGTCCACAGAGTTCCAAATCCACAGTTGTTAAGAGCCTGATTGA
TAACTCTTCAGAAATTGAGGACGAGGATCAAATTTTGGAGAACAGTTCTCAAAAAGAAAACGTGTTTAAATGTGATTCTCTAAAGGAAGAGTGCATTCCTG
AACATATGGTAAGAGGAAGTAAAATAATGGAAGCCGAAAGCCAAAAGGCTACCCGGGAATGTGAGAAATCAGCCCTCACCCCTGGATTCTCAGATAATGCG
ATCATGTTATTCTCACCAGATTTCACTCTTAGGAATACATTAAAGTCTACTTCAGAAGACAGTCTTGTAAAGCAAGAGTGTATCAAAGAAGTGGTTGAAAA
ACGTGAGGCATGTCATTGTGAAGAAGTAAAAATGACTGTTGCTTCAGAAGCTAAAATACAGCTGTCAGATTCAGAGGCAAAATCTCATAGTTCTGCAGATG
ATGCTTCTGCATGGAGTAACATCCAAGAGGCTCCTCTGCAGGATGACAGTTGCTTAAACAATGATATCCCTCACAGCATTCCTTTGGAGCAGGGGTCAAGC
TGCAATGGTCCTGGTCAAACAACCGGTCATCCTTACTACCTTCGGAGTTTCCTTGTGGTGCTGAAAACCGTACTTGAGAATGAAGATGATATGTTGCTCTT
TGATGAGCAGGAGAAGGGAATTGTAACTAAATTTTATCAGTTATCAGCTACTGGTCAGAAGTTATATGTAAGGCTCTTTCAACGTAAATTAAGCTGGATTA
AGATGACCAAATTAGAGTATGAAGAGATTGCCTTAGACTTAACACCTGTGATTGAAGAATTGACGAATGCAGGCTTTCTACAGACAGAATCTGAGTTGCAA
GAACTCTCTGAAGTGCTTGAACTCCTTTCTGCTCCTGAACTAAAATCCCTAGCCAAGACCTTCCACTTGGTGAATCCCAATGGACAGAAACAGCAGCTGGT
GGACGCCTTTCTCAAATTGGCCAAACAGCGTTCAGTCTGCACTTGGGGCAAGAATAAGCCTGGAATTGGTGCAGTGATTTTAAAAAGAGCCAAAGCCTTGG
CTGGACAGTCAGTACGAATCTGTAAAGGCCCCAGGGCTGTGTTTTCCCGCATCTTGCTACTGTTTTCGTTGACCGACTCAATGGAAGATGAAGACGCCGCT
TGTGGAGGTCAGGGACAGCTTTCAACAGTCCTGTTGGTCAACCTCGGCCGAATGGAGTTTCCTAGTTACACCATCAATCGGAAAACCCACATCTTCCAAGA
CAGAGATGATCTTATCAGATATGCAGCAGCCACGCACATGCTGAGTGACATTTCTTCCGCAATGGCCAATGGGAACTGGGAAGAAGCTAAGGAGCTCGCTC
AGTGTGCAAAAAGGGATTGGAACAGACTGAAAAACCACCCTTCTCTGAGATGCCACGAAGATTTACCACTCTTCCTGCGGTGTTTCACTGTTGGGTGGATT
TATACAAGGATTTTGTCTCGGTTTGTGGAAATACTGCAGAGACTTCACATGTATGAGGAAGCCGTCAGAGAACTTGAAAGCCTTTTGTCTCAGAGAATTTA
TTGTCCTGACAGCAGAGGCCGATGGTGGGATCGACTGGCCCTTAATTTACACCAGCACTTGAAGCGCCTGGAACCGACTATCAAGTGCATCACAGAGGGGC
TGGCGGATCCGGAAGTCAGAACGGGACACCGCCTTTCACTGTATCAGCGAGCCGTGCGCCTGCGAGAGTCTCCGAGCTGTAAAAAGTTCAAGCACCTCTTC
CAGCAGCTCCCAGAAATGGCTGTGCAAGATGTGAAACACGTGACCATCACAGGCAGGCTGTGCCCACAGCGTGGGATGTGCAAGTCTGTGTTTGTGATGGA
GGCCGGGGAGGCCGCTGACCCCACCACGGTCCTGTGCTCTGTGGAGGAGCTGGCACTGGCCCATTACAGACGCAGCGGTTTTGACCAGGGGATTCATGGCG
AAGGGTCCACCTTCAGCACCCTGTATGGCCTCCTCCTGTGGGACATCATCTTCATGGATGGGATTCCGGATGTCTTCAGAAACGCCTGTCAGGCATTCCCC
CTGGACTTGTGCACAGACAGCTTCTTCACAAGCAGACGCCCAGCCCTTGAGGCCAGGCTGCAGCTGATTCATGATGCCCCCGAGGAGAGCCTGCGGGCCTG
GGTGGCAGCCACGTGGCATGAGCAGGAAGGCAGAGTGGCTTCCCTTGTCAGCTGGGATCGCTTCACGTCTCTTCAGCAAGCTCAGGATCTTGTCTCCTGCC
TGGGGGGCCCTGTGCTCAGTGGTGTGTGCAGGCACCTGGCTGCTGACTTTCGACACTGTCGAGGGGGCCTCCCCGACCTGGTGGTGTGGAACTCCCAGAGC
CGTCACTTTAAGCTGGTGGAAGTTAAAGGCCCCAATGATCGTCTTTCACATAAGCAGATGATCTGGCTGGCTGAACTGCAGAAGCTGGGGGCTGAAGTAGA
AGTCTGCCACGTGGTTGCAGTTGGAGCTAAG 
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Figure 10.1. Schematic representation of pcDNA5-GFP-FAN1/FRT/TO vector  
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10.5 Sequencing of A2UCOE HTT exon 1 construct CAG repeat regions 
Ref: GGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC 
30Q: GGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC 
70Q: GGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC 
118Q:GGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC 
 
Ref: AGCAGCAGCAGCAGCA---------------------------------------------------- 
30Q: AGCAGCAGCAGCAGCAGCAGCAACAGCAGCAGCAGCAGCAGCAGCAGCA------------------- 
70Q: AGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 
118Q:AGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 
 
Ref: -------------------------------------------------------------------- 
30Q: -------------------------------------------------------------------- 
70Q: CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA 
118Q:CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA 
 
Ref: -------------------------------------------------------------------- 
30Q: -------------------------------------------------------------------- 
70Q: GCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA-------------------------------- 
118Q:GCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC 
 
Ref: -------------------------------------------------------------------- 
30Q: -------------------------------------------------------------------- 
70Q: -------------------------------------------------------------------- 
118Q:AGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 
 
 
Ref: ---------------------------------------------------ACAGCCGCCACCGCCGC 
30Q: ---------------------------------------------------ACAGCCGCCACCGCCGC 
70Q: ---------------------------------------------------ACAGCCGCCACCGCCGC 
118Q:CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG-CAGCCGCCACCGCCGC 
Figure 10.2. Sanger sequencing of A2UCOE HTT exon 1 construct CAG repeat regions. 
Sequencing conducted by Trager et al. (2014). Sequence aligned to the reference genome (Homo sapiens chromosome 4, GRCh38.p12 
Primary Assembly, NCBI Reference Sequence: NC_000004.12) in SnapGene. The polyglutamine repeat is given in red. 
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10.6 MSH3 MiSeq primer sequences 
  MiSeq primer name P5 adaptor sequence  i5 index Sequencing primer binding site Spacer Gene-specific primer Full MiSeq primer sequence 
P5 primers 
(5'-3') 
MSH3-F-S502 AATGATACGGCGACCACCGAGATCTACAC CTCTCTAT ACACTCTTTCCCTACACGACGCTCTTCCGATCT   CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACCTCTCTATACACTCTTTCCCTACACGACGCTCTTCCGATCTCTTCCTCCTCCAGCCCTATC 
MSH3-F-S503 AATGATACGGCGACCACCGAGATCTACAC TATCCTCT ACACTCTTTCCCTACACGACGCTCTTCCGATCT TGA CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACTATCCTCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTGACTTCCTCCTCCAGCCCTATC 
MSH3-F-S505 AATGATACGGCGACCACCGAGATCTACAC GTAAGGAG ACACTCTTTCCCTACACGACGCTCTTCCGATCT GT CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACGTAAGGAGACACTCTTTCCCTACACGACGCTCTTCCGATCTGTCTTCCTCCTCCAGCCCTATC 
MSH3-F-S506 AATGATACGGCGACCACCGAGATCTACAC ACTGCATA ACACTCTTTCCCTACACGACGCTCTTCCGATCT CAAG CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACACTGCATAACACTCTTTCCCTACACGACGCTCTTCCGATCTCAAGCTTCCTCCTCCAGCCCTATC 
MSH3-F-S507 AATGATACGGCGACCACCGAGATCTACAC AAGGAGTA ACACTCTTTCCCTACACGACGCTCTTCCGATCT G CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACAAGGAGTAACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTTCCTCCTCCAGCCCTATC 
MSH3-F-S508 AATGATACGGCGACCACCGAGATCTACAC CTAAGCCT ACACTCTTTCCCTACACGACGCTCTTCCGATCT TCGGA CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACCTAAGCCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTCGGACTTCCTCCTCCAGCCCTATC 
MSH3-F-S510 AATGATACGGCGACCACCGAGATCTACAC CGTCTAAT ACACTCTTTCCCTACACGACGCTCTTCCGATCT AGGAGG CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACCGTCTAATACACTCTTTCCCTACACGACGCTCTTCCGATCTAGGAGGCTTCCTCCTCCAGCCCTATC 
MSH3-F-S511 AATGATACGGCGACCACCGAGATCTACAC TCTCTCCG ACACTCTTTCCCTACACGACGCTCTTCCGATCT AACAGAC CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACTCTCTCCGACACTCTTTCCCTACACGACGCTCTTCCGATCTAACAGACCTTCCTCCTCCAGCCCTATC 
MSH3-F-S513 AATGATACGGCGACCACCGAGATCTACAC TCGACTAG ACACTCTTTCCCTACACGACGCTCTTCCGATCT   CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACTCGACTAGACACTCTTTCCCTACACGACGCTCTTCCGATCTCTTCCTCCTCCAGCCCTATC 
MSH3-F-S515 AATGATACGGCGACCACCGAGATCTACAC TTCTAGCT ACACTCTTTCCCTACACGACGCTCTTCCGATCT ATA CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACTTCTAGCTACACTCTTTCCCTACACGACGCTCTTCCGATCTATACTTCCTCCTCCAGCCCTATC 
MSH3-F-S516 AATGATACGGCGACCACCGAGATCTACAC CCTAGAGT ACACTCTTTCCCTACACGACGCTCTTCCGATCT TG CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACCCTAGAGTACACTCTTTCCCTACACGACGCTCTTCCGATCTTGCTTCCTCCTCCAGCCCTATC 
MSH3-F-S517 AATGATACGGCGACCACCGAGATCTACAC GCGTAAGA ACACTCTTTCCCTACACGACGCTCTTCCGATCT GCAG CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACGCGTAAGAACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAGCTTCCTCCTCCAGCCCTATC 
MSH3-F-S518 AATGATACGGCGACCACCGAGATCTACAC CTATTAAG ACACTCTTTCCCTACACGACGCTCTTCCGATCT G CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACCTATTAAGACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTTCCTCCTCCAGCCCTATC 
MSH3-F-S520 AATGATACGGCGACCACCGAGATCTACAC AAGGCTAT ACACTCTTTCCCTACACGACGCTCTTCCGATCT AGCGA CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACAAGGCTATACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCGACTTCCTCCTCCAGCCCTATC 
MSH3-F-S521 AATGATACGGCGACCACCGAGATCTACAC GAGCCTTA ACACTCTTTCCCTACACGACGCTCTTCCGATCT CAGAGG CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACGAGCCTTAACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGAGGCTTCCTCCTCCAGCCCTATC 
MSH3-F-S522 AATGATACGGCGACCACCGAGATCTACAC TTATGCGA ACACTCTTTCCCTACACGACGCTCTTCCGATCT TAGAGAG CTTCCTCCTCCAGCCCTATC AATGATACGGCGACCACCGAGATCTACACTTATGCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGAGAGCTTCCTCCTCCAGCCCTATC 
                
  MiSeq primer name P7 adaptor sequence  i7 index Sequencing primer binding site Spacer Gene-specific primer Full MiSeq primer sequence 
P5 primers 
(5'-3') 
MSH3-R-N701 CAAGCAGAAGACGGCATACGAGAT TCGCCTTA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC TA AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAAGTTTGGCGCGAAATTGTGG 
MSH3-R-N702 CAAGCAGAAGACGGCATACGAGAT TAGTACG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC AT AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATTAGTACGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCATAGTTTGGCGCGAAATTGTGG 
MSH3-R-N703 CAAGCAGAAGACGGCATACGAGAT TTCTGCCT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC TA AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATTTCTGCCTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAAGTTTGGCGCGAAATTGTGG 
MSH3-R-N704 CAAGCAGAAGACGGCATACGAGAT GCTCAGGA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC G AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATGCTCAGGAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGAGTTTGGCGCGAAATTGTGG 
MSH3-R-N705 CAAGCAGAAGACGGCATACGAGAT AGGAGTCC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC G AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATAGGAGTCCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGAGTTTGGCGCGAAATTGTGG 
MSH3-R-N706 CAAGCAGAAGACGGCATACGAGAT CATGCCTA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC AT AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATCATGCCTAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCATAGTTTGGCGCGAAATTGTGG 
MSH3-R-N707 CAAGCAGAAGACGGCATACGAGAT GTAGAGAG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC TA AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATGTAGAGAGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAAGTTTGGCGCGAAATTGTGG 
MSH3-R-N710 CAAGCAGAAGACGGCATACGAGAT CAGCCTCG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC   AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATCAGCCTCGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCAGTTTGGCGCGAAATTGTGG 
MSH3-R-N711 CAAGCAGAAGACGGCATACGAGAT TGCCTCTT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC AT AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATTGCCTCTTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCATAGTTTGGCGCGAAATTGTGG 
MSH3-R-N712 CAAGCAGAAGACGGCATACGAGAT TCCTCTAC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC TA AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATTCCTCTACGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAAGTTTGGCGCGAAATTGTGG 
MSH3-R-N714 CAAGCAGAAGACGGCATACGAGAT TCATGAGC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC AT AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATTCATGAGCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCATAGTTTGGCGCGAAATTGTGG 
MSH3-R-N715 CAAGCAGAAGACGGCATACGAGAT CTGAGAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC TA AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATCTGAGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAAGTTTGGCGCGAAATTGTGG 
MSH3-R-N716 CAAGCAGAAGACGGCATACGAGAT TAGCGAGT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC AT AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATTAGCGAGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCATAGTTTGGCGCGAAATTGTGG 
MSH3-R-N718 CAAGCAGAAGACGGCATACGAGAT GTAGCTCC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC G AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATGTAGCTCCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGAGTTTGGCGCGAAATTGTGG 
MSH3-R-N719 CAAGCAGAAGACGGCATACGAGAT TACTACGC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC TA AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATTACTACGCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAAGTTTGGCGCGAAATTGTGG 
MSH3-R-N720 CAAGCAGAAGACGGCATACGAGAT GGCTCCG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC   AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATGGCTCCGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCAGTTTGGCGCGAAATTGTGG 
MSH3-R-N721 CAAGCAGAAGACGGCATACGAGAT CAGCGTA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC G AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATCAGCGTAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGAGTTTGGCGCGAAATTGTGG 
MSH3-R-N722 CAAGCAGAAGACGGCATACGAGAT CTGCGCAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC G AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATCTGCGCATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGAGTTTGGCGCGAAATTGTGG 
MSH3-R-N723 CAAGCAGAAGACGGCATACGAGAT GAGCGCTA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC G AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATGAGCGCTAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGAGTTTGGCGCGAAATTGTGG 
MSH3-R-N724 CAAGCAGAAGACGGCATACGAGAT CGCTCAGT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC G AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATCGCTCAGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGAGTTTGGCGCGAAATTGTGG 
MSH3-R-N726 CAAGCAGAAGACGGCATACGAGAT GTCTTAGG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC AT AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATGTCTTAGGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCATAGTTTGGCGCGAAATTGTGG 
MSH3-R-N727 CAAGCAGAAGACGGCATACGAGAT ACTGATCG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC TA AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATACTGATCGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAAGTTTGGCGCGAAATTGTGG 
MSH3-R-N728 CAAGCAGAAGACGGCATACGAGAT TAGCTGCA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC AT AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATTAGCTGCAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCATAGTTTGGCGCGAAATTGTGG 
MSH3-R-N729 CAAGCAGAAGACGGCATACGAGAT GACGTCGA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC G AGTTTGGCGCGAAATTGTGG CAAGCAGAAGACGGCATACGAGATGACGTCGAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGAGTTTGGCGCGAAATTGTGG 
Table 10.1. Nextera XT Index Kit v2 primers for the MSH3 repeat region. 
Oligonucleotide sequences © 2018 Illumina, Inc.  All rights reserved. Derivative works created by Illumina customers are authorised for use with Illumina instruments and products only. All other uses are 
strictly prohibited. 
284 
10.7 PhIX reference sequence 
>Illumina Enterobacteria phage phiX, complete genome 
GAGTTTTATCGCTTCCATGACGCAGAAGTTAACACTTTCGGATATTTCTGATGAGTCGAAAAATTATCTTGATAAAGCAGGAATTACTACTGCTTGTTTAC
GAATTAAATCGAAGTGGACTGCTGGCGGAAAATGAGAAAATTCGACCTATCCTTGCGCAGCTCGAGAAGCTCTTACTTTGCGACCTTTCGCCATCAACTAA
CGATTCTGTCAAAAACTGACGCGTTGGATGAGGAGAAGTGGCTTAATATGCTTGGCACGTTCGTCAAGGACTGGTTTAGATATGAGTCACATTTTGTTCAT
GGTAGAGATTCTCTTGTTGACATTTTAAAAGAGCGTGGATTACTATCTGAGTCCGATGCTGTTCAACCACTAATAGGTAAGAAATCATGAGTCAAGTTACT
GAACAATCCGTACGTTTCCAGACCGCTTTGGCCTCTATTAAGCTCATTCAGGCTTCTGCCGTTTTGGATTTAACCGAAGATGATTTCGATTTTCTGACGAG
TAACAAAGTTTGGATTGCTACTGACCGCTCTCGTGCTCGTCGCTGCGTTGAGGCTTGCGTTTATGGTACGCTGGACTTTGTAGGATACCCTCGCTTTCCTG
CTCCTGTTGAGTTTATTGCTGCCGTCATTGCTTATTATGTTCATCCCGTCAACATTCAAACGGCCTGTCTCATCATGGAAGGCGCTGAATTTACGGAAAAC
ATTATTAATGGCGTCGAGCGTCCGGTTAAAGCCGCTGAATTGTTCGCGTTTACCTTGCGTGTACGCGCAGGAAACACTGACGTTCTTACTGACGCAGAAGA
AAACGTGCGTCAAAAATTACGTGCAGAAGGAGTGATGTAATGTCTAAAGGTAAAAAACGTTCTGGCGCTCGCCCTGGTCGTCCGCAGCCGTTGCGAGGTAC
TAAAGGCAAGCGTAAAGGCGCTCGTCTTTGGTATGTAGGTGGTCAACAATTTTAATTGCAGGGGCTTCGGCCCCTTACTTGAGGATAAATTATGTCTAATA
TTCAAACTGGCGCCGAGCGTATGCCGCATGACCTTTCCCATCTTGGCTTCCTTGCTGGTCAGATTGGTCGTCTTATTACCATTTCAACTACTCCGGTTATC
GCTGGCGACTCCTTCGAGATGGACGCCGTTGGCGCTCTCCGTCTTTCTCCATTGCGTCGTGGCCTTGCTATTGACTCTACTGTAGACATTTTTACTTTTTA
TGTCCCTCATCGTCACGTTTATGGTGAACAGTGGATTAAGTTCATGAAGGATGGTGTTAATGCCACTCCTCTCCCGACTGTTAACACTACTGGTTATATTG
ACCATGCCGCTTTTCTTGGCACGATTAACCCTGATACCAATAAAATCCCTAAGCATTTGTTTCAGGGTTATTTGAATATCTATAACAACTATTTTAAAGCG
CCGTGGATGCCTGACCGTACCGAGGCTAACCCTAATGAGCTTAATCAAGATGATGCTCGTTATGGTTTCCGTTGCTGCCATCTCAAAAACATTTGGACTGC
TCCGCTTCCTCCTGAGACTGAGCTTTCTCGCCAAATGACGACTTCTACCACATCTATTGACATTATGGGTCTGCAAGCTGCTTATGCTAATTTGCATACTG
ACCAAGAACGTGATTACTTCATGCAGCGTTACCATGATGTTATTTCTTCATTTGGAGGTAAAACCTCTTATGACGCTGACAACCGTCCTTTACTTGTCATG
CGCTCTAATCTCTGGGCATCTGGCTATGATGTTGATGGAACTGACCAAACGTCGTTAGGCCAGTTTTCTGGTCGTGTTCAACAGACCTATAAACATTCTGT
GCCGCGTTTCTTTGTTCCTGAGCATGGCACTATGTTTACTCTTGCGCTTGTTCGTTTTCCGCCTACTGCGACTAAAGAGATTCAGTACCTTAACGCTAAAG
GTGCTTTGACTTATACCGATATTGCTGGCGACCCTGTTTTGTATGGCAACTTGCCGCCGCGTGAAATTTCTATGAAGGATGTTTTCCGTTCTGGTGATTCG
TCTAAGAAGTTTAAGATTGCTGAGGGTCAGTGGTATCGTTATGCGCCTTCGTATGTTTCTCCTGCTTATCACCTTCTTGAAGGCTTCCCATTCATTCAGGA
ACCGCCTTCTGGTGATTTGCAAGAACGCGTACTTATTCGCCACCATGATTATGACCAGTGTTTCCAGTCCGTTCAGTTGTTGCAGTGGAATAGTCAGGTTA
AATTTAATGTGACCGTTTATCGCAATCTGCCGACCACTCGCGATTCAATCATGACTTCGTGATAAAAGATTGAGTGTGAGGTTATAACGCCGAAGCGGTAA
AAATTTTAATTTTTGCCGCTGAGGGGTTGACCAAGCGAAGCGCGGTAGGTTTTCTGCTTAGGAGTTTAATCATGTTTCAGACTTTTATTTCTCGCCATAAT
TCAAACTTTTTTTCTGATAAGCTGGTTCTCACTTCTGTTACTCCAGCTTCTTCGGCACCTGTTTTACAGACACCTAAAGCTACATCGTCAACGTTATATTT
TGATAGTTTGACGGTTAATGCTGGTAATGGTGGTTTTCTTCATTGCATTCAGATGGATACATCTGTCAACGCCGCTAATCAGGTTGTTTCTGTTGGTGCTG
ATATTGCTTTTGATGCCGACCCTAAATTTTTTGCCTGTTTGGTTCGCTTTGAGTCTTCTTCGGTTCCGACTACCCTCCCGACTGCCTATGATGTTTATCCT
TTGGATGGTCGCCATGATGGTGGTTATTATACCGTCAAGGACTGTGTGACTATTGACGTCCTTCCCCGTACGCCGGGCAATAATGTTTATGTTGGTTTCAT
GGTTTGGTCTAACTTTACCGCTACTAAATGCCGCGGATTGGTTTCGCTGAATCAGGTTATTAAAGAGATTATTTGTCTCCAGCCACTTAAGTGAGGTGATT
TATGTTTGGTGCTATTGCTGGCGGTATTGCTTCTGCTCTTGCTGGTGGCGCCATGTCTAAATTGTTTGGAGGCGGTCAAAAAGCCGCCTCCGGTGGCATTC
AAGGTGATGTGCTTGCTACCGATAACAATACTGTAGGCATGGGTGATGCTGGTATTAAATCTGCCATTCAAGGCTCTAATGTTCCTAACCCTGATGAGGCC
GTCCCTAGTTTTGTTTCTGGTGCTATGGCTAAAGCTGGTAAAGGACTTCTTGAAGGTACGTTGCAGGCTGGCACTTCTGCCGTTTCTGATAAGTTGCTTGA
TTTGGTTGGACTTGGTGGCAAGTCTGCCGCTGATAAAGGAAAGGATACTCGTGATTATCTTGCTGCTGCATTTCCTGAGCTTAATGCTTGGGAGCGTGCTG
GTGCTGATGCTTCCTCTGCTGGTATGGTTGACGCCGGATTTGAGAATCAAAAAGAGCTTACTAAAATGCAACTGGACAATCAGAAAGAGATTGCCGAGATG
CAAAATGAGACTCAAAAAGAGATTGCTGGCATTCAGTCGGCGACTTCACGCCAGAATACGAAAGACCAGGTATATGCACAAAATGAGATGCTTGCTTATCA
ACAGAAGGAGTCTACTGCTCGCGTTGCGTCTATTATGGAAAACACCAATCTTTCCAAGCAACAGCAGGTTTCCGAGATTATGCGCCAAATGCTTACTCAAG
CTCAAACGGCTGGTCAGTATTTTACCAATGACCAAATCAAAGAAATGACTCGCAAGGTTAGTGCTGAGGTTGACTTAGTTCATCAGCAAACGCAGAATCAG
CGGTATGGCTCTTCTCATATTGGCGCTACTGCAAAGGATATTTCTAATGTCGTCACTGATGCTGCTTCTGGTGTGGTTGATATTTTTCATGGTATTGATAA
AGCTGTTGCCGATACTTGGAACAATTTCTGGAAAGACGGTAAAGCTGATGGTATTGGCTCTAATTTGTCTAGGAAATAACCGTCAGGATTGACACCCTCCC
AATTGTATGTTTTCATGCCTCCAAATCTTGGAGGCTTTTTTATGGTTCGTTCTTATTACCCTTCTGAATGTCACGCTGATTATTTTGACTTTGAGCGTATC
GAGGCTCTTAAACCTGCTATTGAGGCTTGTGGCATTTCTACTCTTTCTCAATCCCCAATGCTTGGCTTCCATAAGCAGATGGATAACCGCATCAAGCTCTT
GGAAGAGATTCTGTCTTTTCGTATGCAGGGCGTTGAGTTCGATAATGGTGATATGTATGTTGACGGCCATAAGGCTGCTTCTGACGTTCGTGATGAGTTTG
TATCTGTTACTGAGAAGTTAATGGATGAATTGGCACAATGCTACAATGTGCTCCCCCAACTTGATATTAATAACACTATAGACCACCGCCCCGAAGGGGAC
GAAAAATGGTTTTTAGAGAACGAGAAGACGGTTACGCAGTTTTGCCGCAAGCTGGCTGCTGAACGCCCTCTTAAGGATATTCGCGATGAGTATAATTACCC
CAAAAAGAAAGGTATTAAGGATGAGTGTTCAAGATTGCTGGAGGCCTCCACTATGAAATCGCGTAGAGGCTTTGCTATTCAGCGTTTGATGAATGCAATGC
GACAGGCTCATGCTGATGGTTGGTTTATCGTTTTTGACACTCTCACGTTGGCTGACGACCGATTAGAGGCGTTTTATGATAATCCCAATGCTTTGCGTGAC
TATTTTCGTGATATTGGTCGTATGGTTCTTGCTGCCGAGGGTCGCAAGGCTAATGATTCACACGCCGACTGCTATCAGTATTTTTGTGTGCCTGAGTATGG
TACAGCTAATGGCCGTCTTCATTTCCATGCGGTGCACTTTATGCGGACACTTCCTACAGGTAGCGTTGACCCTAATTTTGGTCGTCGGGTACGCAATCGCC
GCCAGTTAAATAGCTTGCAAAATACGTGGCCTTATGGTTACAGTATGCCCATCGCAGTTCGCTACACGCAGGACGCTTTTTCACGTTCTGGTTGGTTGTGG
CCTGTTGATGCTAAAGGTGAGCCGCTTAAAGCTACCAGTTATATGGCTGTTGGTTTCTATGTGGCTAAATACGTTAACAAAAAGTCAGATATGGACCTTGC
TGCTAAAGGTCTAGGAGCTAAAGAATGGAACAACTCACTAAAAACCAAGCTGTCGCTACTTCCCAAGAAGCTGTTCAGAATCAGAATGAGCCGCAACTTCG
GGATGAAAATGCTCACAATGACAAATCTGTCCACGGAGTGCTTAATCCAACTTACCAAGCTGGGTTACGACGCGACGCCGTTCAACCAGATATTGAAGCAG
AACGCAAAAAGAGAGATGAGATTGAGGCTGGGAAAAGTTACTGTAGCCGACGTTTTGGCGGCGCAACCTGTGACGACAAATCTGCTCAAATTTATGCGCGC
TTCGATAAAAATGATTGGCGTATCCAACCTGCA  
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10.8 MSH3 reference sequences 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG1_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGT
CTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGT
AGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCT
G 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG2_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGT
AGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCT
G 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG4_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG4_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG5_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG5_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT0 
286 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGC
GCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG1_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGT
AGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCT
G 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG2_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG4_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG4_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGC
GCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG5_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT0 
287 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGC
GCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG5_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGC
GCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG1_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGT
AGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCT
G 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG2_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG4_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG4_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT0 
288 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGC
GCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG5_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGC
GCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG5_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGC
GCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG1_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG2_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCGCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGC
GCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG4_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT0 
289 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGC
GCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG4_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGC
GCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG5_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGC
GCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG5_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT0 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGC
GCCCCCAGCGCCCCCAGCGCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCG
GGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG1_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGT
AGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCT
G 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG2_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT1 
290 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG4_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG4_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGC
TCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG5_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGC
TCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG5_CCCGCAGCG0_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGC
GCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG1_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG2_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT1 
291 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGC
TCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG4_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGC
TCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG4_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGC
GCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG5_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGC
GCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG5_CCCGCAGCG1_CCCCCAGCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGC
GCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCG
GGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG1_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCC
GCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGAT
GATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG2_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT1 
292 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGC
TCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG4_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGC
TCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG4_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGC
GCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG5_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGC
GCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG5_CCCGCAGCG0_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCCCAGC
GCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCG
GGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG1_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCA
GCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCT
CCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG2_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT1 
293 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTT
CCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGC
GGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGC
TCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGC
TCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTGGGTAAGGCG
GGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGC
GCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG4_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGCGCCCCCAGC
GCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG4_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGC
GCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCG
GGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG5_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGCGCCCCCAGC
GCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCG
GGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG5_CCCGCAGCG1_CCCCCAGCG2_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGGCCGCAGCGCCCGCAGC
GCCCCCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCT
GGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAGCG1_GCCGCAGCG1_CCCGCAGCG1_GCCGCAGCG2_CCCGCAGCG1_CCCCCA
GCG1_CCCCCAGCT1 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGCCCGCAGCGGCCGCAGCGCCCGCAGCGGCCGCAGCGGCCGCAGC
GCCCGCAGCGCCCCCAGCGCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCT
GGGGGGGCGGGGCTTGTGGGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAGCG0_CCCCCAGCG5_CCCCCAGCT1 
294 
GAAATTGTGGCCGCCCCGCCCCCCTCGTCCCCATTTGTGCAGGCGAGGCCCCGCCCCCCCGCCCCGGCGCACGCAGGGTCGCGGCGTGCTCGCGCCCGC
AGACGCCTGGGAACTGCGGCCGCGGGCTCGCGCTCCTCGCCAGGCCCTGCCGCCGGGCTGCCATCCTTGCCCTGCCATGTCTCGCCGGAAGCCTGCGTC
GGGCGGCCTCGCTGCCTCCAGCTCAGCCCCTGCGAGGCAAGCGGTTTTGAGCCGATTCTTCCAGTCTACGGGAAGCCTGAAATCCACCTCCTCCTCCAC
AGGTGCAGCCGACCAGGTGGACCCTGGCGCTGCAGCGGCTGCAGCGGCCGCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGCGCCCCCAGC
GCCCCCAGCTCCCGCCTTCCCGCCCCAGCTGCCGCCGCACATAGTAGGTTCTGTCTGGGACTGGGCAGGGCCATCGGGGCTGGGGGGGCGGGGCTTGTG
GGTAAGGCGGGCGGAGGCGGGGACCCTCCGCCCGATGATAGGGCTG 
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10.9 MiSeq library quality control Galaxy workflow 
Step 1: Input dataset 
R1 fastq input 
select at runtime 
 
Step 2: Input dataset 
IlluminaPHIXref 
select at runtime 
 
Step 3: Input dataset 
R2 fastq input 
select at runtime 
 
Step 4: seqtk_sample 
Input FASTA/Q file 
Output dataset 'output' from step 1 
RNG seed 
4 
Subsample (decimal fraction or number) 
200000.0 
 
Step 5: seqtk_sample 
Input FASTA/Q file 
Output dataset 'output' from step 3 
RNG seed 
4 
Subsample (decimal fraction or number) 
200000.0 
 
Step 6: FastQC 
Short read data from your current history 
Output dataset 'default' from step 4 
Contaminant list 
select at runtime 
Submodule and Limit specifing file 
select at runtime 
 
Step 7: Cutadapt 
Single-end or Paired-end reads? 
Single-end 
FASTQ/A file 
Output dataset 'default' from step 4 
Read 1 Options: 
3' (End) Adapters 
3' (End) Adapters 1 
Source 
Enter custom sequence 
Enter custom 3' adapter name (Optional) 
Illumina Seq primer binding site 
Enter custom 3' adapter sequence 
GATCGGAAGAGCACACGTCTGAACTCCAGTCAC 
5' (Front) Adapters 
5' or 3' (Anywhere) Adapters 
Cut bases from reads before adapter trimming 
0 
Adapter Options: 
 
Maximum error rate 
0.39 
Do not allow indels (Use ONLY with anchored 5' (front) adapters). 
False 
Match times 
1 
Minimum overlap length 
3 
Match Read Wildcards 
False 
Filter Options: 
Discard Trimmed Reads 
False 
Discard Untrimmed Reads 
False 
Minimum length 
0 
Maximum length 
0 
Do not trim adapters 
False 
Mask Adapters 
False 
Max N 
Not available. 
Pair filter 
any 
Read Modification Options: 
Quality cutoff 
0 
NextSeq trimming 
0 
Trim Ns 
False 
Prefix 
Empty. 
Suffix 
Empty. 
Strip suffix 
Empty. 
Length 
0 
Length Tag 
Empty. 
Output Options: 
Report 
False 
Info File 
False 
Rest of Read 
False 
Wildcard File 
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False 
Too Short Reads 
False 
Too Long Reads 
False 
Untrimmed Reads 
False 
Step 8: Cutadapt 
Single-end or Paired-end reads? 
Single-end 
FASTQ/A file 
Output dataset 'default' from step 5 
Read 1 Options: 
3' (End) Adapters 
3' (End) Adapters 1 
Source 
Enter custom sequence 
Enter custom 3' adapter name (Optional) 
Illumina Forward Seq primer binding site 
Enter custom 3' adapter sequence 
AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT 
5' (Front) Adapters 
5' or 3' (Anywhere) Adapters 
Cut bases from reads before adapter trimming 
0 
Adapter Options: 
Maximum error rate 
0.1 
Do not allow indels (Use ONLY with anchored 5' (front) adapters). 
False 
Match times 
1 
Minimum overlap length 
3 
Match Read Wildcards 
False 
Filter Options: 
Discard Trimmed Reads 
False 
Discard Untrimmed Reads 
False 
Minimum length 
0 
Maximum length 
0 
Do not trim adapters 
False 
Mask Adapters 
False 
Max N 
Not available. 
Pair filter 
any 
 
Read Modification Options: 
Quality cutoff 
0 
NextSeq trimming 
0 
Trim Ns 
False 
Prefix 
Empty. 
Suffix 
Empty. 
Strip suffix 
Empty. 
Length 
0 
Length Tag 
Empty. 
Output Options: 
Report 
False 
Info File 
False 
Rest of Read 
False 
Wildcard File 
False 
Too Short Reads 
False 
Too Long Reads 
False 
Untrimmed Reads 
False 
Step 9: FastQC 
Short read data from your current history 
Output dataset 'default' from step 5 
Contaminant list 
select at runtime 
Submodule and Limit specifing file 
select at runtime 
 
Step 10: FastQC 
Short read data from your current history 
Output dataset 'out1' from step 7 
Contaminant list 
select at runtime 
Submodule and Limit specifing file 
select at runtime 
 
Step 11: Map with BWA-MEM 
Will you select a reference genome from your history or use a 
built-in index? 
Use a genome from history and build index 
Use the following dataset as the reference sequence 
Output dataset 'output' from step 2 
Algorithm for constructing the BWT index 
Auto. Let BWA decide the best algorithm to use 
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Single or Paired-end reads 
Single 
Select fastq dataset 
Output dataset 'out1' from step 7 
Set read groups information? 
Do not set 
Select analysis mode 
1.Simple Illumina mode 
Step 12: Map with BWA-MEM 
Will you select a reference genome from your history or use a 
built-in index? 
Use a genome from history and build index 
Use the following dataset as the reference sequence 
Output dataset 'output' from step 2 
Algorithm for constructing the BWT index 
Auto. Let BWA decide the best algorithm to use 
Single or Paired-end reads 
Single 
Select fastq dataset 
Output dataset 'out1' from step 8 
Set read groups information? 
Do not set 
Select analysis mode 
1.Simple Illumina mode 
 
Step 13: FastQC 
Short read data from your current history 
Output dataset 'out1' from step 8 
Contaminant list 
select at runtime 
Submodule and Limit specifing file 
select at runtime 
 
Step 14: BAM-to-SAM 
BAM File to Convert 
Output dataset 'bam_output' from step 11 
Header options 
Include header in SAM output (-h) 
 
Step 15: BAM-to-SAM 
BAM File to Convert 
Output dataset 'bam_output' from step 12 
Header options 
Include header in SAM output (-h) 
 
Step 16: Filter 
Filter 
Output dataset 'output1' from step 14 
With following condition 
c5>0 
Number of header lines to skip 
3 
 
Step 17: Filter 
Filter 
Output dataset 'output1' from step 15 
With following condition 
 
c5>0 
Number of header lines to skip 
3 
Step 18: SAM-to-BAM 
Choose the source for the reference genome 
Use a genome from the history 
SAM file to convert 
Output dataset 'out_file1' from step 16 
Using reference file 
Output dataset 'output' from step 2 
 
Step 19: SAM-to-BAM 
Choose the source for the reference genome 
Use a genome from the history 
SAM file to convert 
Output dataset 'out_file1' from step 17 
Using reference file 
Output dataset 'output' from step 2 
 
Step 20: Convert from BAM to FastQ 
Convert the following BAM file to FASTQ 
Output dataset 'output1' from step 18 
Create FASTQ based on the mate info in the BAM R2 and Q2 
tags. 
False 
FASTQ for second end. Used if BAM contains paired-end data. 
BAM should be sorted by query name if creating paired FASTQ 
with this option. 
False 
 
Step 21: Convert from BAM to FastQ 
Convert the following BAM file to FASTQ 
Output dataset 'output1' from step 19 
Create FASTQ based on the mate info in the BAM R2 and Q2 
tags. 
False 
FASTQ for second end. Used if BAM contains paired-end data. 
BAM should be sorted by query name if creating paired FASTQ 
with this option. 
False 
 
Step 22: Cutadapt 
Single-end or Paired-end reads? 
Single-end 
FASTQ/A file 
Output dataset 'output' from step 20 
Read 1 Options: 
3' (End) Adapters 
5' (Front) Adapters 
5' or 3' (Anywhere) Adapters 
Cut bases from reads before adapter trimming 
0 
Adapter Options: 
Maximum error rate 
0.1 
Do not allow indels (Use ONLY with anchored 5' (front) adapters). 
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False 
Match times 
1 
Minimum overlap length 
3 
Match Read Wildcards 
False 
Filter Options: 
Discard Trimmed Reads 
False 
Discard Untrimmed Reads 
False 
Minimum length 
300 
Maximum length 
0 
Do not trim adapters 
False 
Mask Adapters 
False 
Max N 
Not available. 
Pair filter 
any 
Read Modification Options: 
Quality cutoff 
0 
NextSeq trimming 
0 
Trim Ns 
False 
Prefix 
Empty. 
Suffix 
Empty. 
Strip suffix 
Empty. 
Length 
0 
Length Tag 
Empty. 
Output Options: 
Report 
False 
Info File 
False 
Rest of Read 
False 
Wildcard File 
False 
Too Short Reads 
False 
Too Long Reads 
False 
Untrimmed Reads 
False 
Step 23: Cutadapt 
Single-end or Paired-end reads? 
Single-end 
FASTQ/A file 
Output dataset 'output' from step 20 
Read 1 Options: 
3' (End) Adapters 
5' (Front) Adapters 
5' or 3' (Anywhere) Adapters 
Cut bases from reads before adapter trimming 
0 
Adapter Options: 
Maximum error rate 
0.1 
Do not allow indels (Use ONLY with anchored 5' (front) adapters). 
False 
Match times 
1 
Minimum overlap length 
3 
Match Read Wildcards 
False 
Filter Options: 
Discard Trimmed Reads 
False 
Discard Untrimmed Reads 
False 
Minimum length 
390 
Maximum length 
0 
Do not trim adapters 
False 
Mask Adapters 
False 
Max N 
Not available. 
Pair filter 
any 
Read Modification Options: 
Quality cutoff 
0 
NextSeq trimming 
0 
Trim Ns 
False 
Prefix 
Empty. 
Suffix 
Empty. 
Strip suffix 
Empty. 
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Length 
0 
Length Tag 
Empty. 
Output Options: 
Report 
False 
Info File 
False 
Rest of Read 
False 
Wildcard File 
False 
Too Short Reads 
False 
Too Long Reads 
False 
Untrimmed Reads 
False 
Step 24: Cutadapt 
Single-end or Paired-end reads? 
Single-end 
FASTQ/A file 
Output dataset 'output' from step 21 
Read 1 Options: 
3' (End) Adapters 
5' (Front) Adapters 
5' or 3' (Anywhere) Adapters 
Cut bases from reads before adapter trimming 
0 
Adapter Options: 
Maximum error rate 
0.1 
Do not allow indels (Use ONLY with anchored 5' (front) adapters). 
False 
Match times 
1 
Minimum overlap length 
3 
Match Read Wildcards 
False 
Filter Options: 
Discard Trimmed Reads 
False 
Discard Untrimmed Reads 
False 
Minimum length 
100 
Maximum length 
0 
Do not trim adapters 
False 
Mask Adapters 
False 
 
Max N 
Not available. 
Pair filter 
any 
Read Modification Options: 
Quality cutoff 
0 
NextSeq trimming 
0 
Trim Ns 
False 
Prefix 
Empty. 
Suffix 
Empty. 
Strip suffix 
Empty. 
Length 
0 
Length Tag 
Empty. 
Output Options: 
Report 
False 
Info File 
False 
Rest of Read 
False 
Wildcard File 
False 
Too Short Reads 
False 
Too Long Reads 
False 
Untrimmed Reads 
False 
Step 25: Cutadapt 
Single-end or Paired-end reads? 
Single-end 
FASTQ/A file 
Output dataset 'output' from step 21 
Read 1 Options: 
3' (End) Adapters 
5' (Front) Adapters 
5' or 3' (Anywhere) Adapters 
Cut bases from reads before adapter trimming 
0 
Adapter Options: 
Maximum error rate 
0.1 
Do not allow indels (Use ONLY with anchored 5' (front) adapters). 
False 
Match times 
1 
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Minimum overlap length 
3 
Match Read Wildcards 
False 
Filter Options: 
Discard Trimmed Reads 
False 
Discard Untrimmed Reads 
False 
Minimum length 
190 
Maximum length 
0 
Do not trim adapters 
False 
Mask Adapters 
False 
Max N 
Not available. 
Pair filter 
any 
Read Modification Options: 
Quality cutoff 
0 
NextSeq trimming 
0 
Trim Ns 
False 
Prefix 
Empty. 
Suffix 
Empty. 
Strip suffix 
Empty. 
Length 
0 
Length Tag 
Empty. 
Output Options: 
Report 
False 
Info File 
False 
Rest of Read 
False 
Wildcard File 
False 
Too Short Reads 
False 
Too Long Reads 
False 
Untrimmed Reads 
False 
Step 26: Trim  
Input dataset 
Output dataset 'out1' from step 22 
Trim this column only 
0 
Trim from the beginning up to this position 
1 
Remove everything from this position to the end 
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Is input dataset in FASTQ format? 
Yes 
Ignore lines beginning with these characters 
Nothing selected. 
Step 27: FastQC 
Short read data from your current history 
Output dataset 'out1' from step 23 
Contaminant list 
select at runtime 
Submodule and Limit specifing file 
select at runtime 
 
Step 28: Raspberry QC 
Short read data from your current history 
Output dataset 'out1' from step 23 
 
Step 29: Trim 
Input dataset 
Output dataset 'out1' from step 24 
Trim this column only 
0 
Trim from the beginning up to this position 
1 
Remove everything from this position to the end 
100 
Is input dataset in FASTQ format? 
Yes 
Ignore lines beginning with these characters 
Nothing selected. 
 
Step 30: FastQC 
Short read data from your current history 
Output dataset 'out1' from step 25 
Contaminant list 
select at runtime 
Submodule and Limit specifing file 
select at runtime 
 
Step 31: Raspberry QC 
Short read data from your current history 
Output dataset 'out1' from step 25 
 
Step 32: Raspberry QC 
Short read data from your current history 
Output dataset 'out_file1' from step 26 
 
Step 33: Raspberry QC 
Short read data from your current history 
Output dataset 'out_file1' from step 29 
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Step 34: Concatenate datasets 
Concatenate Dataset 
Output dataset 'output' from step 32 
Datasets 
Dataset 1 
Select 
Output dataset 'output' from step 28 
 
Step 35: Concatenate datasets 
Concatenate Dataset 
Output dataset 'output' from step 31 
Datasets 
Dataset 1 
Select 
Output dataset 'output' from step 33 
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10.10 MSH3 repeat genotyping Galaxy workflow 
Step 1: Input dataset 
R1 read file 
select at runtime 
 
Step 2: Input dataset 
R2 read file 
select at runtime 
 
Step 3: Input dataset 
Reference file 
select at runtime 
 
Step 4: Pear 
Dataset type 
Paired-end 
Name of file that contains the forward paired-end reads 
Output dataset 'output' from step 1 
Name of file that contains the reverse paired-end reads 
Output dataset 'output' from step 2 
Specify a p-value for the statistical test 
0.01 
Minimum overlap size 
10 
Maximum possible length of the assembled sequences 
0 
Minimum possible length of the assembled sequences 
50 
Minimum length of reads after trimming the low quality part 
1 
Quality score threshold for trimming the low quality part of a 
read 
0 
Maximal proportion of uncalled bases in a read 
1.0 
Specify the upper bound for the resulting quality score 
40 
Type of statistical test 
Given the minimum allowed overlap, test using the highest OES 
(1) 
Disable empirical base frequencies 
False 
Use N base if uncertain 
False 
Scoring method 
Assembly score (AS) use +1 for match and -1 for mismatch 
multiplied by base quality scores 
Output files 
Assembled reads 
 
Step 5: Cutadapt 
Single-end or Paired-end reads? 
Single-end 
FASTQ/A file 
Output dataset 'assembled_reads' from step 4 
Read 1 Options: 
 
3' (End) Adapters 
5' (Front) Adapters 
5' (Front) Adapters 1 
Source 
Enter custom sequence 
Enter custom 5' adapter name (Optional) 
10 bp of forward gene specific primer 
Enter custom 5' adapter sequence 
CTTCCTCCTC 
5' or 3' (Anywhere) Adapters 
Cut bases from reads before adapter trimming 
0 
Adapter Options: 
Maximum error rate 
0.1 
Do not allow indels (Use ONLY with anchored 5' (front) adapters). 
False 
Match times 
1 
Minimum overlap length 
3 
Match Read Wildcards 
False 
Filter Options: 
Discard Trimmed Reads 
False 
Discard Untrimmed Reads 
True 
Minimum length 
0 
Maximum length 
0 
Do not trim adapters 
False 
Mask Adapters 
False 
Max N 
Not available. 
Pair filter 
any 
Read Modification Options: 
Quality cutoff 
0 
NextSeq trimming 
0 
Trim Ns 
False 
Prefix 
Empty. 
Suffix 
Empty. 
Strip suffix 
303 
Empty. 
Length 
0 
Length Tag 
Empty. 
Output Options: 
Report 
False 
Info File 
False 
Rest of Read 
False 
Wildcard File 
False 
Too Short Reads 
False 
Too Long Reads 
False 
Untrimmed Reads 
False 
Step 6: Cutadapt 
Single-end or Paired-end reads? 
Single-end 
FASTQ/A file 
Output dataset 'out1' from step 5 
Read 1 Options: 
3' (End) Adapters 
3' (End) Adapters 1 
Source 
Enter custom sequence 
Enter custom 3' adapter name (Optional) 
last 10bp of reverse gene specific primer sequence 
Enter custom 3' adapter sequence 
GCGCCAAACT 
5' (Front) Adapters 
5' or 3' (Anywhere) Adapters 
Cut bases from reads before adapter trimming 
0 
Adapter Options: 
Maximum error rate 
0.1 
Do not allow indels (Use ONLY with anchored 5' (front) adapters). 
False 
Match times 
1 
Minimum overlap length 
3 
Match Read Wildcards 
False 
Filter Options: 
Discard Trimmed Reads 
False 
Discard Untrimmed Reads 
 
True 
Minimum length 
0 
Maximum length 
0 
Do not trim adapters 
False 
Mask Adapters 
False 
Max N 
Not available. 
Pair filter 
any 
Read Modification Options: 
Quality cutoff 
0 
NextSeq trimming 
0 
Trim Ns 
False 
Prefix 
Empty. 
Suffix 
Empty. 
Strip suffix 
Empty. 
Length 
0 
Length Tag 
Empty. 
Output Options: 
Report 
False 
Info File 
False 
Rest of Read 
False 
Wildcard File 
False 
Too Short Reads 
False 
Too Long Reads 
False 
Untrimmed Reads 
False 
Step 7: FastQC 
Short read data from your current history 
Output dataset 'out1' from step 5 
Contaminant list 
select at runtime 
Submodule and Limit specifing file 
select at runtime 
 
Step 8: Map with BWA-MEM  
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Will you select a reference genome from your history or use a 
built-in index? 
Use a genome from history and build index 
Use the following dataset as the reference sequence 
Output dataset 'output' from step 3 
Algorithm for constructing the BWT index 
Auto. Let BWA decide the best algorithm to use 
Single or Paired-end reads 
Single 
Select fastq dataset 
Output dataset 'out1' from step 6 
Set read groups information? 
Do not set 
Select analysis mode 
5.Full list of options 
Set algorithmic options? 
Set 
Minimum seed length 
19 
Band width for banded alignment 
100 
Off-diagonal X-dropoff 
100 
Look for internal seeds inside a seed longer than -k * THIS 
VALUE 
1.5 
Seed occurrence for the 3rd round seeding 
20 
Skip seeds with more than that many occurrences 
500 
Drop chains shorter than this fraction of the longest overlapping 
chain 
0.5 
Discard a chain if seeded bases shorter than THIS VALUE 
0 
Perform at most this many rounds of mate rescues for each read 
50 
Skip mate rescue 
False 
Skip pairing; mate rescue performed unless -S also in use 
False 
Discard full-length exact matches 
False 
Set scoring options? 
Set 
Score for a sequence match 
1 
Penalty for a mismatch 
5 
Gap open penalties for deletions and insertions 
6,6 
Gap extension penalties; a gap of size k cost '-O + -E*k'. If two 
numbers are specified, the first is the penalty of extending a 
deletion and the second for extending an insertion 
1,1 
Penalties for 5'-end and 3'-end clipping 
5,5 
Penalty for an unpaired read pair 
17 
Set input/output options 
Do not set 
Step 9: FastQC 
Short read data from your current history 
Output dataset 'out1' from step 6 
Contaminant list 
select at runtime 
Submodule and Limit specifing file 
select at runtime 
 
Step 10: BAM-to-SAM 
BAM File to Convert 
Output dataset 'bam_output' from step 8 
Header options 
Include header in SAM output (-h) 
 
Step 11: Filter 
Filter 
Output dataset 'output1' from step 10 
With following condition 
c5>0 
Number of header lines to skip 
84 
 
Step 12: Repeat Counter 
Short read data from your current history 
Output dataset 'out_file1' from step 11 
 
Step 13: Convert 
Convert all 
Commas 
in Dataset 
Output dataset 'repeat_counts.csv' from step 12 
Strip leading and trailing whitespaces 
True 
Condense consecutive delimiters in one TAB 
True 
 
Step 14: Sort 
Sort Dataset 
Output dataset 'out_file1' from step 13 
on column 
2 
with flavor 
Numerical sort 
everything in 
Descending order 
Column selections 
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10.11 MSH3 variant calling Galaxy workflow 
Step 1: Input dataset 
BAM input 
select at runtime 
 
Step 2: Input dataset 
Reference file 
select at runtime 
 
Step 3: Naive Variant Caller (NVC) 
Choose the source for the reference list 
History 
BAM files 
BAM file 1 
BAM file 
Output dataset 'output' from step 1 
Using reference file 
Output dataset 'output' from step 2 
Restrict to regions 
Restrict to regions 1 
Chromosome 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG1_CCCGCAG
CG0_CCCCCAGCG1_CCCCCAGCT0 
Start 
1 
End 
483 
Restrict to regions 2 
Chromosome 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAG
CG0_CCCCCAGCG1_CCCCCAGCT1 
Start 
1 
End 
501 
Restrict to regions 3 
Chromosome 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAG
CG0_CCCCCAGCG0_CCCCCAGCT1 
Start 
1 
End 
501 
Restrict to regions 4 
Chromosome 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAG
CG0_CCCCCAGCG1_CCCCCAGCT1 
Start 
1 
End 
510 
Restrict to regions 5 
Chromosome 
 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAG
CG1_CCCCCAGCG1_CCCCCAGCT1*_CCCCCAGCT1 
Start 
1 
End 
510 
Restrict to regions 6 
Chromosome 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAG
CG0_CCCCCAGCG1_CCCCCAGCT1 
Start 
1 
End 
510 
Restrict to regions 7 
Chromosome 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAG
CG1_CCCCCAGCG1_CCCCCAGCT1 
Start 
1 
End 
519 
Restrict to regions 8 
Chromosome 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG2_CCCGCAG
CG0_CCCCCAGCG2_CCCCCAGCT1 
Start 
1 
End 
519 
Restrict to regions 9 
Chromosome 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAG
CG0_CCCCCAGCG2_CCCCCAGCT1 
Start 
1 
End 
519 
Restrict to regions 10 
Chromosome 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG3_CCCGCAG
CG1_CCCCCAGCG1_CCCCCAGCT1 
Start 
1 
End 
519 
Restrict to regions 11 
Chromosome 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAG
CG0_CCCCCAGCG1_CCCCCAGCT1 
Start 
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1 
End 
537 
Restrict to regions 12 
Chromosome 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAG
CG1_CCCCCAGCG1_CCCCCAGCT1 
Start 
Not available. 
End 
Not available. 
Restrict to regions 13 
Chromosome 
>MSH3_reference_GCTGCAGCG1_GCCGCAGCG4_CCCGCAG
CG1_CCCCCAGCG1_CCCCCAGCT1 
Start 
Not available. 
End 
Not available. 
Restrict to regions 14 
Chromosome 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG1_CCCGCAG
CG0_CCCCCAGCG5_CCCCCAGCT1 
Start 
Not available. 
End 
Not available. 
Restrict to regions 15 
Chromosome 
>MSH3_reference_GCTGCAGCG2_GCCGCAGCG3_CCCGCAG
CG1_CCCCCAGCG2_CCCCCAGCT1 
Start 
Not available. 
End 
Not available. 
Restrict to regions by files 
Minimum number of reads needed to consider a REF/ALT 
100 
Minimum base quality 
20 
Minimum mapping quality 
1 
Ploidy 
2 
Only write out positions with possible alternate alleles 
False 
Report counts by strand 
True 
Show Advanced Options 
Hide Advanced Options 
Step 4: VCFfilter: 
Specify filterting expression 
-f "AF > 0.4"  
VCF dataset to filter 
Output dataset 'output_vcf' from step 3 
Filter
ing 
for 
allele 
freqe
uncy 
Step 5: VCFtoTab-delimited: 
Select VCF dataset to convert 
Output dataset 'out_file1' from step 4 
Report data per sample 
True 
Fill empty fields with 
Nothing 
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10.12 Base-wise conservation scores across the MSH3 9bp tandem repeat region 
Table 10.2. Base-wise conservation scores across the MSH3 exon 1 9bp tandem repeat region. 
PhastCons and PhyloP generated values are displayed for bases on chromosome 5 at positions 80654862 to 80654969. Tandem 
repeat region is shown in bold. Generated on UCSC. 
Chromosomal position PhastCons PhyloP 
80654862 0 -0.01 
80654863 0 -0.34 
80654864 0 0.07 
80654865 0 -0.17 
80654866 0 0.23 
80654867 0 -0.42 
80654868 0 -3.83 
80654869 0 -0.09 
80654870 0 -0.09 
80654871 0 0.07 
80654872 0 -0.58 
80654873 0 -0.17 
80654874 0 -2.53 
80654875 0.45 3.24 
80654876 0 -0.74 
80654877 0 0.23 
80654878 0 -0.09 
80654879 0.02 3.4 
80654880 0 -0.82 
80654881 0 1.04 
80654882 0 0.07 
80654883 0 -0.42 
80654884 0 -0.66 
80654885 0 0.64 
80654886 0.01 0.07 
80654887 0.01 0.07 
80654888 0.01 0.07 
80654889 0.01 -0.01 
80654890 0.01 -0.01 
80654891 0.01 -0.01 
80654892 0.01 -0.01 
80654893 0.01 -0.01 
80654894 0.01 -0.01 
80654895 0.01 -0.01 
80654896 0 -0.01 
80654897 0 -0.01 
80654898 0 -0.42 
80654899 0 -0.01 
80654900 0 -0.01 
80654901 0 -0.01 
80654902 0 -0.01 
80654903 0 -0.01 
80654904 0 -0.01 
80654905 0 -0.01 
80654906 0 -0.01 
80654907 0 -1.31 
80654908 0.01 0.07 
80654909 0.04 0.39 
80654910 0.09 -0.01 
80654911 0.92 1.77 
80654912 0.93 1.13 
80654913 0.93 0.31 
80654914 0.94 1.13 
80654915 0.97 2.91 
80654916 0.97 0.39 
80654917 0.97 1.37 
80654918 0.96 -0.01 
80654919 0.97 0.39 
80654920 1 2.02 
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80654921 0.99 0.8 
80654922 0.96 2.1 
80654923 0.85 -0.01 
80654924 0.75 -0.01 
80654925 0.64 -0.01 
80654926 0.54 -0.01 
80654927 0.44 -0.01 
80654928 0.34 -0.01 
80654929 0.23 -0.01 
80654930 0.13 -0.01 
80654931 0.02 -2.37 
80654932 0 -1.39 
80654933 0 0.31 
80654934 0 0.15 
80654935 0 -0.58 
80654936 0 0.39 
80654937 0 -0.5 
80654938 0 -0.34 
80654939 0 -1.63 
80654940 0 -0.5 
80654941 0 -0.01 
80654942 0 -1.07 
80654943 0 -0.01 
80654944 0 -0.74 
80654945 0 0.07 
80654946 0 -0.5 
80654947 0 -0.9 
80654948 0 -0.99 
80654949 0 0.07 
80654950 0 -1.31 
80654951 0 -0.34 
80654952 0 0.31 
80654953 0 -0.25 
80654954 0 -0.99 
80654955 0 -0.17 
80654956 0 0.23 
80654957 0 -0.25 
80654958 0 -0.25 
80654959 0 0.15 
80654960 0 -0.82 
80654961 0 -1.23 
80654962 0 -0.25 
80654963 0 -0.34 
80654964 0 0.48 
80654965 0 0.56 
80654966 0 -0.01 
80654967 0 0.39 
80654968 0 -0.09 
80654969 0 0.72 
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10.13 MSH3 and DHFR expression quantitative trait loci (eQTL) 
Table 10.3. MSH3 and DHFR expression quantitative trait loci associated with phenotypes in HD and DM1. 
Data from GTex. NES – normalised effect size, ref – reference allele. 
SNP Id location ref minor allele Gene Symbol p NES Tissue 
rs151182735 5:80654571 C - DHFR 7.80E-92 -1 Muscle - Skeletal 
rs151182735 5:80654571 C - DHFR 5.00E-50 -0.62 Adipose - Subcutaneous 
rs151182735 5:80654571 C - DHFR 3.20E-49 -0.65 Whole Blood 
rs151182735 5:80654571 C - DHFR 8.10E-45 -0.86 Testis 
rs151182735 5:80654571 C - DHFR 3.40E-39 -0.56 Adipose - Visceral (Omentum) 
rs151182735 5:80654571 C - DHFR 3.10E-34 -0.78 Heart - Left Ventricle 
rs151182735 5:80654571 C - DHFR 3.30E-32 -0.3 Cells - Transformed fibroblasts 
rs151182735 5:80654571 C - DHFR 2.40E-28 -0.8 Colon - Sigmoid 
rs151182735 5:80654571 C - DHFR 4.80E-28 -0.69 Esophagus - Muscularis 
rs151182735 5:80654571 C - DHFR 5.90E-27 -0.76 Heart - Atrial Appendage 
rs151182735 5:80654571 C - DHFR 1.40E-23 -0.5 Cells - EBV-transformed lymphocytes 
rs151182735 5:80654571 C - DHFR 1.20E-22 -0.29 Esophagus - Mucosa 
rs151182735 5:80654571 C - DHFR 3.10E-20 -0.42 Colon - Transverse 
rs151182735 5:80654571 C - DHFR 4.90E-20 -0.95 Brain - Cortex 
rs151182735 5:80654571 C - DHFR 3.10E-19 -0.32 Lung 
rs151182735 5:80654571 C - DHFR 1.60E-18 -0.42 Breast - Mammary Tissue 
rs151182735 5:80654571 C - DHFR 2.40E-18 -0.93 Brain - Anterior cingulate cortex (BA24) 
rs151182735 5:80654571 C - DHFR 5.10E-16 -0.31 Skin - Not Sun Exposed (Suprapubic) 
rs151182735 5:80654571 C - DHFR 1.00E-15 -0.42 Artery - Tibial 
rs151182735 5:80654571 C - DHFR 1.90E-15 -0.3 Skin - Sun Exposed (Lower leg) 
rs151182735 5:80654571 C - DHFR 2.90E-15 -0.64 Brain - Nucleus accumbens (basal ganglia) 
rs151182735 5:80654571 C - DHFR 2.00E-14 -0.85 Brain - Frontal Cortex (BA9) 
rs151182735 5:80654571 C - DHFR 3.50E-14 -0.43 Nerve - Tibial 
rs151182735 5:80654571 C - DHFR 5.00E-14 -0.53 Spleen 
rs151182735 5:80654571 C - DHFR 1.50E-13 -0.65 Brain - Caudate (basal ganglia) 
rs151182735 5:80654571 C - DHFR 3.60E-13 -0.76 Brain - Cerebellum 
rs151182735 5:80654571 C - DHFR 4.90E-13 -0.58 Esophagus - Gastroesophageal Junction 
rs151182735 5:80654571 C - DHFR 1.60E-12 -0.64 Brain - Hypothalamus 
rs151182735 5:80654571 C - DHFR 3.10E-12 -0.76 Brain - Cerebellar Hemisphere 
rs151182735 5:80654571 C - DHFR 5.00E-12 -0.62 Brain - Hippocampus 
rs151182735 5:80654571 C - DHFR 2.10E-11 -0.61 Brain - Amygdala 
rs151182735 5:80654571 C - DHFR 5.40E-10 -0.57 Adrenal Gland 
rs151182735 5:80654571 C - DHFR 4.70E-09 -0.49 Pituitary 
rs151182735 5:80654571 C - DHFR 1.60E-08 -0.71 Brain - Spinal cord (cervical c-1) 
rs151182735 5:80654571 C - DHFR 2.00E-08 -0.59 Brain - Substantia nigra 
rs151182735 5:80654571 C - DHFR 3.30E-07 -0.4 Artery - Aorta 
rs151182735 5:80654571 C - DHFR 3.30E-07 -0.47 Artery - Coronary 
rs151182735 5:80654571 C - DHFR 3.80E-07 -0.52 Prostate 
rs151182735 5:80654571 C - DHFR 1.10E-05 -0.4 Brain - Putamen (basal ganglia) 
rs151182735 5:80654571 C - MSH3 2.10E-28 -0.49 Thyroid 
rs151182735 5:80654571 C - MSH3 7.30E-25 -0.42 Skin - Sun Exposed (Lower leg) 
rs151182735 5:80654571 C - MSH3 1.60E-24 -0.49 Artery - Tibial 
rs151182735 5:80654571 C - MSH3 3.30E-23 -0.45 Skin - Not Sun Exposed (Suprapubic) 
rs151182735 5:80654571 C - MSH3 3.00E-21 -0.49 Nerve - Tibial 
rs151182735 5:80654571 C - MSH3 5.70E-21 -0.4 Adipose - Subcutaneous 
rs151182735 5:80654571 C - MSH3 2.00E-18 -0.4 Whole Blood 
rs151182735 5:80654571 C - MSH3 5.80E-16 -0.55 Cells - Transformed fibroblasts 
rs151182735 5:80654571 C - MSH3 1.30E-14 -0.41 Heart - Atrial Appendage 
rs151182735 5:80654571 C - MSH3 2.80E-14 -0.51 Artery - Aorta 
rs151182735 5:80654571 C - MSH3 1.40E-10 -0.32 Adipose - Visceral (Omentum) 
rs151182735 5:80654571 C - MSH3 2.10E-10 -0.44 Pancreas 
rs151182735 5:80654571 C - MSH3 3.70E-09 -0.36 Colon - Sigmoid 
rs151182735 5:80654571 C - MSH3 3.10E-08 -0.42 Adrenal Gland 
rs151182735 5:80654571 C - MSH3 7.50E-08 -0.35 Breast - Mammary Tissue 
rs151182735 5:80654571 C - MSH3 1.50E-07 -0.42 Pituitary 
rs151182735 5:80654571 C - MSH3 2.20E-07 -0.3 Colon - Transverse 
rs151182735 5:80654571 C - MSH3 6.80E-07 -0.26 Esophagus - Muscularis 
rs151182735 5:80654571 C - MSH3 7.00E-07 -0.34 Esophagus - Gastroesophageal Junction 
rs151182735 5:80654571 C - MSH3 7.90E-06 -0.18 Esophagus - Mucosa 
rs10168 5:80654584 C T DHFR 8.90E-92 -1 Muscle - Skeletal 
rs10168 5:80654584 C T DHFR 5.00E-50 -0.62 Adipose - Subcutaneous 
rs10168 5:80654584 C T DHFR 2.50E-49 -0.65 Whole Blood 
rs10168 5:80654584 C T DHFR 5.70E-44 -0.85 Testis 
rs10168 5:80654584 C T DHFR 1.80E-39 -0.56 Adipose - Visceral (Omentum) 
rs10168 5:80654584 C T DHFR 1.40E-34 -0.78 Heart - Left Ventricle 
rs10168 5:80654584 C T DHFR 2.70E-32 -0.3 Cells - Transformed fibroblasts 
rs10168 5:80654584 C T DHFR 2.40E-28 -0.8 Colon - Sigmoid 
rs10168 5:80654584 C T DHFR 4.80E-28 -0.69 Esophagus - Muscularis 
rs10168 5:80654584 C T DHFR 2.60E-27 -0.76 Heart - Atrial Appendage 
rs10168 5:80654584 C T DHFR 1.70E-23 -0.5 Cells - EBV-transformed lymphocytes 
rs10168 5:80654584 C T DHFR 1.20E-22 -0.29 Esophagus - Mucosa 
rs10168 5:80654584 C T DHFR 2.30E-20 -0.42 Colon - Transverse 
rs10168 5:80654584 C T DHFR 4.90E-20 -0.95 Brain - Cortex 
rs10168 5:80654584 C T DHFR 3.10E-19 -0.32 Lung 
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rs10168 5:80654584 C T DHFR 1.20E-18 -0.42 Breast - Mammary Tissue 
rs10168 5:80654584 C T DHFR 2.40E-18 -0.93 Brain - Anterior cingulate cortex (BA24) 
rs10168 5:80654584 C T DHFR 5.10E-16 -0.31 Skin - Not Sun Exposed (Suprapubic) 
rs10168 5:80654584 C T DHFR 1.00E-15 -0.42 Artery - Tibial 
rs10168 5:80654584 C T DHFR 1.90E-15 -0.3 Skin - Sun Exposed (Lower leg) 
rs10168 5:80654584 C T DHFR 2.90E-15 -0.64 Brain - Nucleus accumbens (basal ganglia) 
rs10168 5:80654584 C T DHFR 2.00E-14 -0.85 Brain - Frontal Cortex (BA9) 
rs10168 5:80654584 C T DHFR 3.50E-14 -0.43 Nerve - Tibial 
rs10168 5:80654584 C T DHFR 5.00E-14 -0.53 Spleen 
rs10168 5:80654584 C T DHFR 1.50E-13 -0.65 Brain - Caudate (basal ganglia) 
rs10168 5:80654584 C T DHFR 3.60E-13 -0.76 Brain - Cerebellum 
rs10168 5:80654584 C T DHFR 6.00E-13 -0.58 Esophagus - Gastroesophageal Junction 
rs10168 5:80654584 C T DHFR 1.60E-12 -0.64 Brain - Hypothalamus 
rs10168 5:80654584 C T DHFR 3.10E-12 -0.76 Brain - Cerebellar Hemisphere 
rs10168 5:80654584 C T DHFR 5.00E-12 -0.62 Brain - Hippocampus 
rs10168 5:80654584 C T DHFR 2.10E-11 -0.61 Brain - Amygdala 
rs10168 5:80654584 C T DHFR 5.40E-10 -0.57 Adrenal Gland 
rs10168 5:80654584 C T DHFR 4.70E-09 -0.49 Pituitary 
rs10168 5:80654584 C T DHFR 1.60E-08 -0.71 Brain - Spinal cord (cervical c-1) 
rs10168 5:80654584 C T DHFR 2.00E-08 -0.59 Brain - Substantia nigra 
rs10168 5:80654584 C T DHFR 2.20E-07 -0.47 Artery - Coronary 
rs10168 5:80654584 C T DHFR 3.30E-07 -0.4 Artery - Aorta 
rs10168 5:80654584 C T DHFR 3.80E-07 -0.52 Prostate 
rs10168 5:80654584 C T DHFR 1.10E-05 -0.4 Brain - Putamen (basal ganglia) 
rs10168 5:80654584 C T MSH3 3.80E-28 -0.48 Thyroid 
rs10168 5:80654584 C T MSH3 7.30E-25 -0.42 Skin - Sun Exposed (Lower leg) 
rs10168 5:80654584 C T MSH3 1.60E-24 -0.49 Artery - Tibial 
rs10168 5:80654584 C T MSH3 3.30E-23 -0.45 Skin - Not Sun Exposed (Suprapubic) 
rs10168 5:80654584 C T MSH3 3.00E-21 -0.49 Nerve - Tibial 
rs10168 5:80654584 C T MSH3 5.70E-21 -0.4 Adipose - Subcutaneous 
rs10168 5:80654584 C T MSH3 1.40E-18 -0.41 Whole Blood 
rs10168 5:80654584 C T MSH3 4.80E-16 -0.55 Cells - Transformed fibroblasts 
rs10168 5:80654584 C T MSH3 1.80E-14 -0.4 Heart - Atrial Appendage 
rs10168 5:80654584 C T MSH3 2.80E-14 -0.51 Artery - Aorta 
rs10168 5:80654584 C T MSH3 8.20E-11 -0.33 Adipose - Visceral (Omentum) 
rs10168 5:80654584 C T MSH3 1.50E-10 -0.44 Pancreas 
rs10168 5:80654584 C T MSH3 3.70E-09 -0.36 Colon - Sigmoid 
rs10168 5:80654584 C T MSH3 3.10E-08 -0.42 Adrenal Gland 
rs10168 5:80654584 C T MSH3 7.50E-08 -0.35 Breast - Mammary Tissue 
rs10168 5:80654584 C T MSH3 1.50E-07 -0.42 Pituitary 
rs10168 5:80654584 C T MSH3 2.10E-07 -0.3 Colon - Transverse 
rs10168 5:80654584 C T MSH3 5.70E-07 -0.34 Esophagus - Gastroesophageal Junction 
rs10168 5:80654584 C T MSH3 6.80E-07 -0.26 Esophagus - Muscularis 
rs10168 5:80654584 C T MSH3 7.90E-06 -0.18 Esophagus - Mucosa 
rs2250063 5:80654678 C T DHFR 5.60E-92 -1 Muscle - Skeletal 
rs2250063 5:80654678 C T DHFR 5.70E-51 -0.62 Adipose - Subcutaneous 
rs2250063 5:80654678 C T DHFR 2.70E-48 -0.65 Whole Blood 
rs2250063 5:80654678 C T DHFR 9.70E-46 -0.86 Testis 
rs2250063 5:80654678 C T DHFR 4.10E-41 -0.57 Adipose - Visceral (Omentum) 
rs2250063 5:80654678 C T DHFR 3.30E-33 -0.77 Heart - Left Ventricle 
rs2250063 5:80654678 C T DHFR 1.80E-31 -0.3 Cells - Transformed fibroblasts 
rs2250063 5:80654678 C T DHFR 1.30E-29 -0.82 Colon - Sigmoid 
rs2250063 5:80654678 C T DHFR 4.90E-28 -0.69 Esophagus - Muscularis 
rs2250063 5:80654678 C T DHFR 1.10E-26 -0.76 Heart - Atrial Appendage 
rs2250063 5:80654678 C T DHFR 1.20E-22 -0.29 Esophagus - Mucosa 
rs2250063 5:80654678 C T DHFR 1.40E-22 -0.51 Cells - EBV-transformed lymphocytes 
rs2250063 5:80654678 C T DHFR 3.30E-20 -0.33 Lung 
rs2250063 5:80654678 C T DHFR 5.30E-20 -0.42 Colon - Transverse 
rs2250063 5:80654678 C T DHFR 1.90E-19 -0.95 Brain - Cortex 
rs2250063 5:80654678 C T DHFR 3.80E-19 -0.42 Breast - Mammary Tissue 
rs2250063 5:80654678 C T DHFR 1.00E-17 -0.92 Brain - Anterior cingulate cortex (BA24) 
rs2250063 5:80654678 C T DHFR 4.00E-17 -0.32 Skin - Not Sun Exposed (Suprapubic) 
rs2250063 5:80654678 C T DHFR 7.30E-16 -0.42 Artery - Tibial 
rs2250063 5:80654678 C T DHFR 2.80E-15 -0.3 Skin - Sun Exposed (Lower leg) 
rs2250063 5:80654678 C T DHFR 1.50E-14 -0.64 Brain - Nucleus accumbens (basal ganglia) 
rs2250063 5:80654678 C T DHFR 3.20E-14 -0.43 Nerve - Tibial 
rs2250063 5:80654678 C T DHFR 3.50E-14 -0.86 Brain - Frontal Cortex (BA9) 
rs2250063 5:80654678 C T DHFR 1.00E-13 -0.66 Brain - Caudate (basal ganglia) 
rs2250063 5:80654678 C T DHFR 1.90E-13 -0.52 Spleen 
rs2250063 5:80654678 C T DHFR 2.10E-12 -0.56 Esophagus - Gastroesophageal Junction 
rs2250063 5:80654678 C T DHFR 3.30E-12 -0.64 Brain - Hypothalamus 
rs2250063 5:80654678 C T DHFR 3.80E-12 -0.75 Brain - Cerebellum 
rs2250063 5:80654678 C T DHFR 3.80E-12 -0.63 Brain - Hippocampus 
rs2250063 5:80654678 C T DHFR 1.20E-11 -0.75 Brain - Cerebellar Hemisphere 
rs2250063 5:80654678 C T DHFR 2.80E-11 -0.62 Brain - Amygdala 
rs2250063 5:80654678 C T DHFR 2.00E-10 -0.57 Adrenal Gland 
rs2250063 5:80654678 C T DHFR 7.80E-09 -0.49 Pituitary 
rs2250063 5:80654678 C T DHFR 1.50E-08 -0.73 Brain - Spinal cord (cervical c-1) 
rs2250063 5:80654678 C T DHFR 2.60E-08 -0.6 Brain - Substantia nigra 
rs2250063 5:80654678 C T DHFR 4.70E-08 -0.55 Prostate 
rs2250063 5:80654678 C T DHFR 3.60E-07 -0.47 Artery - Coronary 
rs2250063 5:80654678 C T DHFR 6.80E-07 -0.39 Artery - Aorta 
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rs2250063 5:80654678 C T MSH3 1.00E-27 -0.48 Thyroid 
rs2250063 5:80654678 C T MSH3 9.90E-24 -0.41 Skin - Sun Exposed (Lower leg) 
rs2250063 5:80654678 C T MSH3 1.40E-23 -0.49 Artery - Tibial 
rs2250063 5:80654678 C T MSH3 7.20E-23 -0.45 Skin - Not Sun Exposed (Suprapubic) 
rs2250063 5:80654678 C T MSH3 2.10E-19 -0.38 Adipose - Subcutaneous 
rs2250063 5:80654678 C T MSH3 3.10E-19 -0.47 Nerve - Tibial 
rs2250063 5:80654678 C T MSH3 9.60E-18 -0.4 Whole Blood 
rs2250063 5:80654678 C T MSH3 2.40E-14 -0.52 Cells - Transformed fibroblasts 
rs2250063 5:80654678 C T MSH3 1.40E-13 -0.4 Heart - Atrial Appendage 
rs2250063 5:80654678 C T MSH3 3.10E-13 -0.5 Artery - Aorta 
rs2250063 5:80654678 C T MSH3 4.70E-11 -0.33 Adipose - Visceral (Omentum) 
rs2250063 5:80654678 C T MSH3 4.10E-10 -0.43 Pancreas 
rs2250063 5:80654678 C T MSH3 3.50E-08 -0.35 Colon - Sigmoid 
rs2250063 5:80654678 C T MSH3 3.70E-08 -0.41 Adrenal Gland 
rs2250063 5:80654678 C T MSH3 1.90E-07 -0.42 Pituitary 
rs2250063 5:80654678 C T MSH3 3.00E-07 -0.34 Breast - Mammary Tissue 
rs2250063 5:80654678 C T MSH3 3.20E-07 -0.3 Colon - Transverse 
rs2250063 5:80654678 C T MSH3 1.80E-06 -0.25 Esophagus - Muscularis 
rs2250063 5:80654678 C T MSH3 2.70E-06 -0.32 Esophagus - Gastroesophageal Junction 
rs2250063 5:80654678 C T MSH3 2.20E-05 -0.17 Esophagus - Mucosa 
rs1105525 5:80654689 C T MSH3 4.00E-09 0.47 Cells - Transformed fibroblasts 
rs1105525 5:80654689 C T MSH3 7.90E-07 0.26 Skin - Sun Exposed (Lower leg) 
rs1105524 5:80654693 A G DHFR 1.80E-31 -0.66 Muscle - Skeletal 
rs1105524 5:80654693 A G DHFR 1.20E-28 -0.58 Nerve - Tibial 
rs1105524 5:80654693 A G DHFR 3.60E-28 -0.55 Artery - Tibial 
rs1105524 5:80654693 A G DHFR 3.50E-27 -0.5 Adipose - Subcutaneous 
rs1105524 5:80654693 A G DHFR 1.20E-24 -0.62 Esophagus - Muscularis 
rs1105524 5:80654693 A G DHFR 1.20E-23 -0.7 Artery - Aorta 
rs1105524 5:80654693 A G DHFR 2.80E-20 -0.67 Esophagus - Gastroesophageal Junction 
rs1105524 5:80654693 A G DHFR 4.50E-19 -0.63 Heart - Atrial Appendage 
rs1105524 5:80654693 A G DHFR 9.10E-19 -0.58 Heart - Left Ventricle 
rs1105524 5:80654693 A G DHFR 2.80E-18 -0.29 Lung 
rs1105524 5:80654693 A G DHFR 3.50E-15 -0.38 Breast - Mammary Tissue 
rs1105524 5:80654693 A G DHFR 8.10E-15 -0.29 Skin - Sun Exposed (Lower leg) 
rs1105524 5:80654693 A G DHFR 1.10E-14 -0.35 Adipose - Visceral (Omentum) 
rs1105524 5:80654693 A G DHFR 6.10E-14 -0.42 Thyroid 
rs1105524 5:80654693 A G DHFR 7.70E-14 -0.21 Esophagus - Mucosa 
rs1105524 5:80654693 A G DHFR 3.50E-13 -0.2 Cells - Transformed fibroblasts 
rs1105524 5:80654693 A G DHFR 1.70E-12 -0.66 Adrenal Gland 
rs1105524 5:80654693 A G DHFR 5.90E-12 -0.33 Colon - Transverse 
rs1105524 5:80654693 A G DHFR 1.20E-11 -0.35 Whole Blood 
rs1105524 5:80654693 A G DHFR 2.90E-11 -0.79 Brain - Cerebellum 
rs1105524 5:80654693 A G DHFR 1.50E-10 -0.54 Pituitary 
rs1105524 5:80654693 A G DHFR 1.80E-10 -0.46 Spleen 
rs1105524 5:80654693 A G DHFR 2.00E-10 -0.52 Colon - Sigmoid 
rs1105524 5:80654693 A G DHFR 3.10E-10 -0.44 Testis 
rs1105524 5:80654693 A G DHFR 1.70E-09 -0.76 Brain - Anterior cingulate cortex (BA24) 
rs1105524 5:80654693 A G DHFR 4.40E-09 -0.68 Brain - Cerebellar Hemisphere 
rs1105524 5:80654693 A G DHFR 8.30E-09 -0.22 Skin - Not Sun Exposed (Suprapubic) 
rs1105524 5:80654693 A G DHFR 3.50E-08 -0.54 Brain - Caudate (basal ganglia) 
rs1105524 5:80654693 A G DHFR 4.90E-08 -0.66 Brain - Frontal Cortex (BA9) 
rs1105524 5:80654693 A G DHFR 2.50E-07 -0.53 Artery - Coronary 
rs1105524 5:80654693 A G DHFR 3.20E-07 -0.6 Brain - Cortex 
rs1105524 5:80654693 A G DHFR 1.00E-06 -0.54 Brain - Hypothalamus 
rs1105524 5:80654693 A G DHFR 5.30E-06 -0.43 Brain - Putamen (basal ganglia) 
rs1105524 5:80654693 A G MSH3 9.50E-11 0.38 Liver 
rs1105524 5:80654693 A G MSH3 3.20E-07 0.17 Muscle - Skeletal 
rs1650697 5:80654962 A G DHFR 1.50E-20 0.55 Thyroid 
rs1650697 5:80654962 A G DHFR 8.20E-13 0.41 Artery - Tibial 
rs1650697 5:80654962 A G DHFR 6.70E-12 0.55 Artery - Aorta 
rs1650697 5:80654962 A G DHFR 3.50E-11 0.4 Nerve - Tibial 
rs1650697 5:80654962 A G DHFR 4.60E-08 0.46 Esophagus - Gastroesophageal Junction 
rs1650697 5:80654962 A G DHFR 5.70E-08 0.47 Pancreas 
rs1650697 5:80654962 A G DHFR 9.90E-08 0.36 Esophagus - Muscularis 
rs1650697 5:80654962 A G DHFR 2.20E-07 0.25 Stomach 
rs1650697 5:80654962 A G DHFR 3.60E-06 0.2 Skin - Sun Exposed (Lower leg) 
rs1650697 5:80654962 A G DHFR 9.70E-06 0.17 Lung 
rs1650697 5:80654962 A G MSH3 2.80E-41 -0.83 Cells - Transformed fibroblasts 
rs1650697 5:80654962 A G MSH3 1.20E-30 -0.51 Skin - Sun Exposed (Lower leg) 
rs1650697 5:80654962 A G MSH3 3.80E-30 -0.54 Whole Blood 
rs1650697 5:80654962 A G MSH3 6.30E-28 -0.53 Thyroid 
rs1650697 5:80654962 A G MSH3 1.40E-25 -0.54 Artery - Tibial 
rs1650697 5:80654962 A G MSH3 3.10E-25 -0.5 Skin - Not Sun Exposed (Suprapubic) 
rs1650697 5:80654962 A G MSH3 7.00E-25 -0.56 Nerve - Tibial 
rs1650697 5:80654962 A G MSH3 2.30E-24 -0.38 Esophagus - Mucosa 
rs1650697 5:80654962 A G MSH3 8.30E-23 -0.42 Lung 
rs1650697 5:80654962 A G MSH3 5.20E-22 -0.66 Artery - Aorta 
rs1650697 5:80654962 A G MSH3 5.60E-19 -0.31 Muscle - Skeletal 
rs1650697 5:80654962 A G MSH3 3.00E-18 -0.4 Adipose - Subcutaneous 
rs1650697 5:80654962 A G MSH3 1.10E-17 -0.43 Adipose - Visceral (Omentum) 
rs1650697 5:80654962 A G MSH3 1.40E-15 -0.29 Heart - Left Ventricle 
rs1650697 5:80654962 A G MSH3 6.80E-15 -0.55 Colon - Sigmoid 
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rs1650697 5:80654962 A G MSH3 1.20E-14 -0.39 Esophagus - Muscularis 
rs1650697 5:80654962 A G MSH3 1.90E-14 -0.46 Colon - Transverse 
rs1650697 5:80654962 A G MSH3 6.70E-14 -0.6 Adrenal Gland 
rs1650697 5:80654962 A G MSH3 7.60E-14 -0.5 Pancreas 
rs1650697 5:80654962 A G MSH3 4.80E-13 -0.41 Heart - Atrial Appendage 
rs1650697 5:80654962 A G MSH3 6.00E-13 -0.48 Esophagus - Gastroesophageal Junction 
rs1650697 5:80654962 A G MSH3 7.20E-13 -0.53 Stomach 
rs1650697 5:80654962 A G MSH3 3.60E-10 -0.57 Spleen 
rs1650697 5:80654962 A G MSH3 4.30E-10 -0.41 Breast - Mammary Tissue 
rs1650697 5:80654962 A G MSH3 4.20E-09 -0.36 Liver 
rs1650697 5:80654962 A G MSH3 8.80E-08 -0.45 Artery - Coronary 
rs1650697 5:80654962 A G MSH3 4.60E-07 -0.41 Prostate 
rs1650697 5:80654962 A G MSH3 7.10E-06 -0.45 Small Intestine - Terminal Ileum 
rs1650697 5:80654962 A G MSH3 1.50E-05 -0.41 Pituitary 
rs1677658 5:80655040 G T DHFR 1.80E-26 -0.82 Muscle - Skeletal 
rs1677658 5:80655040 G T DHFR 1.20E-17 -0.77 Testis 
rs1677658 5:80655040 G T DHFR 1.60E-15 -0.56 Whole Blood 
rs1677658 5:80655040 G T DHFR 1.40E-13 -0.75 Heart - Left Ventricle 
rs1677658 5:80655040 G T DHFR 1.60E-12 -0.46 Adipose - Visceral (Omentum) 
rs1677658 5:80655040 G T DHFR 2.70E-12 -0.28 Cells - Transformed fibroblasts 
rs1677658 5:80655040 G T DHFR 2.00E-11 -0.73 Heart - Atrial Appendage 
rs1677658 5:80655040 G T DHFR 3.10E-11 -0.3 Esophagus - Mucosa 
rs1677658 5:80655040 G T DHFR 4.10E-10 -0.41 Adipose - Subcutaneous 
rs1677658 5:80655040 G T DHFR 6.60E-09 -0.42 Artery - Tibial 
rs1677658 5:80655040 G T DHFR 2.10E-08 -0.29 Lung 
rs1677658 5:80655040 G T DHFR 6.60E-08 -0.35 Colon - Transverse 
rs1677658 5:80655040 G T DHFR 1.20E-07 -0.51 Esophagus - Muscularis 
rs1677658 5:80655040 G T DHFR 2.20E-07 -0.45 Cells - EBV-transformed lymphocytes 
rs1677658 5:80655040 G T DHFR 3.90E-07 -0.41 Nerve - Tibial 
rs1677658 5:80655040 G T DHFR 7.40E-07 -0.76 Brain - Cortex 
rs1677658 5:80655040 G T DHFR 2.40E-06 -0.58 Colon - Sigmoid 
rs1677658 5:80655040 G T DHFR 5.90E-06 -0.58 Brain - Caudate (basal ganglia) 
rs1677658 5:80655040 G T DHFR 1.10E-05 -0.64 Brain - Cerebellar Hemisphere 
rs1677658 5:80655040 G T DHFR 1.20E-05 -0.32 Breast - Mammary Tissue 
rs1677658 5:80655040 G T DHFR 2.40E-05 -0.7 Brain - Cerebellum 
rs1677658 5:80655040 G T MSH3 4.00E-15 -0.51 Thyroid 
rs1677658 5:80655040 G T MSH3 4.20E-14 -0.51 Artery - Tibial 
rs1677658 5:80655040 G T MSH3 4.50E-14 -0.5 Skin - Not Sun Exposed (Suprapubic) 
rs1677658 5:80655040 G T MSH3 6.60E-14 -0.43 Skin - Sun Exposed (Lower leg) 
rs1677658 5:80655040 G T MSH3 1.80E-13 -0.54 Nerve - Tibial 
rs1677658 5:80655040 G T MSH3 6.30E-11 -0.4 Adipose - Subcutaneous 
rs1677658 5:80655040 G T MSH3 1.60E-08 -0.56 Cells - Transformed fibroblasts 
rs1677658 5:80655040 G T MSH3 5.40E-08 -0.37 Whole Blood 
rs1677658 5:80655040 G T MSH3 1.90E-07 -0.36 Adipose - Visceral (Omentum) 
rs1677658 5:80655040 G T MSH3 5.80E-07 -0.48 Breast - Mammary Tissue 
rs1677658 5:80655040 G T MSH3 9.10E-07 -0.38 Heart - Atrial Appendage 
rs1677658 5:80655040 G T MSH3 9.20E-07 -0.3 Lung 
rs1677658 5:80655040 G T MSH3 1.40E-05 -0.42 Stomach 
rs1677658 5:80655040 G T MSH3 2.60E-05 -0.25 Esophagus - Mucosa 
rs1677658 5:80655040 G T MSH3 4.10E-05 -0.3 Esophagus - Muscularis 
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10.14 HD transcriptome-wide association study (TWAS) 
Table 10.4. Transcriptome-wide association study (TWAS) of HD prefrontal cortex. 
The method of Gusev et al. (2016) was used to test for association between phenotype and gene expression in control dorsolateral 
prefrontal cortex from the Common Mind Consortium (n=452) using summary statistics of genome-wide association studies. The Z-
score represents the standardized effect size, with positive values indicating later onset (GeM-HD) or faster progression (TRACK-HD 
and REGISTRY). GeM – Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium GWAS (n = 4082) (GeM-HD, 2015). TRACK-
HD and REGISTRY – Hensman Moss et al. (2017b) GWAS (n = 243). Table sorted by TRACK-HD, then TRACK-HD + REGISTRY, then GeM-
HD p-values. MSH3 and FAN1 are highlighted red. 
Gene symbol TRACK-HD progression TRACK-HD + REGISTRY progression GeM-HD age at onset 
Z p Z p Z p 
MSH3 4.71 2.52E-06 6.35 2.23E-10 -3.14 1.71E-03 
DHFR 4.61 4.08E-06 3.51 4.44E-04 0.17 8.68E-01 
THUMPD3 3.51 4.42E-04 3.35 8.01E-04 1.20 2.29E-01 
UBE2G1 -3.51 4.55E-04 - - 0.88 3.78E-01 
RBM47 -3.47 5.30E-04 -3.19 1.41E-03 -0.74 4.60E-01 
FBLL1 -3.43 5.99E-04 - - 1.39 1.64E-01 
WRB -3.33 8.78E-04 - - -1.96 4.98E-02 
TDH -3.32 8.93E-04 - - -1.86 6.34E-02 
ELOVL5 -3.24 1.22E-03 - - 0.31 7.55E-01 
RASGRF2 3.17 1.52E-03 - - -0.51 6.11E-01 
PSMG1 3.15 1.64E-03 - - 0.10 9.17E-01 
LPL -3.06 2.24E-03 - - -0.18 8.58E-01 
ASPRV1 -3.05 2.25E-03 - - 1.92 5.51E-02 
C12orf43 3.05 2.29E-03 - - -0.53 5.95E-01 
SLC15A5 3.05 2.30E-03 - - -0.85 3.96E-01 
EFCAB5 3.01 2.63E-03 - - 0.52 6.03E-01 
KIAA1804 -3.00 2.67E-03 -3.37 7.44E-04 0.63 5.30E-01 
TMEM132B 2.99 2.82E-03 - - 0.18 8.60E-01 
SLC25A37 -2.97 2.94E-03 - - 0.31 7.59E-01 
FAHD1 -2.97 2.96E-03 - - -0.59 5.56E-01 
CD93 2.94 3.30E-03 - - -1.19 2.34E-01 
RNF126 2.92 3.54E-03 - - 0.47 6.42E-01 
ORC5 -2.90 3.78E-03 - - 0.42 6.75E-01 
FBRSL1 2.88 3.97E-03 - - 0.17 8.66E-01 
LOC283683 2.86 4.20E-03 - - -1.28 2.01E-01 
INTS12 -2.86 4.22E-03 - - 0.89 3.75E-01 
ADAMTS19 2.86 4.23E-03 - - -1.56 1.19E-01 
RNASE4 2.85 4.32E-03 - - -0.60 5.47E-01 
GPR124 2.85 4.35E-03 2.90 3.78E-03 -1.45 1.46E-01 
RNF24 2.82 4.85E-03 - - -0.11 9.14E-01 
DNTTIP1 2.82 4.87E-03 - - -1.67 9.43E-02 
NRG4 2.79 5.25E-03 - - -0.43 6.64E-01 
KLHDC4 2.78 5.43E-03 - - 0.02 9.83E-01 
NDUFS5 -2.77 5.68E-03 - - -0.24 8.06E-01 
UBE2G2 -2.76 5.74E-03 - - -1.16 2.47E-01 
GALNT3 2.75 5.97E-03 - - -0.82 4.13E-01 
OMA1 -2.73 6.29E-03 - - 0.01 9.91E-01 
SSH2 2.73 6.30E-03 - - 0.72 4.74E-01 
ATP1B3 2.72 6.59E-03 3.05 2.32E-03 -0.35 7.29E-01 
NCEH1 -2.70 6.86E-03 - - -1.05 2.92E-01 
OGN -2.70 6.94E-03 - - 0.04 9.65E-01 
PHLDA3 2.70 7.03E-03 - - 0.48 6.30E-01 
GSTM3 2.69 7.05E-03 - - -1.03 3.02E-01 
CRYZ -2.68 7.28E-03 - - -0.37 7.14E-01 
RBM23 2.68 7.39E-03 - - 0.72 4.75E-01 
DNAJB11 2.68 7.47E-03 - - 1.00 3.18E-01 
CBLN1 -2.67 7.59E-03 - - -1.59 1.12E-01 
HEATR1 2.66 7.83E-03 - - 0.67 5.05E-01 
CACNA1B 2.65 7.97E-03 - - -1.95 5.15E-02 
PTRF 2.63 8.59E-03 - - -1.53 1.26E-01 
PKNOX1 2.63 8.61E-03 - - 0.03 9.73E-01 
ACSL5 -2.62 8.72E-03 - - -1.83 6.76E-02 
CCDC53 2.62 8.77E-03 3.20 1.37E-03 -0.99 3.20E-01 
LOC339803 2.61 9.10E-03 - - -0.33 7.44E-01 
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ARHGAP22 2.60 9.34E-03 - - -1.97 4.94E-02 
CNKSR3 -2.60 9.40E-03 - - -0.26 7.94E-01 
LRRFIP1 -2.60 9.42E-03 - - -0.14 8.91E-01 
PINX1 2.59 9.69E-03 - - -0.59 5.56E-01 
PLSCR1 -2.58 9.77E-03 - - 0.99 3.22E-01 
PCDHGB4 -2.58 9.80E-03 - - 1.15 2.49E-01 
IFT57 -2.58 9.81E-03 - - -0.76 4.45E-01 
FAM120B -2.58 9.90E-03 - - -3.23 1.22E-03 
POLD2 -2.57 1.02E-02 - - -0.72 4.70E-01 
KLC3 2.55 1.07E-02 - - 0.10 9.21E-01 
EIF2B1 -2.55 1.09E-02 - - 0.13 9.01E-01 
MRGPRF -2.54 1.09E-02 - - -0.55 5.82E-01 
ZNF131 2.54 1.12E-02 - - 0.88 3.81E-01 
PIGN -2.53 1.14E-02 - - -0.71 4.79E-01 
TMEM41B -2.53 1.14E-02 - - -0.33 7.43E-01 
ARL3 -2.52 1.18E-02 - - -1.02 3.06E-01 
INTS10 -2.52 1.18E-02 - - -1.68 9.31E-02 
CYP27C1 -2.51 1.19E-02 - - 0.79 4.27E-01 
PKIB -2.51 1.20E-02 - - -0.36 7.22E-01 
SNRNP27 -2.51 1.21E-02 - - -1.29 1.97E-01 
UBTD2 2.50 1.24E-02 - - -0.56 5.79E-01 
UBE2Q2 2.49 1.28E-02 - - -0.69 4.90E-01 
KRBA1 -2.49 1.28E-02 - - 1.08 2.81E-01 
HKDC1 2.48 1.32E-02 - - 0.34 7.34E-01 
CCND2 -2.47 1.34E-02 - - 1.47 1.42E-01 
CTSC 2.47 1.36E-02 - - -1.54 1.24E-01 
LGALS8 -2.47 1.37E-02 - - -1.18 2.38E-01 
PCDHGA6 2.46 1.39E-02 - - -1.21 2.27E-01 
REEP3 -2.46 1.40E-02 - - 0.52 6.03E-01 
SDHA 2.45 1.41E-02 - - 0.18 8.55E-01 
BMPR1A 2.45 1.41E-02 - - 0.99 3.24E-01 
CLEC4GP1 2.45 1.42E-02 - - 0.37 7.14E-01 
ZNF770 -2.45 1.43E-02 - - 0.93 3.54E-01 
TRIM44 2.44 1.45E-02 - - -0.38 7.03E-01 
PACRGL 2.44 1.45E-02 - - -1.70 9.00E-02 
CBX7 -2.44 1.46E-02 - - 0.09 9.31E-01 
VEZT 2.44 1.46E-02 - - -0.08 9.33E-01 
FAM124B 2.44 1.47E-02 - - -1.57 1.17E-01 
C1orf228 2.44 1.47E-02 - - 1.75 7.94E-02 
HAS1 2.44 1.48E-02 - - -0.42 6.78E-01 
ALX4 -2.43 1.49E-02 -2.94 3.26E-03 1.04 2.99E-01 
ARHGEF11 -2.42 1.54E-02 - - 0.12 9.02E-01 
CSTF2T 2.42 1.54E-02 - - 3.22 1.26E-03 
DENND1B 2.42 1.55E-02 - - 1.16 2.47E-01 
LOC284751 2.41 1.59E-02 - - 0.18 8.58E-01 
PDGFD -2.40 1.62E-02 - - -0.01 9.92E-01 
RAB37 -2.40 1.64E-02 - - -0.22 8.22E-01 
PANK2 2.39 1.68E-02 - - 0.53 5.98E-01 
LOC401321 2.39 1.70E-02 - - -0.84 3.99E-01 
NUP107 -2.38 1.73E-02 - - -1.21 2.27E-01 
IGFALS 2.37 1.76E-02 - - 0.37 7.11E-01 
PNPLA5 2.37 1.77E-02 - - 0.31 7.56E-01 
LMOD1 -2.37 1.78E-02 - - -0.45 6.51E-01 
CCDC127 2.37 1.79E-02 - - 0.26 7.92E-01 
CYB5D2 2.37 1.80E-02 - - -1.18 2.39E-01 
CERS2 -2.36 1.80E-02 - - 1.93 5.40E-02 
PLCB3 -2.36 1.81E-02 - - -0.98 3.26E-01 
SMYD2 2.36 1.82E-02 - - -1.65 9.99E-02 
ZNF667 -2.36 1.84E-02 -3.41 6.58E-04 -1.60 1.09E-01 
ZNHIT6 2.36 1.84E-02 - - 1.67 9.58E-02 
MYO16 -2.36 1.85E-02 - - -1.21 2.28E-01 
ZMYM5 2.35 1.85E-02 - - 0.90 3.69E-01 
LIN37 2.36 1.85E-02 - - 0.56 5.75E-01 
NMD3 -2.35 1.85E-02 - - -0.16 8.70E-01 
FN3KRP -2.35 1.87E-02 - - 0.78 4.35E-01 
ADPRH -2.35 1.87E-02 - - -0.25 8.02E-01 
ACTR1A -2.35 1.89E-02 - - 0.30 7.62E-01 
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ECE2 2.34 1.91E-02 - - 0.42 6.72E-01 
YPEL1 2.34 1.93E-02 - - -0.96 3.38E-01 
IDI2-AS1 2.33 1.97E-02 - - -0.31 7.58E-01 
RILPL1 -2.33 1.98E-02 - - 0.59 5.56E-01 
LOC100505761 2.33 1.98E-02 - - 1.01 3.12E-01 
BCL2L2 -2.33 2.00E-02 - - -1.70 8.97E-02 
HMGN1 2.33 2.01E-02 - - 0.82 4.12E-01 
RRP1B -2.32 2.03E-02 - - 0.94 3.45E-01 
KLHDC1 2.32 2.04E-02 - - -0.22 8.28E-01 
TMEM63A 2.32 2.04E-02 - - 0.03 9.79E-01 
SNRPC -2.32 2.05E-02 - - -1.27 2.05E-01 
LPIN3 2.31 2.06E-02 - - -0.97 3.31E-01 
RSBN1 2.31 2.08E-02 - - -0.16 8.74E-01 
UHRF1BP1 2.31 2.08E-02 - - 1.36 1.74E-01 
TTC38 -2.31 2.09E-02 - - -0.12 9.02E-01 
LCTL -2.31 2.11E-02 - - 1.04 2.98E-01 
TAF9 2.30 2.14E-02 - - -0.20 8.43E-01 
DSC1 -2.30 2.14E-02 - - 0.16 8.73E-01 
HAP1 -2.30 2.14E-02 - - -0.12 9.02E-01 
HERC2 2.30 2.16E-02 - - 0.85 3.95E-01 
ADARB1 2.29 2.18E-02 - - 0.17 8.63E-01 
PDIA4 2.29 2.19E-02 - - 0.42 6.74E-01 
RAB6C 2.29 2.19E-02 - - -0.98 3.27E-01 
MIA3 2.29 2.19E-02 - - 0.34 7.30E-01 
CPS1 2.29 2.21E-02 - - 0.40 6.89E-01 
RBL2 2.29 2.23E-02 - - 0.09 9.25E-01 
CCDC110 -2.28 2.24E-02 - - 0.76 4.48E-01 
MRPS21 -2.28 2.24E-02 - - 0.13 8.96E-01 
SPSB4 2.28 2.25E-02 3.34 8.37E-04 -1.10 2.71E-01 
TTC30A 2.28 2.27E-02 - - 0.79 4.32E-01 
TMED10 2.28 2.28E-02 - - -2.21 2.68E-02 
PEX11A -2.28 2.28E-02 - - 0.29 7.71E-01 
ZNF497 -2.27 2.31E-02 - - -0.07 9.44E-01 
CUBN -2.27 2.34E-02 - - -0.89 3.71E-01 
MRPL53 -2.26 2.36E-02 - - -1.41 1.59E-01 
PKDREJ 2.26 2.36E-02 - - -0.44 6.59E-01 
SLC17A6 2.26 2.36E-02 - - 0.03 9.74E-01 
SNHG8 -2.26 2.37E-02 - - 1.66 9.70E-02 
EIF2AK1 -2.26 2.41E-02 - - 3.38 7.31E-04 
CCDC146 2.25 2.47E-02 - - -1.29 1.97E-01 
MAPK13 -2.25 2.47E-02 - - 0.99 3.20E-01 
ZNF514 2.24 2.49E-02 - - -0.02 9.80E-01 
RNH1 2.24 2.50E-02 - - -1.26 2.07E-01 
SPON1 -2.24 2.50E-02 - - 0.11 9.15E-01 
TMCO3 -2.24 2.51E-02 - - -1.71 8.70E-02 
DSE -2.24 2.52E-02 - - -0.89 3.72E-01 
CFTR 2.24 2.54E-02 - - -0.40 6.91E-01 
CNKSR1 2.23 2.55E-02 - - 0.37 7.15E-01 
HTR1A -2.22 2.63E-02 - - -1.11 2.67E-01 
FLJ20021 -2.22 2.65E-02 - - -0.30 7.62E-01 
SLC16A10 -2.21 2.69E-02 -2.92 3.46E-03 0.12 9.02E-01 
SNF8 2.21 2.69E-02 - - -2.50 1.24E-02 
RTBDN 2.21 2.69E-02 3.31 9.29E-04 -0.81 4.18E-01 
HPSE2 -2.21 2.71E-02 - - -0.53 5.95E-01 
CKMT1B 2.21 2.73E-02 - - 0.40 6.89E-01 
CENPP -2.21 2.73E-02 - - 0.41 6.85E-01 
CCDC82 -2.21 2.73E-02 -3.33 8.75E-04 2.32 2.05E-02 
MCTP1 -2.21 2.73E-02 - - -0.27 7.90E-01 
CRIPAK -2.21 2.75E-02 - - -0.05 9.64E-01 
RSPO2 -2.20 2.75E-02 - - 0.18 8.60E-01 
GNPTAB -2.20 2.76E-02 - - -0.35 7.25E-01 
KRBA2 -2.20 2.78E-02 - - -0.82 4.11E-01 
KIF24 2.20 2.80E-02 - - -1.30 1.94E-01 
CCDC102B 2.20 2.80E-02 - - 0.22 8.26E-01 
GEMIN4 2.19 2.86E-02 - - -0.11 9.15E-01 
LOC100128288 -2.19 2.86E-02 - - -0.72 4.73E-01 
VRK1 2.19 2.87E-02 - - -1.27 2.06E-01 
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KIF17 2.19 2.87E-02 - - 0.63 5.27E-01 
CES1 -2.19 2.89E-02 - - 1.58 1.14E-01 
GABRA1 2.18 2.90E-02 - - -0.38 7.08E-01 
IGFLR1 -2.18 2.94E-02 - - -0.60 5.51E-01 
BCL2L13 -2.18 2.94E-02 - - -2.26 2.37E-02 
BTBD8 -2.18 2.94E-02 - - 1.42 1.55E-01 
ADSSL1 2.17 2.98E-02 - - -1.17 2.41E-01 
C6orf165 2.17 3.00E-02 - - -0.31 7.59E-01 
ABCC11 -2.17 3.01E-02 - - 1.30 1.94E-01 
VASH2 -2.17 3.03E-02 - - -0.31 7.55E-01 
RTP4 -2.16 3.04E-02 - - 1.01 3.14E-01 
GUSBP11 2.16 3.06E-02 - - 1.28 2.01E-01 
TSNARE1 2.16 3.10E-02 - - -2.32 2.05E-02 
YWHAH -2.16 3.10E-02 - - 0.00 9.98E-01 
PELI2 2.16 3.10E-02 - - -1.37 1.71E-01 
TMTC3 2.15 3.12E-02 - - 1.31 1.90E-01 
C6orf62 -2.15 3.13E-02 - - -0.72 4.73E-01 
ANKRD40 2.14 3.26E-02 - - 1.20 2.30E-01 
FAM201A -2.13 3.31E-02 - - 1.20 2.29E-01 
FAM83H -2.13 3.32E-02 - - -2.11 3.49E-02 
ZBTB41 2.13 3.32E-02 - - 0.64 5.22E-01 
ADCY3 2.13 3.33E-02 - - 0.21 8.32E-01 
NEFL -2.13 3.34E-02 - - -1.40 1.62E-01 
NBAS -2.13 3.34E-02 - - -0.83 4.07E-01 
TRIM9 -2.13 3.34E-02 - - 0.75 4.53E-01 
CISD2 2.13 3.35E-02 - - -0.05 9.59E-01 
PLCD1 2.12 3.38E-02 - - 0.99 3.22E-01 
EEF2K -2.12 3.40E-02 - - -1.16 2.45E-01 
EIF2B2 -2.12 3.44E-02 - - 2.62 8.81E-03 
ZNF132 -2.11 3.46E-02 - - -0.04 9.70E-01 
URB1 -2.11 3.46E-02 - - 0.02 9.87E-01 
VSTM4 -2.11 3.47E-02 - - -0.62 5.34E-01 
BNIP1 -2.11 3.48E-02 - - -1.67 9.57E-02 
MYCBPAP -2.11 3.50E-02 - - -0.92 3.56E-01 
SGCE 2.11 3.51E-02 - - -1.09 2.77E-01 
C10orf67 2.10 3.55E-02 - - 0.95 3.42E-01 
MUL1 2.10 3.58E-02 - - 0.14 8.86E-01 
CCNG1 -2.10 3.58E-02 - - 0.60 5.48E-01 
HTR1F 2.09 3.64E-02 - - -0.20 8.43E-01 
OAF -2.09 3.65E-02 - - -0.36 7.16E-01 
CYFIP1 2.09 3.66E-02 - - 1.53 1.25E-01 
LOC100131320 2.09 3.67E-02 - - -0.94 3.48E-01 
SETD8 2.09 3.67E-02 - - -0.70 4.87E-01 
RPS5 2.09 3.69E-02 - - -1.00 3.19E-01 
REEP6 2.09 3.69E-02 - - -1.12 2.64E-01 
SELRC1 2.08 3.74E-02 - - 0.16 8.76E-01 
KIAA1586 2.08 3.76E-02 - - -0.17 8.63E-01 
SLC33A1 -2.08 3.76E-02 - - -1.02 3.08E-01 
EIF3E 2.08 3.78E-02 - - 0.70 4.87E-01 
LOC100128361 -2.08 3.79E-02 - - 0.47 6.38E-01 
STX12 -2.07 3.84E-02 - - -0.38 7.06E-01 
SGCB 2.07 3.86E-02 - - 1.67 9.55E-02 
DLG5 -2.07 3.87E-02 - - 0.80 4.23E-01 
ZNF519 2.07 3.88E-02 - - -1.49 1.37E-01 
MPZL1 2.07 3.88E-02 - - 0.62 5.39E-01 
SESTD1 2.07 3.89E-02 - - -1.42 1.54E-01 
FAM129B 2.07 3.89E-02 - - -1.44 1.50E-01 
NDUFA2 2.06 3.93E-02 - - -1.16 2.45E-01 
COL6A1 -2.06 3.94E-02 - - -0.11 9.15E-01 
IFI16 -2.06 3.98E-02 - - 0.11 9.10E-01 
PGAP3 -2.05 4.00E-02 - - 0.82 4.11E-01 
PLEKHA1 -2.05 4.03E-02 - - -1.00 3.16E-01 
ZNF445 -2.05 4.03E-02 - - -1.28 2.02E-01 
RASA4 -2.05 4.05E-02 - - -1.38 1.67E-01 
CHKB -2.05 4.09E-02 - - -0.79 4.30E-01 
HN1L 2.04 4.09E-02 - - -0.39 6.94E-01 
CYP1B1-AS1 2.04 4.10E-02 - - -0.66 5.10E-01 
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GAS5 -2.04 4.14E-02 - - -2.03 4.23E-02 
KIAA0825 -2.04 4.14E-02 - - -0.50 6.18E-01 
SCARB2 2.04 4.16E-02 - - -0.05 9.63E-01 
TXK -2.04 4.16E-02 - - -0.93 3.54E-01 
FLVCR1 2.03 4.23E-02 2.94 3.25E-03 -0.42 6.72E-01 
VAMP1 2.03 4.23E-02 - - 0.25 8.06E-01 
AKTIP 2.03 4.24E-02 - - 0.22 8.24E-01 
GOSR1 -2.03 4.25E-02 - - -1.04 2.98E-01 
SLC26A1 2.03 4.25E-02 - - -0.04 9.69E-01 
APRT -2.03 4.25E-02 - - -0.15 8.83E-01 
SLC22A3 -2.03 4.26E-02 - - -1.38 1.66E-01 
DENND1A -2.02 4.31E-02 - - -0.53 5.99E-01 
VILL -2.02 4.32E-02 - - -2.06 3.98E-02 
SOD2 -2.02 4.33E-02 - - -0.19 8.46E-01 
PTPN3 -2.02 4.34E-02 - - 0.38 7.07E-01 
PSMB5 -2.02 4.34E-02 - - -1.17 2.40E-01 
CD52 2.02 4.34E-02 - - -0.46 6.44E-01 
ABCA11P 2.01 4.46E-02 - - -0.71 4.78E-01 
JAK2 2.01 4.48E-02 - - -0.09 9.25E-01 
WDR76 -2.01 4.49E-02 - - 0.23 8.22E-01 
MED13 -2.00 4.51E-02 - - 0.55 5.82E-01 
BTBD10 2.00 4.57E-02 - - -0.66 5.10E-01 
C10orf32 2.00 4.57E-02 - - 0.25 8.03E-01 
YES1 2.00 4.57E-02 - - 0.12 9.06E-01 
CENPQ -2.00 4.58E-02 - - 0.62 5.33E-01 
SFRP5 -2.00 4.60E-02 - - 0.67 5.03E-01 
MBLAC1 -1.99 4.61E-02 - - -1.64 1.02E-01 
GPRC5B 1.99 4.61E-02 - - -1.57 1.16E-01 
LOC441242 -1.99 4.64E-02 - - 0.82 4.10E-01 
PRKCB 1.99 4.69E-02 - - 0.73 4.63E-01 
SLC36A4 -1.99 4.70E-02 - - 0.49 6.26E-01 
ZNF593 -1.99 4.71E-02 - - -0.14 8.88E-01 
ADAM17 1.98 4.72E-02 - - 0.29 7.74E-01 
MLH3 -1.98 4.73E-02 - - 2.64 8.36E-03 
SLC26A11 1.98 4.75E-02 - - 0.81 4.19E-01 
MPP6 1.98 4.76E-02 - - -0.67 5.03E-01 
DENND3 1.98 4.78E-02 - - -0.36 7.19E-01 
SYNE2 1.98 4.79E-02 - - -0.41 6.79E-01 
HELB -1.98 4.80E-02 - - -0.80 4.26E-01 
MOV10L1 1.98 4.80E-02 - - -0.43 6.65E-01 
BRD3 1.98 4.81E-02 - - -0.69 4.88E-01 
PKDCC -1.98 4.81E-02 - - 0.25 8.03E-01 
UBE2Q2P1 1.98 4.81E-02 - - -0.13 8.98E-01 
ZNF584 1.98 4.81E-02 - - -0.59 5.56E-01 
B4GALT4 1.97 4.85E-02 - - -0.74 4.60E-01 
NUBP2 1.97 4.85E-02 - - 0.25 8.03E-01 
FDXR 1.97 4.86E-02 - - 0.37 7.12E-01 
SGK223 -1.97 4.88E-02 - - 0.76 4.48E-01 
C21orf128 1.97 4.89E-02 - - 1.40 1.63E-01 
RPF1 -1.97 4.90E-02 - - 1.91 5.58E-02 
PSD4 -1.97 4.92E-02 - - 0.63 5.31E-01 
FAM179B 1.97 4.92E-02 - - 1.07 2.84E-01 
SEMA4F 1.96 4.96E-02 - - 0.49 6.24E-01 
INPP1 1.96 4.98E-02 - - -0.71 4.80E-01 
ABCC3 -1.96 4.99E-02 - - -1.05 2.93E-01 
C1orf52 -1.96 5.00E-02 - - -2.61 8.93E-03 
FAN1 - - -3.78 1.58E-04 6.99 2.80E-12 
CUTC - - -3.12 1.81E-03 1.09 2.77E-01 
LRP2BP - - -3.05 2.32E-03 -0.43 6.68E-01 
ZNF492 - - 3.02 2.53E-03 -0.46 6.45E-01 
EPM2AIP1 - - 3.00 2.66E-03 -0.68 4.97E-01 
UFSP2 - - -3.00 2.73E-03 -1.61 1.06E-01 
LEFTY1 - - 2.94 3.27E-03 -0.53 5.95E-01 
SGCD - - - - 4.30 1.70E-05 
SUMF2 - - - - 3.92 8.99E-05 
GPR161 - - - - 3.55 3.86E-04 
ARID3B - - - - 3.35 8.19E-04 
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DDX20 - - - - 3.22 1.28E-03 
PRKG1 - - - - 3.22 1.28E-03 
PMS2 - - - - 3.20 1.39E-03 
RBM6 - - - - 3.17 1.53E-03 
CCZ1 - - - - -3.15 1.62E-03 
PMS1 - - - - 3.10 1.91E-03 
NEU3 - - - - 3.08 2.08E-03 
PRICKLE1 - - - - -3.08 2.10E-03 
B3GAT1 - - - - -3.07 2.11E-03 
TRANK1 - - - - -3.07 2.15E-03 
MST1R - - - - -3.02 2.51E-03 
NEDD4 - - - - -2.98 2.88E-03 
SNCAIP - - - - 2.96 3.03E-03 
DPM2 - - - - -2.96 3.06E-03 
FRRS1 - - - - -2.94 3.24E-03 
GMPPB - - - - -2.94 3.26E-03 
LYPLAL1 - - - - -2.91 3.58E-03 
OXGR1 - - - - 2.91 3.67E-03 
SQSTM1 - - - - 2.90 3.77E-03 
DGKE - - - - 2.87 4.14E-03 
SNAP91 - - - - 2.86 4.20E-03 
SLC4A8 - - - - -2.86 4.21E-03 
SLCO2B1 - - - - -2.84 4.48E-03 
SURF4 - - - - 2.84 4.54E-03 
NHLRC1 - - - - -2.83 4.61E-03 
DBT - - - - 2.82 4.86E-03 
PSMA4 - - - - 2.82 4.88E-03 
TECPR2 - - - - 2.78 5.39E-03 
ADAMTS3 - - - - 2.77 5.59E-03 
MCAT - - - - -2.77 5.62E-03 
IFITM10 - - - - 2.77 5.64E-03 
PTPRK - - - - 2.76 5.70E-03 
BCL2L11 - - - - -2.73 6.31E-03 
SULT1A1 - - - - 2.73 6.36E-03 
PLEKHG5 - - - - -2.71 6.65E-03 
C5orf45 - - - - 2.71 6.83E-03 
GOLIM4 - - - - -2.70 7.03E-03 
DCLK3 - - - - -2.69 7.20E-03 
LCA5L - - - - -2.68 7.30E-03 
FMO4 - - - - 2.68 7.32E-03 
PRTFDC1 - - - - 2.68 7.40E-03 
CREG2 - - - - 2.58 9.84E-03 
TMC5 - - - - 2.58 9.95E-03 
GALNT2 - - - - -2.57 1.02E-02 
LRRFIP2 - - - - 2.56 1.04E-02 
VOPP1 - - - - 2.56 1.06E-02 
TRAF4 - - - - -2.55 1.08E-02 
ZNF280D - - - - -2.54 1.11E-02 
RHPN1 - - - - -2.53 1.13E-02 
HPS4 - - - - -2.53 1.14E-02 
SNUPN - - - - 2.53 1.14E-02 
TTC21A - - - - 2.52 1.18E-02 
SNHG1 - - - - -2.51 1.19E-02 
ZNF329 - - - - 2.52 1.19E-02 
C6orf120 - - - - -2.49 1.27E-02 
SLCO3A1 - - - - 2.49 1.29E-02 
KIAA0040 - - - - -2.48 1.30E-02 
LOC100131564 - - - - 2.48 1.31E-02 
C1orf229 - - - - 2.48 1.32E-02 
USP46 - - - - -2.48 1.32E-02 
CHRNA5 - - - - 2.47 1.35E-02 
PCOLCE2 - - - - -2.46 1.39E-02 
SCRG1 - - - - -2.45 1.42E-02 
NUPL2 - - - - 2.45 1.43E-02 
ABHD14B - - - - 2.44 1.46E-02 
C10orf18 - - - - -2.44 1.46E-02 
NWD1 - - - - -2.44 1.46E-02 
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ACBD7 - - - - -2.44 1.47E-02 
LOC283177 - - - - -2.44 1.47E-02 
POLR2J4 - - - - -2.43 1.51E-02 
PIGX - - - - -2.43 1.52E-02 
PRKD1 - - - - -2.42 1.55E-02 
S1PR2 - - - - 2.42 1.57E-02 
CCDC102A - - - - 2.41 1.58E-02 
RPA3 - - - - -2.41 1.59E-02 
PPP1CB - - - - 2.41 1.61E-02 
COMMD4 - - - - -2.40 1.63E-02 
MEF2BNB - - - - -2.40 1.64E-02 
ZNF75A - - - - -2.38 1.72E-02 
BCR - - - - -2.38 1.73E-02 
CCT6P1 - - - - 2.38 1.73E-02 
TXNDC12 - - - - 2.38 1.75E-02 
ORMDL1 - - - - -2.37 1.76E-02 
STAG3L4 - - - - 2.37 1.80E-02 
GPX1 - - - - -2.36 1.81E-02 
MCM7 - - - - 2.36 1.82E-02 
MRPL24 - - - - 2.34 1.91E-02 
HEATR2 - - - - -2.34 1.93E-02 
RHOA - - - - -2.34 1.93E-02 
CYP24A1 - - - - -2.34 1.94E-02 
ASNSD1 - - - - 2.34 1.95E-02 
FIG4 - - - - -2.33 1.96E-02 
CBS - - - - 2.33 1.97E-02 
LRPPRC - - - - -2.33 1.99E-02 
ENO3 - - - - 2.32 2.01E-02 
QRICH2 - - - - 2.32 2.03E-02 
KIAA1731 - - - - 2.32 2.04E-02 
GPR179 - - - - 2.32 2.05E-02 
WDR36 - - - - -2.31 2.06E-02 
ANO7 - - - - -2.31 2.10E-02 
C6orf70 - - - - -2.31 2.10E-02 
LYPD6 - - - - -2.31 2.10E-02 
TRIOBP - - - - -2.30 2.13E-02 
ECM2 - - - - 2.29 2.21E-02 
IFT52 - - - - -2.29 2.21E-02 
RRP7B - - - - -2.28 2.25E-02 
LEMD3 - - - - 2.28 2.26E-02 
GNPDA2 - - - - 2.28 2.28E-02 
RIIAD1 - - - - 2.28 2.28E-02 
INCA1 - - - - 2.28 2.29E-02 
SLCO4C1 - - - - 2.28 2.29E-02 
GAN - - - - -2.27 2.31E-02 
LRRC1 - - - - 2.27 2.31E-02 
TMEM165 - - - - -2.27 2.34E-02 
ZNF334 - - - - -2.26 2.38E-02 
MAP3K4 - - - - -2.26 2.40E-02 
RPP38 - - - - 2.25 2.42E-02 
STEAP1 - - - - -2.25 2.43E-02 
LOC285889 - - - - 2.25 2.44E-02 
RARRES1 - - - - -2.25 2.44E-02 
DGCR2 - - - - -2.25 2.45E-02 
ZKSCAN1 - - - - 2.25 2.45E-02 
ZNF669 - - - - -2.24 2.50E-02 
PARD3 - - - - 2.24 2.51E-02 
ZNF639 - - - - 2.24 2.52E-02 
ADCK3 - - - - 2.23 2.60E-02 
NANS - - - - -2.23 2.60E-02 
PPAT - - - - -2.23 2.60E-02 
ABCC6P1 - - - - -2.22 2.64E-02 
MDGA1 - - - - 2.21 2.71E-02 
ZNF681 - - - - -2.21 2.71E-02 
GLOD4 - - - - -2.21 2.73E-02 
ZFAT - - - - -2.20 2.77E-02 
ZNF713 - - - - -2.20 2.77E-02 
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METTL21D - - - - -2.20 2.78E-02 
ZFP1 - - - - 2.20 2.78E-02 
TMCC3 - - - - 2.19 2.82E-02 
MCM8 - - - - 2.19 2.84E-02 
NFATC2IP - - - - -2.19 2.84E-02 
PCP4L1 - - - - -2.19 2.84E-02 
IPO11 - - - - -2.19 2.86E-02 
FRG1 - - - - -2.18 2.89E-02 
PRKD3 - - - - 2.18 2.90E-02 
P4HTM - - - - 2.18 2.91E-02 
ZNF814 - - - - -2.18 2.94E-02 
RYK - - - - -2.18 2.96E-02 
TDRD9 - - - - 2.17 2.97E-02 
ZNF670 - - - - -2.17 2.97E-02 
PAQR4 - - - - 2.17 3.03E-02 
NCBP2 - - - - 2.16 3.05E-02 
ERCC3 - - - - -2.16 3.08E-02 
GPR133 - - - - 2.16 3.10E-02 
OR2D3 - - - - -2.16 3.10E-02 
SLC27A2 - - - - -2.16 3.11E-02 
C17orf107 - - - - 2.15 3.12E-02 
PSMB6 - - - - 2.15 3.12E-02 
ARHGEF37 - - - - 2.15 3.14E-02 
HSDL1 - - - - -2.15 3.14E-02 
SIL1 - - - - -2.15 3.14E-02 
MDFIC - - - - 2.15 3.17E-02 
ABCC5 - - - - 2.14 3.21E-02 
HEY2 - - - - -2.14 3.24E-02 
CLPTM1 - - - - -2.14 3.25E-02 
ATOH7 - - - - -2.13 3.28E-02 
GSTZ1 - - - - -2.12 3.41E-02 
ATL3 - - - - -2.12 3.44E-02 
EXOC4 - - - - -2.11 3.44E-02 
NLRC3 - - - - -2.11 3.50E-02 
LRGUK - - - - 2.11 3.51E-02 
NIT2 - - - - -2.11 3.51E-02 
CKS2 - - - - 2.10 3.59E-02 
RDH10 - - - - 2.10 3.60E-02 
VSTM2L - - - - -2.10 3.61E-02 
FOXD4 - - - - -2.09 3.62E-02 
UFSP1 - - - - -2.09 3.62E-02 
LOC100506343 - - - - -2.09 3.65E-02 
PDPN - - - - -2.09 3.67E-02 
CARM1 - - - - -2.08 3.71E-02 
PPOX - - - - 2.08 3.71E-02 
FGD4 - - - - -2.08 3.78E-02 
PIGH - - - - 2.08 3.78E-02 
KIAA1033 - - - - -2.07 3.82E-02 
ATP5G1 - - - - -2.06 3.89E-02 
ITIH4 - - - - 2.06 3.92E-02 
PCM1 - - - - -2.06 3.93E-02 
EMILIN2 - - - - 2.06 3.95E-02 
TMEM216 - - - - 2.06 3.95E-02 
MRAP2 - - - - -2.06 3.96E-02 
CDK6 - - - - 2.06 3.98E-02 
TSPAN18 - - - - -2.05 3.99E-02 
ALG5 - - - - -2.05 4.03E-02 
ALG1L - - - - 2.05 4.05E-02 
NNT - - - - 2.05 4.05E-02 
AGRN - - - - -2.05 4.06E-02 
MRP63 - - - - 2.05 4.08E-02 
EFS - - - - -2.04 4.13E-02 
IRF6 - - - - -2.04 4.17E-02 
MTCH2 - - - - -2.04 4.17E-02 
ZNF429 - - - - 2.04 4.18E-02 
WFDC1 - - - - -2.03 4.19E-02 
HMGXB3 - - - - 2.03 4.24E-02 
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NOS2 - - - - -2.03 4.25E-02 
TMEM26 - - - - -2.03 4.25E-02 
ZFYVE16 - - - - -2.03 4.25E-02 
ZNF197 - - - - -2.03 4.27E-02 
TMEM229A - - - - 2.03 4.28E-02 
SSTR1 - - - - 2.02 4.31E-02 
MKRN2 - - - - 2.02 4.34E-02 
UBE2Z - - - - -2.02 4.37E-02 
IFNW1 - - - - 2.02 4.38E-02 
TCFL5 - - - - 2.02 4.39E-02 
ITGA8 - - - - 2.01 4.40E-02 
COPS3 - - - - 2.01 4.41E-02 
ASNS - - - - 2.01 4.42E-02 
G3BP1 - - - - 2.00 4.51E-02 
PDZRN4 - - - - 2.00 4.52E-02 
ALG6 - - - - -2.00 4.53E-02 
COL14A1 - - - - 2.00 4.58E-02 
ANKRD26 - - - - -1.99 4.67E-02 
KIF12 - - - - 1.99 4.67E-02 
DNAJA3 - - - - -1.99 4.69E-02 
FAM180B - - - - -1.99 4.70E-02 
RCBTB1 - - - - -1.99 4.70E-02 
TET1 - - - - -1.98 4.74E-02 
DRD5 - - - - 1.98 4.79E-02 
PPP1R13B - - - - 1.98 4.82E-02 
FAM69A - - - - -1.97 4.83E-02 
RPL23AP82 - - - - 1.97 4.84E-02 
SRSF12 - - - - -1.97 4.86E-02 
DYNLL1 - - - - -1.97 4.88E-02 
EPHA10 - - - - 1.97 4.88E-02 
SRR - - - - -1.97 4.88E-02 
TRIM61 - - - - -1.97 4.88E-02 
C11orf49 - - - - 1.97 4.89E-02 
ROBO1 - - - - 1.97 4.92E-02 
USP48 - - - - -1.96 4.95E-02 
PTK7 - - - - 1.96 5.00E-02 
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